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Abstract 
 
Ankylosing spondylitis (AS) is an inflammatory arthritis that primarily affects the spine and 
sacroiliac joints in the pelvis. It is relatively common, affecting 0.4 – 1.4% of white 
Europeans. It is a complex genetic disease with high heritability, and with environmental 
factors playing only a minor role. HLA-B*27 is present in 80 - 90% of AS patients and is 
one of the strongest associations between a major histocompatibility allele and disease 
known. 
 
Anterior uveitis (AU) occurs commonly in ankylosing spondylitis and is inflammation of the 
anterior part of the uveal tract encompassing the iris and pars ciliaris of the ciliary body. 
Infectious agents can cause AU but in European populations immune-mediated processes 
cause nearly all cases. It is a common complication of AS, but also occurs in isolation.  
Immune-mediated AU typically has a sudden unilateral onset and limited duration, and this 
is termed acute anterior uveitis. Acute anterior uveitis is also strongly associated with HLA-
B*27. 
 
This thesis examines the genetics of AS and acute anterior uveitis using array based 
genotyping and statistical genetic techniques to: 
 (1) Investigate the complex chromosome 5q15 locus that has previously been associated 
with AS, using data from the Illumina Immunochip genotyping platform,  
(2) Investigate the genetic associations of acute anterior uveitis, using the data from 
Illumina Immunochip genotyping platform,  
(3) Investigate the genetic associations of acute anterior uveitis using the Illumina Human 
Exomechip platform, and  
(4) Investigate the genetic associations of AS using data from the Illumina Human 
Exomechip platform. 
 
Participants were recruited from rheumatology clinics and ophthalmology departments 
from Australia, the United Kingdom, the United States and New Zealand. Anterior uveitis 
samples were recruited from rheumatology clinics and ophthalmology clinics in Australia, 
the United Kingdom, the United States and New Zealand. 
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The first chapter reviews of the clinical features, epidemiology, immunology and genetics 
of AS and acute anterior uveitis. It identifies the major associations reported to date and in 
AS the different ethnic genetic associations described. It discusses how this has 
contributed to our understanding of disease mechanisms in AS and acute anterior uveitis. 
 
The second chapter describes the detailed analysis of the chromosome 5q15 locus in the 
AS Immunochip based experiment. This analysis utilized 9,074 cases and 13,607 controls 
of European descent and 1,550 cases and 1,567 controls of east Asian descent. The locus 
was examined for association using logistic regression, linear mixed models and Bayesian 
analysis methods. Association in the genes ERAP2/LNPEP that is seen in HLA-B*27 
negative subjects, or on conditioning on the major risk alleles in ERAP1, is described.  
 
The third chapter details the Immunochip analysis of acute anterior uveitis in 289 cases 
with acute anterior uveitis alone, 1,422 cases with AS and acute anterior uveitis, and 2,339 
cases with AS and without acute anterior uveitis.  Novel associations are identified using 
genotyped and imputed data. 
 
The fourth chapter describes the Exomechip analysis of AS in 4,599 cases and 23,554 
healthy controls. This study found novel associations that were genome wide signifciant in 
USP8, C1orf106, and CDKAL1, Novel suggestive associations were found in FAM118A, 
C7orf72, FAM114A1 and PNPLA1. The associations with C1orf106, CDKAL1 and C7orf72 
are associated with inflammatory bowel disease. There was also a secondary signal in the 
TLR10 gene after conditioning on the association evident in FAM114A1.  
 
The fifth chapter describes a study using Exomechip data to investigate the genetic 
associations of acute anterior uveitis. This experiment used 2 designs, firstly AS patients 
with acute anterior uveitis were compared to AS patients without acute anterior uveitis. 
Secondly AS patients with acute anterior uveitis were compared to healthy controls and 
AS patients without acute anterior uveitis were compared to healthy controls. A 
heterogeneity test was then applied to determine if the effect size of associations were 
different between these two groups. This study confirmed previous findings that HLA-B*27 
is an risk factor for acute anterior uveitis in addition to AS disease status. SNPs in ERAP1 
(rs30187) and ERAP2 (rs2549794) were found to have significantly different effect sizes 
between the two disease groups tested against healthy controls. 
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Microarray genotyping was used to perform the experiments because it is cheap, and can 
be used in a high throughput way to accurately assay many variants across the genome. 
Other alternates like sequencing are too expensive and single variant testing is not 
appropriate when many thousands of variants need to be assayed. 
 
The thesis therefore details extensive investigation of the genetic associations of AS and 
acute anterior uveitis. The associations at genome wide level are likely to be robust true 
findings, however the associations reported at a suggestive level of significance require 
replication. In the conclusions chapter the implications of the associations, limitations of 
the research and future directions are explored. In summary this thesis reports new 
genetic associations at both genome wide and a suggestive level of significance in AS and 
acute anterior uveitis. 
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1
1 Introduction 
 
1.1 Ankylosing spondylitis 
Ankylosing Spondylitis (AS) is an inflammatory arthritis that primarily affects the spine and 
the sacroiliac joints in the pelvis. It is one of a group of diseases called spondyloarthritidies 
(SpA) that also includes the clinically recognisable entities of reactive arthritis, arthritis of 
inflammatory bowel disease, psoriatic arthritis and undifferentiated spondyloarthritis. Hip 
involvement, peripheral arthritis, and enthesitis (inflammation where tendons insert into 
bone) also occur commonly in AS. Over time, ankylosis occurs in AS, where bridges of 
bone form between the vertebrae in the spine and in the pelvis. These bony bridges cause 
the spine to become a solid, inflexible structure with a significant loss of movement (see 
Figure 1.1). This results in significant limitation in the social and occupational functioning of 
patients. 
 
 
 
Figure 1.1 Ankylosis in the lumbar spine of a patient with AS 
 
AS has a variable worldwide prevalence of between 0.1 - 1.4% and this is strongly 
correlated to the frequency of the class I major histocompatibility complex (MHC) allele 
human leucocyte antigen (HLA)-B*27 [1]. In European populations, the prevalence of AS is 
approximately 0.9% [2]. About 80 - 90% of people with AS have the HLA-B*27 gene [3, 4]. 
However, only 1 - 5% of people with HLA-B*27 will develop AS [5, 6].  
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Men are more commonly affected (approximate ratio 2 - 3:1) by AS and it generally has an 
onset in early adulthood [7]. In the majority of cases symptoms start before the age of 40. 
 
1.2 Treatment of AS 
AS has traditionally been treated with non-steroidal anti-inflammatory drugs (NSAIDs) and 
physiotherapy. Tumour necrosis factor inhibitors (TNFi) are now also a mainstay of 
therapy [8]. These are monoclonal antibodies or fusion proteins that inactivate TNF. TNFi 
improve symptoms and function, but there is currently no compelling evidence they 
prevent progression of ankylosis [9]. TNFi agents also need to be continued indefinitely as 
patients flare on withdrawal [10]. There remains a significant need for treatments that 
prevent this irreversible change in the spine and sacroiliac joints, and the consequent 
impact on quality of life and function. 
 
1.3 AS Associated Conditions 
There are three main conditions that co-occur with AS and share genetic risk factors. 
These are psoriasis, inflammatory bowel disease (IBD) and anterior uveitis (AU). Psoriasis 
is a chronic inflammatory skin condition that has a population prevalence of approximately 
2 - 3%. About 10 - 15% of AS patients have psoriasis. There are a number of shared 
associations between AS and psoriasis including RUNX3, IL23R, the 2p15 chromosome 
region, ERAP1, ERAP2-LNPEP, ZMZI1, and UBE2L3 [11]. 
 
There is a strong association between AS and inflammation in the large and small bowel 
[12]. About 10% of AS patients have overt IBD, 30% have macroscopic bowel 
inflammation on colonoscopy and about 60% have microscopic bowel inflammation on 
histology [13, 14]. In addition, relatives of patients with AS have increased bowel 
permeability [15]. Relatives of IBD patients also have an increased risk of AS [16]. There 
are a number of common risk loci shared between AS and IBD including IL23R, FCGR2A, 
GPR25-KIF21B, GPR35, GPR65, ERAP2-LNPEP, IL12B, KIF21B, IL1R2-IL1R1, ZMIZ1, 
NKX2-3, IL27-SULT1A1, TYK2, ICOSLG, UBE2L3, PTGER4, chromosome regions 2p15 
and 21q22 and CARD9 [17, 18]. The strong correlation between genetic association 
suggests there may be a causal link between them, as discussed below. 
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AU, which is inflammation of the iris and ciliary body, also occurs in 30 - 40% of AS 
patients [19]. HLA-B*27 is also a risk factor for AU (see later). Psoriasis, IBD and AU are 
all effectively treated with TNFi [20-22]. 
 
1.4 Hypotheses of AS Aetiology 
Heredity has long been known to play an important role in AS [23]. In 1973 it was 
discovered that >90% of AS patients carry the HLA-B*27 allele [3, 4, 24]. Modelling in 
families has shown that a significant proportion (estimated at 97%) of a person’s risk of AS 
is genetically determined [25]. HLA-B*27 is the most significant contribution to that risk. 
This has meant HLA-B*27 has featured strongly in the theories of AS aetiology. An outline 
of the major theories follows. 
 
1.4.1 AS Aetiology Theory 1: The Arthritogenic Peptide Hypothesis, Molecular 
Mimicry & Intestinal Inflammation/Infection 
The strong association of HLA-B*27, a class I MHC molecule, with AS has meant that 
pathological MHC class I antigen presentation has been implicated in the cause of AS. 
The arthritogenic peptide hypothesis proposes that an arthritogenic peptide is presented 
on HLA-B27 and due to its unique properties or the interaction between the presented 
peptide and HLA-B27, a pathogenic immune response is created.  
 
Evidence to support this hypothesis includes the observation that some subtypes of HLA-
B*27 are not associated with AS. These subtypes have amino acid changes in their 
binding groove which means the peptide repertoire presented differs between AS and non-
AS associated subtypes [26]. 
 
In addition, there is evidence that HLA-B27 is itself immunogenic as a number of studies 
have demonstrated that different forms of HLA-B27 are recognised by a number of 
components of the immune system [27]. Cluster of differentiation (CD) 4+ T cells which 
recognise HLA-B27 have been isolated from HLA-B27 positive AS patients, but the study 
that reported this did not identify the antigen presented by HLA-B27 [28]. However, there is 
evidence that components of HLA-B27 (specifically its cytoplasmic tail) can be self-
presented by HLA-B27 [29]. HLA-B27 subtypes that were not associated with AS only 
bound the HLA-B27 cytoplasmic tail peptide weakly or not at all compared to AS 
associated HLA-B27 subtypes [29]. Other components of the immune system have also 
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demonstrated an ability to recognise HLA-B27, including killer cell immunoglobulin 
receptors and immunoglobulin-like transcripts [27]. 
 
This HLA-B27 cytoplasmic tail derived antigen also shares significant homology to a 
Chlamydia derived antigen [29]. This similarity between HLA-B27 and Chlamydia means 
molecular mimicry may provide an explanation for the association.  Molecular mimicry is 
the purported process by which foreign and self-antigens that are similar are ‘confused’ by 
the immune system, and trigger T cell expansion against the self-antigen in error. This 
mechanism is known to occur in other diseases, for example rheumatic fever with a 
Streptococcal protein [30]. Further suggestive evidence comes from the observation that 
reactive arthritis, a related SpA, is triggered by infections with microbes like Chlamydia or 
Campylobacter [31].  
 
1.4.1.1 The Germ Free Environment & Disease Development 
Further evidence to support microorganism involvement comes from the observation that 
in the HLA-B*27 transgenic rat, an animal model of SpA and colitis, the disease phenotype 
does not develop in a germ free environment [32]. A germ free environment is one in 
which no micro-organisms are present, so animals have no resident flora in or on them. 
Interestingly, multiple animal models of IBD and/or SpA have reduced phenotypes in the 
germ free environment [32, 33]. When only certain bacterial strains are introduced into the 
animal’s environment, one is able to examine their ability to induce disease. Sinkorova and 
colleagues performed an elegant experiment in the ANKENT arthritis model where they 
introduced specific bacteria and determined that arthritis was precipitated by commensal 
anaerobic gut bacteria like Bacteroides and Enterococcus, but not by Lactobacillus [34]. 
 
1.4.1.2 Intestinal Inflammation/Infection 
A theory that bowel inflammation contributes to the aetiology of AS has been proposed 
due to the high prevalence of bowel inflammation in those with AS [14, 35]. This theory is 
supported by the findings in animal models in germ free environments. The same 
observation that germ free environments do not trigger disease is true of some IBD 
models, suggesting that the intestinal infection, or an aberrant immune response to this, 
precipitates bowel inflammation and this may in turn lead to AS. This may be the source of 
the ‘arthritogenic’ peptide. Alternatively AS may be a disease caused by a deficiency in 
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controlling or maintaining mucosal immunological homeostasis, resulting in mucosal 
surface immune dysfunction or immunodeficiency, discussed below [36]. However one 
limitation in drawing conclusions from animals in a germ free environment is that it is likely 
immune system development depends upon commensal microbes and therefore these 
experiments have to be interpreted in this light [37, 38].  
 
Recent work has found an increased proportion of γσ T cells in AS expressing IL23R and 
secreting IL-17 [39]. γσ T cells have pattern recognition receptors like toll-like receptors 
and dectin-1, which recognise micro-organisms directly. These cells are enriched in the 
bowel and may be involved in triggering the immune response that leads eventually to 
disease because they could provide a source of IL-17 in response to micro-organisms. In 
addition another subset of cells that may be important in SpA is the invariant natural killer 
T cell (iNKT) cell. These cells recognise glycolipids antigens presented on the non-
classical MHC molecule CD1a. iNKT cells can detect the presence of microbes because of 
the presentation of microbial glycolipid ligands. In the TNF delta ARE murine model of 
SpA, where there is constitutive TNF production, CD1a is up-regulated [40]. In SpA 
patients CD1a is also up-regulated to a similar degree suggesting this cell type may be 
relevant to human SpA [40]. 
 
However, there are some conflicting findings from animal models, as removing CD8+ T 
lymphocytes does not change the phenotype of the HLA-B*27 transgenic rat arthritis, as 
this model has been shown to be dependent on CD4+ T-lymphocytes [41]. CD8+ T 
lymphocytes are the primary immune cells that interact with HLA class I presented on the 
cell surface. This suggests that this cell type isn’t important in this animal model of SpA. 
The other issue with the HLA-B*27 transgenic rat model is the greatly expanded, non-
physiological, number of copies of HLA-B*27 required to induce disease [42]. In addition, 
the negative control animal used expresses the HLA-B*04 allele, an allele in fact 
demonstrated to be protective of disease, hampering reliable comparison (Cortes et al. in 
press) 
 
The arthritogenic peptide hypothesis is topical, especially considering the recent 
observation that the SKG mouse model of peripheral arthritis can develop features of 
spondyloarthritis, including uveitis and dactylitis (inflammation of an entire finger or toe), 
with intra-peritoneal injection of curdlan [43]. Curdlan is known to initiate an innate immune 
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response through dectin-1 signalling [44].  Microorganisms can also stimulate an innate 
immune response with their cell wall components, therefore this may be the source of the 
arthritogenic peptide which then causes an innate immune response and consequent AS 
development. 
 
Debate about this group of theories and experimental observations has been animated 
and long standing. Proponents draw attention to the significant body of evidence 
suggesting an association, but there still remains no direct evidence to support the 
arthritogenic peptide hypothesis. 
 
1.4.2 AS Aetiology Theory 2: HLA-B27 Folding and the Unfolded Protein Response 
(UPR)  
The unfolded protein response (UPR) hypothesis is another theory of AS aetiology 
involving HLA-B27. HLA-B27 heavy chains have been observed to fold slowly and remain 
in the ER for extended periods of time compared to other class MHC I molecules [45]. This 
HLA-B27 misfolding can precipitate a cellular response called the UPR. This response is a 
homeostatic mechanism initiated by the cell in an attempt to return itself to a normal state 
[46].  
 
The HLA-B*27 transgenic rat is an animal model of SpA and colitis. Treatment of bone 
marrow derived macrophages from these animals with interferon up-regulates HLA-B27 
expression, which in turn induces HLA-B27 misfolding and the UPR. Treatment with 
lipopolysaccharide (and no interferon) also induces the UPR. The HLA-B27 misfolding 
induces IL-23 production in the lamina propria of the bowel (both IL23p19 and IL12/23p40, 
but not IL12p35). This is also accompanied by an increase in IL-17 and interferon γ [47]. 
IL-17 and IL-23 are prominent in animal models and human studies of SpA [39, 43, 48-50]. 
 
In addition, Ruuska and colleagues have demonstrated that tyrosine 701 on HLA-B27 is 
highly phosphorylated in a HLA-B27 expressing monocyte cell line. This phosphorylated 
HLA-B27 molecule can induce interferon regulated genes and thus demonstrates a 
potential mechanism by which HLA-B27 could induce its own misfolding [51]. 
 
These data are consistent with the observation of increased IL-17 production by human 
AS peripheral blood mononuclear cells post stimulation and the increased IL-23 seen in 
 
 
7
the terminal ileum of AS patients [39, 48, 49]. The observation that CD8+ T cells are not 
required for animal models of SpA also fits with this theory of AS aetiology [52]. Since IL-
23 can induce Th17 responses, these data could support a model where the bowel micro-
organism induced interferon γ could induce the UPR and subsequently promote IL-23 
production and a pathogenic Th17 response which causes disease [47]. 
 
Follow-up of the HLA-B*27 transgenic rat UPR findings in macrophages from AS patients 
failed to demonstrate a statistically significant up-regulation of the UPR in response to 
interferon and lipopolysaccharide (LPS) (10 patients, 10 controls, ERdj4 2.2 fold increase, 
P = 0.31), but it did demonstrate a 29-fold increase in IL-23 production (ERdj4 is an ER 
chaperone that assists with destroying misfolded proteins) [53, 54]. This study is likely to 
be underpowered to answer the question of whether the animal model findings translate to 
human disease. 
 
The criticism of this animal data is that to demonstrate UPR in B27 transgenic rats requires 
a greatly increased number of HLA-B27 copies. This is not reflective of human disease. 
Recent work has demonstrated that UPR target genes are not upregulated in blood or 
synovium of AS patients [55]. Unpublished work from Tony Kenna performed on peripheral 
blood and terminal ilieal samples also supports the view that the UPR is not a prominent 
finding (unpublished observations, Tony Kenna). The differential HLA-B*27 subtype 
associations with disease and the interaction between HLA-B*27 and ERAP1 (discussed 
below) are not adequately explained by this aetiological theory either. 
 
1.4.3 AS Aetiology Theory 3: HLA-B27 Homodimer Formation 
HLA-B27 can also form disulphide bonds with other proteins and homodimerise, and these 
homodimers have been observed on the cell surface [56, 57]. Notably other MHC class I 
alleles have been shown to form homodimers on the cell surface, namely HLA-B07 and 
HLA-G, but not to the same degree as HLA-B27 [57, 58]. 
 
These homodimers can bind killer-cell immunoglobulin like receptors (KIR). Antigen 
presenting cells (APCs) expressing HLA-B27 homodimers stimulate the proliferation of 
Th17 cells that carry a KIR that binds HLA-B27 homodimers [59]. These APCs bearing 
HLA-B27 homodimers also stimulate IL-17 production in these Th17 cells, and these Th17 
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cells account for most of the IL23R expression peripherally. Their production of IL-17 by 
these Th17 cells was also increased by IL-23 [59]. These findings provide a link between 
HLA-B27 and the findings of elevated IL-17 in SpA.  
 
1.4.4 AS Aetiology Theory 4: Aminopeptidase induced immunodeficiency 
This is a more contemporary theory borne out of the associations of ERAP1 and ERAP2 
with AS and the demonstration of the functional effects of variants associated with AS. 
ERAP1 and ERAP2 trim antigens in the endoplasmic reticulum after they are produced by 
the proteasome so they are the correct size for loading onto MHC class I molecules. 
 
ERAP1 is only associated with AS when HLA-B*27 is present. Changes in ERAP1 function 
influenced by the associated variants rs30187 and rs10050860 influence the trimming rate 
of the enzyme [60]. Elegant functional work on the peptidomes of cell lines expressing 
different ERAP1 variants has shown that these variants influence the molecular weight, 
length and amount of peptide presented [61]. There was also observed differences in the 
thermostability of the HLA-B2704 molecule dependent on the ERAP1 variant expressed in 
the cell. The cell line with the variants associated with protection (and reduced trimming) 
has less thermostable HLA-B2704. These observations need further development but 
these data certainly suggests that the repertoire of antigens being presented is 
significantly different between the ERAP1 variants.  
 
This observation is further supported by the finding that ERAP2 has sequence variation 
consistent with balanced selection in the population [62]. In addition the balanced selection 
signature was observed in different ethnic groups suggesting that the agent influencing 
selection was agnostic to a specific population. There is also evidence of this balanced 
selection on ERAP1. These findings suggest that ERAP1 and ERAP2 are important in 
dealing with a ubiquitous environmental agent, such as a widespread micro-organism or 
other such agent. This would be consistent with a ubiquitous environmental agent 
precipitating AS.  
 
Further supporting this is the finding that mice that have had the ERAP1 homologue 
ERAAP knocked out have increased susceptibility to Toxoplasma, an intracellular 
pathogen demonstrating the important role for ERAP1 in anti-microbial defence [63]. 
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Therefore the change in peptide repertoire that ERAP1 and 2 variants impose could be the 
driving force behind the dysfunction in the immune system that leads to AS development. 
This recent theory certainly requires additional experimental validation. How the changes 
in peptide presentation may influence the immune control of gut microflora is one theory 
that deserves attention especially in view of the strong association between AS and bowel 
inflammation. 
 
Conclusion 
The cause of AS is currently unknown and there is experimental evidence to support and 
refute all the theories proposed. The further description of genetic associations along with 
concomitant functional work may in the future further clarify the likely aetiology of AS. 
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1.5 Anterior Uveitis 
Anterior uveitis is an inflammatory condition of a specific part of the eye. The anatomy, 
physiology and features of this condition are reviewed to give context to the following 
experimental material.  
1.5.1 Anatomy and physiology 
The uvea is the middle component of the three layers that make up the eye (see Figure 
1.2). The outer layer is the sclera and cornea and the inner layer is the retina. The anterior 
uvea is considered to be the iris and ciliary body. The lens sits directly behind the iris. The 
anterior chamber is the space anterior to the iris that is filled with aqueous fluid (called 
‘aqueous humour’). The aqueous humour is made in the ciliary processes and enters the 
anterior chamber through the pupil. It then drains through a mesh of tissue called the 
trabecular meshwork and drains into the Canal of Schlemm. The posterior component of 
the uvea is the choroid and sits between the sclera externally and the retina internally. The 
jelly-like vitreous humour fills the space behind the lens. 
 
Figure 1.2 The Anatomy of the Human Eye  
(Source: Commons, public domain [64]) 
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1.5.2 Causes and nomenclature of anterior uveitis 
AU can be caused by (1) infectious agents like Toxoplasmosis and cytomegalovirus, (2) 
systemic immune mediated diseases that manifest inflammatory disease either through 
autoimmunity or auto-inflammation, and (3) medications, for example bisphosphonates. 
This thesis addresses the immune mediated causes of AU and therefore the other causes 
of AU are beyond the scope of this work. For the purposes of this work AU will refer to 
immune-mediated AU. Even within the realm of anterior uveitis there are different types 
with distinct clinical features and different disease associations. Acute anterior uveitis 
associated with AS is the focus of this work. 
 
1.5.3 Epidemiology and impact of anterior uveitis 
Uveitis, as a whole, is responsible for 10% of the legal blindness in America, which 
equates to approximately 30,000 Americans per year. Anatomically, AU accounts for 
approximately 72% of uveitis with intermediate uveitis 6% and posterior/panuveitis 21% 
[65]. In a large recent series infectious causes made up only 22%, so immune mediated 
AU is the commonest manifestation of uveitis in America [65]. 
 
A large recent study based on Hawaiian Kaiser Permanente data found an overall 
incidence rate of 25 cases per 100,000 person years and a prevalence rate of 58 per 
100,000 persons [65]. There was no difference between genders in incidence rates but the 
prevalence rate was higher in females (65 - 70/100,00 and 46 – 50/100,000 in females and 
males respectively). Both prevalence and incidence increased with age. Prevalence 
ranges between 14 – 36/100,000 in 15 – 24 year olds and 60 – 164/100,000 in those 
greater or equal to 65 years old. Pacific islanders had lower prevalence rates than non-
Pacific Islanders, likely reflecting the lower rate of HLA-B*27. Two previous studies both 
also based on US health maintenance organisation records have reported prevalence and 
incidence. A study from Oregon and Washington reported very similar rates with an 
incidence rate of 26 per 100,000 person years and a prevalence of 69 cases per 100,000 
persons [66]. However the other study from Northern California reported an incidence rate 
of 52 per 100,000 person years and a prevalence of 115 per 100,000 persons [67]. All 
studies have reported prevalence rates approximately double that of incidence rates. The 
differences in absolute rates between the studies may relate to ethnicity differences 
between the cohorts or systematic differences in the characteristics of the people enrolled 
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in each health maintenance organisation. Women have higher prevalence than men 
suggesting they have higher recurrence rates or more chronic uveitis. 
 
1.5.4 Clinical features of anterior uveitis 
Anterior uveitis caused by an immune mediated aetiology presents with pain and can also 
feature redness around the iris in the area known as the limbus. It is almost always 
unilateral. There is also often a constricted pupil. Proteinaceous material (known as ‘flare’) 
and inflammatory cells can be seen in the anterior chamber and if they settle in the inferior 
aspect of the anterior chamber this is termed hypopyon. Complications of AU include band 
keratopathy (deposition of calcium in the epithelium of the cornea), posterior synechiae 
(adhesion of the iris to the lens behind), cataract and glaucoma (therapeutic steroid use 
also increases this risk). 
 
1.5.5 Genetics of anterior uveitis 
The strong association of HLA-B*27 and acute anterior uveitis was reported by Brewerton 
in 1973 [68]. Numerous small studies have described other genetic associations, but many 
have not been validated. These include genes involved in regulating the immune response 
such as TNF [69, 70], HLA-A*02 [71, 72], HLA-DRB1*08:03 [73], HLA-B*58 [74], HLA-
DRB1*0103 [74], MICA [75], IL10 [69], the complement components CFB, CFH and C2 
[76, 77], the Killer Immunoglobulin Receptor (KIR) region [78], CYP27B1 [79]. The 9p 
chromosome region has also been associated [80]. 
 
Tumour necrosis factor (TNF) is a pro-inflammatory cytokine produced from the TNF gene 
that is important in the pathogenesis of acute anterior uveitis. TNF is secreted by a range 
of immune cells including macrophages, monocytes, neutrophils and T-cells. TNF is of 
importance in a wide range of immune conditions including AS, rheumatoid arthritis, 
psoriasis and IBD. Agents that inhibit TNF have been a major advance in treating these 
conditions. Although not licensed for use, anti-TNF agents are very effective for treating 
AU [20]. The TNF gene has also been associated with Crohn’s disease and neonatal lupus 
[81, 82]. Kuo and colleagues studied 98 single episode and recurrent AU patients and 354 
controls. Using sequence primers they identified a significant difference in the frequency of 
the TNF-857T allele (rs1799724) in patients compared to controls (15.3% vs. 7.3%, P = 
6.0  10-4). Uncorrected subgroup analysis also suggested the TNF-238 (rs361525) and 
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TNF-308 (rs1800629) alleles in the TNF gene are associated with AU in a study by Atan 
and colleagues but this association needs confirmation in an independent cohort [69]. 
None of these studies controlled for the presence of HLA-B*27 so there is potential for the 
findings to be due to LD with this important known risk allele. Animal studies and human 
studies also support the involvement of TNF [20, 83-85]. 
 
Atan described associations between IL10 SNPs (rs6703630, corrected P (Pc) = 0.01; 
rs2222202, Pc = 0.012; and rs3024490, Pc = 0.024) and AU in 192 AU patients and 92 
controls [69]. IL-10 has a number of actions to control or limit inflammation, for example 
down regulating cytokines and signaling through pro-inflammatory pathways. 
 
HLA-A*02 has been associated with AU in two studies. Khan and colleagues examined AS 
patients, and of the 103 HLA-B*27 positive patients who had both HLA-A and HLA-B 
determined 24 of 68 HLA-A*02 positive patients had AU compared to 5 of 35 HLA-A*02 
negative patients (P < 0.025) [72]. Although independent association of HLA-A*02 couldn’t 
be established the result suggests HLA-A*02 is a risk factor for AU in those who are HLA-
B*27 positive. In the second study Keino examined 12 Japanese psoriasis patients who 
developed AU and found all 12 had HLA-A*02 and 1 had HLA-B*27, this frequency was 
significantly higher than an ethnically matched population control (P = 8.7 10-5 and P = 
2.6  10-3 respectively). Importantly thought it cannot be discounted that the causal 
association was actually with psoriasis [71]. In addition HLA-A*02 has been associated 
with AS independent of HLA-B*27 in the recent Immunochip experiment [86]. 
 
Monowarul Islam and colleagues investigated the association of HLA-DR8 in AS patients 
with AU. They took 42 Japanese AS patients and found 13 of 20 with AU had HLA-
DRB1*0803 and only 1 of 22 without AU had DRB1*0803 (P < 0.001) [73]. 
 
In 976 ulcerative colitis patients and 483 Crohn’s disease patients Orchard and colleagues 
described associations between AU and HLA-B*27 (P = 1.0  10-4, RR = 4.5), HLA-B*58 
(P = 0.01, RR = 13.1), and HLA-DRB*1:0103 (P = 0.048, RR = 3.2) [74].  
 
Goto and colleagues described an association between AU and MICA in Japanese HLA-
B*27 positive AU patients (P = 0.042) [75]. The association was still significant when HLA-
B*27 controls were used in an attempt to control for LD between HLA-B*27 and MICA. The 
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MICA protein is stress induced and is expressed on the cell surface where it is recognised 
by γσ T cells that have been noted to be increased in AS [39]. 
 
In two separate studies Yang and colleagues reported associations between AU and 
complement components [76, 77]. The complement system is a protein based constituent 
of the innate immune system, the culmination of the system is formation of the membrane 
attack complex that kills cells. The first study analysed 98 AU patients and 308 healthy 
controls and assessed three SNPs in the CFH gene. They found association between AU 
and rs800292 (P = 0.003). In the second study they analysed 98 Chinese AU patients and 
291 unrelated controls and assessed 5 SNPs in the CFB and C2 genes. They found 
association with rs1048709 in the CFB gene (P = 2.67  10-4).  
 
KIRs are present on the surface of natural killer (NK) cells and interact with MHC class I 
molecules on other cells to regulate the killer function of these NK cells. Levinson and 
colleagues used 143 AU patients, 72 had no features of SpA and 71 had features of axial 
SpA. There was a significant difference in the activating KIR 2DS5 in AU patients with SpA 
compared to controls. The frequency was 31.9% in controls, 23.8% in all AU subjects and 
18.3% in those AU patients with SpA features (P = 0.05, OR, 0.48; 95% CI, 0.25–0.90) 
[78].  
 
A cytochrome protein known to metabolise vitamin D (CYP27B1) was studied by 
Steinwender and colleagues for association with AU [79]. They recruited 159 HLA-B*27 
positive AU patients and 238 controls, 138 HLA-B*27 negative and 100 HLA-B*27 positive. 
They determined the frequency of rs703842 between cases and controls and found a 
significant difference between AU cases and HLA-B*27 positive controls (P = 0.03) but not 
between AU cases and HLA-B*27 negative controls (P = 0.97) suggesting this may be a 
chance finding. 
 
A linkage study was completed by Martin and colleagues on 76 sibling pairs found strong 
association at a marker called D9S157 on chromosome 9p21–9p24 (LOD = 3.72) [80]. 
This region was AU specific and was not associated with AS.  
 
Rothova and colleagues have described the disease associations of HLA-B27 positive 
acute anterior uveitis. They found male gender, early onset of disease, unilateral disease 
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and a lack of progression to chronic uveitis [87]. The same group went on to describe the 
systemic disease associations of acute anterior uveitis in large cohorts [88]. 
1.5.6 Immunology of anterior uveitis 
While anterior uveitis can be a heterogeneous disease, associated with different systemic 
conditions there are few models that mimic the acute anterior uveitis of AS perfectly. There 
are a number of different models that have contributed to theories about the 
aetiopathogenesis of anterior uveitis and they are discussed below. 
 
Immunologically, uveitis is thought to be a T-cell mediated disease [89]. In the animal 
model ‘experimental autoimmune uveitis’ (EAU) both Th1 and Th17 cell involvement is 
observed [90-92]. As suggested by the genetics the pro-inflammatory cytokine TNF plays 
a role as suppressing TNF in the EAU model limits migration of macrophages and CD4+ T 
cells into the eye [93]. IL-23, IL-17 and interferon are all up regulated in Behçet’s patients 
with active AU [94]. STAT3 involvement has also been implicated in promoting IL-17 
involvement in EAU highlighting the TNF-IL-6 pathway [95, 96]. EAU is suppressed by 
regulatory T cell involvement [97, 98]. Genetics also influences this model with HLA-B*27 
carriage potentially influencing severity of disease [99]. However, this model is primarily a 
model of posterior uveitis, with AU being a spill-over phenomenon [100, 101]. Supporting 
the involvement of Th17 lymphocytes in EAU, IL-6 and IL-23p19 deficient mice have 
ameliorated disease [102]. Blockage of T cell co-stimulation abrogates EAAU in animal 
models [103] and has been reported to be effective in human AU associated with juvenile 
idiopathic arthritis, however this type of uveitis differs from acute anterior uveitis [104].  
Therefore the immunological players are similar to SpA, and this is also indicated by the 
efficacy of TNF inhibitor treatment in AU [20]. 
 
Recently a new animal model of SpA has been described, based on the SKG mouse 
model first described by Sakaguchi and colleagues [105]. The model recapitulates many 
aspects of human SpA including axial skeleton and peripheral joint inflammation, bowel 
inflammation, skin disease and AU [43]. The model is initiated with curdlan injection into 
the abdomen. Curdlan stimulates the innate immune system through signalling via dectin-1 
receptors. Dectin-1 is present on many antigen presenting cells and activation induces 
production of IL-1β, IL-12p35, IL-12p40, and IL-23p19 [106, 107]. These proinflammatory 
cytokines have been identified to be important in SpA, and in addition a number of their 
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genes are associated with AS, including IL12B, IL23R and STAT3 [18, 50]. The AU 
described in this model occurs in 25 - 40% of mice and is unilateral, consistent with the 
human disease. It is characterised by inflammatory infiltrate and fibrotic deposits in the 
anterior chamber and the ciliary body. There was also some vitritis noted. Further 
characterisation of this model is awaited including cellular characterisation and the 
chronicity and spontaneous remission rate, but this model holds some promise of an 
animal model that reflects human AU very well. 
 
1.6 Complex Disease Genetics  
Genetics forms an integral part of the presented work and therefore I have outlined the 
salient concepts in the following section. The term ‘complex disease’, in a genetic context, 
refers to a disease with many genes contributing to susceptibility. This is distinct from 
Mendelian disease, where solitary genes are involved and inheritance patterns such as 
autosomal recessive and autosomal dominant are recognised. 
 
1.6.1 Genetic Variation and Mutation 
There are a number of changes that can occur in deoxyribonucleic acid (DNA). The most 
common currently studied change in DNA is the single nucleotide polymorphism (SNP). 
SNPs are common, with the average human carrying 3 million SNPs compared to a 
‘reference’ genome.  
 
Some genetic variations cause significant change and some cause no change to the 
resultant protein. Change in DNA through mutation and then natural selection on the basis 
of reproductive fitness is thought to be the basis for evolution [108]. The impact of these 
amino acid changes on the protein ranges from neutral, to minor change in function, to a 
profound change in function or complete absence of protein. 
 
At one extreme, some changes in the sequence of DNA have no impact on the protein 
sequence, either due to the genetic change occurring in a non-coding site or due to the 
fact that there are multiple triplet codes, often very similar, for the same amino acid. For 
example, a mutation of CCA to CCG will usually have no effect on the resultant protein as 
both of these triplet codes encode a proline residue. Changes in DNA that do not change 
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the protein sequence are called synonymous changes and DNA changes that do change 
the protein sequence are called non-synonymous changes. 
 
Variable changes can be made by substituting one amino acid for another. The functional 
effect of these changes depends on the structure and charge of the amino acids involved. 
Different amino acids have different chemical characteristics including charge, size and 
disassociation constants. If an amino acid is replaced by another with very similar 
chemical characteristics, then there may be no change in the function of the protein. If an 
amino acid is replaced by another with differing chemical characteristics, there can be 
significant change to the function of the protein. The other determinant of whether a 
change will affect the function of the protein is where in the protein the change occurs. A 
very small change in a critical region may render the resultant protein non-functional. A 
large change in a non-critical region may have no effect at all in the resultant function. 
Changes introducing premature stop codons into the sequence of DNA are most likely to 
be pathogenic. A shortened form of the protein is then produced. These proteins often 
cannot function at all, or result in nonsense mediated RNA decay, and absence of 
translated product. 
 
In different tissues different genes are active and being transcribed. Therefore changes in 
the DNA sequence may have no effect in one tissue but a significant effect in another 
tissue where it is being transcribed continuously. Equally, different physiological or 
pathological conditions will mean that different genes are transcribed. So the impact of an 
individual DNA sequence change may become more or less pronounced depending on the 
specific transcriptional changes associations with a tissue or state. 
 
Many associations from genome wide association studies (GWAS) have been reported 
with synonymous mutations and non-protein coding regions, and these may contribute to 
disease through splice variation, transcription regulation or other, as yet unknown, 
functions [109]. Currently, these functional changes are not as well understood as non-
synonymous mutations in the coding regions of genes. Large projects to characterise the 
genome wide characteristics and consequences of these changes and make them 
available to the wider scientific community will help determine their role better. The 
ENCODE project is an example of this led by the National Institutes of Health in the United 
States and contributed to by laboratories all over the world [110]. 
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1.6.2 The Case Control Microarray Genetic Study 
1.6.2.1 Study design and significance thresholds 
This thesis describes 4 studies that utilise the case control design. This is the current 
predominant study design in complex disease genetics and offers relatively cheap 
coverage of genetic variants of interest to the investigator that can be implemented in 
thousands of individuals. Historically linkage studies in families were used but these had 
limitations including only pinpointing an association to a broad region and also the need to 
have multiple affected families and to study multiple members of one family which can 
present ethical issues like non-biological parentage.  
 
Large case control studies using genetically unrelated individuals have become the design 
of choice for gene discovery. The advantages they offer include that of significant power if 
enough individuals can be recruited. Depending on the density of the variants selected to 
go onto the microarray chip very fine scale detail of variant association can be assessed.  
 
The disadvantages include the need to recruit large numbers of people to gain sufficient 
power to detect associations with variants of small effect or variants that are not common 
in the population. To detect association with variants of small effect or low frequency much 
larger sample sizes are required. There are alternate approaches to detecting these 
variants including extreme phenotyping, for example recruiting people with very low bone 
density and comparing them to people with very high bone density. For detection of rare 
variants a number of methods have been developed which focus on assessing variants as 
a group instead of individually, these tests, for example burden tests increase the power to 
detect rare variants in a locus. In addition because many thousands or millions of 
individual tests will be performed there is a significant multiple testing burden that has to 
be bore. The most common current approach is the Bonferroni correction, whereby the 
required significance is divided by the number of tests to be performed. However in 
GWAS, the accepted significance level of P = 5 x 10-8, derived from 1 million tests divided 
by 0.05. There is no accepted definition for suggestive associations. The Bonferroni 
correction is arguably conservative because it assumes each test is independent of the 
others but since many SNPs share LD this is in fact not the case. Using such a high 
threshold means there is a significant risk of type 2 error. Jian Yang and colleagues have 
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demonstrated that regardless of the level of association found using all SNPs in an 
analysis results in a larger estimate of the variance explained [111, 112]. Finding a 
consistent way to separate out the false negatives from the true negatives would boost the 
yield of genetic studies that employ huge numbers of statistical tests like GWAS.  
 
Other disadvantages can include population stratification, whereby systematic differences 
in allele frequencies between or within ethnic populations can cause false positive results. 
The problem of population stratification has largely been dealt with for common variants 
using principle component analysis or mixed models. The issue of population stratification 
for rare variants is one that is not well understood and there are no approaches that have 
gained widespread acceptance. From a technical perspective the probes on the 
microarray can theoretically map to multiple sites in the genome thereby giving a cluster 
plot that looks of high quality but in fact giving incorrect results.  
 
Microarray genotyping in the form of a genome wide association study takes advantage of 
the significant linkage dysequilibirum in the genome to test markers that represent many 
others around them. However other variant selections can be made, for example the 
Immunochip looking at immunological variants and the Exomechip looking at just the 
coding regions of the genome. There will always be the possibility when you don’t assess 
the entire genomic sequence that the association you recognise is but a proxy for the 
causal variant. This requires follow-up genotyping, in silico work or functional work to 
ascertain the true causal variant. 
 
Identifying the correct disease cases is as critical in a genetic study as it is in any study. To 
achieve the best design possible using a robust and specific classification criteria is 
required. This should be reproducible and not be prone to subjective assessments. AS has 
a good rigid criteria set in the modified New York criteria. However immune mediated 
acute anterior uveitis does not, even if seen by an ophthalmologist the diagnosis is often 
one of exclusion. In the case of this thesis, the majority of the patients were self-report and 
that introduces the potential for misclassification. Misclassification has the potential to not 
only prevent true findings from being recognised but also potentially introducing false 
positive findings. As such replication in independent sample sets if available is ideal to 
confirm the veracity of the findings. 
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Therefore what may one take from demonstrating an association that has a P value less 
than 5 x 10-8? It is likely to be a true result, not withstanding technical error. The 
significance of suggestive associations is variable. Some definitions use P < 5 x 10-5 and 
others P < 5 x 10-7and numbers in between. However, the purpose of reporting suggestive 
associations is that many of these results will be true associations but they require a better 
powered GWAS study, or a study of a different design that doesn’t have such a high 
multiple testing burden, for example a single variant Taqman study to demonstrate their 
association unequivocally. Reporting suggestive associations can stimulate others to try to 
replicate the result. In reality the GWAS threshold of 5 x 10-8 is arguably arbitrary, as few 
microarrays test 1 million SNPs currently, they usually test many more. However some 
recognised standard that balances type 1 and type 2 error must be reached, and it current 
stands at 5 x 10-8. 
 
1.6.2.2 Microarray Genotyping 
Microarray genotyping is utilised in all the experiments detailed in this thesis. Microarrays 
allow large scale assessment of single bases in the genome in a large number of people 
with good accuracy and reproducibility. To design a microarray chip a variant is chosen 
that is to be assayed. The complementary sequence of DNA that includes this variant 
(around 50 bases) is attached in a well in a microarray chip. This DNA acts as a template 
for the patients DNA to bind to so its sequence can be assessed. 
 
To test a specific individual, their DNA is extracted from white cells of the blood and 
fragmented so it no longer exists as a long chain but as short fragments 300 – 600 
basepairs long. This DNA is then incubated with the microarray and binds to it 
complementary sequence. Additional bases are added that bind depending on the allele 
present. These additional bases also fluoresce, and are read by a laser which produces an 
intensity plot that can be read as a homozygote for one allele, a heterozygote or a 
homozygote for the alternate allele. Microarray plates vary in the number of variants they 
test but it ranges from 100,000 – several million.  
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1.7 Class I Antigen Presentation 
1.7.1 Introduction 
A brief summary of class I MHC antigen presentation pathway and the role of ERAP1 is 
presented below for understanding the context of its function. ERAP1 has been previously 
associated with AS in multiple studies so its role is examined in detail. 
 
1.7.2 Immune Recognition  
The immune system has roles to defend against invasion by bacteria and other micro-
organisms, to prevent uncontrolled cellular proliferation that could develop into cancer and 
to prevent autoimmune disease. To enable these tasks, the immune system has to 
differentiate between ‘self’ and non-‘self’ components. ‘Self’ components are all the normal 
structures in the body, non-‘self’ components include micro-organisms and also mutated or 
cancerous ‘self’ structures. The innate immune system is the first line of defence against 
invading pathogens, and components of the innate immune system recognise non-‘self’ 
structures by using common evolutionarily conserved patterns on micro-organisms. The 
adaptive immune system is the other major component of the immune system and is 
composed of two groups of specialised cells called T lymphocytes and B lymphocytes. 
CD8+ T cells of the adaptive immune system recognise non-‘self’ antigens presented by 
all cells in the body on MHC class I molecules on the cell surface. 
  
1.7.3 MHC Class I Presentation 
Under normal circumstances, almost all cells in the body display MHC class I molecules 
loaded with protein from the cell cytoplasm. Proteins that are located in the cellular 
cytoplasm are continually being sampled and presented to CD8+ T cells. All proteins 
present in the cell cytoplasm, ‘self’ or otherwise, are presented on MHC class I molecules. 
These proteins are fragments of cellular organelles, microorganisms or tumour antigens. 
This demonstrates to the immune system the protein content of the cell cytoplasm. This is 
important because processes such as microbial infection and cancer can compromise the 
cell, and without MHC class I presentation, it may not be externally evident.  
 
Proteins are marked for destruction in a process called ubiquination. Ubiquitin tags are 
placed on proteins that mark them for destruction by the proteasome. The proteasome is a 
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large cellular multi-catalytic enzyme complex in the cytoplasm that cleaves proteins into 
smaller fragments (See Figure 1.3). Peptides of a wide variety of sizes are produced by 
proteasomes, and some are destroyed completely. A transporter called transporter 
associated with antigen processing (TAP) transports peptides into the ER of the cell where 
they can be either loaded onto MHC class I molecules directly or further reduced in size.  
 
A group of enzymes in the cell acts on peptides requiring further size reduction by cleaving 
further peptides from them. These enzymes are termed aminopeptidases, and they reside 
and act both in the cytoplasm and in the ER. Aminopeptidases sequentially trim peptides 
from the N-terminal end of proteins. The C-terminal end is determined by the proteasome, 
and is not altered following this [113].  
 
 
 
Figure 1.3 MHC class I presentation pathway 
 
There have been many cytoplasm resident aminopeptidase identified. These include 
insulin regulated aminopeptidase (IRAP), puromycin sensitive aminopeptidase (PSA), 
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bleomycin hydrolase (BH), leucine aminopeptidase (LAP), thimet oligopeptidase (TOP) 
and tripeptidyl peptidase II (TPPII).  LAP, TOP, BH and PSA all have been shown to trim 
peptides of differing lengths and sequences [114-117]. BH and PSA have also been 
suggested to have a role in pre-presentation antigen processing [118] [119]. IRAP is 
thought to be involved in a process called cross-presentation whereby exogenous antigens 
are presented on class I MHC molecules [120].  
 
There are two main aminopeptidases present in the human ER. The ER resident 
aminopeptidases are endoplasmic reticulum aminopeptide 1 (ERAP1) and endoplasmic 
reticulum aminopeptidase 2 (ERAP2). New aminopeptidases continue to be described and 
complete functional characterisation of existing known aminopeptidases is not complete. 
 
There are 3 highly polymorphic MHC class I molecules, HLA-A ( > 700 alleles), HLA-B ( > 
1,100 alleles) and HLA-C ( > 400 alleles), and three less polymorphic MHC class I 
molecules HLA-E (10 alleles), HLA-F (22 alleles) and HLA-G (47 alleles). Each molecule 
has different preferences for peptides depending on their structure and the charge of the 
amino acid side chains. 
 
Once trimmed down to the correct size, the peptide is loaded into the peptide binding 
groove of the MHC class I molecule. Once a peptide is loaded, the MHC molecule can fold 
correctly and has increased stability. The MHC:peptide complex is transported to the cell 
surface and displayed for passing CD8+ T lymphocytes to sample. Cytotoxic T 
lymphocytes kill cells that present antigens indicative of infection or significant cellular 
dysfunction. 
 
Some microorganisms increase their pathogenicity by down regulating the MHC class I 
antigen presentation pathway, and some specifically target ERAP1, for example human 
cytomegalovirus (CMV) [121]. Cancerous transformation can also lead to decreased or 
absent MHC class I molecules on the cell surface. In this case, natural killer cells, which 
are a type of cytotoxic T lymphocyte, may detect this lack of MHC class I display and 
initiate killing of the cell. 
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1.8 Genetics of Ankylosing Spondylitis  
Currently, our knowledge of the genetics of AS indicates that it is a complex genetic 
disease with polygenic aetiology and that environment plays a smaller role than genetics 
[122]. Risk recurrence analysis from families (assuming a prevalence of 0.1%) has 
estimated that in monozygotic twins the recurrence risk is 63%, first degree relatives 8.2%, 
second degree relatives 1.0% and third degree relatives 0.7% [122]. This risk of a child 
developing AS if a parent has AS is 7.9%.  
 
1.8.1 HLA-B*27 
The association with HLA-B*27 was the first step in identifying the genetic associations of 
AS [3, 4, 24]. HLA-B*27 is present in 80 - 90% of patients with AS. HLA-B*27 is present is 
about 7 - 9% of Europeans. HLA-B*27 homozygosity also confers double the risk of AS 
compared to heterozygosity [86, 123, 124]. 
 
Most subtypes of HLA-B*27 are associated with disease except HLA-B*2706 and HLA-
B*2709 [125]. HLA-B*2705 is the likely ancestral allele [125]. The HLA-B*27 discovery 
precipitated a significant body of work, which is still ongoing, into the mechanism by which 
it contributes to the cause of AS (see previous). In Europeans, the main AS associated 
subtypes are HLA-B*2705 and HLA-B*2702, whereas in Asian populations, the main AS 
associated subtypes are HLA-B*2704 and HLA-B*2707. 
 
1.8.2 Genome Wide Association Studies 
In 2007, the Welcome Trust Case Control Consortium (WTCCC) and the Australo-Anglo-
American Spondylitis Consortium (TASC) published a genome wide scan of 14,436 non-
synonymous SNPs and 897 MHC SNPs in 922 AS cases and 1,466 controls [126].  SNPs 
in ERAP1 and the IL-23 receptor gene IL23R were found to be associated with AS [126].  
 
In 2010, TASC published a GWAS of 2,053 AS cases and 5,140 controls, with replication 
in 898 cases and 1,518 controls. Again, SNPs in ERAP1 and IL23R were found to be 
associated with AS. Two intergenic regions on chromosome 2p15 and 21q22, and the 
genes ANTXR2 and IL1R2 were also found to be associated with AS [127]. The 
association with intergenic regions suggests that they may harbour non-coding functional 
elements or be involved in regulating the expression of other genes [128, 129]. ANTXR2 
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encodes capillary morphogenesis protein-2 and IL1R2 is a decoy receptor that interferes 
with IL-1 binding to IL1R1. 
 
The clinical association and shared genetic associations with IBD risk prompted a study 
into the prevalence of Crohn’s disease (CD) associated genes in patients with AS [130]. 
Danoy and colleagues genotyped 53 markers from 30 CD associated genetic regions in 
2,773 AS cases and 2,215 controls. This again confirmed the association with IL23R. The 
study identified STAT3 and an intergenic region at chromosome 1q32 near the gene 
KIF21B as AS-associated loci. STAT3 is activated by signalling through IL-23R and IL-6R 
so this again implicates these pathways in AS aetiology [1]. KIF21B is a kinesin motor 
protein that functions to transport material along microtubules. The associated region was 
not in KIF21B, but close by and so KIF21B may not be the causal gene. There is a G-
protein coupled receptor (GPR) gene nearby (GPR25) and considering three other GPR 
genes have been associated with AS certainly means GPR25 is a possible candidate. If 
KIF21B is the causal gene, the mechanism by which it contributes to AS aetiology is not 
immediately obvious.  
 
TASC and WCCC2 published another, larger GWAS in 2011 involving 3,023 AS cases 
and 9,141 controls, which also included some samples from previous GWAS studies [60]. 
A replication study was then performed in an independent cohort including 2,109 AS cases 
and 4,410 controls. This study replicated the previous findings in HLA-B, ERAP1, IL23R, 
the intergenic regions chromosomes 2p15 and 21q22 and KIF21B. It reported new 
associations with RUNX3, LTBR-TNFRSF1A, TBKBP1, PTGER4 and IL12B.  RUNX3 
polymorphisms were shown to be associated with CD8+ lymphocyte counts in healthy 
people [60]. The LTBR-TNFRSF1A association is at a TNF receptor locus. TNF is elevated 
in AS, and TNFi agents are in wide clinical use to treat AS. In close association with the 
LTBR-TNFRSF1A finding, TBKBP1 is a binding protein involved in the TNF/NFκβ 
pathway. Also at this locus is the aminopeptidase gene NPEPPS and the TBX21 gene. 
TBX21 is a Th1 specific transcription factor that controls interferon γ production and innate 
lymphoid cells [131]. Interferon γ upregulates ERAP1 and can induce the UPR in the ER. 
PTGER4 is a gene that encodes a receptor for prostaglandin E2. This is an interesting and 
topical finding as non-steroidal anti-inflammatory drugs (NSAIDs) block prostaglandin 
production. Clinically NSAIDs are used to treat AS, and can be very effective. There is 
some evidence that continuous high dose NSAIDs may retard the radiographic 
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progression of AS [132-134]. IL12B encodes part of the cytokines IL-12 and IL-23, which 
along with the IL23R association supports an important involvement of this pathway in AS 
aetiology. The study also identified that ERAP1 was only associated with AS in those who 
were HLA-B*27 positive, as discussed below [60]. 
 
Lin and colleagues published a GWAS of 1,837 Han Chinese AS patients and 4,231 
controls and followed up 30 SNPs in 2,100 AS patients and 3,496 controls [135]. They 
described two novel loci at rs4552569 between EDIL3 and HAPLN1 at 5q14.3 (P = 8.77 × 
10−10) and at rs17095830, an intronic variant in ANO6 at 12q12 (P = 1.63 × 10−8). The two 
associations failed to replicate in the AS Immunochip study (described below) 
subsequently [86]. Considering the persuasive sharing in all other AS associations 
between European and east Asian ethnicities this means these require further replication 
before they are confirmed. 
 
In 2013, the AS Immunochip study was conducted with 10,619 cases and 15,145 controls 
[86]. Although not strictly a GWAS it did examine many variants across the genome. It was 
designed for both fine mapping of existing known associations and discovery of new 
associations. The research groups contributing regions for the design of the microarray 
included rheumatoid arthritis, AS, systemic lupus erythematosus, type 1 diabetes, 
autoimmune thyroid disease, celiac disease, multiple sclerosis, ulcerative colitis, Crohn’s 
disease and psoriasis [136]. The contributed regions were then consolidated and the 
microarray therefore samples an extensive number of immune associated regions across 
the genome. The AS Immunochip study significantly increased the number of genome-
wide genetic associations with new associations in or near IL6R, FCGR2A, UBE2E3, 
GPR35, BACH2, ZMIZ1, NKX2-3, SH2B3, GPR65, SULT1A1, NOS2, TYK2 and ICOSLG. 
Therefore at this current time those AS associations demonstrated in GWAS or large well 
powered studies in white Europeans are shown in Table 1.1 and those demonstrated in 
East Asians are shown in Table 1.2. 
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Table 1.1 AS genetic associations in white Europeans and their putative function 
 
Chr Base Position 
HG19 
SNP OR (95% CI) P value Gene/nearby 
gene 
Function or potential mechanism Ref 
2p15 62,568,445 rs6759298 1.20* 7.0 × 10−16 2p15 Unknown [127] 
21q22 40,466,744 rs2836883 1.19* 1.8 × 10−14 21q22 Non-coding RNA [127] 
4q21 80,946,475 rs4389526 1.10 (1.02 - 
1.19) 
9.4 × 10−8 ANTXR2 Extracellular matrix adhesion [60] 
6q15 90,665,773 rs17765610 1.17*  3.3 × 10−8 BACH2 B-cell class switching and somatic hypermutation [86] 
6q15 90,991,131 rs639575 1.08* 8.6 × 10−5 BACH2 As above [86] 
9q34 139,253,839 rs1128905 1.12*  1.6 × 10−9 CARD9 Innate immune signalling [60] 
3p24 27,794,907 rs13093489 1.12* 1.1 × 10-7 EOMES CD8 positive immune cell function [86] 
5q15 96,124,330 rs30187 1.32* 1.3 × 10−41 ERAP1 Antigen processing [126] 
5q15 96,147,733 rs10045403 1.20* 5.8 × 10−14 ERAP1 Antigen processing [126] 
5q15 96,252,589 rs2910686 1.17* 4.5 × 10−17 ERAP2 Antigen processing [86] 
1q23 161,479,745 rs1801274 1.12* 9.9 × 10−10 FCGR2A Immunoglogulin receptor [86] 
1q23 160,854,445 rs2039415 1.09* 7.4 × 10−5 FCGR2A Immunoglogulin receptor [86] 
1q32 200,877,850 rs41299637 1.20* 7.0 × 10−16 GPR25-KIF21B G-protein coupled signalling [86] 
2q37 241,563,739 rs4676410 1.13* 2.1 × 10−7 GPR35 G-protein coupled receptor [86] 
7q31 124,439,599 rs2402752 1.11* 2.4 × 10-6 GPR37 G-protein coupled receptor [86] 
14q31 88,488,821 rs11624293 1.23* 1.8 × 10−10 GPR65 G-protein coupled receptor [86] 
1q32 210,794,808 rs12758027 1.09* 6.0 × 10-6 HHAT Unknown [86] 
6p21 31,344,916 rs116488202 46* <1 × 10-100 HLA-B*27 Multiple; discussed elsewhere [3, 4, 24] 
6p22 29,943,656 rs2394250 1.54* 8.0 × 10-51 HLA-A*02 Antigen presentation [86] 
21q22 45,615,741 rs7282490 1.10* 1.4 × 10−6 ICOSLG Inducible T-cell co-stimulator ligand [86] 
2q12 102,769,373 rs2192752 1.11* 4.1 × 10−6 IL1R2-IL1R1 Innate immune function [86] 
2q11 102,647,300 rs4851529 1.10* 1.0 × 10-6 IL1R2-IL1R1 Innate immune function [86] 
1q21 154,426,264 rs4129267 1.18* 2.1 × 10−15 IL6R IL-6 induced inflammation [86] 
5p13 35,881,443 rs11742270 1.11* 1.9 × 10-6 IL7R Immune cell regulation [86] 
5q33 158,826,792 rs6871626 1.12* 6.0 × 10−8 IL12B Encodes the IL-23 cytokine [60] 
5q33 158,818,745 rs6556416 1.11* 4.4 × 10−6 IL12B Encodes the IL-23 cytokine [60] 
1p31 67,705,958 rs11209026 1.65* 6.0 × 10−28 IL23R Decreased IL23 induced signalling [126] 
1p31 67,747,436 rs12141575 1.15* 9.4 × 10−11 IL23R Decreased IL23 induced signalling [126] 
12p13 6,446,777 rs1860545 1.13* 8.3 × 10−10 LTBR-
TNFRSF1A 
TNF pathway [60] 
12p13 6,491,125 rs7954567 1.11* 1.2 × 10−7 LTBR-
TNFRSF1A 
TNF pathway [60] 
Chr 6 2,702,271- MICA*007:01 60.66* 2.6 ×10−269 MICA Immune cell regulation [137] 
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2,716,888 
17q21 47,497,840 rs9901869 1.15* 2.3 × 10−12 NPEPPS-
TBKBP1-TBX21 
Aminopeptidase, TNF pathway gene and Th1 
transcription factor  
[86] 
10q24 101,278,725 rs11190133 1.18* 1.7 × 10−14 NKX2-3 Transcription factor [86] 
17q11 26,148,167 rs2531875 1.12* 1.3 × 10−8  NOS2 Nitric oxide synthase 2, reactive oxygen species [86] 
17q11 26,096,597 rs2297518 1.13* 6.3 × 10−7 NOS2 As above [86] 
5p13 40,524,860 rs12186979 1.09* 5.4 × 10−6 PTGER4 Arachidonic acid inflammatory cascade [86] 
1p36 25,305,114 rs6600247 1.16* 1.3 × 10−14 RUNX3 Regulation of CD8+ lymphocytes [60] 
12q24 111,862,575 rs11065898 1.13* 1.7 × 10−7 SH2B3 Growth factor signalling [86] 
17q21 40,499,533 rs6503695 0.86 (0.79 – 
0.93) 
3.4 × 10−4 STAT3 Intracellular signalling [130] 
17q21 40,514,201 rs744166 0.84 (0.77 – 
0.91) 
3.8 × 10-5 STAT3 Intracellular signalling [130] 
16p11 28,525,386 16:28525386† 1.11* 1.4 × 10−7 SULT1A1 Sulphate conjugation enzyme [86] 
16p11 28,328,747 rs35448675 1.24* 2.4 × 10−4 SULT1A1 Sulphate conjugation enzyme [86] 
19p13 10,525,181 rs35164067 1.16* 6.5 × 10−9 TYK2 Intra-cellular signalling, eg. IL-10 [86] 
19p13 10,625,067 rs6511701 1.10* 1.4 × 10−4 TYK2 Intra-cellular signalling, eg. IL-10 [86] 
2q31 182,048,452 rs12615545 1.11* 2.3 × 10−7 UBE2E3 Antigen processing [86] 
22q11 21,956,653 rs2283790 1.12* 1.2 × 10-6 UBE2L3 Antigen processing [86] 
10q22 81,060,317 rs1250550 1.11* 5.8 × 10−7 ZMIZ1 Regulates transcription factors [86] 
Derived from refs [86, 130, 137] † Human genome build 18/NCBI build 36 *Confidence interval not stated 
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Table 1.2 AS associations in East Asians and their putative function 
Chr Base Position (HG19) SNP OR P value Gene/nearby 
gene 
Function or potential mechanism Ref 
2p15 62,568,445 rs6759298 1.28* 1.6 × 10−6 2p15 Unknown [86] 
21q22 40,466,744 rs2836883 1.30* 3.5 × 10−5 21q22 Non-coding RNA [86] 
12q12 45,774,908 rs17095830 1.29 (1.18–1.41)  1.6 × 10−8 ANO6 Osteoclast function [135] 
5q15 96,124,330 rs30187 1.36* 2.0 × 10−5 ERAP1 Antigen processing [86] 
2q37 241,563,739 rs4676410 1.15* 8.4 × 10−3 GPR35 G-protein coupled receptor [86] 
5q14 83,173,593 rs4552569 1.21 (1.14–1.29) 8.8 × 10−10 HAPLN1-EDIL3 Cartilage development [135] 
6p21 31,344,583 rs13202464 42 (35 – 49)  <1 × 10−324 HLA-B*27 Multiple; discussed in Introduction [86] 
5q33 158,818,745 rs6556416 1.18 (1.00–1.39) 0.048 IL12B IL-23 cytokine [86] 
1p31 67,421,184† 1:67421184† 0.61 (0.43–0.87) 0.0054 IL23R Decreased IL23 induced signalling [86] 
21q22 45,615,741 rs7282490 1.18* 1.3 × 10−3 ICOSLG Inducible T-cell co-stimulator ligand [86] 
Chr 6 2,702,271-2,716,888 MICA*019  14 (10 - 20) 2.8 × 10−69 MICA Immune cell regulation [137] 
Chr 6 2,702,271-2,716,888 MICA*007:01  12 (7 – 21) 7.8 × 10−26 MICA Immune cell regulation [137] 
17q11 26,148,167 rs2531875 1.2* 4.6 × 10−4 NOS2 Nitric oxide synthase 2, reactive oxygen 
species 
[86] 
17q21 47,497,840 rs9901869 1.18* 0.002 NPEPPS-
TBKBP1-TBX21 
Aminopeptidase, TNF pathway gene 
and Th1 transcription factor 
[86] 
1p36 25,305,114 rs6600247 1.12* 0.047 RUNX3 Regulation of CD8+ lymphocytes [60] 
16p11 28,525,386 16:28525386‡ 1.16* 0.012 SULT1A1 Sulphate conjugation enzyme [86] 
2q31 182,048,452 rs12615545 1.20* 8.5 × 10−4 UBE2E3 Antigen processing [86] 
10q22 81,060,317 rs1250550 1.20* 3.9 × 10−4 ZMIZ1 Regulates transcription factors [86] 
Derived from refs [86, 135, 138] † NCBI build 130 ‡ Human genome build 18/NCBI build 36 
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1.8.3 Pathways Implicated by genetic associations 
There are now many genetic associations for AS and they implicate a number of 
pathways. Many have been discussed above, but are revisited here for completeness. 
 
Abnormalities with the MHC class I presentation implicated by genes including HLA-B27, 
ERAP1, ERAP2, LNPEP and NPEPPS may be where the inciting event occurs either 
through presenting a specific antigen, a class of antigen or a volume of antigen sufficient 
to initiate disease. The IL-23 pathway, as implicated by associations in the IL-23 receptor 
and IL-6 receptor is a central disease induction pathway. IL-23 has been noted to be 
increased in AS (discussed above) and this pathway seems to be the effector pathway for 
disease manifestations. Simply overexpressing IL-23 in mice induces an SpA type disease 
with marked similarity to humans [50]. How the IL-23 is produced or where it is produced is 
not currently known definitively but many hypothesise it is coming from the bowel. The 
contributions made by other genetic associations is currently unclear, a number of 
receptors and regulators of the innate and adaptive immune system are also associated. It 
is currently unclear whether they are contributing to the primary aetiological event or 
whether these associations mean disease is able to propagate further or contribute to 
different manifestations. Further functional and genetic analyses will be required to 
delineate this. 
 
1.9 Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) 
The ERAP1 gene is strongly associated with AS and it’s role in antigen presentation is 
now reviewed to provide background to the genetic studies of ERAP1 association with 
described later in the thesis. ERAP1 is one of the ER resident aminopeptidases involved in 
peptide production prior to MHC class I antigen presentation. Hattori and colleagues 
originally discovered ERAP1 in 1999 through searching an expressed sequence tag 
database for enzymes similar to IRAP [139]. The discovery of its function to trim peptides 
prior to class I MHC loading was not reported until 2002 when Saric and colleagues 
isolated ERAP1 from liver microsomes [140]. They reported its ability to trim peptides and 
its substrate length preference. At approximately the same time, Serwold and colleagues 
identified the mouse homologue of human ERAP1, which they named endoplasmic 
reticulum aminopeptidase associated with antigen processing (ERAAP) [141]. ERAAP has 
86% structural homology to human ERAP1 [142]. 
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Cells from mice which are ERAAP deficient have decreased MHC class I peptide 
presentation [143]. HeLa cells (a human cell line) with short interfering ribonucleic acid 
(siRNA) ERAP1 inhibition (about 90% effective) show an increased amount of MHC class I 
on their cell surface [144]. The reason for this inconsistency may relate to total gene 
knockout compared to siRNA knockdown. 
 
1.9.1 ERAP1 Function 
Experimental evidence has localised ERAP1 to the endoplasmic reticulum (ER) [140], cell 
membrane [145] and as a secreted extracellular protein [146]. Multiple groups have 
demonstrated that ERAP1 cleaves at the N-terminus [140, 147-149].  
 
ERAP1 displays trimming preferences depending on the composition of the peptide being 
trimmed. Changes at the N-terminus, C-terminus and the internal sequence of the peptide 
all influence its trimming ability [147, 148, 150]. The addition of the non-substrate peptide 
SIINFEKL significantly increases the rate of trimming and it is proposed that this is due to 
allosteric activation via binding to a regulatory site [147, 148].  
 
Three groups have published crystal structures of the ERAP1 enzyme [149, 151, 152]. 
Based on the structure and functional experiments it seems ERAP1 works to trim peptides 
of a very specific size. This is achieved because the enzyme has both a regulatory site 
and an active cleaving site. Peptides of the length of 9-11 amino acids catalyse a change 
in conformation of the enzyme by one end occupying the regulatory site and the other the 
active site. This conformational change enhances the speed at which the enzyme cleaves 
peptides. Small peptides are still cleaved by the enzyme but at a much lower rate. 
Changes to the protein structure of ERAP1 have been shown to change the function of the 
enzyme [60, 147, 151, 153]. AS associated ERAP1 enzyme variants show reduced 
peptide cleaving ability compared to wildtype control ERAP1 [60]. The AS-associated 
genetic variants map to the hinge region of the enzyme that controls the conformational 
change required to increase efficiency. Therefore it is likely AS-protective variants impair 
the conformational change required to increase cleaving speed and therefore decrease the 
function of the enzyme. 
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1.9.2 ERAP1/ERAP2 Heterodimers 
Endoplasmic reticulum aminopeptidase 2 (ERAP2) is a closely related aminopeptidase 
that performs a similar function to ERAP1. ERAP1 and ERAP2 have overlapping peptide 
specificities. There is some evidence that ERAP1 and ERAP2 form heterodimers to a 
minor degree (10 - 30%) [154]. This is consistent with the differing peptide specificities that 
the two enzymes have, and it has been suggested the two enzymes work in concert to trim 
longer peptides, based on the ERAP1 preference for hydrophobic residues and the 
ERAP2 preference for basic residues [154, 155]. 
 
1.10 ERAP1 genetic associations with AS 
 
1.10.1 White European Genetic Associations 
The WTCCC/TASC association scan published in 2007 was the first study to report the 
association between ERAP1 and AS [126]. Five non-synonymous coding SNPs in ERAP1 
were identified (rs27044, rs17482078, rs10050860, rs30187 and rs2287987). These had P 
values of 1.2 × 10-8 to 3.4 × 10-10. 
 
In a follow-up to the WTCCC/TASC study, Harvey and colleagues performed a case 
control study of ERAP1 in 730 European AS patients and 1,021 controls [156]. They 
genotyped the four SNPs in ERAP1 found to be significant previously (rs27044, 
rs10050860, rs30187 and rs2287987) and confirmed the association with AS. They then 
combined the results with the WTCCC/TASC results and found that the strongest 
association was with rs27044 (P = 1.1 × 10-9).  
 
A Canadian study was published in the same year that described a haplotype associated 
with AS in a study of 992 cases and 1,437 controls. The haplotype 
rs27044/rs10050860/rs30187 was associated with AS with an odds ratio (OR) of 1.8 (P = 
7 ×10-7) [157]. The haplotype rs30187/rs26618/rs26653 was protective with an OR of 0.8 
(P = 910-5). 
 
The following year, a multiplex family study which included 199 families and genotyped 
three ERAP1 SNPs and one ERAP2 SNP was reported. SNP rs30187 was associated 
with AS, and an ERAP1/ERAP2 haplotype which included 2 of the SNPs from the previous 
Canadian study (rs27044/rs30187/rs2549782) was also associated with AS [158].  
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In 2010, TASC reported the first GWAS for AS, again identifying SNPs in ERAP1 (rs27037 
and rs27434), with combined cohort P values of 8.2 × 10-11 and 5.3 × 10-12, respectively 
[127]. 
 
TASC and WTCCC2 completed another large GWAS in AS in 2011. The discovery set 
included 3,023 cases and 8,779 controls and the replication set 2,111 cases with 4,483 
controls [60]. In this study, a program called Genecluster was used to examine the ERAP1 
findings [159]. Genecluster is a programme that models the evolution of haplotypes 
through history and attempts to estimate the affected haplotypes and therefore the likely 
causal variants. Using this method rs31087 and rs10050860/rs17482078 (these 2 SNPs 
are in complete linkage disequilibrium) were identified as the two independent signals in 
the ERAP1 gene. A genetic interaction between ERAP1 and HLA-B*27 was also observed 
(see following).  
 
1.10.2 Other European Population Genetic Associations 
A small number of studies have also investigated ERAP1 in specific European 
subpopulations and confirmed the ERAP1 associations.  
 
Pazar and colleagues performed a case control study of 297 Hungarian cases and 200 
gender and ethnically matched controls [160]. They genotyped rs27044, rs17482078, 
rs10050860, rs30187, and rs2287987 in ERAP1. The study demonstrated significant 
associations of all SNPs except rs30187 where the P value was 0.051.  
 
Using 358 Portuguese AS cases and 285 ethnically matched controls, Pimentel-Santos 
and colleagues investigated 5 ERAP1 SNPs with Taqman (rs31087, rs27044, rs10050860, 
rs17482078 and rs2287987)  [161]. In this experiment rs31087 and rs27044 were found to 
be significantly associated with AS with P values of 0.035 and 0.044. However the other 
SNPs were not associated with P values for rs17482078, rs10050860, rs2287987 of 
0.096, 0.057 and 0.074 respectively. These P values suggest that the experiment may 
have been underpowered to detect these associations although the Hungarian experiment 
discussed above used many fewer cases and found significant associations at these 
SNPs. 
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Single SNP genotyping was performed in a cohort of 300 Spanish AS cases and 300 
healthy controls on five ERAP1 variants: rs30187 P = 0.035, rs17482078 P = 0.030, 
rs2287987 P = 0.028, rs26653 P = 0.041 and rs10050860 P = 0.018 found they were all 
associated. Three of the associated SNPs (rs17482078, rs2287987 and rs10050860) were 
from the same ‘rs10050860’ haplotype [162]. 
 
A French and Belgian cohort collectively of 734 cases and 632 healthy controls were 
investigated for ERAP1 association [163]. The samples were selected on the basis of the 
Amor criteria and the European Spondyloarthritis study group (ESSG) criteria [164, 165]. 
However a subgroup analysis of 436 AS cases who met the modified New York criteria 
[166] and 632 controls was analysed and the SNPs rs30187, rs10050860 and rs17482078 
showed significant association with AS (P values of 4.1 × 10-4, 0.001 and 0.035 
respectively). rs10050860 and rs17482078 are from the same haplotype (r2 ~ 1). 
1.10.3 Han Chinese Genetic Associations 
Three studies have found associations between ERAP1 SNPs and AS in Han Chinese. A 
case control study of 527 Han Chinese AS cases and 945 controls was published by 
Brown and his Chinese collaborators [167]. Thirty eight ERAP1 SNPs were genotyped. 
Two ERAP1 SNPs were found to be associated at a P value of ≤0.01 and five additional 
SNPs at a P value of ≤0.05. The two strongest associations were rs27980 (OR = 0.80, P = 
0.0048) and rs7711564 (OR = 0.81, P = 0.0081) 
 
Researchers from Guangzhou conducted a two stage study in which they initially 
sequenced the exonic ERAP1 sequence in 50 Han Chinese AS patients and controls, and 
then proceeded to a confirmatory group where they determined genotypes for six ERAP1 
SNPs by polymerase chain reaction/restriction fragment length polymorphism [168]. They 
did not assess the five SNPs previously known to be associated with AS (rs27044, 
rs17482078, rs10050860, rs30187 and rs2287987). They genotyped the 6 newly identified 
associated SNPs (rs26653, rs27434, rs27640, rs27529, rs26510 and rs27582) in a follow 
up group of 471 Han Chinese AS patients and 456 controls. They found two SNPs with 
significant association to AS rs27434 (OR = 1.38, P = 3.9  10-4) and rs27529 (OR = 
1.23, P = 8.3  10-3). 
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Most recently the Guangzhou group published a Han Chinese AS GWAS that included 
1,837 cases and 4,231 controls in the discovery set and 2,100 cases and 3,496 controls in 
the validation cohort [135]. They confirmed the previous association finding at rs30187 
(OR = 1.35, P = 1.8  10-27).  
 
Two studies in Korean AS patients have also described ERAP1 associations [169, 170]. In 
the Bang study two ERAP1 SNPs were found to be associated namely rs27037 (OR 1.31, 
P = 1.31  10–4) and rs27434 (OR 1.36, P = 4.59  10–6)[169]. In the Choi study two 
ERAP1 SNPs were associated rs27044 (P = 9.37  10−7) and rs30187 (P = 7.16  
10-6)[170]. The Choi study did not report an OR. 
 
1.10.4 Implications of multi-ethnic associations 
Consistent with a common founder population the majority of white European ERAP1 
variants robustly associated with AS are also associated in European sub-populations. 
The variation observed in specific experiments likely relates to either lack of experimental 
power, selection bias or technical error.    
 
To date disease associations in one ethnic population have extended to other populations, 
for example from European to east Asian. The exception is where a specific variant is not 
polymorphic in the population, for example the IL23R variant rs11209026 in East Asians 
[167]. However in this case other polymorphic variants in the same gene that were also 
protective were detected by a more intensive sequencing based investigation [138]. 
 
This is not a surprising finding in AS because different ethnic populations do not differ in 
their clinical features. The clinical features drive the phenotype allocation, disease 
classification and subsequently recruitment for genetic studies and therefore it would 
follow that their genetic associations are approximately the same. A situation in which this 
assumption would not hold is with disease phenocopies. Where multiple biologically 
separate pathways to disease development exist (based on different genetic risk variants) 
and one ethnic population utilises predominately or exclusively one type where another 
population utilises an alternate pathway. This scenario is impossible to prove or disprove 
until we have a more complete picture of the aetiology of AS but the almost complete 
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sharing of associated genetic variants between populations to date would argue strongly 
against this.  
 
1.10.5 HLA-B*27 – ERAP1 Genetic Interaction 
The TASC GWAS identified a genetic interaction between the presence of the HLA-B*27 
allele and an ERAP1 SNP [60]. HLA-B*27 was shown to be tagged by rs4349859 with a 
sensitivity of 98% and a specificity of 99%. This HLA-B*27 tag SNP significantly interacted 
with the non-synonymous coding SNP rs30187 in ERAP1, interaction regression co-
efficient 0.35, standard error 0.079, P = 7.3 x 10-6, using 5,134 AS cases and 13,262 
controls. In AS patients negative for rs4349859 (effectively HLA-B*27 negative), there was 
no association between the ERAP1 SNP rs30187 and AS.  
 
A GWAS of psoriasis has also identified a genetic interaction between ERAP1 and a class 
I MHC allele SNP in HLA-C rs10484554 [171]. Similar to the case in AS, an SNP in 
ERAP1 (rs27524) was only associated with psoriasis in those with at least one copy of the 
HLA-C SNP rs10484554. In Behçet’s disease ERAP1 interacts with HLA-B*51 in a 
recessive manner [172]. ERAP1 has also been associated with enthesitis related arthritis 
(ERA), a subtype of juvenile idiopathic arthritis (JIA) that shares many clinical features with 
AS [173]. It seems likely the interaction would also be present in this group but this has not 
been explored. This would suggest that aminopeptidase-MHC classical allele interactions 
may be widespread in immune mediated disease.  
 
These genetic interactions are interesting in view of the association between psoriasis and 
AS. Class I MHC alleles and ERAP1 are both involved in antigen processing and 
presentation, and immune regulation more generally. This provides support for the 
aetiology of AS, psoriasis and Behçet’s being a defect in antigen processing or 
presentation.  
 
1.11 Other Aminopeptidases  
1.11.1 ERAP2 
Tsui and colleagues conducted a study of 199 multiplex families in 2010. They identified 
an AS associated haplotype spanning ERAP1-ERAP2, this haplotype included the ERAP2 
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SNP rs2549782, P = 0.009 [158]. Subsequent to this SNP level experiments of ERAP2 
association in AS have been conducted and are reported in Chapter 2. 
 
1.11.2 NPEPPS and Puromycin sensitive aminopeptidase 
Evans and colleagues reported as part of the TASC-WTCCC GWAS a locus on 
chromosome 17 as being AS associated [60]. The suspected putative gene was TBKBP1, 
a component of the TNF signalling pathway. Subsequently as part of the AS Immunochip 
study Cortes et al. confirmed association at this chromosome 17 locus [86]. The 
association spans a number of genes of immunological interest. These are NPEPPS, 
TBX21 and TBKBP1. The signal of association spans a recombination hotspot and 
conditional analysis shows there are at least two independent signals. Conditional analysis 
is where an additional component to the logistic regression model is added to try to 
ascertain the relationship between the dependent variable and another model component 
without the influence of the unwanted signal in the logistic regression analysis. This 
potentially implicates association not only to TBKBP1 but also to a gene called NPEPPS. 
NPEPPS encodes an aminopeptidase called PSA. PSA is a cytoplasmic aminopeptidase 
that has been identified as important in clearing Tau protein in animal models of 
neurodegenerative diseases characterised by protein accumulation [174]. In addition PSA 
has been suggested to be the only cytoplasmic aminopeptidase able to process protein 
with extensive polyQ sequences [175, 176]. This is potentially relevant to AS because 
protein clearance is important to autophagy, a process of importance to IBD. AS patients 
have a high prevalence of IBD and the majority have at least microscopic bowel 
inflammation. But to counter this there have been no reported associations in adequately 
powered studies between AS and autophagy associated genes such as NOD2 that have 
been reported in IBD [177]. Potentially of most relevance to AS is the observation that PSA 
contributes substantially to antigen processing prior to MHC class I presentation on the cell 
surface [119, 178]. This is analogous to the role that ERAP1 and ERAP2 play. In 
behaviour very similar to ERAP1 PSA knockout cells display more MHC class I molecules 
on their cell surface suggesting PSA destroys antigens prior to presentation [119]. This 
genetic association needs further fine mapping and confirmation in independent cohorts. 
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1.12 Functional Effects of ERAP1 and ERAP2 SNPs 
Lead SNPs in the 2 independent ERAP1 haplotypes associated with AS have been shown 
to reduce the function of the enzyme in substrate trimming studies [60]. The SNPs have 
been mapped to the hinge region of the enzyme and therefore likely impair the ability of 
the enzyme to change conformation [152]. 
 
The ERAP2 haplotype associated with AS harbours 2 SNPs that have known functional 
effect. The first is rs2248374 that changes the strength of the splice site for exon 10 and 
means a truncated protein is produced that is destroyed by nonsense mediated decay 
[179]. Another SNP on the same haplotype, rs2549782, changes the specificity of the 
enzyme, but because the former SNP causes no ERAP2 protein to be produced this 
altered specificity enzyme is unlikely to ever be made [180]. 
 
Both these associations indicate that lack of, or decreased activity of, aminopeptidase is 
associated with protection from disease. Therefore the actions of these aminopeptidases 
is somehow promoting AS disease development. How exactly this is occurring is not 
currently known but may be due to the type or volume of antigen that is being presented. 
 
1.13 Summary 
There has been extensive progress in the last five years in discovering the genetic basis 
for complex disease. The effort focused on AS has yielded extensive associations both 
anticipated from previous work and in novel unsuspected pathways like ERAP1. The other 
outcome of the studies of immune mediated disease genetics is the extensive sharing of 
risk loci between diseases, both with concordant directions of effect and opposing 
directions of effect. 
 
Anterior uveitis has not been such a focus of genetic investigation but it will undoubtedly 
benefit from the outcome of research into related diseases like IBD and AS. There still 
continues to be extensive morbidity like glaucoma and cataract created by the use of 
corticosteroids in this condition and therefore the field could undoubtedly benefit from the 
discovery of agents with similar or better efficacy and reduced side effect profile. 
Identification of specific AU genetic variants may enable pre-symptomatic identification of 
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high risk AS patients. This could potentially guide therapy of AS to potentially prevent the 
occurrence of AU in these individuals completely. 
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2 Immunochip Chromosome 5q15 Locus Study 
2.1 Introduction 
This chapter describes the Immunochip analyses of the 5q15 locus that contains the 
genes ERAP1, ERAP2 and LNPEP. These data has now been published [86]. Important 
variants in the gene region are shown in Table 2.1 and Figure 2.1. 
The Immunochip is a custom Illumina Infinium genotyping chip which contains candidate 
regions from a number of immune mediated diseases [136] [1]. These diseases share 
clinical features, are already known to share genetic risk loci, are commonly co-familial, 
and also frequently co-occur in the same individual (eg. coeliac disease and rheumatoid 
arthritis).  Therefore investigating potentially shared genetic risk loci was thought likely to 
be fruitful in the search for further disease-associated loci. 
At the point of performing the ankylosing spondylitis (AS) Immunochip study two 
independent common variant associations in individuals of European descent were known 
in ERAP1, rs30187 and rs10050860, located on separate haplotypes [60]. SNPs in ERAP1 
have also been associated with AS in a number of Chinese and Korean studies [135, 167-
170]. 
An association with LNPEP, the gene beside ERAP2, and AS was suggested in 2007 by 
Burton and colleagues in the association scan of 14,500 non-synonymous SNPs. The 
described association rs2303138 was in complete LD with the ERAP1 association rs27044 
also described in that study. They did not describe the relationship of this signal to the 
SNPs in ERAP2. In 2010 an association with ERAP2 was suggested from a haplotype 
analysis of 199 multiplex AS families by Robert Inman and colleagues [158]. They reported 
a haplotype at the ERAP1 and ERAP2 locus (rs27044[G], rs30187[T], rs2549782[T], 
p=0.009) was associated with AS. An association has also been reported in Crohn’s 
disease at a single nucleotide polymorphism (SNP) in ERAP2 (rs2549794) [82]. The aim 
was to investigate the 5q15 locus for undescribed common and low frequency variants 
associated with AS using a custom genotyping beadchip designed to assess immune 
related loci. 
This chapter describes the analysis of the 5q15 locus in the AS Immunochip dataset. 
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Table 2.1 Important genetic variants in HLA-B*27 and 5q15 
Variant Chromosome Base Pair Position* Functional significance of the genetic variant 
rs17482078 5 96,118,866 ERAP1 SNP in strong LD with rs10050860 
rs2927613 5 96,198,692 Lead SNP in the east Asian cohort 
rs10050860 5 96,122,210 One of the two independent ERAP1 AS associations 
rs30187 5 96,124,330 One of the independent ERAP1 AS associations 
rs2549782 5 96,231,000 The change of catalytic activity of ERAP2 SNP[180] 
rs2248374 5 96,235,896 The ERAP2 SNP causing complete loss of ERAP2 mRNA 
rs2549794¶ 5 96,244,549 The ERAP2 SNP described to be associated with Crohn’s disease 
rs13202464¶ 6 31,344,583 East Asian HLA-B*27 tag SNP described by Lin [135] 
rs4349859¶ 6 31,365,787 HLA-B*27 European tag SNP described by Evans [60] 
*Human genome build 19; ¶ Not assayed on Immunochip
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Figure 2.1 Important genetic variants in the 5q15 locus and the recombination rate across the locus
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2.2 Methods 
2.2.1 Sample Collection 
Samples were collected primarily by rheumatologists from a number of countries in 
Europe, North and South America, Australia, New Zealand, Taiwan, Korea and 
China. The majority of patients fulfilled the modified New York criteria for AS [166]. 
The exception was one patient cohort of general practitioner diagnosed AS which 
was included from the Norway based Nord-Trøndelag health (HUNT) study (n = 506) 
[181]. To decrease the chance of these HUNT patients not having modified New 
York criteria classified AS only HLA-B*27 positive cases from this cohort were 
included. Two additional sets of controls were used, the 1958 British Birth Cohort 
genotyped at the Wellcome Trust Sanger Institute in Cambridge, UK and a set of 
controls supplied by Peter Gregersen that were genotyped at the University of 
Virginia, USA [182].  
2.2.2 Genotyping, Clustering & Quality Control 
The Immunochip is a custom Illumina Infinium genotyping chip. The sample 
deoxyribonucleic acid (DNA) is amplified, fragmented, suspended in ethanol and 
then precipitated. The DNA is then placed onto the Infinium beadchip and hybridised 
overnight to the 50-mer oligo-DNA probes present on the chip. These DNA oligos 
have a nucleotide sequence complementary to the genomic sequence adjacent to 
the SNP being analysed.  A reaction adds a single nucleotide complementary to the 
sample DNA at the genomic position of the SNP being genotyped. A marker that 
fluoresces under laser is then added to the complementary base by an additional 
reaction. The chip with the bound DNA is then placed in the scanner and the signal 
intensity read by a laser. This produces a graphical readout on an x/y axis called a 
cluster plot, see Figure 2.2 for an example. A computer algorithm then “clusters” this 
readout and assigns genotypes. 
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Figure 2.2 Example of an X-Y cluster plot 
Clustering was completed using the program Opticall [183]. Post clustering quality 
control (QC) to exclude poor genotyping and poor assays was completed following 
standard protocols [184-186]. The thresholds used are shown in Table 2.2. PI_HAT 
is the estimated proportion of markers shared ‘identity by descent’ (IBD). IBD is the 
proportion of markers you share which are not only identical, but have also arisen 
from the same ancestor. 
 
Table 2.2 Thresholds used for data quality control.  SNPs or individuals not 
achieving these thresholds were excluded. 
Metric Threshold 
Hardy-Weinberg equilibrium P < 10-6 
Missingness by person P < 10-7 
Missingness by centre P < 10-7 
Identity-by-descent PI_HAT > 0.2 
Call rate < 98% 
 
Assessment of the ethnic differences between samples was achieved through 
principal components analysis of the sample genotypes in comparison to the 
HapMap populations CEU (European), CHB (Chinese), JPT (Japanese), YRI 
(Yoruba from West Africa) [187, 188]. Samples were excluded if they did not cluster 
with the European or east Asian HapMap clusters. SHELLFISH was used to 
compute the principal components [189]. 
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2.2.3 Genotype parsing and analysis 
PLINK is a command line programme implemented in Linux which provides wide 
functionality with genotyping data [190]. PLINK was used for linkage disequilibrium 
(LD) calculation, identity by state (IBS) and IBD analysis, LD trimming and the 
generation of different file formats to use with other genotype analysis programmes.  
2.2.4 Logistic Regression of Haplotypes with R 
Logistic regression was completed with R and the first four principal components 
were incorporated into the model to control for population structure [191]. This 
resulted in a genomic control across the whole genome of < 1.05. 
2.2.5 Case-control and Conditioned Analysis 
A linear mixed model (LMM) was used to analyse the data. LMMs are methods that 
can simultaneously account for both population structure and relatedness amongst 
samples, without having to separate these individual effects [192].  LMMs relate 
phenotype (Y) to a mixture of both fixed (X) and random effects, the random effects 
are divided into hereditary random effects (u) and non-hereditary random effects (ε). 
Each SNP effect is modelled with the equation (1). 
 
Y = Xβ + u + ε         (1) 
 
The variance of u represents the kinship matrix. A kinship matrix is a pairwise matrix 
of n by n entries (where n is the number of samples) presenting the genetic similarity 
between individuals. The values that make up the matrix represent the probability 
that a randomly selected allele will be identity by descent between the two 
individuals compared. The matrix can be built in a number of different ways that 
affect the results of the analysis. β is the coefficient of the fixed effect that can be 
applied to control for gender differences for example. 
 
Numerous LMM have been published for use with genetic data [193, 194]. The 
computational demands of large sample sizes and SNP numbers have required the 
development of less intensive methods which retain the benefits of previous 
methods. A method called “FaST-LMM” (Factored Spectrally Transformed -LMM) 
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was used for analysis of the AS Immunochip genotyping results [195]. This is an 
adapted LMM that is computationally efficient to allow use with large data sets. 
When building the kinship matrix the SNPs on chromosome 5 and the major 
histocompatibility complex (MHC) SNPs were excluded from the matrix (Human 
genome build 18/NCBI 36, chr6: 20,500,000-38,500,000). These SNPs were 
excluded to prevent null-model contamination, a phenomenon of the model which 
causes inflated P values if these SNPs are included in the kinship matrix 
construction. The result of including these SNPs would have been significant inflation 
of the genomic control statistic (GC or λ). GC is a measure used to test for the 
inflation of test statistics in GWAS studies which can result from poor study design, 
for example, inclusion of related individuals, population stratification, cryptic 
relatedness, and genotyping error [195, 196], as well as true association. SNPs were 
filtered to exclude those in high LD with each other. SNPs for the kinship matrix 
construction were also filtered on a minor allele frequency (MAF) of 0.01 because 
FaST-LMM was unable to compute the matrix on SNPs with a MAF of 0. In addition 
the stratification of rare and low frequency SNPs is likely to be different to common 
SNPs, as they are likely to have arisen more recently [197] [198]. Transformation of 
the SNP effects from the linear to liability scale was completed according to the 
Cortes et al. method [86]. 
To investigate for multiple independent signals at a locus, SNP weights can be 
added as a fixed effect into the LMM using the β term in the model equation. This 
removes the effect of the SNP/s and allows recognition of other secondary effects at 
the same locus. 
2.2.6 GeneCluster 
GeneCluster is a programme which attempts to model the evolution of haplotypes 
over time and using Bayesian methods estimate the identity of disease associated 
SNPs [159]. The method recognises that SNPs may be tagged poorly by genotyped 
SNPs or there may be in fact be multiple associated SNPs on haplotypes so uses a 
panel of known haplotypes (in this case HapMap) and an estimate of recombination 
rate to construct an approximation of genealogy of haplotypes in the panel. This 
creates a framework with each branch being a mutational event. The pattern of 
genotype mutation with the predicted genotypes and their uncertainties are then 
examined for disease association using a Bayesian approach. A Bayes factor (BF) is 
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used by comparing a model of association to a null model. The Bayes factors over 
the entire branch are averaged to get a BF that captures the evidence of a causal 
mutation at that branch position. One, two or more mutations can be modelled on 
each branch. The models are then compared to a null model and each other to 
examine for evidence of allelic heterogeneity in the study. 
 
Genecluster was used to distinguish the two common variant associations in ERAP1 
in the Australo-Anglo-American (TASC) AS genome wide association study (GWAS) 
previously [60]. A program called Treesim is used to create a tree which models the 
evolution of the haplotypes [199]. Using this haplotype evolution tree the genotypes 
of the case and control individuals are then modelling based on the constructed tree. 
The branches of the tree represent mutational events in the haplotypes. Observing 
where disease association starts to occur as one travels down the haplotype tree 
allows estimation of the disease associated SNP. An example of a constructed 
haplotype tree is shown in Figure 2.3.  
 
Figure 2.3 An example of a haplotype tree produced by Treesim & Genecluster. The 
coloured dots on the tree are the locations of the estimated phenotype-associated 
mutational events. 
Genecluster was used initially with the directly genotyped SNP data only and 500 
sampled haplotypes. The data were then imputed with the genotype imputation 
programmes MaCH and minimac and reassessed with Genecluster.  
2.2.7 Genotype and MHC Allele Imputation 
Imputation is using non-study genetic data, for example the Hapmap project data, to 
infer information about ungenotyped SNPs in genotype data [188]. This is possible 
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due to the LD shared by neighbouring SNPs. Imputation was completed largely with 
IMPUTE2 [200] or MaCH/Minimac [201]. The IMPUTE2 Immunochip data was 
imputed with 1000 genomes data (Build 37, 1000 genomes phase 1, interim data, 
June 2011). The MACH imputation was performed with 1000 genomes June 2010 
release. Post imputation quality control used a threshold of 0.5 for ‘info’ statistic 
produced by IMPUTE2 and 0.5 for the ‘RSq’ statistic produced by MACH/Minimac.  
Imputation was also used to estimate classical human leukocyte antigen (HLA) 
alleles from the genotyping data in individuals of European descent using HLA*IMP 
version 1 [202, 203]. This programme has been validated against polymerase chain 
reaction (PCR) based HLA typing in the 1958 British Birth Cohort. The following 
classical HLA types can be imputed with HLA-IMP version 1: HLA-A, HLA-B, HLA-C, 
HLA-DQA, HLA-DQB and HLA-DRB. The accuracy of the programme is 97-99% at 2 
digit accuracy, and 92-97% at 4 digit accuracy [202]. 
HLA*IMP has not been validated in east Asian populations so the HLA-B*27 tag SNP 
(rs13202464) previously described by Lin and colleagues was used to infer HLA-
B*27 status [135]. This may not a perfect tag as conditioning on this SNP in their 
east Asian AS cohort reduces the odds of disease association from 79.2 to 5.7 at the 
HLA-B locus; the high residual HLA-B association likely indicates residual HLA-B*27 
association. The sensitivity and specificity of this tag SNP compared to traditional 
laboratory PCR typing is 99% and 92%, respectively [86].  
The rs13202464 SNP was not on the Immunochip and so this was imputed with 
1000 genomes data. This gave posterior probabilities ranging from 0-2, 
corresponding to the total number of alleles carried by each individual, this is shown 
in Figure 2.4.  
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Figure 2.4 Posterior probability of rs13202464 “A” allele in the east Asian cohort 
With these posterior probabilities values of >1.8 were assigned a value of 2 (AA), 
values greater than 0.8 and less than 1.2 were assigned a value of 1 (AG), and 
values less than 0.2 were assigned a value of 0 (GG). This only meant 62 cases had 
values of 0.2 – 0.8 or 1.2 – 1.8 and were unable to be assigned genotypes for HLA-
B*27 based on these posterior probabilities.  
2.2.8 Low Frequency Variants 
Low frequency variants reported here were defined as a minor allele frequency of 
less than 0.05. The cluster plots of all reported low frequency variants were checked 
manually to confirm that the automated Opticall clustering was accurate. 
2.2.9 Normalising Case/Control Number and ERAP1 allele frequencies 
To determine whether the association observed in ERAP2 was not due to 
confounding from uneven numbers of cases or controls analyses were performed to 
equalise the number of cases and controls. In addition, analyses were performed 
which normalised both the case/control numbers and the total numbers of alleles of 
rs30187 and rs10050860 in the cases/controls. An example of the R code used to 
normalise the numbers of cases/controls and rs10050860 alleles is presented in 
Figure 2.5.  
 
 
50
 
  
X <- sum(neg.ca[,"rs10050860"],na.rm=TRUE) 
 
(1) 
  
vector1.p <- c() 
vector1.ts <- c() 
 
(2) 
  
for(i in 1:10000) { 
 
 
(3) 
 sample <- c() 
 
(4) 
 for (i in 1:1000000) 
{sample <-neg.co[sample(7428,1190,replace=FALSE),] 
if (sum(sample[,"rs10050860"],na.rm=TRUE)==X) break 
 }  
 
(5) 
 set <- rbind(sample,neg.ca) 
model1 <- glm(AS~HapSNP,family=binomial("logit"),data=set) 
vector1.p[i] <- summary(model1)$coefficients[2,4] 
vector1.ts[i] <- summary(model1)$coefficients[2,3]  
} 
 
(6) 
 
Figure 2.5 R code for normalising the number of rs10050860 alleles in the HLA-B*27 
negative cases and controls to ascertain whether the strength of association is 
affected by the number of alleles at ERAP1. Code (1) sets the number of alleles that 
the control group has to equal. Code (2) & (4) sets the variables which are added to 
by the function. Code (3) is the start of the outer loop, which in (5) samples from the 
larger control set until a set of controls is found with an equal number of rs10050860 
alleles to the case set, the number of rs10050860 alleles in the case set is denoted 
by ‘X’ in code (1). Once this set has been determined it is then tested in logistic 
regression in code (6) for association with the lead SNP in the ERAP2 haplotype, 
denoted by ‘HapSNP’ in code (6). ‘neg.ca’ indicates the HLA-B*27 negative case set 
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and ‘neg.co’ indicates the HLA-B*27 negative control set. The numbers 7,428, 
indicates the total number of HLA-B*27 negative controls and 1,190 indicates the 
number of controls to be sampled, 1,190 is the number of HLA-B*27 negative cases.  
2.2.10 Phenotype Determination 
Using the Australo-Anglo-American Spondylitis Consortium (TASC) ‘BC-SNPmax’ 
database which stores phenotype information for the AS samples it was possible to 
extract phenotype information and match it to genotype information to assess for 
genotype-phenotype correlations for psoriasis and inflammatory bowel disease. This 
phenotype information is collected from patients by their treating rheumatologists. 
2.2.11 Power Calculations 
Power calculations for the Asian rs10050860 association were performed using 
Shaun Purcell’s Genetic Power Calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/) 
[204]. Assumptions used for calculating the power achieved in this study were a 
disease prevalence of 0.005, an allelic dominant risk of 0.76, rs10050860 allele 
frequency of 0.038, case number 1,550, case:control ratio 0.9892 and an alpha of 
0.05 and 5 x 10-8 (to test two different scenarios), and rs10050860 was assumed 
either to be the directly associated variant or in 100% LD with the true disease-
associated variant. For the calculation of required cases, the above settings were 
used except for a required beta (power) of 0.8 (80%). 
2.2.12 Graphing 
Graphing of the association analysis was completed with LocusZoom [205]. Cirles 
that are open in LocusZoom plots indicate that there is not LD information available 
for them. LD graphing was completed with Haploview [206]. Graphing of the 
Genecluster results and all other graphs was completed with R. 
2.2.13 Linkage Disequilibrium Calculation 
LD was calculated with PLINK for the Immunochip datasets. In phase allele 
calculation is the process by which you determine the alleles which are in phase 
which each other when there is LD between markers, so for example two SNPs may 
share high LD (eg. r2 = 0.8) but determining which alleles occur together on the 
haplotype requires in phase allele determination. So if SNP A: T/C and SNP B: G/A 
are in complete LD, in phase allele determination will be able to specific that SNP A’s 
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T allele travels with SNP B’s G allele. This was performed with the programme 
Haploxt (www.genome.sph.umich.edu/wiki/Haploxt). 
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2.3 Results 
2.3.1 Samples and Quality Control 
After excluding samples for poor genotyping and relatedness there remained 9,074 
European cases and 13,607 European controls and in the east Asian cohort there 
remained 1,550 east Asian cases and 1,567 east Asian controls. The origin of these 
samples is shown in Table 2.3. 
Table 2.3 Origin of AS cases and controls. Ancestry determined to be European or 
east Asian by comparing to the HapMap populations, compared with site of 
recruitment.  
European   East Asian   
 Cases Controls  Cases Controls 
United Kingdom 4231 10551 Korean 657 725 
USA 1135 747 Chinese 643 619 
Canada 729  Taiwanese 195 178 
Spain 522 530 Canadian 25  
Norway (HUNT) 506 952 USA 25 42 
France 355 352 UK 2  
Norway 342  French 1  
Netherlands 312  Netherlands 1  
Finland 293 230 Australia 1  
Australia 235 56 Norwegian  3 
Portugal 183 160    
Belgian 144     
New Zealand 82     
 
After quality control and exclusion of monomorphic SNPs there remained 129,029 
SNPs in the European cohort and 139,880 SNPs in the east Asian cohort. 
2.3.2 Linkage Disequilibrium Mapping 
The LD map of the 5q15 locus is shown in Figure 2.6. No substantial differences in 
LD between European cases and European controls were evident (data not shown). 
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Figure 2.6 European samples LD map of the 5q15 locus. The location of the genes is 
indicated by lines above the plot. Each dot represents a pairwise comparison 
between two individual SNPs. The more intense the black the higher the linkage 
disequilibrium between the two SNPs. LD is measured in r2 on this graph which 
ranges from 0 (indicated by a white square), to 1 (indicated by a black square). An r2 
of 1 indicates the two SNPs are in complete linkage disequilibrium, meaning the 
allele at one position can be used to predict the allele at the other position. Likewise 
an r2 of 0 indicates complete independence between these 2 genomic positions in a 
given population and therefore the allele at one position offers no predictive 
information about the allele at the other position. 
2.3.3 European case-control analysis 
The case-control analysis in the European set replicated strong association at the 
5q15 locus, shown in Figure 2.7. The SNP rs27529 showed the strongest 
association (P = 2.4 x 10-43, allele A, OR = 1.30). The two SNPs in ERAP1 previously 
described to have functional importance were strongly associated: rs30187 (P = 1.3 
x 10-41, allele A, OR = 1.30) and rs10050860 (P = 3.2 x 10-32, allele G, OR = 1.30). 
Detailed results are shown in Table 2.9 & Table 2.10. Some low frequency variants 
were identified, shown in Table 2.4, but no coding variants were identified. 
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Figure 2.7 European FaST-LMM case-control analysis. The left hand scale is the –
log10 of the P value, the higher this value is the smaller the P value. The right hand 
axis is the recombination rate which corresponds to the light blue line along the 
bottom of the graph. The location of the genes and genomic position on 
chromosome 5 are shown below the graph. The exons in the genes are represented 
by vertical blue lines on the line representing the gene. Graph markers represent 
individual SNPs, the colours represent the LD in r2 between the SNP and the most 
associated SNP in the region chr5:96152064 (LD legend in the top right of graph). 
The shapes of the marks represent functional annotations: ! is a coding mutation, ! 
non-synonymous change, " is a framestop or splice change, ! and " is no 
annotation. 
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Table 2.4 Low frequency variants in the European case-control analysis with P value of less than 1 x 10-3 identified in the 5q15 
locus  
SNP [Allele] Position 
(HG18) 
MAF 
Cases 
MAF 
Controls 
P value OR Function 
rs62376445 [A] 96222477 0.042 0.054 1.79 x 10-8 0.79 intergenic 
imm_5_96379614* [C] 96379614 0.049 0.038 2.45 x 10-8 1.28 intronic LNPEP 
rs62376390 [G] 96172128 0.025 0.035 9.49 x 10-8 0.75  intronic ERAP1 
rs62377085 [A] 96395536 0.014 0.020 1.23 x 10-7 0.68 intergenic 
SNP single Nucleotide polymorphism, MAF minor allele frequency; OR odds ratio; *no rs ID exists, HG18 human genome build 18/NCBI build 36. 
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2.3.4 European Conditional Analysis 
When the effect of rs30187 in ERAP1 is removed a haplotype over ERAP2/LNPEP 
becomes significant (see Figure 2.8), and the effect is also seen when the other 
major common variant risk association in ERAP1 rs10050860 is removed (see 
Figure 2.9), but note the different scale on the two graphs. The haplotype becomes 
more significant when both their effects are removed by conditioning (see Figure 
2.10). Low frequency variants associated with AS in the rs30187, rs10050860 and 
combined rs30187/rs10050860 conditioned analyses are shown in Table 2.5, Table 
2.6 and Table 2.7 respectively. 
 
Figure 2.8 European FaST-LMM case-control analysis conditioned on rs30187. The 
left hand axis is the –log10 of the P value, the higher this value is the smaller the P 
value. The right hand scale is the recombination rate which corresponds to the light 
blue line along the bottom of the graph. The location of the genes and genomic 
position on chromosome 5 are shown below the graph. The exons in the genes are 
represented by vertical blue lines on the line representing the gene. Graph markers 
represent individual SNPs, the colours represent the linkage disequilibrium (LD) in r2 
between the SNP and the most associated SNP in the region chr5:96278345 (LD 
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legend in the top right of graph). The shapes of the marks represent functional 
annotations: ! is a coding mutation, ! non-synonymous change, " is a framestop 
or splice change, the star is a conserved predicted transcription factor binding site, 
the square box with a cross inside it is highly conserved in placental mammals, ! 
and " is no annotation. 
Table 2.5 European low frequency variants with a P value of less than 1 x 10-3 in the 
5q15 locus when the effect of rs30187 is removed 
SNP [Allele] Position 
(HG18) 
MAF  
Cases 
MAF 
Controls 
P value OR Function 
rs62377085 [A] 96395536 0.014 0.020 3.04 x 10-5 0.75 DS LNPEP 
rs62376390 [G] 96172128 0.025 0.035 3.29 x 10-4 0.83 ERAP1 intron 
rs62376445 [A] 96222477 0.042 0.054 3.56 x 10-4 0.86 Intergenic 
SNP single Nucleotide polymorphism, MAF minor allele frequency; OR odds ratio; DS downstream, HG18 human 
genome build 18/NCBI build 36. 
 
 
Figure 2.9 European FaST-LMM case-control analysis with the effect of rs10050860 
removed. The left hand axis is the –log10 of the P value, the higher this value is the 
smaller the P value. The right hand scale is the recombination rate which 
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corresponds to the light blue line along the bottom of the graph. The location of the 
genes and genomic position on chromosome 5 are shown below the graph. The 
exons in the genes are represented by vertical blue lines on the line representing the 
gene. Graph markers represent individual SNPs, the colours represent the linkage 
disequilibrium (LD) in r2 between the SNP and the most associated SNP in the 
region chr5:96152064 (LD legend in the top right of graph). The shapes of the marks 
represent functional annotations: ! is a coding mutation, ! non-synonymous 
change, " is a framestop or splice change, a star is a conserved predicted 
transcription factor binding site, the square box with a cross inside it is highly 
conserved in placental mammals, ! and " is no annotation. 
Table 2.6 European low frequency variants with a P value of less than 1 x 10-3 in the 
5q15 locus when the effect of rs10050860 is removed 
SNP [Allele] Position 
(HG18) 
MAF  
Cases 
MAF  
Controls 
P value OR Function 
rs62376445 [A] 96222477 0.042 0.054 1.37 x 10-12 0.73 Intergenic 
rs62376390 [G] 96172128 0.025 0.035 9.69 x 10-11 0.70 ERAP1 intron 
rs62377085 [A] 96395536 0.014 0.020 1.16 x 10-9 0.64 DS LNPEP 
imm_5_96379614* 96379614 0.049 0.038 5.58 x 10-6 1.23 LNPEP intron 
DS downstream, *no rsID, HG18 human genome build 18/NCBI build 36, MAF minor allele frequency 
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Figure 2.10 European FaST-LMM case-control analysis with the effects of rs30187 
and rs10050860 removed. The left hand axis is the –log10 of the P value, the higher 
this value is the smaller the P value. The right hand scale is the recombination rate 
which corresponds to the light blue line along the bottom of the graph. The location 
of the genes and genomic position on chromosome 5 are shown below the graph. 
The exons in the genes are represented by vertical blue lines on the line 
representing the gene. Graph markers represent individual SNPs, the colours 
represent the linkage disequilibrium (LD) in r2 between the SNP and the most 
associated SNP in the region chr5:96278345 (LD legend in the top left of graph). The 
shapes of the marks represent functional annotations: ! is a coding mutation, ! 
non-synonymous change, " is a framestop or splice change, a star is a conserved 
predicted transcription factor binding site, the square box with a cross inside it is 
highly conserved in placental mammals, ! and " is no annotation. 
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Table 2.7 European low frequency variants with P values of less than 1 x 10-3 in the 
5q15 locus when conditioned on rs30187 and rs10050860 
SNP [Allele] Position 
(HG18) 
MAF  
Cases 
MAF 
Controls 
P value OR Function 
rs62376445 [A] 96222477 0.042 0.054 4.34 x 10-7 0.80 Intergenic 
rs62377085 [A] 96395536 0.014 0.021 7.00 x 10-7 0.70 DS LNPEP 
rs62376390 [G] 96172128 0.025 0.035 1.87 x 10-6 0.78 ERAP1 intron 
DS downstream, * no rsID, MAF minor allele frequency, SNP single nucleotide polymorphism, OR Odds ratio, 
HG18 human Genome Build 18/NCBI build 36. 
 
2.3.5 European functionally important associated variants 
In the associated haplotype over ERAP2 and LNPEP there were 150 genotyped 
SNPs. This included two SNPs of particular functional importance. The first is 
rs2248374, whose G allele causes a splicing change which results in nonsense 
mediated decay of the ERAP2 mRNA and consequently no ERAP2 protein [62]. This 
loss of ERAP2 is protective of AS. This is analogous to the ERAP1 scenario where 
SNPs that decrease the function of ERAP1 are protective of AS. The second 
functionally important variant is rs2549782 that is associated with a change in the 
function of the ERAP2 enzyme [180]. The change can affect the catalytic rate of the 
enzyme up to 165 fold, and changes the specificity so it removes hydrophobic N-
terminal residues, similar to ERAP1. The association result for these variants is 
shown in Table 2.10. 
2.3.6 European HLA-B*27 stratified analysis 
When the data was stratified by HLA-B*27 status the HLA-B*27 positive group 
showed strong association over ERAP1 and no additional association signals were 
seen, as shown in Figure 2.11. When HLA-B*27 negative cases and controls were 
analysed this demonstrated no association over ERAP1 but an associated haplotype 
over ERAP2/LNPEP, shown in Figure 2.12. This is the same association 
signal/haplotype seen when the ERAP1 SNPs rs30187 and rs10050860 are 
conditioned out of the full analysis, both individually and together. 
 
 
62
Table 2.8 Number of cases and controls in the HLA-B*27 stratified cohorts 
 HLA-B*27 Negative Cohort HLA-B*27 Positive Cohort 
Cases 1,320 6,954 
Controls 9,223 894 
 
There were no low frequency variants in either the HLA-B*27 positive or HLA-B*27 
negative analysis with a P value of less than 1 x 10-3. 
 
Figure 2.11 European FaST-LMM HLA-B*27 positive stratified case-control analysis. 
The left hand axis is the –log10 of the P value, the higher this value is the smaller the 
P value. The right hand scale is the recombination rate which corresponds to the 
light blue line along the bottom of the graph. The location of the genes and genomic 
position on chromosome 5 are shown below the graph. The exons in the genes are 
represented by vertical blue lines on the line representing the gene. Graph markers 
represent individual SNPs, the colours represent the linkage disequilibrium (LD) in r2 
between the SNP and the most associated SNP in the region chr5:96173489 (LD 
legend in the top left of graph). The shapes of the marks represent functional 
annotations: ! is a coding mutation, ! non-synonymous change, " is a framestop 
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or splice change, a star is a conserved predicted transcription factor binding site, the 
square box with a cross inside it is highly conserved in placental mammals, ! and " 
is no annotation. 
 
Figure 2.12 European FaST-LMM HLA-B*27 negative stratified case-control 
analysis. The left hand axis is the –log10 of the P value, the higher this value is 
smaller the P value. The right hand scale is the recombination rate which 
corresponds to the light blue line along the bottom of the graph. The location of the 
genes and genomic position on chromosome 5 are shown below the graph. The 
exons in the genes are represented by vertical blue lines on the line representing the 
gene. Graph markers represent individual SNPs, the colours represent the linkage 
disequilibrium (LD) in r2 between the SNP and the most associated SNP in the 
region chr5:96278345 (LD legend in the top left of graph). The shapes of the marks 
represent functional annotations: ! is a coding mutation, ! non-synonymous 
change, " is a framestop or splice change, a star is a conserved predicted 
transcription factor binding site, the square box with a cross inside it is highly 
conserved in placental mammals, ! and " is no annotation. 
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Table 2.9 Lead SNP in each separate European case-control analysis 
Analysis Base 
Position* 
rs ID Minor Major MAF 
Cases 
MAF 
Controls 
P Value Minor OR (96% CI) Risk OR [Risk] 
Case-control 96,126,308 rs27529 A G 0.41 0.34 2.4 x 10-43 1.30 (1.29 - 1.31) A 1.30 
Case-control imputed 96,121,152 rs2032890 C A 0.24 0.31 1.6 x 10-43 0.76 (0.75 - 0.76) C 1.32 
rs30187 effect removed 96,252,589 rs2910686 G A 0.45 0.44 4.5 x 10-17 1.17 (1.16 - 1.18) G 1.17 
rs10050860 effect 
removed 
96,126,308 rs27529 A G 0.41 0.34 2.7 x 10-24 1.24 (1.23 - 1.25) A 1.24 
rs30187 & rs10050860 
effects removed 
96,252,589 rs2910686 G A 0.45 0.44 1.3 x 10-16 1.17 (1.16 -1.17) G 1.17 
HLA-B*27 negative 96,265,000 rs716848 T G 0.47 0.42 8.5 x 10-6 1.20 (1.19 -1.21) T 1.20 
HLA-B*27 negative 
imputed 
96,257,829 rs251343 T C 0.45 0.40 1.7 x 10-6 1.24 (1.24 - 1.25) T 1.24 
HLA-B*27 positive 96,147,733 rs10045403 G A 0.21 0.29 3.6 x 10-14 0.66 (0.65 - 0.66) A 1.53 
CI confidence interval, ID identifier, MAF minor allele frequency, OR odds ratio, *Human genome 19 
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Table 2.10 European case-control analysis detailed results of important variants 
rs ID Conditioned 
on 
Minor Major MAF Cases MAF Controls P value Minor OR (95% CI) Risk OR [Risk] 
rs30187  A G 0.41 0.34 1.27 x 10-41 1.29 (1.29-1.30) A 1.29 
rs30187 rs10050860 A G 0.41 0.34 6.94 x 10-23 1.23 (1.22-1.24) A 1.23 
          
rs10050860  A G 0.18 0.23 3.15 x 10-32 0.77 (0.76-0.77) G 1.30 
rs10050860 rs30187 A G 0.18 0.23 2.20 x 10-13 0.85 (0.84-0.85) G 1.18 
          
rs2248374   G A 0.49 0.50 0.0042 0.95 (0.94-0.96) A 1.05 
rs2248374  rs10050860 G A 0.49 0.50 0.00013 0.93 (0.93-0.94) A 1.07 
rs2248374  rs30187 G A 0.49 0.50 5.96 x 10-12 0.87 (0.87-0.88) A 1.14 
rs2248374  rs10050860 & 
rs30187 
G A 0.49 0.50 1.65 x 10-11 0.88 (0.87-0.88) A 1.14 
          
rs2549782   T G 0.49 0.50 0.0034 0.95 (0.94-0.95) G 1.05 
rs2549782  rs10050860 T G 0.49 0.50 9.49 x 10-5 0.93 (0.93-0.94) G 1.07 
rs2549782  rs30187 T G 0.49 0.50 3.45 x 10-12 0.87 (0.87-0.88) G 1.15 
rs2549782  rs10050860 & 
rs30187 
T G 0.49 0.50 9.47 x 10-12 0.88 (0.87-0.88) G 1.14 
          
HLA-B*27 
Negative 
         
rs30187  A G 0.35 0.34 0.61 [NS] 1.032 [NS] A 1.03 [NS] 
rs10050860  A G 0.21 0.22 0.25 [NS] 0.93 [NS] G 1.08 [NS] 
rs2248374   A G 0.53 0.49 5.08 x 10-5 1.18 (1.17-1.19) A 1.18 
rs2549782   G T 0.53 0.49 5.08 x 10-5 1.19 (1.18-1.20) G 1.19 
HLA-B*27 Neg 
Imputed 
         
rs2549794   C T 0.47 0.42 7.92 x 10-6 1.21 (1.21-1.22) C 1.21 
Fullset Imputed          
rs2549794  C T 0.43 0.43 0.070 1.034 [NS] T 1.034 [NS] 
          
NS not significant, Neg negative, Imput imputed, MAF minor allele frequency, Minor minor allele, OR odds ratio
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2.3.7 European imputed results 
In an attempt to better characterise the association seen over ERAP2/LNPEP 
phasing and imputing with MaCH/Minimac was performed. The imputation did not 
better characterise this region of strong LD with no SNP/s in the associated 
haplotype showing differential association, as shown in Figure 2.13. 
 
Figure 2.13 European HLA-B*27 negative analysis imputed with 1000 genomes 
data. The left hand axis is the –log10 of the P value, the higher this value is the 
smaller the P value. The right hand scale is the recombination rate which 
corresponds to the light blue line along the bottom of the graph. The location of the 
genes and genomic position on chromosome 5 are shown below the graph. The 
exons in the genes are represented by vertical blue lines on the line representing the 
gene. Graph markers represent individual SNPs, the colours represent the linkage 
disequilibrium (LD) in r2 between the SNP and the most associated SNP in the 
region: chr5:96257829 (LD legend in the top left of graph). The shapes of the marks 
represent functional annotations: ! is a coding mutation, ! non-synonymous 
change, " is a framestop or splice change, and ! and " is no annotation. 
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2.3.8 Excluding confounding as a cause for the ERAP2/LNPEP Association 
Due to the conditional nature of the association and the small sample size available, 
along with the lack of genome wide significant association further analysis was 
completed to confirm the association was not due to confounding or sampling bias. 
Excluding HLA-B*27 positive cases and controls would exclude an uneven number 
of ERAP1 alleles, this is because the frequency of AS is higher in those who are 
HLA-B*27 positive and consequently the ERAP1 risk alleles are also higher in this 
group. A permutation analysis was completed where an equal number of controls to 
match the number of cases was sampled. This was completed 100 times and the 
mean Chi squared test statistic was obtained, the result is shown in Figure 2.14. The 
result demonstrated that when the number of cases and controls are equalised there 
still remains an association over ERAP2/LNPEP. 
 
Figure 2.14 Mean association Chi squared value of the SNPs in the 5q15 locus after 
equalising the case and control numbers and performing the analysis 100 times. 
Therefore to further determine if the allele frequencies at different SNPs within 
ERAP1 influenced the association an analysis was performed which sampled equal 
numbers of cases and controls, but also ensured the number of ERAP1 alleles was 
equal in the cases and controls. This would have the effect of reducing power 
 
 
68
however would help to try to and demonstrate that confounding was not impacting on 
the result. For the first analysis the frequency of the ERAP1 SNP rs30187 allele was 
the same in both the case and control group. This sampling was repeated multiple 
times and association was tested for each time. The graph of the distribution of the 
test statistic is shown in Figure 2.15.  
 
Figure 2.15 Association Chi squared value of the lead SNP (rs2910686) in the 
associated ERAP2 haplotype in European HLA-B*27 negative cases and controls 
after making the number of rs30187 alleles equal and the number of cases and 
controls equal. The solid horizontal line at 4.9 is the –log10 P value when the allele 
frequencies and case-control numbers are uncorrected.  
This graph demonstrates that when the total number of rs30187 alleles in the case 
and control group are equal then the association of the ERAP2 haplotype is reduced 
in significance but is still present.   
This analysis was repeated to normalise the number of cases and controls and the 
total number of rs10050860 alleles in the case and control group, shown in Figure 
2.16.  
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Figure 2.16 Association Chi squared value of the lead SNP (rs2910686) in the 
associated ERAP2 haplotype in European HLA-B*27 negative cases and controls 
after making the number of rs10050860 alleles equal. The solid horizontal line at 4.9 
is the –log10 P value when the allele frequencies and case-control numbers are 
uncorrected. 
Therefore normalising the number of alleles at rs10050860 has the same effect as 
normalising the number of alleles at rs30187. The effect is to reduce the significance 
of association but the nature of the association remains. Finally the analysis was 
repeated to normalise the number of cases and controls and equalise both rs30187 
and rs10050860 alleles in the case and control groups. This is shown in Figure 2.17. 
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Figure 2.17 European HLA-B*27 negative analysis of the lead SNP (rs716848) when 
the ERAP1 allele frequencies of rs30187 and rs10050860 have been made equal 
between cases and controls. The solid horizontal line at 4.9 is the –log10 P value 
when the allele frequencies and case-control numbers are uncorrected. 
All these analyses demonstrate that the association is unlikely to be the result of 
confounding from unequal numbers of cases or uneven numbers of ERAP1 risk 
alleles between the case and control groups. This is because the association 
remained significant even when case and control numbers were equalised and the 
number of risk alleles at ERAP1 was equalised. 
2.3.9 European Shared Associations 
In the HLA-B*27 negative analysis the ERAP2 SNP associated with Crohn’s disease 
(rs2549794, allele C, P = 7.9 x 10-6, OR = 1.21) is also associated with AS [82]. In 
the Crohn’s disease study rs2549794, allele C was associated with a P value of 1.1 x 
10-10, at an OR of 1.05 (1.02-1.09). Therefore the direction of effect is the same 
between Crohn’s disease and AS. 
In psoriasis there is also an ERAP2 association, of a similar nature to the AS 
association in that it is only apparent after conditioning on the strong neighbouring 
signal in ERAP1 [207]. The authors did not report whether this association was 
confined to a sub-group carrying a specific class I allele but considering the similar 
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behaviour to the AS association this may be the case and should be investigated in 
the psoriasis dataset to confirm this. 
Psoriasis is also associated with SNPs in ERAP1. In an almost identical situation to 
AS, the lead SNP in the Strange et al. study, rs10484554, is only associated with 
disease if at least one copy of the psoriasis classical HLA risk allele HLA-Cw6 is 
present [171].  
In Behçet’s disease an association with rs10050860 and rs17482078 has been 
described. Interestingly the described association is only in the recessive model. It is 
also in the opposite direction to that of AS and psoriasis, and has a much larger 
effect size, OR = 4.56, P = 4.73 x 10-11. In addition they described an interaction 
between these SNPs and the classical MHC allele HLA-B51. In a similar situation to 
AS and psoriasis, those individuals with recessive homozygosity for the ERAP1 
variants only have increased risk of Behçet’s disease if they have HLA-B51. The OR 
for Behçet’s disease is 3.78 (1.94-7.35) for HLA-B51 positive individuals and 1.48 
(0.78-2.80) for HLA-B51 negative individuals [172].  
2.3.10 European Phenotype ERAP2/LNPEP Correlation 
To determine if the ERAP2/LNPEP association was caused by specific 
subphenotypes like psoriasis or inflammatory bowel disease (IBD) further analyses 
were undertaken. Phenotypes for 2,906 AS samples with psoriasis and inflammatory 
bowel disease (Crohn’s disease and ulcerative colitis) were obtained. The 
proportions of each phenotype in the HLA-B*27 negative and HLA-B*27 positive 
cases are shown in Table 2.11.  
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Table 2.11 Percentage of Psoriasis and Inflammatory Bowel Disease in the HLA-
B*27 Positive and HLA-B*27 Negative AS Cases. The denominators are different 
between the different phenotype groups within the HLA-B*27 positive and negative 
analyses due to missing data. 
Phenotype HLA-B*27 Negative 
Cases 
HLA-B*27 Positive 
Cases 
P value 
Psoriasis 71/396 (17.9%) 321/2139 (15.0%) 0.16 
Any IBD 45/394 (17.9%) 171/2122 (8.1%) 0.037 
Crohn’s disease 29/394 (7.4%) 75/2129 (3.5%) 0.00072 
Ulcerative colitis 26/393 (6.6%) 127/2125 (6.0%) 0.71 
Indeterminate IBD 2/120 (1.7%) 2/826 (0.24%) 0.14 
IBD – Inflammatory bowel disease 
This analysis shows there was a significant difference in the number of Crohn’s 
disease cases between the HLA-B*27 positive and negative groups. This is 
consistent with the previous observations of a lower HLA-B*27 carriage rate in AS 
associated with IBD [208]. There is no different in UC frequency between HLA-B*27 
positive and negative suggesting AS is more strongly associated with Crohn’s 
pathology than UC. In view of the significant difference in the number of cases with 
Crohn’s disease between the HLA-B*27 positive and negative groups the genotype 
frequency differences between those cases with Crohn’s disease and those without 
was assessed. These are shown in Table 2.12. The analysis demonstrates that 
although the frequency of Crohn’s disease is different between the HLA-B*27 
positive and negative groups the frequency of the associated SNPs is not different. 
This suggests that the inclusion of those with IBD is not a major driver of the 
association over ERAP2/LNPEP although the numbers being analysed in the 
Crohn’s disease group were small. 
 
 
73
Table 2.12 Comparison of ERAP2 allele frequencies between those AS cases with 
and without Crohn’s disease 
 Allele Crohn’s Disease 
Present 
n=30 
Crohn’s 
Disease Absent 
n=912 
P value 
rs2549782  T 0.48 0.47 0.93 
rs2248374   G 0.48 0.47 0.93 
rs2910686 G 0.45 0.47 0.82 
 
Table 2.13 Comparison of allele frequencies between AS cases with any diagnosis 
of inflammatory bowel disease and those without any diagnosis of inflammatory 
bowel disease 
 Allele Any IBD 
Present 
Any IBD 
Absent 
P value 
rs2549782  T 0.49 0.47 0.68 
rs2248374   G 0.49 0.47 0.69 
rs2910686 G 0.46 0.47 0.75 
 
2.3.11 Identification of Causal Variants in the European Cohort 
In an attempt to identify the causal variant/s out of the 150 associated SNPs over 
ERAP2/LNPEP a number of different strategies were employed. The first involved 
removing the effect of the different layers of SNPs (separated by LD groupings) by 
adding their dosage weights as a fixed effect in the LMM. When the effect of the 
haplotype with LD of 0.6 - 0.8 to the lead SNP (yellow SNPs in Figure 2.12) is 
removed then the association analysis is shown in Figure 2.18. 
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Figure 2.18 HLA-B*27 negative analysis with the effect of the lower line of SNPs 
removed (yellow SNPs in Figure 2.12). The left hand axis is the –log10 of the P value, 
the higher this value is the smaller the P value. The right hand scale is the 
recombination rate which corresponds to the light blue line along the bottom of the 
graph. The location of the genes and genomic position on chromosome 5 are shown 
below the graph. The exons in the genes are represented by vertical blue lines on 
the line representing the gene. Graph markers represent individual SNPs, the 
colours represent the linkage disequilibrium (LD) in r2 between the SNP and the 
most associated SNP in the region chr5:96254981 (LD legend in the top right of 
graph). The shapes of the marks represent functional annotations: ! is a coding 
mutation, ! non-synonymous change, " is a framestop or splice change, a star is a 
conserved predicted transcription factor binding site, the square box with a cross 
inside it is highly conserved in placental mammals, ! and " is no annotation. 
When the effects of the highest correlated SNPs to the lead SNP are removed (red 
SNPs in Figure 2.12 LD r2 0.8-1) the association analysis is shown in Figure 2.19.  
 
 
75
 
Figure 2.19 HLA-B*27 negative analysis with the effect of the upper line of SNPs 
removed (Red SNPs in Figure 2.12). The left hand axis is the –log10 of the P value, 
the higher this value is the smaller the P value. The right hand scale is the 
recombination rate which corresponds to the light blue line along the bottom of the 
graph. The location of the genes and genomic position on chromosome 5 are shown 
below the graph. The exons in the genes are represented by vertical blue lines on 
the line representing the gene. Graph markers represent individual SNPs, the 
colours represent the linkage disequilibrium (LD) in r2 between the SNP and the 
most associated SNP in the region chr5:96380128 (LD legend in the top right of 
graph). The shapes of the marks represent functional annotations: ! is a coding 
mutation, ! non-synonymous change, " is a framestop or splice change, a star is a 
conserved predicted transcription factor binding site, the square box with a cross 
inside it is highly conserved in placental mammals, ! and " is no annotation. 
Both of these analyses demonstrate the region has high LD. The different levels of 
association seen demonstrated by the two lines of SNPs is likely due to differences 
in LD between the SNPs and the lead SNP in the haplotype. 
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2.3.12 European Genecluster Analysis 
The next approach was to use Genecluster to analyse the SNPs in the region to 
determine if using a Bayesian approach modelling evolutionary haplotypes would be 
able to identify the causal SNP/s. The result of the Genecluster analysis with the 
Bayes factor is shown in Figure 2.20. 
 
Figure 2.20 Initial European HLA-B*27 negative Genecluster results using genotyped 
SNPs and 400 haplotypes. The green line is the post-test log10 Bayes Factor of 
SNPs being the causal variant/s in the HLA-B*27 negative unimputed European 
case-control analysis under the two mutation model. The upper red line is the post 
test probability of SNPs being the causal variants under the one mutation model. The 
top panel shows the log10 Bayes factor on the y axis and the genomic position on the 
x axis. The lower panel shows the distance from hit SNP (purple line) and 
recombination frequency (red line). The different coloured lines in the graph 
represent the models assuming either 1 (red) mutation or 2 (green) mutations.  
The Bayes factors for the unimputed Genecluster results were 2.71 for the one 
mutation model and 2.70 for the 2 mutation model. In this initial analysis the 
algorithm was unable to determine any SNPs with a higher post-test probability of 
being the causal variant/s (data not shown). 
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In an effort to try to improve the predictive power of the Genecluster programme the 
data was imputed to 1000 genomes and then analysed again with Genecluster. The 
imputed Genecluster result is shown in Figure 2.21. 
 
 
Figure 2.21 Imputed Genecluster result of HLA-B*27 negative Europeans. The top 
panel shows the log10 Bayes factor on the y axis and the genomic position on the x 
axis. The lower panel shows the distance from hit SNP (purple line) and 
recombination frequency (red line). The different coloured lines in the graph 
represent the models assuming either 1 (red) mutation or 2 (green) mutations. 
In the imputed Genecluster analysis the log10 Bayes factor for the 1 mutation model 
was 2.45, and the log10 Bayes Factor for the 2 mutation model was 2.51. This would 
marginally favour the 2 mutation model over the 1 mutation model. The model is not 
able to always predict the most likely SNPs in the most favoured model but produces 
a list of possible candidates that are more likely. The functionally important SNPs 
rs2549782 and rs2248374 was in the list of candidates for both the 1 and 2 mutation 
models. 
We were not able to separate these SNPs with this method, however the actual 
practical significance of doing this is low because rs2248374[G] causes a complete 
absence of ERAP2 enzyme and the rs2549782 SNP changes the catalytic activity 
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and specificity of ERAP2  [180, 209]. From European 1000 genomes data the in-
phase alleles are rs2549782 [T]-rs2248274[G], with a D’ of 1.0000 and r2 of 0.9037 
(1000 genomes June 2010 CEU data). It has been reported the N392K (T allele) 
amino acid change of rs2549782 reduces its catalytic turnover [180]. The C allele at 
the rs2549782 SNP changes the specificity of the enzyme to make it cleave more 
hydrophobic residues from the N-terminus similar to the activity of ERAP1. The 
complete loss of mRNA SNP (rs2248374[G]) is in almost complete LD with the SNP 
predicted to reduce catalytic activity (rs2549782[T]), meaning in reality this will have 
little functional effect as the enzyme is never made. 
2.3.13 Linkage Disequilibrium in Europeans and Asians 
Table 2.14 Summary of linkage disequilibrium and in phase alleles between ERAP1 
and ERAP2 in Europeans and east Asians 
Metric & Set ERAP1: rs30187- 
ERAP1: rs10050860 
ERAP1: rs30187-
ERAP2: rs2548792 
ERAP1: rs10050860-
ERAP2: rs2549782 
    
EUROPEAN    
1000 Genomes    
r2 0.16 0.07 0.53 
D’ 1.00 0.38 0.08 
    
PLINK    
r2 0.15 0.08 0.01 
D’ 1.00 0.37 0.17 
    
In phase alleles T-C T-T C-T 
    
ASIAN    
1000 Genomes    
r2 0.03 0.17 0.00 
D’ 1.00 0.55 0.34 
    
PLINK    
r2 0.05 0.30 0.00 
D’ 0.99 0.63 0.36 
    
In phase alleles* T-C C-G C-G 
1000 Genomes release: European – June 2010 CEU, Asian June 2010 CHT & JPT. *From 1000 genomes 
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2.3.14 European ERAP1/ERAP2 Haplotype Analysis 
Haplotype analysis was performed with phased haplotypes using Beagle, and 
population structure controlled with eigenvectors, which are covariates constructed 
using principle component analysis. The LD between rs30187 and rs2549782 is 
modest (see Table 2.14). The haplotype analysis with HLA-B*27 negative and 
positive combined is shown in Table 2.15, and then the analysis stratified by HLA-
B*27 status is shown in Table 2.16. 
In both these haplotype analyses the effect of the rs30187 alleles has been labelled 
wildtype (WT) and risk for its alleles C and T respectively. The wildtype allele of 
rs30187 has a relative protective effect when compared to the risk allele. Rs2549782 
has 50:50 allele frequency so is labelled as risk or protective. In the effect column 
the test statistic is presented, a positive value being risk effect and a negative value 
a protective effect. 
First examining Table 2.15, this shows the combined case and control analysis 
incorporating both HLA-B*27 positive and negative participants. On the first line the 
wildtype[ERAP1]-risk[ERAP2] haplotype of CG has no effect on risk of AS (P = 0.34). 
But when the ERAP2 allele is changed to the protective allele there is now a strong 
protective effect of this haplotype (P < 2 x 10-16). Both the haplotypes containing the 
risk allele of rs30187 ‘T’ confer risk (P values < 2 x 10-16 and P < 6.7 x 10-10). 
Now if you examine Table 2.16 the CG haplotype (ERAP1-WT/ERAP2-Risk) has a 
negligible effect in HLA-B*27 positive participants (P = 0.03), but if you examine its 
effect in HLA-B*27 negative patients you see it has a risk effect (P = 4.5 x 10-6). If 
you now examine the CT haplotype (ERAP1-WT-ERAP2-Protective) there is now a 
significant protective effect in both HLA-B*27 positives and negatives (P = 1.1 x 10-7 
and P = 2.0 x 10-5 respectively). If you now examine both haplotypes with the ERAP1 
risk allele “T”, one sees in HLA-B*27 positive participants the haplotypes infer a risk 
effect (P = 1.2 x 10-5 and P = 6.7 x 10-5), as expected by the epistasis known to exist. 
If you now examine the effect of the haplotypes with the rs30187 risk allele T in HLA-
B*27 negatives there is no effect of either of the ERAP2 alleles (P = 0.53 and P = 
0.85). This is not the expected result if our hypothesis is true that ERAP1 has no 
effect in HLA-B*27 negative patients. The interpretation of this data is complicated by 
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LD between ERAP1 and ERAP2 and the fact there is also another risk haplotype of 
ERAP1 (tagged by rs10050860) that may be complicating the analysis. 
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Table 2.15 Haplotype Analysis of European ERAP1 and ERAP2 haplotypes 
Haplotypes  HLA-B*27 Positive and Negative Combined 
   Haplotype Counts Haplotype Frequency Effect P value 
rs30187 rs2549782  Cases Controls Cases Controls   
WT Risk CG 6,260 7,774 0.38 0.39 -0.02 0.34 
WT Pro CT 3,514 5,447 0.22 0.27 -0.31 <2 x 10-16 
Risk Pro TT 4,480 4,690 0.27 0.23 0.22 <2 x 10-16 
Risk Risk TG 2,086 2,145 0.13 0.11 0.20 6.7 x 10-10 
Pro – Protective, WT – wildtype, rs30187(ERAP1), rs2549782(ERAP2) 
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Table 2.16 Haplotype Analysis of European ERAP1 and ERAP2 haplotypes stratified by HLA-B*27 status 
Haplotypes  HLA-B*27 Positive Cohort HLA-B*27 Negative Cohort 
   Haplotype Counts Haplotype Freq Effect P value Haplotype Counts Haplotype Freq Effect P value 
rs30187 rs2549782  Cases Controls Cases Controls   Cases Controls Cases Controls   
WT Risk CG 5,221 723 0.38 0.4 -0.12 0.0255 1,039 7,051 0.43 0.39 0.20 4.48 x 10-6 
WT Pro CT 2,949 476 0.21 0.27 -0.31 1.11 x 10-7 565 4,971 0.23 0.27 -0.22 1.96 x 10-5 
Risk Pro TT 3,918 416 0.28 0.23 0.27 1.18 x 10-5 562 4,274 0.23 0.23 -0.03 0.53 
Risk Risk TG 1,820 173 0.13 0.1 0.34 6.73 x 10-5 266 1,972 0.11 0.11 -0.01 0.85 
Pro – protective, Freq – frequency, WT - wildtype, Pro - protective 
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2.3.15 Epistasis with classical HLA alleles 
Classical HLA alleles for HLA-A, HLA-B, HLA-C, HLA-DQA, HLA-DQB and HLA-
DRB1 were imputed with HLA*IMP version 1. The allele genotypes were then 
converted into dosage data and genotype data from the 5q15 locus was integrated 
using R. Logistic regression using an interaction term was performed in the HLA-
B*27 negative group with the important ERAP2 SNPs and sequentially substituted 
HLA-classical alleles. The HLA-B*27 negative group was selected because the 
frequency of HLA-B*27 and its strong effect meant that including HLA-B*27 positive 
samples in the analysis would have resulted in all non-HLA-B*27  ‘B’ alleles having a 
protective effect, due to confounding. In total 114 alleles were tested in this way and 
no interaction was found between ERAP2 and any classical allele, alleles previously 
implicated in AS are shown in Table 2.17.  
 
Table 2.17 Selected important interaction results between the important ERAP2 SNP 
rs2549782 and classical HLA alleles imputed by HLA*IMP in HLA-B*27 negative 
cases and controls. Bonferroni correction results in no association results of 
significance (Threshold = 4.4 x 10-4) 
Classical MHC Allele rs2549782 
 P value Odds Ratio 
HLA-A*02 0.13 0.90 
HLA-B*40 0.50 1.07 
HLA-DRB1*0101 0.03 1.27 
HLA-DRB1*1501 0.07 0.84 
 
2.3.16 European Interaction Analysis 
Using logistic regression incorporating eigenvectors to control for population 
structure the evidence for interaction between HLA-B*27 and important ERAP1 
SNPs was investigated. Whether there is evidence for interaction between ERAP2 
with HLA-B*27 was also tested. The results are shown in Table 2.18, negative 
coefficients indicate protective effect and positive coefficients indicate risk effect. The 
results indicate robust evidence for association at all the previously described SNPs 
(rs30187 and rs10050860). It also demonstrates strong evidence for an interaction of 
 
 
84
the ERAP1 SNPs rs30187 and rs10050860 and HLA-B*27, as previously described 
[60].  
At ERAP2 in the full set there is nominal association at rs2549782 (P = 0.003), and 
there is no significant interaction with HLA-B*27 (P = 0.005). But in the model 
incorporating the interaction term between rs2549782 and HLA-B*27 the rs2549782 
SNP is protective of AS with a P value of 7.6 x 10-6. Therefore there is some 
evidence for an interaction. There is, however, as shown previously, association 
demonstrated in HLA-B*27 negative patients and this may be mediated by an 
alternate effect. This may be due to the significant effect size of ERAP1-HLA-B*27, 
and the ERAP2 effect is masked by this in the full group. This would explain why the 
effect becomes more significant when HLA-B*27 is either incorporated into the 
model as a factor or as an interaction term. The other possibility is that there is a 
‘hidden’ subgroup that is partially tagged by HLA-B*27 negative status, and when 
this group is stratified out this effect is seen but the effect is diluted to nothing in the 
entire case-control analysis. 
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Table 2.18 Logistic Regression Analysis of European ERAP1 and ERAP2 
association 
Logistic Regression Model Component Odds ratio P Value 
AS~HLA-B*27 HLA-B*27 55.2 <2 x 10-16 
    
AS~rs30187 [A] rs30187 0.76 <2 x 10-16 
    
AS~rs10050860 [A] rs10050860 0.74 <2 x 10-16 
    
AS~rs2549782 [T]* rs2549782 0.94 0.0031 
    
AS~rs30187+HLA-B*27 rs30187 0.87 0.38 x 10-5 
 HLA-B*27 54.1 <2 x 10-16 
    
AS~rs30187*HLA-B*27 rs30187 1.04 0.34 
 HLA-B*27 98.5 <2 x 10-16 
 Interaction  8.98 x 10-11 
    
AS~rs10050860+HLA-B*27 rs10050860 0.97 4.2 x 10-7 
 HLA-B*27 54.5 <2 x 10-16 
    
AS~rs10050860*HLA-B*27 rs10050860 0.97 0.58 
 HLA-B*27 65.4 <2 x 10-16 
 Interaction  5.9 x 10-8 
    
AS~rs2549782+HLA-B*27 rs2549782 0.89 0.00045 
 HLA-B*27 55.15 <2 x 10-16 
    
AS~rs2549782*HLA-B*27 rs2549782 0.83 7.60 x 10-6 
 HLA-B*27 46.1 <2 x 10-16 
 Interaction  0.0052 
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AS~rs10050860*HLA-B*27+ 
rs30187*HLA-B*27 
rs10050860 0.94 0.31 
 rs30187 1.06 0.21 
 HLA-B*27 101.5 <2 x 10-16 
 rs10050860 
int 
 0.00094 
 rs30187 int  3.02 x10-7 
    
AS~rs10050860+rs30187+rs2549782+H
LA-B*27 
rs10050860 0.84 0.00019 
 rs30187 0.87 0.00028 
 rs2549782 0.85 1.77 x 10-6 
 HLA-B*27 54.1 <2e-16 
    
    
AS~rs10050860*HLA-B*27+ 
rs30187*HLA-B*27+ rs2549782+HLA-
B*27 
rs10050860 -0.05 0.33 
 rs30187 0.95 0.82 
 rs2549782 0.83 1.39 x10-5 
 HLA-B*27 95.6 <2 x10-16 
 rs10050860 
int 
 0.0013 
 rs30187 int  1.06 x 10-6 
 rs2549782 int  0.45 
 
2.3.17 Comparative Results with Previous European Studies 
Previous studies on European populations have published a number of results from 
various SNPs. The previous results along with the equivalent Immunochip marker 
and result is shown in Table 2.19.  
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Table 2.19 Comparative Analysis with Previous European ERAP1 studies 
Study SNP Cas/Con Population Allele P Value Odds 
Ratio 
Maksymowych rs26653 992/1437 Canadian C 0.001 1.23 
Current rs26653 9074/13607 EuroDes C 1.2 x 10-18 1.19 
       
Reveille rs27037 2951/6558 UK & NAm A 8.2 x 10-11 1.36 
Current rs27037 Not present - - - - 
       
Burton rs27044 912/1500 UK NS 1 x 10-6 1.40 
Pi-San rs27044 358/285 Portuguese G 0.044 1.26 
Pazar rs27044 297/200 Hungarian G 0.001 NS 
Current rs27044 Not present - - - - 
       
Reveille rs27434 2951/6558 UK & NAm A 5.3 x 10-12 1.33 
Current rs27434 Not present - - - - 
       
Pi-San rs30187 358/285 Portuguese T 0.04 1.26 
Burton rs30187 912/1500 UK NS 3 x 10-6 1.33 
Evans rs30187 4810/13579 UK & NAm T 1.8 x 10-27 1.28 
Maksymowych rs30187 992/1437 Canadian T 0.001 1.34 
Pazar rs30187 297/200 Hungarian T 0.05 NS 
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Current rs30187 9074/13607 EuroDes A 1.3 x 10-41 1.29 
       
Pi-San rs2287987 358/285 Portuguese C 0.07 0.77 
Burton rs2287987 912/1500 UK NS 1.6 x 10-4 0.75 
Pazar rs2287987 297/200 Hungarian T 0.002 NS 
Current rs2287987 Not present     
       
Pazar rs10050860 297/200 Hungarian C 0.006 NS 
Burton rs10050860 912/1500 UK NS 1.1 x 10-4 0.75 
Maksymowych rs10050860 992/1437 Canadian T 0.001 0.79 
Pi-San rs10050860 358/285 Portuguese T 0.06 0.76 
Evans rs10050860 4810/13579 UK C 1.9 x 10-7 1.22 
Current rs10050860 9074/13607 EuroDes A 3.2 x 10-32 0.77 
       
Burton rs17482078 912/1500 UK NS 2.3 x 10-4 0.76 
Pazar rs17482078 297/200 Hungarian C 0.04 NS 
Pi-San rs17482078 358/285 Portuguese T 0.10 0.78 
Current rs17482078 9074/13607 Euro Des T 7.7 x 10-31 0.77 
NS – Not stated 
2.3.18 Asian Linkage Disequilibrium  Maps 
The Asian case-control LD map is shown in Figure 2.22 and shows a similar pattern 
of linkage disequilibrium compared to the European cohort (shown in Figure 2.6).  
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Figure 2.22 Asian case and control linkage disequilibrium map of 5q15 locus. Each 
dot represents a pairwise comparison between two individual single nucleotide 
polymorphisms (SNPs). The more intense the black the higher the linkage 
disequilibrium between the two SNPs. Linkage disequilibrium is measured in r2 on 
this graph which ranges from 0 (indicated by a white squared), to 1 (indicated by a 
black square). An r2 of 1 indicates the two SNPs are in complete linkage 
disequilibrium and there is no cross over observed between these two genomic 
positions, meaning the allele at one position can be used to predict the allele at the 
other position. Likewise an r2 of 0 indicates there is always cross over between these 
two genomic positions and therefore the allele at one position offers no predictive 
information about the allele at the other position. 
2.3.19 Asian Case-control Analysis & Power Considerations 
The zoom plot of the Asian case-control analysis is shown in Figure 2.23. Low 
frequency variants are not shown due to the low power to detect these. The result 
shows association over ERAP1, but at a lower level of significance compared to the 
European analysis, likely due to reduced power from a lower sample size, see Figure 
2.23. The study had good power to detect the rs30187 association in east Asians, 
but due to the difference in allele frequencies of rs10050860 in east Asians 
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compared to Europeans (‘A’ allele in east Asian AS cases 0.04 vs 0.18 in European) 
there was much greater reduced in power to detect this association. The power 
calculations are shown in Table 2.20 and demonstrate that at an alpha of 0.05 we 
had a power (1-β) of 0.47, but if we using an α of 5 x 10-8 our power was only 
0.00018. To achieve power of 0.80 with a genome wide significant P value we would 
require 17,382 cases. 
Table 2.20 Power calculations for rs10050860 association in the east Asian cohort. 
A: Power achieved in this study. B: Number of cases required to achieve power at an 
α = 0.05 or 5 x 10-8. 
A:   
α required Power attained Case number present 
0.05 0.47 1,550 
5 x 10-8 0.00018 1,550 
 
B: 
  
α required Power required Case number required 
0.05 0.80 3,445 
5 x 10-8 0.80 17,382 
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Figure 2.23 Asian case-control analysis. The left hand scale is the –log10 of the P 
value, the higher this value is the smaller the P value. The right hand axis is the 
recombination rate which corresponds to the light blue line along the bottom of the 
graph. The location of the genes and genomic position on chromosome 5 are shown 
below the graph. The exons in the genes are represented by vertical blue lines on 
the line representing the gene. Graph markers represent individual SNPs, the 
colours represent the linkage disequilibrium (LD) in r2 between the SNP and the 
most associated SNP in the region chr5:96146015 (LD legend in the top right of 
graph). The shapes of the marks represent functional annotations: ! is a coding 
mutation, ! non-synonymous change, " is a framestop or splice change, a star is a 
conserved predicted transcription factor binding site, the square box with a cross 
inside it is highly conserved in placental mammals, ! and " is no annotation. 
Taking the Asian case-control analysis and removing the effect of rs30187 showed 
minor association over ERAP2 and no real association remaining over ERAP1, 
demonstrating the poor power to detect the rs10050860 association, shown in Figure 
2.24. Detailed results are shown in Table 2.24. 
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Figure 2.24 Asian case-control analysis after removing the effect of rs30187. The left 
hand axis is the –log10 of the P value, the higher this value is the smaller the P value. 
The right hand scale is the recombination rate which corresponds to the light blue 
line along the bottom of the graph. The location of the genes and genomic position 
on chromosome 5 are shown below the graph. The exons in the genes are 
represented by vertical blue lines on the line representing the gene. Graph markers 
represent individual SNPs, the colours represent the linkage disequilibrium (LD) in r2 
between the SNP and the most associated SNP in the region chr5:96237497 (LD 
legend in the top left of graph). The shapes of the marks represent functional 
annotations: ! is a coding mutation, ! non-synonymous change, " is a framestop 
or splice change, a star is a conserved predicted transcription factor binding site, the 
square box with a cross inside it is highly conserved in placental mammals, ! and " 
is no annotation. 
Removing the effect of the rs10050860 allele does not affect the association plot in 
any significant way because there is no significant association with this allele in east 
Asians, shown in Figure 2.25. Detailed results are shown in Table 2.24. 
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Figure 2.25 Asian case-control analysis conditioned on rs10050860. The left hand 
axis is the –log10 of the P value, the higher this value is the smaller the P value. The 
right hand scale is the recombination rate which corresponds to the light blue line 
along the bottom of the graph. The location of the genes and genomic position on 
chromosome 5 are shown below the graph. The exons in the genes are represented 
by vertical blue lines on the line representing the gene. Graph markers represent 
individual SNPs, the colours represent the linkage disequilibrium (LD) in r2 between 
the SNP and the most associated SNP in the region chr5:96146015 (LD legend in 
the top right of graph). The shapes of the marks represent functional annotations: ! 
is a coding mutation, ! non-synonymous change, " is a framestop or splice 
change, a star is a conserved predicted transcription factor binding site, the square 
box with a cross inside it is highly conserved in placental mammals, ! and " is no 
annotation. 
When the effect of rs30187 and rs10050860 are simultaneously removed there is 
very little association, see Figure 2.26. But of interest there is a very slight rise over 
ERAP2/LNPEP, perhaps analogous to what was observed in the European dataset. 
This could potentially suggest that the ERAP2/LNPEP finding could be replicated in 
Asians if a large enough sample size could be assembled. 
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Figure 2.26 Asian Case-control Analysis conditioned on rs30187 and rs10060850. 
The left hand axis is the –log10 of the P value, the higher this value is the smaller the 
P value. The right hand scale is the recombination rate which corresponds to the 
light blue line along the bottom of the graph. The location of the genes and genomic 
position on chromosome 5 are shown below the graph. The exons in the genes are 
represented by vertical blue lines on the line representing the gene. Graph markers 
represent individual SNPs, the colours represent the linkage disequilibrium (LD) in r2 
between the SNP and the most associated SNP in the region chr5:9623747 (LD 
legend in the top left of graph). The shapes of the marks represent functional 
annotations: ! is a coding mutation, ! non-synonymous change, " is a framestop 
or splice change, a star is a conserved predicted transcription factor binding site, the 
square box with a cross inside it is highly conserved in placental mammals, ! and " 
is no annotation. 
Detailed results and odds ratios of all the Asian analyses are shown in Table 2.24. 
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Figure 2.27 Asian Case-control Analysis conditioned on rs2927613. The left hand 
axis is the –log10 of the P value, the higher this value is the smaller the P value. The 
right hand scale is the recombination rate which corresponds to the light blue line 
along the bottom of the graph. The location of the genes and genomic position on 
chromosome 5 are shown below the graph. The exons in the genes are represented 
by vertical blue lines on the line representing the gene. Graph markers represent 
individual SNPs, the colours represent the linkage disequilibrium (LD) in r2 between 
the SNP and the most associated SNP in the region chr5:96367084 (LD legend in 
the top right of graph). The shapes of the marks represent functional annotations: ! 
is a coding mutation, ! non-synonymous change, " is a framestop or splice 
change, a star is a conserved predicted transcription factor binding site, the square 
box with a cross inside it is highly conserved in placental mammals, ! and " is no 
annotation. 
2.3.20 East Asian differential SNP association and LD pattern 
The differing association of rs2927613 between the European and east Asian cohort 
is of interest. There are clear differences in the LD between these two SNPs, shown 
in Table 2.21 and Table 2.22. 
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The SNP’s T allele is associated in Europeans with a P value of 4.02 x 10-6 and an 
OR = 0.92. Its association P value drops to 2.01 x 10-6 when the effect of rs30187 is 
removed, and when the effect of rs10050860 is removed its association is similar at 
2.24 x 10-5. 
. 
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Table 2.21 Linkage disequilibrium pattern across the 5q15 locus in Europeans (cases/controls) 
rsID  rs30187 rs2927613 rs2549782 rs2248374 rs2910686 
 Position 96150086 96224448 96256756 96261652 96278345 
rs30187 96150086 1.000 r2 = 0.00/0.00 r2 = 0.11/0.07 r2 = 0.11/0.07 r2 = 0.20/0.15 
       
rs2927613 96224448 D’ = 0.05/0.00 1.000 r2 = 0.04/0.03 r 2 = 0.04/0.03 r2 = 0.06/0.05 
       
rs2549782 96256756 D’ = 0.40/0.36 D’ = 0.26/0.22 1.000 r2 = 1.00/1.00 r2 = 0.79/0.80 
       
rs2248374 96261652 D’ = 0.40/0.07 D = 0.256/22 D’ = 1.00/1.00 1.000 r2 = 0.79/0.80 
       
rs2910686 96278345 D’ = 0.60/0.62 D’ = 0.37/0.32 D’ = 1.00/1.00 D’ = 1.00/1.00 1.000 
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Table 2.22 Linkage disequilibrium pattern across the 5q15 locus in east Asian cases/controls 
rsID  rs30187 rs2927613 rs2549782 rs2248374 rs2910686 
 Position 96150086 96224448 96256756 96261652 96278345 
rs30187 96150086 1.000 r2= 0.12/0.14 r2=0.35/0.25 r2=0.35/0.25 r2=0.35/0.25 
       
rs2927613 96224448 D’= 0.81/0.81 1.000 r2=0.00/0.01 r2=0.00/0.01 r2=0.00/0.01 
       
rs2549782 96256756 D’= 0.65/0.60 D’=0.09/0.19 1.000 r2=1.00/1.00 r2=0.96/0.97 
       
rs2248374 96261652 D’= 0.65/0.60 D’=0.09/0.18 D’=1.00/1.00 1.000 r2=0.97/0.97 
       
rs2910686 96278345 D’= 0.65/0.60 D’=0.18/0.25 D’=0.95/0.99 D’=0.99/0.99 1.000 
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2.3.21 Asian Results Summary 
 
Table 2.23 Lead SNP in each Asian case-control analysis 
Analysis Immunochip ID Rs ID Minor Major MAF Cases MAF 
Controls 
P Value Minor OR (95% CI) Risk OR[Risk] 
Case-control imm_5_96224448 rs2927613 T C 0.13 0.18 6.05x10-8 0.69 (0.67-0.71) C 1.45 
Conditioned on 
rs30187 
imm_5_96224448 rs2927613 T C 0.13 0.18 4.0 x 10-5 0.74 (0.73-0.76) C 1.34 
Conditioned on 
rs10050860 
imm_5_96224448 rs2927613 T C 0.13 0.18 1.1 x 10-6 0.70 (0.69-0.72) C 1.43 
Conditioned on 
rs2927613 
imm_5_96281951 No rs ID A G 0.05 0.07 4.6 x 10-4 0.68 (0.66-0.70) G 1.48 
Conditioned on 
rs30187 and 
rs10050860 
imm_5_96224448 rs2927613 T C 0.13 0.18 1.1 x 10-4 0.75 (0.73-0.77) C 1.34 
OR odds ratio, ID identifier, MAF minor allele frequency, CI confidence interval 
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Table 2.24 Detailed Asian Case-control Analysis Results 
Immunochip ID rs ID Conditioned 
on 
Minor Major MAF 
Cases 
MAF 
Controls 
P value Minor OR (95% CI) Risk OR[Risk] 
ccc-5-96150086-T-C rs30187  G A 0.46 0.51 2.09 x 10-5 0.81 (0.79-0.83) A 1.24 
ccc-5-96150086-T-C rs30187 rs10050860 G A 0.46 0.51 1.13 x 10-4 0.82 (0.80-0.84) A 1.22 
ccc-5-96150086-T-C rs30187 rs2927613 G A 0.46 0.51 0.01 0.88 [NS] A 1.14 [NS] 
           
ccc-5-96147966-C-T rs10050860  A G 0.04 0.05 0.02 0.76 (0.740-0.775) G 1.32 
ccc-5-96147966-C-T rs10050860 rs30187 A G 0.04 0.05 0.15 0.85 [NS] G 1.18 [NS] 
ccc-5-96147966-C-T rs10050860 rs2927613 A G 0.04 0.05 0.61 0.94 [NS] G 1.06 [NS] 
           
imm_5_96224448 rs2927613  T C 0.13 0.18 6.05 x 10-8 0.69 (0.669-0.703) C 1.46 
imm_5_96224448 rs2927613 rs30187 T C 0.13 0.18 3.98 x 10-5 0.74 (0.726-0.763) C 1.34 
imm_5_96224448 rs2927613 rs10050860 T C 0.13 0.18 9.88 x 10-7 0.70 (0.679-0.716) C 1.43 
OR odds ratio, ID identifier, MAF minor allele frequency, CI confidence interval 
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2.3.22 East Asian Interaction Logistic Regression Analysis 
To examine for HLA-B*27-ERAP1-ERAP2 interactions logistic regression analysis was 
performed, rs30187 had a strong association with AS (P = 4.6x10-5), but rs10050860 only 
had nominal association (P = 0.009). The SNP in the associated ERAP2/LNPEP haplotype 
(rs2549782) in Europeans was not associated in Asians (P = 0.37). Using the Lin et al. tag 
SNP as a HLA-B*27 tag, and testing for interaction with rs30187 and HLA-B*27 there was 
no significant interaction (P = 0.63). There was also no interaction demonstrated between 
rs2549782 from the ERAP2/LNPEP haplotype and HLA-B*27 (P = 0.57), likely due to a 
lack of power. Putting all the SNPs and adding interaction terms into a full logistic 
regression model failed to demonstrate any interactions. Details are shown in Table 2.25. 
 
Table 2.25 Logistic Regression Analysis of east Asian ERAP1 and ERAP2 association 
Logistic Regression Model Component Coefficient P Value 
AS~HLA-B*27 HLA-B*27 4.02 <2 x 10-16 
AS~rs30187 rs30187 -0.21 4.6 x 10-5 
AS~rs10050860 rs10050860 -0.33 0.009 
AS~rs2549782 rs2549782 -0.05 0.37 
AS~rs30187+HLA-B*27 rs30187 -0.31 8.2 x 10-5 
 HLA-B*27 4.04 <2 x 10-16 
AS~rs30187*HLA-B*27 rs30187 -0.24 0.1180 
 HLA-B*27 4.12 <2 x 10-16 
 Interaction -0.09 0.63 
AS~rs10050860+HLA-B*27 rs10050860 -0.62 0.0005 
 HLA-B*27 4.04 <2 x 10-16 
AS~rs10050860*HLA-B*27 rs10050860 -0.57 0.21 
 HLA-B*27 4.04 <2 x 10-16 
 Interaction -0.07 0.89 
AS~rs2549782+HLA-B*27 rs2549782 -0.11 0.15 
 HLA-B*27 4.02 <2 x 10-16 
AS~rs2549782*HLA-B*27 rs2549782 -0.19 0.23 
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 HLA-B*27 3.94 <2 x10-16 
 Interaction 0.10 0.57 
    
AS~rs10050860*HLA-B*27+ 
rs30187*HLA-B*27 
rs10050860 -0.45 0.33 
 rs30187 -0.20 0.20 
 HLA-B*27 4.13 0.33 
 rs10050860 
int 
-0.059 0.91 
 rs30187 int -0.083 0.65 
AS~rs10050860+ 
rs30187+rs2549782+HLA-B*27 
rs10050860 -0.49 0.009 
 rs30187 -0.28 0.004 
 rs2549782 0.034 0.73 
 HLA-B*27 4.05 <2 x 10-16 
AS~rs10050860*HLA-B*27+ 
rs30187*HLA-B*27+ rs2549782+HLA-
B*27 
rs10050860 -0.52 0.27 
 rs30187 -0.13 0.50 
 rs2549782 -0.14 0.45 
 HLA-B*27 4.06 <2 x10-16 
 rs10050860 
int 
0.056 0.91 
 rs30187 int -0.22 0.31 
 rs2549782 int 0.24 0.26 
 
 
2.3.23 Comparative East Asian Results 
Results of previous studies reporting east Asian ERAP1 associations are shown in Table 
2.26 with the equivalent Immunochip marker and result. 
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Table 2.26 Comparative east Asian Results 
Study SNP Cas/Con Population Allele P Value Odds 
Ratio 
Bang rs27037 1164/752 Korean T 1.3 x 10-4 1.31 
Davidson rs27037 527/945 Han Chinese T 0.01 1.22 
Current rs27037 1550/1567 East Asian T 2.90 x10-4 1.21 
       
Davidson rs27038 527/945 Han Chinese G 0.005 0.80 
Current rs27038 1550/1567 East Asian G 6.92 x 10-5 0.82 
       
Choi rs27044 872/403 Korean G 9.37 x 10-7 NS 
Current rs27044 1550/1567 East Asian G 1.83 x 10-6 1.27 
       
Davidson rs27433 527/945 Han Chinese A 0.04 1.18 
Current rs27433 1550/1567 East Asian A 7.44 x 10-4 1.18 
       
Bang rs27434 1164/752 Korean A 4.6 x 10-6 1.36 
Li rs27434 472/456 Han Chinese A 3.9 x10-4 1.38 
Lin rs27434 1837/4231 Han Chinese A 6.68 x 10-4 1.15 
Davidson rs27434 527/945 Han Chinese A 0.14 1.12 
Current rs27434 1550/1567 East Asian A 5.21 x 10-6 1.25 
       
Li rs27529 471/456 Han Chinese G 0.008 1.23 
Current rs27529 1550/1567 East Asian G 4.73 x 10-6 1.25 
       
Davidson rs27619 527/945 Han Chinese G 0.05 0.85 
Current rs27619 1550/1567 East Asian G 3.23 x 10-4 0.83 
       
Davidson rs27980 527/945 Han Chinese G 0.005 0.80 
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Current rs27980 1550/1567 East Asian G 0.06 0.91 
       
Choi rs30187 872/403 Korean A 7.16 x 10-6 NS 
Lin rs30187 1837/4231 Han Chinese A 6.71 x10-4 1.15 
Current rs30187 1550/1567 East Asian A 1.20 x 10-5 1.25 
       
Davidson rs7711564 527/945 Han Chinese C 8.07 x10-3 0.81 
Current rs7711564 1550/1567 East Asian C 0.06 0.91 
       
Choi rs10050860 872/403 Korean C 0.38 NS 
Current rs10050860 1550/1567 Current C 0.02 1.34 
NS – not stated 
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2.4 Discussion 
The presented work has shown that there is a conditional association spanning 
ERAP2/LNPEP in European AS patients. The association includes strong functional 
candidates, primarily the loss of ERAP2 enzyme SNP rs2248374. This intronic variant 
change causes an altered splice site and premature truncation of the ERAP2 mRNA. This 
causes nonsense mediated decay of the ERAP2 mRNA and consequently no ERAP2 
enzyme [179]. There is another functional SNP in LD with rs2248372 (rs2549782) that 
changes the function of ERAP2 but this form of the enzyme is almost never made. 
Considering the strong genetic and functional association that loss of function variants in 
ERAP1 have with AS it has high biological plausibility that loss of the ERAP2 enzyme 
would provide protection from AS. 
 
Other work supports this finding in AS. Firstly the association of a haplotype spanning 
ERAP1 and ERAP2 in Canadian multiplex AS families [158]. Further supporting evidence 
includes the shared association with the Crohn’s disease associated SNP rs2549794 [82]. 
The observation that up to two thirds of AS patients have at least subclinical bowel 
inflammation and about 10% have overt inflammatory bowel disease strengthens the basis 
of this shared association [13] [14]. 
2.4.1.1 Cross presentation and its potential relevance 
Due to the association of the HLA class I antigen HLA-B*27 with AS since 1973 the MHC 
class I antigen presentation pathway has been repeatedly implicated in the pathogenesis 
of AS. With the discovery of the association of ERAP1, and then the epistasis between 
HLA-B*27 and ERAP1 further evidence implicating this pathway began to accumulate. But 
naïve CD8 T cells, which interact with class I MHC molecules like HLA-B*27 on the cell 
surface, require activation by antigen presenting cells (APCs) to become cytotoxic effector 
cells. However, when APCs are not infected themselves, they have no source of antigen 
and need to take in antigen in order to prime T cells. This process is known as cross 
presentation and is best characterised in dendritic cells [210]. 
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Figure 2.28 Vacuolar and cytosolic cross presentation pathways 
Cross presentation occurs through two pathways (see Figure 2.28). Antigens may be 
taken up through phagocytosis into a phagosome and there loaded onto MHC class I 
molecules, then trafficked directly to the cell surface, this is termed the vacuolar pathway. 
Alternately, antigens may be taken up into a phagosome and released into the cytosol, 
then processed through the proteasome. Subsequently the digested antigen can either 
traffic back into the phagosome where it is loaded onto an MHC class I molecules and 
presented on the cell surface or trafficked to the ER and incorporated into the traditional 
MHC class I antigen presentation pathway. Aminopeptidases are involved in all of these 
processes. IRAP has been localised to cytosolic phagosomes where processing of cross-
presented antigens occurs [120]. IRAP is encoded by the gene LNPEP which sits beside 
ERAP2 on chromosome 5. The associated SNP haplotype extends to include LNPEP. 
ERAP1 and ERAP2 process antigens in the ER either from the cytosol or from antigen 
external to the cell which are undergoing cross-presentation. One can then see how 
changes in the function or absence of these processing enzymes could have an impact on 
the priming of cytotoxic effector CD8 cells. 
2.4.1.2 Limitations 
There are limitations to this work. The lack of a confirmation set of samples means that 
confirmation of low frequency variants is not possible. This is a problem that affects all 
studies of low frequency genetic variants. Large sample sizes are required to find the 
variants, thereby requiring equally large sample sizes to confirm the associations. The 
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confirmation of the low frequency variants will have to be done largely in functional in vivo 
or in vitro experiments to demonstrate the effect of rare changes. Rare changes are more 
likely to be functional, as demonstrated by their low frequency and impact on survival and 
therefore suggesting their functional effects may be greater than common genetic variants 
with low effect sizes [211]. 
There are limitations in assigning HLA-B*27 status to both European and Asian samples. 
All methods will have errors and using either HLA*IMP or a tag SNP approach will not be 
absolutely sensitive or specific. This problem can be mitigated by increasing sample size 
which was possible for the European cohort, but not for the east Asian cohort. 
The east Asian analysis is limited by sample size, and consequently has modest statistical 
power. 
2.4.1.3 Implications 
The finding that at least two and possibly three aminopeptidases are associated with AS is 
important progress. The finding that ERAP1 was associated with AS, and more importantly 
that loss of function variants were protective, provided an attractive avenue to pursue for 
future therapeutic potential. Confirmation that a loss of function variant in ERAP2 has also 
been associated with protection from AS expands this potential further. The questions that 
will help inform this work include, what is the effect of inhibiting ERAP1 in established AS? 
What is the effect of inhibiting ERAP1 in those with a high risk of developing AS? Then 
these questions can be extended to include ERAP2, and combined inhibition. If functional 
variants in IRAP are also associated, then further triple enzyme inhibition may also be an 
option. 
2.4.1.4 Further Work 
Further work to investigate this could include examining the ERAP2/LNPEP association in 
adequately powered cohorts of different ethnic groups. This may allow the better 
characterisation of the association. Further genotyping in European sample sets is unlikely 
to be significantly productive because of the dense coverage of the Immunochip. 
Sequencing may allow the discovery of novel associated variants, especially low 
frequency variants. 
2.4.1.5 Conclusion 
Functional work on this newly described conditional ERAP2 association in AS has the 
potential to provide support for investigation of more broad aminopeptidase inhibition than 
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just ERAP1 as a therapy for AS. Relevant functional work would be examining the effect of 
ERAP2 knockout on MHC class I expression inside cells and on the cell surface. In 
addition investigating the cell surface heavy chain levels by genotype would be important. 
Finally examining for differences in levels of pro-inflammatory cytokines by the different 
genotypes would be of value. 
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3 Genetic Dissection of Acute Anterior Uveitis Reveals Similarities and 
Differences in Associations observed with Ankylosing Spondylitis 
 
The work described in this chapter has been e-published in Arthritis and Rheumatology on 
the 8th of September 2014. 
3.1 Abstract  
 
3.1.1 Objective  
 
To use high density genotyping to investigate the genetic associations of acute anterior 
uveitis in patients both with and without ankylosing spondylitis (AS).  
3.1.2 Method  
 
We genotyped 1,711 patients with acute anterior uveitis (either primary or with acute 
anterior uveitis and AS), 2,339 AS patients without acute anterior uveitis, and 10,000 
controls on the Illumina Immunochip Infinium microarray. We also used data on AS 
patients from previous genomewide association studies to investigate the AS risk locus 
ANTXR2 for its putative effect in acute anterior uveitis. ANTXR2 expression in mouse eyes 
was investigated by RT-PCR. 
3.1.3 Results 
 
Comparing all acute anterior uveitis cases with healthy controls (HC), strong association 
was seen over HLA-B corresponding to the HLA-B*27 tag SNP rs116488202. Three non-
MHC loci IL23R, the intergenic region 2p15 and ERAP1 were associated at genome-wide 
significance (P < 5 x 10-8). Five loci harboring the immune-related genes IL10 - IL19, 
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IL18R1 - IL1R1, IL6R, the chromosome 1q32 locus harboring KIF21B, as well as the eye 
related gene EYS, were also associated at a suggestive level of significance (P < 5 x 10-6). 
A number of previously confirmed AS associations demonstrated significant differences in 
effect size between AS patients with acute anterior uveitis and AS patients without acute 
anterior uveitis. ANTXR2 expression was found to vary across eye compartments. 
3.1.4 Conclusion 
 
These findings, with both novel acute anterior uveitis specific associations, and 
associations shared with AS demonstrate overlapping but also distinct genetic 
susceptibility loci for acute anterior uveitis and AS. The associations in IL10 and IL18R1 
are shared with inflammatory bowel disease, suggesting common etiologic pathways. 
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Introduction 
Acute anterior uveitis has a cumulative incidence rate in the Caucasian general population 
of 0.2%, but in those who are HLA-B*27 positive (8 – 10% of the Caucasian population) 
the cumulative incidence rate is 1% [212]. Recurrent acute anterior uveitis may lead to 
glaucoma, cataract development and significant visual loss. Uveitis is a major cause of eye 
disease, affecting an estimated 2 million Americans, and accounts for up to 10% of 
blindness [67, 92]. 
 
Evidence from both humans and animal models suggests a large genetic component to 
uveitis with strong familiality demonstrated [213]. The first-degree recurrence risk of acute 
anterior uveitis is 6% compared to a population prevalence of only 0.038 - 0.38% [214]. 
Acute anterior uveitis occurs in 30 - 40% of individuals with ankylosing spondylitis (AS) 
suggesting a shared aetiology [18]. It is strongly associated with HLA-B*27 both in those 
with AS, and those without, with more than 50% of those with primary acute anterior 
uveitis being HLA-B*27 positive [215]. There is evidence that genes other than HLA-B 
influence the risk of developing acute anterior uveitis. The prevalence of acute anterior 
uveitis in the HLA-B*27 positive first-degree relatives of probands with acute anterior 
uveitis (13%) is much higher than in the normal HLA-B*27 positive (Dutch) population 
(1%), indicating that other genetic factors besides HLA-B*27 are involved [214]. In the 
same Dutch acute anterior uveitis prevalence study, 11% of HLA-B*27 positive first-degree 
relatives >45 years of age had AS compared with an expected frequency of AS in HLA-
B*27 carriers of ~1%, highlighting the strong co-familiality of AS and acute anterior uveitis. 
Other genetic associations described for acute anterior uveitis include HLA-A*02 [71], 
HLA-DRB1*08:03 [73], HLA-B*58 [74], MICA [75], LMP2 [216], CYP27B1 [79], IL10 [69], 
the complement components CFB, CFH and C2 [76, 77], TNF [70, 217], the Killer 
Immunoglobulin Receptor (KIR) region [78], and suggestive linkage has been reported to 
112 
 
the chromosome 9p region [80]. No findings have achieved genomewide significance (P < 
5 x 10-8), and few associations have been replicated [18]. Few of these studies were 
adequately powered to identify genes involved in acute anterior uveitis reliably so we 
sought to investigate its association in the largest data set assembled for this purpose to 
date. 
 
3.2 Patients And Methods 
To identify acute anterior uveitis genetic associations, two main analyses were performed.  
AS patients with acute anterior uveitis (as cases) were first compared with AS patients 
without acute anterior uveitis (as controls). Whilst this analysis studies acute anterior 
uveitis genetic associations controlling for AS-comorbidity, potential issues such as 
delayed onset of uveitis and subclinical disease affect it. Therefore a second analysis 
compared all acute anterior uveitis patients with healthy controls (HC), with a subsequent 
heterogeneity test performed to assess whether associated SNPs had differing effect sizes 
in AS patients with and without uveitis. Genetic associations identified comparing AS 
patients with acute anterior uveitis to HC, that were not identified by the larger and better 
powered International Genetics of Ankylosing Spondylitis (IGAS) Consortium AS 
Immunochip study [86], are likely to be acute anterior uveitis-specific associations. 
 
3.2.1 Immunochip Sample Collection and Phenotyping 
AS cases (defined by the modified New York criteria [166]) of European descent either 
with (n = 1,422) or without acute anterior uveitis (n = 2,339) were recruited. The cases 
were collected from Australia, New Zealand, Canada, the United Kingdom and the United 
States of America. Ophthalmologists also collected 289 patients with acute anterior uveitis 
(in whom the AS status was unknown). AS cases had either self-reported or 
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ophthalmologist diagnosed acute anterior uveitis (Supplementary Table 3.1). Patients were 
positively selected on the basis of their phenotype, no exclusions were applied. Historical 
genotypes from 10,000 Caucasian controls from the 1958 British Birth Cohort and the UK 
National Blood Transfusion Service were used as common controls. All patients gave 
informed consent and ethical approval was obtained from all relevant institutional ethics 
committees. 
 
After quality control (Supplementary Table 3.2) there remained 9,564 controls, 1,199 AS 
cases with acute anterior uveitis, 238 acute anterior uveitis cases with acute anterior 
uveitis alone and 1,731 AS cases without acute anterior uveitis patients. 
 
Samples were genotyped on the Illumina Immunochip microarray. Intensity data was 
processed and normalized in the Illumina GenomeStudio software and subsequently 
clustered with optiCall [183].  
 
3.2.2 Quality Control 
 
The thresholds used were a genotyping missingness rate of 0.03, between centre 
missingness threshold of 1 x 10-7, individual missingness rate of 0.03, a Hardy Weinberg 
Equilibrium (HWE) threshold in controls of 1 x 10-7. Heterozygosity versus missingness 
outliers beyond 3 SD were excluded. Identity by descent (IBDes) threshold of PI-HAT 
(Proportion(IBDes = 2) + 0.5(IBDes = 1)) 0.20 was used. Principal components were then 
computed using SHELLFISH 
(http://www.stats.ox.ac.uk/~davison/software/shellfish/shellfish.php) including the 
HAPMAP populations.  Individuals identified as non-European, by model-based 
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unsupervised clustering implemented in R by the MCLUST package, were excluded. 
Details of SNPs excluded are shown in Supplementary Table 3.3.  
 
3.2.3 Association Analysis 
Case-control analysis was performed with SNPTEST version 2.5 beta using the ‘expected’ 
method and including 10 eigenvectors, scree plots are shown in Supplementary Figure 
3.1. Genomic inflation factor 1000 values for the Immunochip control SNPs were 1.058 for 
the acute anterior uveitis versus HC analysis and 1.035 for the AS with acute anterior 
uveitis versus AS without acute anterior uveitis analysis. Genomic inflation factor 1000 
values are genomic inflation values scaled to a sample size of 1000 cases and 1000 
controls to avoid the fact that the genomic control statistic scales with sample size, I used 
the method of De Baaker et al for calculations [218]. The Q-Q plots for the studies are 
shown in Supplementary Figure 3.2. Results were deemed significant if they had P < 5 x 
10-8 (genome-wide significance), and suggestive if they had P values > 5 x 10-8 but < 5 x 
10-6. After conditional analyses, analyses with significance of P < 1 x 10-4 were reported. 
 
3.2.4 Imputation 
Data was phased with SHAPEIT version 2 [219], and imputed with IMPUTE2 [220] using 
the 1000G phase 1 integrated variant reference set. A post-imputation quality control 
threshold of 0.8 ‘info’ score from IMPUTE2 was used. Classical Major Histocompatibility 
Complex (MHC) alleles were imputed from the genotype data with SNP2HLA [221] against 
the supplied type 1 diabetes reference set. The carriage rate of HLA-B*27 was calculated 
using imputed SNP2HLA doses and a dosage threshold of 0.6. 
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3.2.5 Tag SNP calculation 
Imputed genotypes of each individual and their classical alleles imputed by SNP2HLA 
were used to calculate sensitivity and specificity of the SNPs for tagging classical alleles. 
 
3.2.6 Interaction Analysis 
This was completed using the formula: 
logit(ψ) = β0 +βSNPSNP+βB27B27+ βi
i=1
10
∑ ×PCi +βintSNP×B27  
where the uveitis phenotype ψ  and the imputed SNP dosage of rs2032890 (βSNPSNP , lead 
ERAP1 associated SNP) and imputed SNP2HLA dosage of the HLA-B*27 (βB27B27) and 
ten eigenvectors ( βi ×PCi
i=1
10
∑ ) were regressed with an interaction term between the SNP 
and HLA-B*27 (βintSNP×B27). β0 is the intercept. 
 
3.2.7 Comparison of SNP effects between AS with and without acute anterior 
uveitis 
The HC were split into two by random sampling and allocated as controls to either the AS 
with acute anterior uveitis cases or the AS without acute anterior uveitis cases to ensure 
the independence of the two regressions. These two sets of cases and controls were then 
allocated a dummy variable of 1 or 0 coded as Z. The following regression model was then 
used: 
 
logit(ψ) = β0 +βsnpSNP+ βi
i=1
10
∑ ×PCi +βZZ +βZ 2SNP× Z  
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where ψ  is the uveitis phenotype (either 1=uveitis in the ‘AS with acute anterior uveitis’ 
cases, or 1 = no uveitis in the ‘AS without acute anterior uveitis’ cases, controls in both 
sets were coded = 0). βsnp is the regression coefficient for the SNP dose, SNP is the 
dosage of the SNP genotype. βi
i=1
10
∑  are the regression coefficients of the ten principal 
components,PCi  from 1-10 are the ten principal components. βZ is the regression co-
efficient for the dummy variable Z. BZ2 is the regression co-efficient for the interaction term 
between the dummy variable and the SNP dosage: SNP×Z. β0 is the intercept. We also 
analysed the model with the HLA- B*27 as a component: 
log it(ψ)= β0 +βsnpSNP+βB27B27+ βi
i=1
10
∑ ×PCi +βZZ + βZ 2SNP× Z  
In this modelβB27B27is the SNP2HLA imputed dosage of HLA-B*27. Odds ratios were 
deemed to be significant if the P value < 0.05. 
 
3.2.8 Ankylosing spondylitis GWAS data for ANTXR2 analysis 
The post quality control data from the Australo-Anglo-American Spondylitis Consortium 
(TASC) and Wellcome Trust Case Control Consortium-2 (WTCCC2) studies and an 
unpublished Canadian AS genome wide association study (GWAS) were taken through 
the same quality control process as the Immunochip data in this study. The Canadian 
study using the Illumina OmniExpress microarray and included 189 AS patients. Briefly, 
the WTCCC2-TASC study genotyped 3,023 cases and 8,779 controls [60]. The TASC 
study examined 2,951 AS cases and 6,658 HC, with 439 cases removed in QC [127].  
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ANTXR2 locus imputation was completed with SHAPEIT and IMPUTE2 identical to the 
Immunochip data. The MHC SNPs were used to impute classical alleles using SNP2HLA 
to determine HLA-B*27 dosage (range 0 - 2).  
 
3.2.9 Previously Reported Acute Anterior Uveitis Genetic Associations 
Where the exact SNP was not present on the Immunochip microarray, the SNP with the 
highest LD represented on the Immunochip was determined from 1000 genomes data. 
 
3.2.10 Concordance of Effect Directions 
To assess whether shared associations had the same or opposite directions of effect the 
in-phase alleles were calculated using HaploXT 
(http://genome.sph.umich.edu/wiki/Haploxt) and 1000 genomes reference data. 
 
3.2.11 HLA-B*27 Heterozygosity and Homozygosity Calculations 
To calculate the odds of the disease for homozygosity and heterozygosity of HLA-B*27 the 
SNP2HLA imputed doses of HLA-B*27 in the acute anterior uveitis group versus HC were 
used. Contingency table analysis and the cross-products ratio were used. 
 
3.2.12 ANTXR2 Expression RNA isolation 
For each experiment, total RNA was isolated from a 25-50 mg piece of mouse lung or the 
dissected components pooled from 5 mouse eyes using the PureLink RNA kit (Ambion). 
Eyes were dissected to isolate the following components: (i) cornea, (ii) iris including ciliary 
body, (iii) choroid and sclera, (iv) retina. Briefly, tissues were collected, placed directly into 
lysis buffer containing β−mercaptoethanol and homogenised using a Tissue Lyzer II 
(Qiagen). The lysates was then put through PureLink RNA columns, treated with DNase I 
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and eluted in RNase free water. The purity and quantity of RNA was assessed with a 
BioPhotometer (Eppendorf). 
 
3.2.13 ANTXR2 Expression Real-time quantitative PCR 
The relative expression of ANTXR1 and ANTXR2 mRNA was determined using a two-step 
RT-PCR assay by comparison to L32 mRNA. First, cDNA was generated from 2µg of total 
RNA using random primers and M-MLV Reverse Transcriptase (Promega). Second, cDNA 
samples were then used in the RT-PCR using the Bio-Rad SsoAdvanced Universal SYBR 
Green Supermix and run on a Bio-Rad CFX Connect system. The primer sequences used 
for ANTXR1 and ANTXR2 were from the Harvard Primer Bank (ANTXR1; ID# 32189436a1 
and ANTXR2; ID# 13278124a1). The primer sequences for L32 were L32-F (5’-
CATCGGTTATGGGAGCAAC-3’) and L32-R (5’-GCACACAAGCCATCTACTCAT-3’). 
Samples were run in triplicate and the assay repeated 3 times. The amounts of ANTXR1 
and 2 mRNA in the lung and various eye compartments were normalized relative to L32 
mRNA as lung has been shown to express both ANTXR1 and ANTXR2 genes [222]. 
 
3.3 Results 
To examine for the validity of the self-report diagnosis of acute anterior uveitis we 
calculated HLA-B*27 carriage rates. The frequency of HLA-B*27, as inferred from 
SNP2HLA imputation, was 81.8% (613/749) in the ophthalmologist diagnosed acute 
anterior uveitis group and 92.0% (633/688) in the self-report acute anterior uveitis group. 
Of note the self-report group were entirely AS patients whereas the ophthalmologist 
diagnosed acute anterior uveitis group included both acute anterior uveitis cases with and 
without AS. 
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3.3.1 Major Histocompatibility Complex Associations 
Acute anterior uveitis has been linked with classical MHC alleles previously so we 
examined the MHC for association. In the comparison of AS with acute anterior uveitis 
versus AS without acute anterior uveitis, single nucleotide polymorphisms (SNPs) in the 
MHC Class I region harboring HLA-B were strongly acute anterior uveitis-associated, see 
Supplementary Figure 3.3 (rs115879499, P = 4.9 x 10-18, OR = 1.4, 95% CI 1.2 – 1.5). 
Conditioning on this SNP showed association at rs9274411 in HLA-DQB1 (P = 6.4 x 10-5, 
OR = 1.2, 95% CI 1.1 - 1.3). Conditioning on these top 2 associations showed no further 
association (P > 1 x 10-4). When HLA-B*27 negative subjects (as determined by SNP2HLA 
classical MHC allele imputation, see later) were analysed separately there was moderate 
association at rs114199502 (P = 2.6 x 10-5, OR = 2.9, 95% CI 1.3 – 6.6) between HLA-
DRA and HLA-DRB5. Controlling for the effect of rs114199502 there was moderate 
association at the intronic variant rs71542449 in HLA-DQB2 (P = 4.7 x 10-5, OR = 0.57, 
95% CI 0.39 - 0.84). 
 
In the analysis of all acute anterior uveitis versus HC, strong association was also seen in 
the MHC, the lead SNP being the previously described [86] HLA-B*27 tag SNP 
rs116488202 (P < 1x10-300, OR = 16.8, 95% CI 15.0 – 18.7). On conditioning on this SNP 
the next associated SNP was rs114102658, between HLA-B and MICA, see Figure 3.1 (P 
= 1.2 x 10-41, OR = 17.4, 95% CI 16.7 – 19.4). Conditioning on both rs116488202 and 
rs114102658 lead association was seen with rs149567432, just centromeric to HLA-B (P = 
4.9 x 10-9, OR = 9.0, 95% CI 8.2 – 9.9). None of these SNPs tag any classical class I allele 
accurately (all sensitivities and specificities < 70%).  Conditioning on these top three 
signals, association was seen with rs114977878 in the MHC Class II locus in the gene 
HLA-DQA2 (P = 3.8 x 10-6, OR = 1.4, 95% CI 1.3 – 1.6). Conditioning on these 4 SNPs 
revealed association at rs115711695, an intronic variant in HLA-DRB5 (P = 6.2 x 10-6, OR 
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= 1.7, 95% CI 1.5 – 1.9). Conditioning on these top 5 SNPs still left association in the HLA-
B locus at rs114560492 (P = 3.1 x 10-5, OR = 1.9, 95% CI 1.7 – 2.0). Conditioning on 
these top 6 associations left no further residual signals (P > 1 x 10-4). 
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Figure 3.1 Major histocompatibility complex association plot for all acute anterior uveitis versus healthy controls 
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Some AS patients do not carry HLA-B*27 so to examine for MHC associations 
in this group we analysed HLA-B*27 negative patients, as assessed by any 
imputed dose of the SNP2HLA imputed HLA-B*27. In the all acute anterior 
uveitis versus HC analysis there was association at the HLA-B locus at 
rs115937001 (P = 2.0 x 10-5, OR = 1.8, 95% CI 1.5 – 2.3). This SNP tags 
HLA-B0801 with 76% specificity and 94% sensitivity. Conditioning on this 
SNP left no residual association (P > 10-4).  
 
Allelic diversity at classical HLA loci is extensive, and challenging to impute 
with single SNPs. Therefore imputation with multiple SNPs was performed 
with SNP2HLA, to provide a potentially more accurate assessment of 
classical MHC allele-disease associations [221].  In analysis of AS with acute 
anterior uveitis versus AS without acute anterior uveitis, the classical allele 
HLA-B*27 was again strongly associated (P = 1.4 x 10-16, OR = 2.1, 95% CI 
1.8 – 2.5). Controlling for the HLA-B*27 effect showed residual association 
with HLA-DQB1:05 (P = 2.1 x 10-5, OR = 0.78, 95% CI 0.70 – 0.87). In the all 
acute anterior uveitis versus HC analysis, strong association with HLA-B*27 
was evident (P < 1 x 10-300, OR = 59.7, 95% CI 51.4 – 69.5). Controlling for 
the HLA-B*27 effect, HLA-DRB*1:0103 was associated (P = 2.0 x 10-5, OR = 
1.9, 95% CI 1.4 – 2.5). 
 
The question of whether HLA-B*27 exerts its influence through a dominant or 
additive genetic model was assessed. In the all acute anterior uveitis versus 
HC analysis heterozygosity for HLA-B*27 (as determined by SNP2HLA 
imputation) confers OR for acute anterior uveitis of 66.8 (95% CI 66.7 – 67.0), 
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homozygosity for HLA-B*27 confers OR of 130.6 (95% CI 130.1 - 131.1), and 
the risk of two HLA-B*27 alleles over one HLA-B*27 allele confers an OR of 
2.0 (95% CI 1.5 – 2.4). Thus homozygosity for HLA-B*27 does confer 
additional risk of acute anterior uveitis over heterozygosity (see 
Supplementary Table 3.4). 
 
The carriage rates for HLA-B*27 (as determined by SNP2HLA imputation) 
were 91.2% in AS cases with acute anterior uveitis 80.6%, in AS cases 
without acute anterior uveitis, and only 63.9% in the small cohort of acute 
anterior uveitis patients with unknown AS status (recruited by 
ophthalmologists).  
 
3.3.2 Non-MHC Associations 
A number of non-MHC associations have been described for acute anterior 
uveitis previously so we sought to examine non-MHC areas for association. In 
the comparison of AS cases with acute anterior uveitis versus AS cases 
without acute anterior uveitis, association was observed with variants within 
ERAP1 (rs2032890, P = 9.0 x 10-6, OR = 1.3, 95% CI 1.2–1.5), see 
Supplementary Table 3.5 and Supplementary Figure 3.4. In AS there is an 
interaction between ERAP1 and HLA-B*27 [60].  Controlling for HLA-B*27 
using SNP2HLA dosages [86] as a covariate in the analysis, association was 
essentially unchanged at rs2032890 (P = 2.9 x 10-5, OR = 1.3, 95% CI 1.2 – 
1.5). Performing a regression analysis with an interaction term between HLA-
B*27 (as determined by SNP2HLA) and rs2032890 was negative (P = 0.28). 
However, when subjects were split into HLA-B*27 negative (409 controls and 
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130 cases) and HLA-B*27 positive groups (1,663 controls and 1,321 cases) 
and the rs2032890 SNP was assessed with logistic regression in each group 
it was associated in the HLA-B*27 positive group but not the negative group 
(P = 1.6 x 10-5, OR = 1.26, 95% CI 1.13 – 1.40 and P = 0.76, OR = 1.05, 95% 
CI 0.78 – 1.42 respectively).   
 
In the all acute anterior uveitis cases vs HC analysis, genomewide significant 
associations were observed at ERAP1, the intergenic region chromosome 
2p15, and IL23R.  The observed associations were concordant with 
associations with AS, involving the same haplotypes with the same direction 
of effect (Table 3.1 and Supplementary Figure 3.5 – Supplementary Figure 
3.12). In this study the logistic regression model examining the interaction 
between the ERAP1 SNP rs2032890 and HLA-B*27 was strongly significant 
(P < 2 x 10-16). In HLA-B*27 negative participants (as determined by 
SNP2HLA imputation) there was association over ERAP2 (lead SNP: 
rs4869314, P = 8.8 x 10-5), consistent with that previously seen in HLA-B*27 
negative AS [86]. After conditioning on this SNP no residual association was 
seen in ERAP2 (P > 10-4). 
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Table 3.1 Association results for all acute anterior uveitis cases versus healthy controls 
rsid Chr Position* P value 
Risk 
Allel
e 
Prote
ctive 
Allele 
RAF 
(Cases/Contr
ols) Odds Ratio (85% CI) Nearby Genes 
Also AS 
associated 
rs2032890 5q15 96,121,152 2.11 x 10-16 A C 0.77/0.69 1.51 (1.37-1.66) ERAP1/ERAP2/LNPEP Yes 
rs4672507 2p15 62,570,573 2.05 x 10-12 T A 0.43/0.36 1.38 (1.27-1.50) intergenic Yes 
rs79755370 1p31 67,699,915 1.27 x 10-8 C A 0.96/0.94 1.80 (1.45-2.23) IL23R Yes 
rs12132349 1q32 200,875,242 1.57 x 10-7 T A 0.76/0.71 1.31 (1.19-1.44) KIF21B-C1orf106 Yes 
rs6690230 1q21 154,432,877 1.09 x 10-6 C G 0.41/0.36 1.23 (1.13-1.34) IL6R Yes 
rs17351243 1q32 206,959,527 1.46 x 10-6 A G 0.51/0.45 1.24 (1.14-1.35) IL10-IL19 No 
rs10197284 2q12 102,982,703 1.67 x 10-6 G A 0.26/0.22 1.25 (1.14-1.38) IL18R1-IL1R1 No 
rs665873 6q12 65,298,551 4.99 x 10-6 A G 0.98/0.97 2.03 (1.48-2.79) EYS No 
Chr Chromosome, *Human genome build 19, RAF Risk allele frequency, OR Odds ratio, AS ankylosing spondylitis 
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In the analysis of all acute anterior uveitis cases with HC, five loci had 
suggestive levels of association (P < 5 x 10-6). These loci included both loci 
known to be associated with AS (IL6R, chromosome 1q32) and novel loci not 
previously reported to be AS-associated including interleukin (IL)10 - IL19, the 
gene encoding the alpha chain of the IL-18 receptor (IL18R1) - IL1R1, and the 
EYS gene  (Eyes shut Drosophila homolog, a gene associated with retinitis 
pigmentosa [223, 224]). The IL6R and chromosome 1q32 acute anterior 
uveitis associations are concordant with the AS associations (alleles are in 
phase and r2 = 0.98 and 1.0, respectively). On conditioning on the 1q32 
association (rs12132349), a secondary association nearby at rs10920074 
became apparent (P = 1.7 x 10-7, OR = 1.3 95% CI 1.2 – 1.4), LD between 
these SNPs is D’ = 0.87 and r2 = 0.48 (source: 1000 genomes). No further 
association was apparent after conditioning on both rs10920074 and 
rs12132349 (P > 1 x 10-4). At the IL18R1-IL1R1 association conditioning on 
rs10197284 shows a secondary signal at rs6750020 (P = 1.2 x 10-4, OR = 1.2, 
95% CI 1.1 – 1.4), linkage disequilibrium (LD) between these SNPs is D’ = 
0.92 and r2 = 0.85. Conditioning on rs6750020 in addition to rs10197284 
removes all association (P > 10-4). The IL18R1 - IL1R1 acute anterior uveitis 
rs10197284 association is not in LD with the previously reported [86] 
suggestive AS association at rs4851529 (r2 = 0.00, D’ = 0.07). The other loci 
had no secondary signals on conditioning on the top SNP (P > 1 x 10-4).  
 
The IL10 SNP rs17351243 has LD (D’ = 0.65, r2 = 0.52, source:1000 
genomes) with the inflammatory bowel disease (IBD) associated SNP 
rs3024505 [177], and the direction of association is the same. The IL18R1 - 
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IL1R1 SNP rs10197284 is in strong LD with previously reported celiac 
disease [225] and IBD [177] SNPs, and in lesser LD with asthma [226] and 
eosinophil count [227] SNPs (Supplementary Table 3.6). The IBD and celiac 
disease associations share the same direction of effect, but the asthma and 
eosinophil count SNPs have opposite directions of effect. The EYS SNP 
rs665873 has low frequency (HapMap CEU MAF = 0.051) but is in tight LD 
with the common (MAF = 0.43) statin-myopathy associated SNP rs3857532 
[228], (D’ = 0.91, r2 = 0.01, source:1000 genomes), and with six SNPs 
associated with retinitis pigmentosa [223] (D’ = 1, r2 = 0.001) (Supplementary 
Table 3.7). The acute anterior uveitis, statin-myopathy and retinitis 
pigmentosa SNPs all have the same direction of effect.  
 
3.3.3 Odds Ratio Comparisons 
We assessed whether the shared associations influence AS and acute 
anterior uveitis with differing magnitudes using a heterogeneity test. All SNPs 
associated with acute anterior uveitis (P < 5 x 10-6) in the all acute anterior 
uveitis cases versus HC analysis and all SNPs associated with AS from the 
recently published IGAS Immunochip study [86] were assessed. We used two 
models, the first (model 1) has the SNP and principal components; the second 
(model 2) includes HLA-B*27 dose as a model covariate, reflecting the 
previously demonstrated interaction between ERAP1 SNPs and HLA-B*27 in 
AS.  
 
The two AS-associated intergenic loci, chromosomes 2p15 and 21q22, both 
had significantly different effect sizes in AS patients with acute anterior uveitis 
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versus HC compared to AS patients without acute anterior uveitis versus HC 
in model 2 but not model 1 (Table 3.2). At chromosome 2p15 both models 
showed a larger effect size in AS cases without acute anterior uveitis versus 
HC compared to AS with acute anterior uveitis versus HC, but this only 
reached statistical significance in model 2 (model 1: SNP rs4672507 P = 0.17 
and SNP rs6759298 P = 0.13 and model 2: SNP rs4672507 P = 0.06 and 
SNP rs6759298 P = 0.05). The lead acute anterior uveitis associated ERAP1 
SNP had a significantly stronger effect size in the AS with acute anterior 
uveitis versus HC compared to AS without acute anterior uveitis versus HC, 
even after taking into account HLA-B*27 (model 2). The EYS SNP rs665873 
had a significant effect size (OR = 0.92, 95% CI 0.88 - 0.97, P = 6 x 10-5) in 
the AS with acute anterior uveitis analysis whereas it was not associated in 
the AS without acute anterior uveitis analysis (OR = 0.97, 95% CI 0.93 – 1.01, 
P = 0.14). The heterogeneity test for this SNP was non-significant (P = 0.09).  
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Table 3.2 Heterogeneity test results between AS with acute anterior uveitis versus healthy controls and AS without acute anterior 
uveitis versus healthy controls 
Model 1: SNP + Principle Components Model 2: SNP + HLA-B*27 + Principle Components Interaction term 
  SNP effects  SNP effects   
SNP Gene/Region 
AS with 
AAU P 
value 
AS with AAU 
OR 
AS without 
AAU P 
value 
AS without 
AAU OR 
AS with 
AAU P 
value 
AS with 
AAU OR 
AS without 
AAU P 
value 
AS without 
AAU OR 
Model 1 
P value 
Model 2 
P value 
rs2283790 UBE2LE 8.7 x 10-1 1.00 7.0 x 10-3 0.98 8.9 x 10-1 0.99 1.2 x 10-1 0.99 0.05 0.29 
rs2836883 21q22 5.9 x 10-3 1.02 3.0 x 10-2 1.03 2.6 x 10-1 1.01 1.7 x 10-4 1.02 0.19 0.04 
rs2032890 ERAP1 1.8 x 10-17 1.06 3.3 x 10-4 1.03 2.0 x 10-2 1.02 2.0 x 10-2 1.01 1 x 10-3 0.08 
rs30187 ERAP1 4.8 x 10-19 1.06 1.0 x 10-7 1.04 2.0 x 10-2 1.02 3.0 x 10-3 1.02 0.02 0.24 
rs10045403 ERAP1 1.1 x 10-14 1.05 5.3 x 10-4 1.02 3.6 x 10-4 1.02 3.0 x 10-2 0.01 0.01 0.50 
rs2910686 ERAP2 1.8 x 10-1 1.01 3.0 x 10-2 0.99 7.1 x 10-1 1.00 1.4 x 10-1 0.99 0.01 0.43 
rs6759298 2p15 8.5 x10-16 1.06 1.7 x 10-22 1.07 2.0 x 10-6 1.02 9.7 x 10-12 1.04 0.13 0.05 
rs4333130 ANTXR2 4.8 x10-2 0.98 3.0 x 10-4 0.97 7.7 x 10-1 1.00 5.6 x 10-3 0.98 0.28 0.04 
Suggestive 
rs7282490 ICOSLG 9.8 x 10-1 1.00 7.0 x 10-3 1.02 4.1 x 10-1 1.00 1.0 x 10-2 1.013 0.05 0.17 
rs665873 EYS 6.1 x 10-5 0.92 1.4 x 10-1 0.97 2.0 x 10-3 0.96 2.0 x 10-1 0.98 0.09 0.30 
rs4672507 2p15 4.0 x 10-16 1.06 2.9 x 10-22 1.07 2.6 x 10-7 1.02 1.1 x 10-12 1.04 0.17 0.06 
SNP – single nucleotide polymorphism, AS ankylosing spondylitis, AAU acute anterior uveitis, OR odds ratio 
130 
 
3.3.4 ANTXR2 Odds Ratio Comparison 
The AS associated ANTXR2 SNP rs4389526 showed a significant difference 
in effect size between AS with acute anterior uveitis and AS without acute 
anterior uveitis in model 2 (P = 0.04). The rs4389526 SNP had an effect in the 
AS without acute anterior uveitis cohort (P = 5.6 x 10-3, OR = 0.98, 95% CI 
0.97 – 0.99) but no effect in the AS with acute anterior uveitis cohort (P = 
0.77, OR = 1.00, 95% CI 0.99 – 1.02). 
 
3.3.5 Analysis of ANTXR2 expression in the eye using real-time 
quantitative RT-PCR 
Given the lack of association between ANTXR2 SNP rs4389526 and AS with 
acute anterior uveitis, we examined the expression of ANTXR2, and the 
related ANTXR1 (for comparison), in the eye using a murine model. ANTXR1 
and ANTXR2 mRNA was detected in all the tested eye compartments, as well 
the lung (Figure 3.2). ANTXR1 expression was equivalent in the iris/ciliary 
body, cornea and choroid/sclera, and slightly lower in the retina (Part A). By 
contrast, ANTXR2 was expressed most abundantly in the choroid/sclera, 
iris/ciliary body and retina, compared with the cornea, where expression of 
ANTXR2 was minimal (Part B). 
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Figure 3.2 Expression of ANTXR1 and ANTXR2 in eye compartments. Total RNA was isolated from different compartments of the 
eye, as well as the lung and real-time RT-PCR performed to determine the relative abundance of ANTRX1 and ANTRX2 mRNA by 
reference to L32 mRNA. The results represent mean and SEM from three independent experiments, each including triplicate 
samples 
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3.3.6 Previous Acute Anterior Uveitis associations 
A number of previous non-MHC associations have been reported for acute 
anterior uveitis. Therefore we sought to examine whether there was evidence 
to support their reported association. While not all previously reported acute 
anterior uveitis genetic associations were on the Immunochip microarray, we 
were able to investigate a number of regions previously reported to be 
associated with acute anterior uveitis. Of the previously reported acute 
anterior uveitis associations within the MHC, all were strongly associated in 
the acute anterior uveitis versus HC analysis (Table 3.3). After controlling for 
the lead MHC SNP (rs116488202), no residual association was seen with 
TNF SNPs previously reported to be acute anterior uveitis-associated, 
although nominal association was seen with TNF-238 (rs1800629, P = 0.003).  
This association disappeared after conditioning on the next two associated 
HLA Class I SNPs rs114102658 and rs149567432 (P = 0.08).  Outside the 
MHC, nominally significant associations were observed with SNPs previously 
reported to be acute anterior uveitis associated in IL10 and CYP27B1 (IL10, 
rs6703630, P = 0.04 and CYP27B1, rs703842, P = 0.003). As mentioned 
above, much stronger association was seen in the current study with the IL10 
SNP rs17351243; this SNP is in moderately strong LD with the previously 
reported IL10 association rs6703630 (D’ = 0.87 and r2  = 0.24 current dataset; 
D’ = 0.71 and r2 = 0.09 1000 Genomes) [69]. This suggests that they may tag 
the same association, as controlling for association at rs17351243 means 
rs6703630 becomes non-significant (P = 0.7). 
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Table 3.3 Previous Acute Anterior Uveitis Associations 
Chr Position* rsid Gene 
Uncond P 
value 
B*27 Cond P 
value 
Top two Cond 
P value 
Top Three 
Cond P value 
Reference 
1 206948639 rs6703630 IL10 3.8 x 10-2 [69] 
1 206945381 rs2222202 IL10 5.5 x 10-1 [69] 
1 206945311 rs3024490 IL10 1.2 x 10-1 [69] 
6 31542482 rs1799724 TNF-857 7.0 x 10-40 0.18 0.01 0.01 [70, 217] 
6 31543101 rs361525 TNF-308 2.7 x 10-11 0.07 0.24 0.36 [70, 217] 
6 31543031 rs1800629 TNF-238 7.8 x 10-32 0.002 0.02 0.08 [70, 217] 
6 31542308 rs1799964 TNF-103 2.7 x 10-18 0.065 0.34 0.30 [70] 
6 31542476 rs1800630 TNF-863 3.6 x 10-9 0.24 0.58 0.44 [70] 
6 31914935 rs1048709 CFB 4.1 x 10-9 0.20 0.75 0.40 [76] 
12 58162739 rs703842 CYP27B1 3.8 x 10-3 [79] 
*Human genome build 19, Uncond: Unconditioned result. B*27 Cond: Conditioned on HLA-B*27 dose as imputed by SNP2HLA. 
Top two Cond: Result after conditioning on rs116488202 and rs114102658. Top Three Cond: Result after conditioning on 
rs116488202, rs114102658 and rs149567432 
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3.3.7 AS associations 
Given the extensive co-morbidity between AS and acute anterior uveitis we 
examined all SNPs previously reported to be associated with AS in the AS 
with acute anterior uveitis versus AS without acute anterior uveitis, and the all 
acute anterior uveitis versus HC studies. The strength of association is 
significantly weaker than reported for AS, likely explained by small numbers of 
participants and hence greatly reduced power. The results are reported in 
Supplementary Table 3.8 and Supplementary Table 3.9.  
 
3.4 Discussion 
This study reports genetic associations specific to acute anterior uveitis, as 
well as shared associations with AS that have both similar and significantly 
different effect sizes and directions of association in the two related diseases. 
 
We found evidence to suggest that MHC class I or class II alleles besides 
HLA-B*27 contribute to acute anterior uveitis susceptibility. HLA-B08, which 
we found to be tagged by rs115937001 in HLA-B*27 negative patients, has 
been associated previously with acute anterior uveitis and in addition with 
sarcoidosis, a disease in which acute anterior uveitis also occurs [229-231]. In 
conditional analyses HLA-DQB1:05 and HLA-DRB1:0103 have been 
implicated, and SNPs in or around HLA-DRA, HLA-DRB5 and HLA-DQA2 
have also shown association with acute anterior uveitis. This suggests that 
additional non-HLA-B*27 MHC factors affect the etiology of acute anterior 
uveitis. In our study HLA-B*27 does show association even comparing acute 
anterior uveitis cases with AS to acute anterior uveitis patients without AS, 
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confirming the long held view that HLA-B*27 is an acute anterior uveitis risk 
gene regardless of whether AS is present or not.   
 
We observed a number of genetic associations shared with IBD [11, 12]. The 
IL10 gene is associated with IBD, and IL-10 is important in an animal model of 
experimentally-induced uveitis, as treatment with IL-10 abrogates disease in 
this model [232]. It has also been shown recently that IL-10 is important in IL-
35 induced B regulatory cell suppression of EAU [233]. In humans with acute 
anterior uveitis, peripheral blood mononuclear cells (PBMCs) show up-
regulation of both IL-10 and IL-19 [234]. Curnow and colleagues have noted 
an increase in IL-10 in uveitis using multiplex bead immunoassay [235]. 
Patients with AS who also have IBD have much lower rates of HLA-B*27, 
offering relative protection from acute anterior uveitis. In patients with IBD up 
to 3.8% develop uveitis, a rate substantially lower than in AS [236]. 
  
The suggestive association of the IL-18 receptor highlights the importance of 
the innate immune recognition of foreign microorganisms and the triggering of 
an appropriate adaptive immune response. Research has linked infection with 
organisms such as chlamydia with acute anterior uveitis, and the mechanism 
of this association may be related to inappropriate or abnormal activation of a 
cell-mediated immune response by IL-18 [237, 238]. In sarcoidosis, a 
condition in which acute anterior uveitis occurs, enhanced expression of IL-
18R alpha chain has been noted in CD4 T cells [239].  
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In considering the shared associations between AS and acute anterior uveitis, 
the intergenic region chromosome 21q22 and ANTXR2 have an effect in only 
AS patients without acute anterior uveitis, and not in AS patients with acute 
anterior uveitis.  Further, the chromosome 2p15 intergenic region shows 
significantly greater association in AS without acute anterior uveitis. These 
findings suggest that there may be genetic subgroups in AS with 
heterogeneity in the genetic profiles of AS patients, and that genetic factors 
influence which AS patients develop acute anterior uveitis and which do not.  
A suggestive association between SNPs 17kb upstream of ANTXR2 and 
myopia has been described [240]. But with no effect in the AS with acute 
anterior uveitis cohort it seems ANTXR2 is potentially an AS risk locus alone. 
However, the difference in ANTXR2 expression across the different 
components of the eye is of interest in view of the positive genetic 
associations. The mechanisms for disease association have not been 
identified at either chromosomes 2p15 or 21q22; long non-coding mRNA 
transcripts have been identified, but their function is currently unknown [17]. 
 
These results should be interpreted in light of several limitations; the study is 
underpowered and additional cases are likely to result in new associations. In 
addition, the suggestive associations require replication to be considered 
robustly associated. The use of self-report acute anterior uveitis is a potential 
limitation, although self-report has been shown to differ little from 
ophthalmologist diagnosis in SpA patients previously [19]. The high incidence 
of acute anterior uveitis in AS, and the progressive increase in acute anterior 
uveitis penetrance with disease duration, means that many AS cases 
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currently classified as acute anterior uveitis negative may ultimately develop 
acute anterior uveitis (Figure 3.3).  There may also have been issues with 
under diagnosis of acute anterior uveitis in subclinical cases, AS treatment 
suppressing acute anterior uveitis manifesting or where the diagnosis was 
missed even if clinically apparent. Accurately quantifying the power of the 
study is not possible because the size of these effects is completely unknown. 
Finally there are environmental factors in the etiology of acute anterior uveitis, 
and therefore there is the potential issue of incomplete penetrance of acute 
anterior uveitis susceptibility loci.  
 
 
Figure 3.3 Proportion of AS patients with acute anterior uveitis by AS disease 
duration. Source: AS GWAS patient cohort 
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Because of these problems we took advantage of the availability of a large 
study of AS-susceptibility loci, reasoning that any novel loci found with the 
acute anterior uveitis patient sets compared to HC in the small sample sizes 
used were highly likely to be acute anterior uveitis associated loci. From this 
analysis we have been able to identify a number of novel immune related loci 
associated with acute anterior uveitis. The two shared associations with IBD 
are of particular interest because these are not associations shared with AS. 
The pathways identified will help identify novel treatment strategies for this 
common and important disease and highlights further pathways shared 
between AS, IBD and acute anterior uveitis. 
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3.5 Supplementary Tables 
 
Supplementary Table 3.1 Diagnosis status of acute anterior uveitis by cohort 
  Ophthalmologist Diagnosed Self-Reported Total 
     
Immunochip Samples Australian Samples 0 104 104 
 United Kingdom Samples 0 642 642 
 Canadian Samples 198 0 198 
 United States Samples 767 0 767 
    1,711 
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Supplementary Table 3.2 Subject quality control 
 Pre-QC 
Subjects 
Extreme 
Heterozygosity 
Excessive 
Missingness 
PCA excluded IBD Excluded Post-QC 
Subjects 
Immunochip Cases 3,144 33 0 95 142 2,874 
Immunochip Controls 10,000 45 26 22 343 9,564 
PCA principle component analysis (ethnicity exclusions); IBD identity by descent (relatedness exclusions)  
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Supplementary Table 3.3 SNP quality control 
 Pre-QC SNPs Missingness BCM HWE Monomorphic Post-QC SNPs 
Immunochip SNPs 192,402 4,612* 11,443* 50,229* 31,111 106,525 
BCM Between centre missingness; HWE Hardy-Weinberg Equilibrium; *SNPs failed at multiple steps 
 
142 
 
 
Supplementary Table 3.4 Homozygote and heterozygote HLA-B*27 risk in the all acute anterior uveitis versus healthy control analysis 
 HLA-B*27 homozygotes HLA-B*27 heterozygotes HLA-B*27 negative 
Cases 70 1,426 234 
Controls 24 956 10,479 
OR (95% CI) 130.61 (130.13 - 131.10) 66.80 (66.65 – 66.95) 1.96 (1.48 – 2.43) 
OR – Odds ratio; CI Confidence interval  
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Supplementary Table 3.5 AS with acute anterior uveitis versus AS without acute anterior uveitis primary association analysis result 
SNP Chr Position P value Risk Protective RAF Odds ratio (95% CI) 
rs115879499 6 31360289 4.85E-18 G A 0.49/0.41 1.36 (1.22-1.52) 
rs2032890 5 96121152 9.04E-06 A C 0.78/0.72 1.34 (1.18 – 1.52) 
SNP: single nucleotide polymorphism, RAF: Risk allele frequency, CI: Confidence interval, Chr: Chromosome  
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Supplementary Table 3.6 EYS association linkage disequilibrium 
SNP 1 SNP 2 D prime R2 Phenotype Reference 
rs10197284 rs3771166 1.000 0.239 Asthma [226] 
rs10197284 rs917997 0.888 0.781 Inflammatory bowel disease [177] 
rs10197284 rs917997 0.888 0.781 Celiac disease [225] 
rs10197284 rs1420101 0.735 0.124 Eosinophil counts  [227] 
 
145 
 
 
Supplementary Table 3.7 Linkage disequilibrium between acute anterior uveitis EYS associated SNP and retinitis pigmentosa EYS 
associated SNP 
SNP 1 SNP 2 D prime R2 
rs665873 rs17404123 1.00 0.0014 
rs665873 rs12663916 1.00 0.0014 
rs665873 rs12662610 1.00 0.0014 
rs665873 rs12663622 1.00 0.0014 
rs665873 rs12663619 1.00 0.0014 
rs665873 rs17403955 1.00 0.0014 
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Supplementary Table 3.8 AS associated SNPs in the all acute anterior uveitis versus healthy controls analysis 
All Acute Anterior Uveitis versus Healthy Controls Analysis 
Chr SNP ID 
Position 
(HG19) Risk Allele 
Protective 
Allele 
RAF 
Cases 
RAF 
Controls P value 
Odds Ratio  
(95% CI) 
1 25305114 rs6600247 C T 0.532 0.501 2.6 x 10-3 1.13 (1.04-1.23) 
1 67705958 rs11209026 G A 0.961 0.933 1.7 x 10-8 0.57 (0.46 -0.70) 
1 154426264 rs4129267 C T 0.629 0.585 2.2 x 10-5 0.83 (0.76-0.90) 
1 161479745 rs1801274 A G 0.521 0.473 7.5 x 10-5 0.83 (0.76-0.90) 
1 200877850 rs41299637 T G 0.759 0.706 1.6 x 10-7 0.76 (0.69-0.84) 
1 210794808 rs12758027 C T 0.479 0.449 5.4 x 10-3 1.13 (1.04-1.22) 
2 62568445 rs6759298 G C 0.447 0.372 5.5 x 10-12 0.73 (0.67-0.80) 
2 102647300 rs4851529 G A 0.648 0.612 8.7 x 10-4 0.86 (0.79-0.93) 
2 182048452 rs12615545 C T 0.444 0.421 3.4 x 10-2 1.10 (1.01-1.20) 
2 241563739 rs4676410 A G 0.235 0.207 5.6 x 10-4 1.17 (1.06-1.29) 
3 27794907 rs13093489 A C 0.389 0.347 1.8 x 10-4 1.20 (1.10-1.30) 
5 35881443 rs11742270 G A 0.759 0.726 7.9 x 10-4 0.84 (0.77-0.93) 
5 40524860 rs12186979 G A 0.522 0.507 9.3 x 10-2 1.06 (0.98-1.15) 
5 96124330 rs30187 T C 0.412 0.333 1.9 x 10-13 0.71 (0.66-0.78) 
5 158826792 rs6871626 A C 0.353 0.338 8.3 x 10-2 1.07 (0.98-1.16) 
6 90665773 rs17765610 G A 0.134 0.121 1.3 x10-1 1.13 (1.00-1.27) 
147 
 
7 124439599 rs2402752 T C 0.720 0.708 1.3 x10-1 0.95 (0.86-1.04) 
9 139253839 rs1128905 C T 0.477 0.506 4.5 x 10-3 1.12 (1.03-1.22) 
10 81060317 rs1250550 C A 0.676 0.643 6.8 x 10-3 0.86 (0.79-0.94) 
10 101278725 rs11190133 C T 0.719 0.710 3.5 x 10-3 0.96 (0.87-1.05) 
12 6446777 rs1860545 G A 0.622 0.602 6.3 x 10-2 0.92 (0.84-1.00) 
12 111862575 rs11065898 T C 0.237 0.217 1.7 x10-2 1.12 (1.01-1.23) 
14 88488821 rs11624293 C T 0.101 0.086 1.7 x 10-2 1.18 (1.03-1.36) 
16 28566158 rs3859172 T G 0.436 0.418 5.4 x 10-2 1.08 (0.99-1.17) 
16 28617885 rs75301646 A G 0.382 0.360 2.6 x10-2 1.10 (1.01-1.19) 
17 26148167 rs2531875 G T 0.391 0.365 3.3 x 10-2 0.90 (0.82-0.98) 
17 45575206 rs9901869 A G 0.548 0.517 2.5 x 10-3 1.13 (1.04-1.23) 
19 10525181 rs35164067 G A 0.816 0.796 2.1 x 10-2 0.88 (0.79-0.98) 
21 40466744 rs2836883 G A 0.757 0.736 1.2 x 10-2 0.89 (0.81-0.98) 
21 45615741 rs7282490 G A 0.397 0.394 7.3 x10-1 0.99 (0.91-1.07) 
22 21956653 rs2283790 G A 0.195 0.189 6.0 x10-1 1.04 (0.94-1.15) 
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Supplementary Table 3.9 AS associated SNPs in the AS with Acute Anterior Uveitis versus AS without Acute Anterior Uveitis analysis 
AS with Acute Anterior Uveitis versus AS without Acute Anterior Uveitis Analysis 
Chr SNP ID 
Position 
(HG19) 
Risk 
Allele 
Protective 
Allele 
RAF 
Cases 
RAF 
Controls P value Odds Ratio (95% CI) 
1 rs6600247 25305114 T C 0.458 0.457 0.91 0.99 (0.89-1.11) 
1 rs11209026 67705958 G A 0.9612 0.9561 0.32 0.88 (0.67-1.16) 
1 rs4129267 154426264 C T 0.635 0.619 0.22 0.94 (0.84-1.05) 
1 rs1801274 161479745 A G 0.474 0.497 0.11 0.91 (0.82-1.02) 
1 rs41299637 200877850 T G 0.759 0.74 0.14 0.90 (0.80-1.03) 
1 rs12758027 210794808 C T 0.49 0.472 0.22 1.07 (0.96-1.20) 
2 rs6759298 62568445 C G 0.547 0.536 0.45 1.04 (0.93-1.16) 
2 rs4851529 102647300 G A 0.653 0.643 0.45 0.96 (0.85-1.07) 
2 rs12615545 182048452 T C 0.556 0.554 0.76 0.99 (0.98-1.11) 
2 rs4676410 241563739 A G 0.25 0.244 0.72 1.03 (0.91-1.17) 
3 rs13093489 27794907 A C 0.388 0.37 0.21 1.08 (0.96-1.21) 
5 rs11742270 35881443 G A 0.759 0.75 0.33 0.95 (0.84-1.08) 
5 rs12186979 40524860 A G 0.476 0.468 0.55 0.97 (0.87-1.08) 
5 rs30187 96124330 T C 0.417 0.384 0.02 0.87 (0.78-0.98) 
5 rs6871626 158826792 C A 0.645 0.63 0.23 0.94 (0.84-1.05) 
6 rs17765610 90665773 A G 0.864 0.86 0.66 0.97 (0.83-1.13) 
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7 rs2402752 124439599 T C 0.725 0.716 0.44 0.95 (0.84-1.08) 
9 rs1128905 139253839 C T 0.527 0.522 0.78 1.02 (0.91-1.14) 
10 rs1250550 81060317 C A 0.675 0.667 0.49 0.97 (0.86-1.09) 
10 rs11190133 101278725 T C 0.278 0.263 0.26 1.08 (0.96-1.22) 
12 rs1860545 6446777 A G 0.378 0.37 0.51 1.04 (0.93-1.16) 
12 rs11065898 111862575 T C 0.24 0.226 0.26 1.08 (0.95-1.23) 
14 rs11624293 88488821 C T 0.105 0.095 0.23 1.12 (0.93-1.34) 
16 rs3859172 28566158 G T 0.573 0.564 0.44 0.96 (0.86-1.07) 
16 rs75301646 28617885 G A 0.625 0.622 0.74 0.99 (0.88-1.10) 
17 rs2531875 26148167 T G 0.608 0.592 0.23 1.07 (0.96-1.20) 
17 rs9901869 45575206 A G 0.548 0.547 0.90 1.01 (0.90-1.12) 
19 rs35164067 10525181 G A 0.819 0.805 0.17 0.91 (0.79-1.05) 
21 rs2836883 40466744 A G 0.239 0.219 0.08 1.12 (0.98-1.27) 
21 rs7282490 45615741 A G 0.598 0.578 0.12 1.09 (0.97-1.22) 
22 rs2283790 21956653 A G 0.809 0.781 0.01 0.84 (0.73-0.96) 
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3.6 Supplementary Figures 
 
 
Supplementary Figure 3.1 Scree plots of genomic control versus number of eigenvectors used: A. All acute anterior uveitis versus 
healthy controls, B. AS with acute anterior uveitis versus AS without acute anterior uveitis 
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Supplementary Figure 3.2 Quantile-quantile plots for the Immunochip experiments A. All acute anterior uveitis versus healthy controls B. 
AS with acute anterior uveitis versus AS without acute anterior uveitis 
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Supplementary Figure 3.3 AS with acute anterior uveitis versus AS without acute anterior uveitis Chromosome 6 SNP rs115879499 locus 
plot 
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Supplementary Figure 3.4 AS with acute anterior uveitis versus AS without acute anterior uveitis Chromosome 5 SNP rs2032890 locus 
plot 
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Supplementary Figure 3.5 All acute anterior uveitis versus healthy controls Chromosome 5 SNP rs2032890 locus plot 
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Supplementary Figure 3.6 All acute anterior uveitis versus healthy controls Chromosome 2 SNP rs4672507 locus plot 
156 
 
 
 
Supplementary Figure 3.7 All acute anterior uveitis versus healthy controls Chromosome 1 SNP rs79755370 locus plot 
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Supplementary Figure 3.8 All acute anterior uveitis versus healthy controls Chromosome 1 SNP rs12132349 locus plot 
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Supplementary Figure 3.9 All acute anterior uveitis versus healthy controls Chromosome 1 SNP rs6690230 locus plot 
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Supplementary Figure 3.10 All acute anterior uveitis versus healthy controls Chromosome 1 SNP rs17351243 locus plot 
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Supplementary Figure 3.11 All acute anterior uveitis versus healthy controls Chromosome 2 SNP rs10197284 locus plot 
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Supplementary Figure 3.12 All acute anterior uveitis versus healthy controls Chromosome 4 SNP rs665873 locus plot 
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4 Exome microarray genotyping in ankylosing spondylitis 
4.1 Introduction 
To date, 41 independent genetic associations have been identified and shown to be 
associated with ankylosing spondylitis (AS) susceptibility [18]. These variants have been 
found with coding variant scans [126], genomewide association studies [60, 127], 
candidate gene studies [3, 4, 24, 130] or studies targeting immunologically important 
regions [86], this study uses the Illumina Exomechip microarray to focus on the exonic 
regions of AS patients. The more AS risk SNPs you have the greater your risk of having 
AS, whether people can have no risk SNPs and still have AS depends on knowing all of 
the risk SNPs and we do not currently know them all. Non-coding SNPs probably 
contribute in other ways like splicing (for example the ERAP2 SNP that causes nonsense 
mediated decay of the protein) or through other mechanisms like non-coding RNA, like 
have been identified in chromosome regions 21q22 and 2p15. 
 
Exomes are proposed to carry a disproportionately high number of clinically important 
variants because their potential to profoundly change the resultant function of proteins 
transcribed from genes [241]. Much of the variation found in exomes is also rare [242, 
243]. Recent exome analyses have described the huge number of rare and damaging 
variants present in human exomes, with approximately 313 genes per person predicted to 
be adversely affected by exonic variants. The Illumina Exomechip was used to investigate 
AS patients for variants in exomes associated with susceptibility. Classical alleles were 
imputed with SNP2HLA and specific statistical approaches for low frequency alleles were 
used to assess their significance. 
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4.2 Methods 
4.2.1 Patient Cohorts  
AS patients of European descent who met the modified New York criteria [166] from the 
United Kingdom (n = 4,686), Australia (n = 264) and New Zealand ( n = 82) were recruited 
(total = 5,040). Healthy controls were provided by the following groups (1) 1958 British 
Birth Cohort (n = 5,964); (2) GoDarts type 2 diabetes cohort  (n = 1,793); (3) Oxford 
Biobank (n = 4,522); (4) Twins UK cohort (n = 1,189); (5) Anglo-Australasian Osteoporosis 
Genetics Consortium (AOGC, n = 7,665). Patients were included from the AOGC cohort if 
they were recruited as part of a population study; no patients recruited on the basis of their 
bone mineral density were included as controls. All patients gave written informed consent 
and ethical approval was given by all appropriate institutional review boards. 
 
4.2.2 Genotyping and Quality Control 
Each cohort was genotyped using the Illumina Infinium HumanExome BeadChip version 
1.2. This Illumina microarray has ~240,000 markers, made up of exonic variants, splice 
variants, stop altering variants, ancestry informative markers and MHC tag SNPs. 
Genotype calling was completed with zCall [244]. Each cohort had quality control (QC) 
completed separately, assessing missingness by individual (threshold <3%), missingness 
by genotype (threshold >97%), Hardy-Weinberg equilibrium in controls (threshold P = 
0.01), extreme heterozygosity (threshold > 3 standard deviations from mean) and identity 
by descent threshold of PI_HAT 0.20 was used. After laboratory QC that excluded ~3,000 
– 5,000 SNPs per cohort, 20,714 – 22,864 SNPs were removed from each set to form a 
common SNP basis, 1,033 SNPs were removed due to excess missingness, 526 SNPs 
were removed from control sets due to failing Hardy-Weinberg equilibrium and 11,711 
SNPs were removed due to allele and frequency inconsistencies between the cohorts. 
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During QC 219 subjects were removed due to non-European ethnicity status, 979 subjects 
were removed due to excess relatedness, 207 were excluded due to extreme 
heterozygosity, and 2 were excluded due to excessive missingness (after SNP QC). 
 
Shared genotyped SNPs between cohorts with MAF > 0.05 were then used to perform 
principal component analysis (PCA) for ethnicity identification using SHELLFISH 
(http://www.stats.ox.ac.uk/~davison/software/shellfish/shellfish.php). Unsupervised model 
based clustering implemented in R with MCLUST was used to exclude patients deemed to 
be not European/Caucasian after plotting with HapMap controls. This model assigns a 
cluster to each individual based on their PCA values and in consideration to the weighted 
centre of each cluster and therefore assigns non membership status to those who don’t 
cluster with core Hapmap groups.  
 
Classical alleles were imputed with SNP2HLA using genotyped SNPs that passed quality 
control. All MHC SNPs with a P < 10-3 (n = 1,427) were checked manually prior to 
SNP2HLA classical allele imputation. The supplied Type 1 Diabetes Genetics Consortium 
reference set (n = 5,225) was used as the imputation reference. 
 
4.2.3 Association analysis 
For single variant and low frequency variant analysis we followed the procedure used by 
Peloso et al. [245]. For single variant analysis we restricted analysis to variants where the 
frequency was greater than 0.08%, meaning that 20 or more copies of the minor allele 
were present. We used Plink to perform association analyses with one eigenvector as a 
covariate for population stratification control. Significance levels used were, genomewide P 
< 5 x 10-8, and suggestive 5 x 10-8 > P < 5 x 10-6. 
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For low frequency variant analysis we used the sequence kernel association test-Optimal 
(SKAT-O) test that computes the SKAT test [246] and a burden test [247-250] and then 
selects the test with the best power [251]. This was implemented with the ‘skatMeta’ R 
package. For the low frequency variant analysis we used variants with a frequency of less 
than 5%. We also only included gene based tests where there were at least 2 variants 
contributing each with MAF greater than 0.08%, thus ensuring there were at least 40 
copies of the minor alleles in the test. Three sets of variants were sequentially used as 
inputs into the SKAT-O test. This is because non-damaging variants can reduce the power 
to detect associations in burden tests. The sets used were (a) All variants, (b) “Polyphen2 
set”: Polyphen-2 [252] predicted possibly damaging or probably damaging, and (c) 
“Damaging Set”: Variants causing the following consequences: frameshift substitution, 
nonframeshift substitution, nonframeshift deletion, nonframeshift insertion, frameshift 
deletion, frameshift insertion, nonsynonymous single nucleotide variant (SNV), stopgain 
SNV, stoploss SNV, missense variant, splice acceptor variant, splice donor variant, splice 
region variant, initiator codon variant, stop retained variant, incomplete terminal codon 
variant. 
 
Cluster plots for reported SNPs were checked manually in the case cohort and the 1958 
British Birth Cohort. Association of classical alleles was completed with imputed SNP2HLA 
classical alleles and one principle component in R. The level of significance for this 
analysis was 1.2 x 10-4 as 424 classical alleles were tested for association. Conditional 
analyses were completed by adding the allele being conditioned as a covariate to the 
logistic regression model. Odds ratios were deemed significant if significance testing 
showed a P value of 0.05 or less. 
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4.3 Results 
4.3.1 Participants and SNPs 
After participant QC there were 20,164 controls and 4,602 cases. After SNP QC there 
were 207,193 SNPs. The genomic control-1000 calculated using the designer suggested 
control SNPs (which includes MHC SNPs, total n = 5,000) was 1.045 using one 
eigenvector. The consortium that designed the Exomechip provided a list of 5,000 SNPs  
random synonymous variants to use to calculate the genomic control figure, details are 
available at: http://genome.sph.umich.edu/wiki/Exome_Chip_Design. The genomic control-
1000 is the genomic control scaled to a sample size of 1000 cases and 1000 controls, this 
is done because the genomic control statistic scales with sample size [218]. The scree plot 
showing the genomic control versus eigenvector for each additional eigenvector is shown 
in Figure 4.1 and demonstrates no additional decrease in GC is achieved by additional 
eigenvectors, and the absolute number is acceptable, so 1 eigenvector was used for the 
analysis. The quantile-quantile (QQ) plot for the experiment is shown in Figure 4.2. 
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Figure 4.1 Scree plot of genomic control-1000 of control SNPs versus number of 
eigenvectors used 
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Figure 4.2 Quantile-quantile plot for experiment 
 
4.3.2 Single Variant Analysis: MHC 
The single variant analysis of the MHC demonstrated an expected signal of large effect 
over HLA-B*27 that corresponded to the previously described HLA-B*27 tag SNP 
rs4349859 (P < 1 x 10-300, A allele, OR = 44.6, 95% confidence interval (CI) 53.5 – 83.4). 
After conditioning on rs4349859 a SNP in HLA-A*02 was the next strongest associated, 
rs9261438 (P = 5.6 x 10-18, T allele, OR = 1.34, 95% CI 1.26 – 1.35). This SNP has r2 of 
0.40 and D’ of 0.78 with the previously described HLA-A*02 AS associated SNP 
rs2394250 and so likely tags the same association. After conditioning on both rs4349859 
and rs9261438 no other signals were evident (P > 5 x 10-6). The pattern of association 
after conditioning on the HLA-B*27 tag SNP rs4349859 is shown in Figure 4.3.
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Figure 4.3 Local genome plot of the MHC showing the pattern of association after conditioning on the HLA-B*27 tag SNP (shown in 
red) and after conditioning on the next highest signal of association rs9261438 (shown in blue) 
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4.3.3 Single Variant Analysis: Non-MHC Loci 
The single variant analysis demonstrated 11 known AS genetic associations 
(Table 4.1 and Figure 4.5 - Figure 4.15). The associations in ERAP1, IL23R, 
the intergenic regions chromosomes 2p15 and 21q22, KIF21B-GPR25, 
GPR35 and IL6R were replicated at genomewide significance level. In 
addition, ANTXR2, IL1R1 and FCGR2A were replicated at a suggestive 
threshold of significance. The association in NOS2 (rs2297518) has been 
reported previously as a secondary signal at the NOS2 locus to the 
rs2531875 SNP found to be the primary signal in the Cortes et al. study [86]. 
All SNPs previously reported to be associated with AS that were typed in this 
study showed evidence of replication. A genome wide plot is shown in Figure 
4.4. 
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Figure 4.4 Genome wide association plot of AS Exomechip 
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Table 4.1 Replicated AS genetic associations in previously associated loci 
Gene/locus Current SNP P Value Risk/Prot OR, 95% CI RAF 
Case/Con 
Previously 
reported SNP 
Previous 
OR 
r2 D’ Study 
Replicated           
ERAP1 rs30187 2.95 x 10-34 T/C 1.34 (1.28-1.41) 0.40/0.34 rs31087 1.33 1.00 1.00 Burton et al.[126] 
IL23R rs11465804 1.32 x 10-25 T/G 1.85 (1.65-2.01) 0.96/0.93 rs11209026 1.59 0.89* 0.97* Burton et al.[126] 
IL23R rs11465804 1.32 x 10-25 T/G 1.85 (1.65-2.01) 0.96/0.93 rs11209032 1.30 0.03 1.00 Evans et al.[60] 
2p15 rs10865331 1.22 x 10-22 A/G 1.26 (1.20-1.32) 0.43/0.38 rs10865331 1.27 1.00 1.00 Reveille et al.[127] 
21q22 rs2836878 1.10 x 10-16 G/A 1.25 (1.19-1.32) 0.77/0.73 rs2836878 NR 1.00 1.00 Reveille et al.[127] 
KIF21B-GPR25 rs7554511 3.77 x 10-16 C/A 1.24 (1.18 – 1.30) 0.75/0.71 rs2297909 1.25 0.89 0.96 Evans et al. [86] 
GPR35 rs3749171 4.97 x 10-12 T/C 1.22 (1.15-1.29) 0.21/0.18 rs4676410 1.13 0.86 1.00 Cortes et al.[86] 
IL6R rs2228145 1.87 x 10-8 A/C 1.14 (1.09-1.20) 0.62/0.59 rs4129267 1.18 0.97 1.00 Cortes et al.[86] 
ANTXR2 rs4333130 5.3 x 10-8 T/C 1.14 (1.09-1.20) 0.66/0.63 rs4333130 1.15 1.00 1.00 Evans et al.[60] 
IL1R1 rs2310173 2.31 x 10-7 T/G 1.13 (1.08-1.18) 0.50/0.47 rs4851529 1.10 0.48 0.89 Cortes et al.[86] 
IL1R1 rs2310173 2.31 x 10-7 T/G 1.13 (1.08-1.18) 0.50/0.47 rs2192752 1.11 0.02 0.23 Cortes et al.[86] 
FCGR2A rs1801274 4.58 x 10-6 A/G 1.11 (1.06-1.16) 0.50/0.47 rs1801274 1.12 1.00 1.00 Cortes et al.[86] 
NOS2 rs2297518 2.69 x 10-6 A/G 1.14 (1.08-1.21) 0.21/0.19 rs2297518 1.13 1.00 1.00 Cortes et al.[86] 
LD calculated from 1000 genomes data via the SNAP Browser from the Broad Institute. RAF – Risk allele frequency; SNP – Single 
nucleotide polymorphism; *Calculated from this dataset; NR – Not reported 
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Figure 4.5 Local genome plot of ERAP1 showing association at rs30187
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Figure 4.6 Local genome plot of IL23R showing association at rs11465804 
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Figure 4.7 Local genome plot of intergenic region chromosome 2p15 showing association at rs10865331 
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Figure 4.8 Local genome plot of intergenic region chromosome 21q22 showing association at rs2836878 
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Figure 4.9 Local genome plot of KIF21B-GPR25 showing association at rs7554511
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Figure 4.10 Local genome plot of GPR35 showing association at rs3749171 
179 
 
 
 
Figure 4.11 Local genome plot of IL6R showing association at rs2228145 
180 
 
 
 
Figure 4.12 Local genome plot of ANTXR2 showing association at rs4333130 
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Figure 4.13 Local genome plot of IL1R1-IL1R2 showing association at rs2310173 
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Figure 4.14 Local genome plot of FCGR2A showing association at rs1801274 
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Figure 4.15 Local genome plot of NOS2 showing association at rs2297518 
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Novel common variant associations were evident in USP8 (P = 3.5 x 10-52, 
OR = 1.97) and CDKAL1 (P = 1.8 x10-8, OR = 1.18) at a genomewide level of 
significance (Table 4.2 and Figure 4.16 - Figure 4.21). Two variants in USP8 
have been associated with psoriasis [253].  These variants are not included 
on Exomechip, and rs148783236 is not in 1000 genomes to compute LD 
calculations, so the AS-association may represent the same association, but 
we cannot test that in this dataset. The CDKAL1 SNP rs6908425 has been 
associated with Crohn’s disease in two large studies previously [82, 254]. 
Common variants in FAM118A (P = 5.9 x 10-8, OR = 1.16), C7orf72 (P = 1.9 x 
10-7, OR = 1.14) and FAM114A1 (P = 1.4 x 10-6, OR = 1.14) were associated 
at a suggestive level of association. SNPs in C7orf72 have been associated 
with Crohn’s disease [82, 255]. A novel low frequency association was found 
in patatin-like phospholipase domain containing 1 (PNPLA1) at a suggestive 
level of significance (P = 1.5 x 10-6, OR = 2.6). 
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Table 4.2 Novel AS associations 
Chr SNP Position* 
Risk 
Allele 
Prot 
Allele Cases RAF Cont RAF OR (95% CI) P value 
Gene/nearby 
gene 
Genomewide association        
15 rs148783236 50,785,016 A G 0.9340 0.8773 1.97 (1.81 - 2.15) 3.51 x 10-52 USP8 
6 rs6908425 20,728,731 C T 0.8108 0.7843 1.18 (1.11 - 1.25) 1.79 x 10-8 CDKAL1 
          
Suggestive association         
22 rs6007594 45,728,370 G A 0.7670 0.7395 1.16 (1.10 - 1.22) 5.90 x 10-8 FAM118A 
7 rs1456896 50,304,461 T C 0.6930 0.6646 1.14 (1.08 - 1.20) 1.85 x 10-7 C7orf72 
4 rs11555334 38,880,046 T C 0.7467 0.7218 1.14 (1.08 - 1.20) 1.37 x 10-6 FAM114A1 
6 rs141744967 36,270,205 T C 0.0044 0.0017 2.63 (1.77 - 3.89) 1.46 x 10-6 PNPLA1 
Chr – Chromosome; Prot – protective; RAF – risk allele frequency. *Human genome build 19 
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Figure 4.16 Local genome plot of USP8 showing association at rs148783236 
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Figure 4.17 Local genome plot of CDKAL1 showing association at rs6908425 
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Figure 4.18 Local genome plot of FAM118A showing association at rs6007594 
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Figure 4.19 Local genome plot of C7orf72 showing association at rs1456896
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Figure 4.20 Local genome plot of FAM114A1 showing association at rs11555334 
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Figure 4.21 Local genome plot of PNPLA1 showing association at rs141744967 
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After conditioning on the primary association signals there were secondary 
signals observed in ERAP1 and IL23R (Table 4.3 and Figure 4.22 - Figure 
4.25). The pattern of secondary association at ERAP1 is consistent that 
previous work that describes two independent haplotypes at ERAP1, tagged 
by the functional variants rs30187-T (primary signal) and rs10050860-C 
(primary unconditioned signal, P = 3.1x10-24, allele C, OR = 1.35, 95% CI 1.27 
– 1.43 and conditioned on rs30187 P = 9.7 x 10-10, allele C, OR = 1.22, 95% 
CI 1.14 – 1.30). The LD between rs30187 and rs10050860 is r2 = 0.156 and 
D’ = 1.00. There is also association in the neighbouring ERAP2 gene after 
conditioning on rs30187 (rs2549794, P = 2.8 x 10-14, allele C, OR = 1.22, 95% 
CI 1.16 – 1.28). After controlling for both rs30187 and rs10050860, the 
ERAP2 association remains at rs2549794 (P = 4.7 x 10-14, allele C, OR = 
1.22, 95% CI 1.16 – 1.28). 
 
There was a second independent signal at the IL23R locus, evident after 
conditioning on rs11465804, from rs10889677 (P = 9.8 x 10-9, allele A, OR = 
1.15, 95% CI 1.10 – 1.20); this variant is already known to be associated with 
AS [126]. The intronic variant rs11465804 was slightly more significantly 
associated than the previously reported rs11209026 variant previously 
reported (P = 1.32 x 10-25 and P = 4.55 x 10-25 respectively), and they are in 
high LD (r2 = 0.89, D’ = 0.97) suggesting the rs11465804 variant tags this 
previously demonstrated functional SNP [256, 257]. 
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An independent signal supported by multiple SNPs was evident after 
conditioning on the main SNP at the FAM114A1 locus; these SNPs sit in the 
TLR10 gene.   
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Table 4.3 Secondary associations observed at loci with association already observed 
 
Chr SNP Position* Gene P Value Risk/Non-
Risk 
RAF 
Case/Con 
OR (95% CI) Conditional SNP 
5 rs2549794 96,244,549 ERAP2 2.85 x 10-14 C/T 0.44/0.43 1.22 (1.16 – 1.28) rs30187 
5 rs10050860 96,122,210 ERAP1 1.6 x 10-9 C/T 0.82/0.77 1.21 (1.14-1.29) rs30187/rs2549794 
1 rs10889677 67,725,120 IL23R 9.7 x 10-9 A/C 0.69/0.65 1.15 (1.10 – 1.21) rs11465804 
4 rs11096955 38,776,107 TLR10 3.5 x 10-4 G/T 0.32/0.30 1.09 (1.04 – 1.15) rs11555334 
OR – Odds ratio; CI – Confidence interval; SNP – Single nucleotide polymorphism; Chr – Chromosome; RAF – Risk allele 
frequency. *Human genome build 19 
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Figure 4.22 Local genome plot of ERAP1 showing at rs2549794 after conditioning on rs30187
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Figure 4.23 Local genome plot of ERAP1 showing association at rs10050860 after conditioning on rs30187 and rs2549794
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Figure 4.24 Local genome plot of IL23R showing association at rs10889677 after conditioning on rs11465804  
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Figure 4.25 Local genome plot of FAM114A1 showing association at rs11096955 after conditioning on rs11555334  
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4.3.4 Rare variant burden tests 
Using the SKAT-O test no genes were significantly associated with AS at either a 
genomewide or suggestive level of significance. This was the case for all the sets of 
variants incorporated into the burden equation including (a) “Damaging set”, (b) “Polyphen 
set” and (c) all variants. No association was evident even after removing the restrictive 
minor allele filter of 0.05 and including SNPs of all frequencies. 
 
4.3.5 Imputed classical MHC allele analysis 
The classical allele HLA-B*27 is known to be strongly associated with AS. To examine for 
further classical allele associations we examined SNP2HLA imputed classical alleles. 
Firstly examining 2 digit resolution HLA types, there was strong association in the MHC 
corresponding to HLA-B*27 (P  < 10-300, OR = 48.1, 95% CI 43.9 – 52.6). After 
conditioning on HLA-B*27, HLA-A*02 was associated (P = 3.6 x 10-13, OR = 1.28, 95% CI 
1.20 – 1.37). After conditioning on both HLA-B*27 and HLA-A*02 the B allele HLA-B*40 
was associated (P = 1.8 x 10-8, OR = 1.46, 95% CI 1.28 – 1.67). After conditioning on 
HLA-B*27, HLA-A*02 and HLA-B*40 there remained a protective association with HLA-
B*07 (P = 9.7 x 10-7, OR = 0.76, 95% CI 0.68 – 0.85). After conditioning on HLA-B*27, 
HLA-A*02, HLA-B*40 and HLA-B*07 there was residual association at the MHC class II 
allele HLA-DPB1*06 (P = 1.5 x 10-5, OR = 1.87, 95% CI 1.41 – 2.48). After conditioning on 
HLA-B*27, HLA-A*02, HLA-B*40, HLA-B*07 and HLA-DPB1*06 there was no association 
with P < 1 x 10-4. 
 
Examining 4 digit resolution, after conditioning on HLA-B*27 (because it is known that 
multiple subtypes of this allele are associated with AS), there was association in HLA-
A*0201 (P = 5.0 x 10-15, OR = 1.31, 95% CI 1.23 - 1.41), after this allele the next subtype 
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of HLA-A*02 associated was HLA-A*0211 (P = 4.6 x 10-3, OR = 6.67, 95% CI 1.8 – 24.8). 
After conditioning on both HLA-B*27 and HLA-A*0201, HLA-B*0702 was associated (P = 
4.3 x 10-8, OR = 0.73, 95% CI 0.65  – 0.82). The next subtype of HLA-B*07 (HLA-B*0704) 
was not associated P = 0.14. After conditioning on HLA-B*27, HLA-A*0201 and HLA-
B*0702, HLA-DPB1*0601 was associated (P = 1.0 x 10-6, OR = 2.02, 95% CI 1.52 – 2.68). 
 
Just considering the HLA-B locus HLA-B*27 was associated in the regression with 1 
eigenvector (P  < 10-300, OR = 48.1, 95% CI 43.9 – 52.6).  After conditioning on HLA-B*27, 
HLA-B*40 was associated (P = 8.4 x 10-10, OR = 1.51, 95% CI 1.32 – 1.72). Conditioning 
on both HLA-B*27 and HLA-B*40, HLA-B*07 was associated with a protective direction of 
effect (P = 1.2 x 10-6, OR = 0.76, 95% CI 0.68 – 0.85). No other 2 digit alleles were 
associated at P values below our significance threshold, but the 4 digit allele HLA-B*5701 
was associated at P = 9.0 x 10-5, OR = 0.66 95% CI 0.53 – 0.81. The 2 digit allele HLA-
B*57 fell just outside our Bonferroni significance level at P = 1.6 x 10-4, OR = 0.67, 95% CI 
0.54 – 0.82) 
 
4.4 Discussion 
This study replicates 11 known AS genetic associations both in the MHC and outside of 
the MHC (Table 4.1). It also describes two novel associated variants that achieve genome-
wide significance, all of which are common variants. In addition four associations at a 
suggestive level of significance are described (Table 4.2).  
 
Two of the novel AS associated variants (discussed above) have also been associated 
with inflammatory bowel disease (IBD), namely CDKAL1 and Corf72 (Table 4.1, Table 4.2, 
Figure 4.17 and Figure 4.19). CDKAL1 was genotyped in the AS Immunochip study 
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however no association was reported. There is a high prevalence of inflammatory bowel 
disease in patients with AS [14, 35]. Around 10% of AS patients have clinical IBD and up 
to 70% have subclinical bowel inflammation demonstrated histologically. Many other 
genetic associations of AS are also shared with IBD including ERAP2 and IL23R [11]. 
There has been strong interest in the gut-joint link in AS because of the high prevalence of 
inflammation found in AS cases [12]. In addition, reactive arthritis, which is a type of 
spondyloarthritis, can be triggered by enteric infections such as Campylobacter, 
Salmonella, and Shigella. 
 
USP8 was the lead novel association found in this study and encodes a protein called 
ubiquitin specific peptidase 8 (Figure 4.16). The variant was not genotyped on 
Immunochip. The variant in USP8 identified to be associated with AS (rs148783236) is a 
missense variant causing a change from threonine to alanine. The Polyphen-2 score for 
this change is unavailable from the Polyphen-2 server. Alanine is a non-polar hydrophobic 
amino acid with a neutral side chain and a molecular weight of 89 Da. Threonine is polar 
amino acid with a neutral side chain and a molecular weight of 119 Da. This change 
therefore is more likely to lead to important functional effects than if the replacement amino 
acid was also non-polar and of the same molecular weight. USP8 ubiquinates other 
proteins in the cell cytoplasm. Ubiquination is an integral part of the MHC class I 
presentation pathway. Several other genes in this pathway have been associated with AS 
including HLA-B*27, ERAP1, ERAP2, NPEPPS, LNPEP and UBE2E3. In addition USP8 
has been identified to traffic transmembrane proteins and regulate basal cytokine receptor 
levels. Psoriatic arthritis and psoriasis have also been associated with two variants in this 
gene, rs4775912 and rs3803369 [253]. These variants are 495-590KB telomeric from the 
AS associated variant rs148783236.  Of note, the candidate gene TNFAIP8L3 gene is 
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560KB telomeric. The LD is unavailable with these variants because rs148783236 is not in 
1000 genomes. The TNFAIP8L3 gene is part of the TNF-alpha inducible protein 8 family. 
Tumour necrosis factor-α-induced protein-8 (TIPE2, 1q21), which is another member of 
this family, has been shown to regulate innate immune responses and apoptosis through 
caspase binding [258]. TIPE2 is constitutively expressed in lymphoid tissue with neither 
fibroblasts or myeloma cells having this constitutive expression. Homozygous deletion of 
TIPE2 in mice results in multi-organ inflammation, splenomegaly, and premature death. 
The USP8 association may tag an association with this member of the TNF pathway [258]. 
 
One of the associations found at a suggestive level was FAM114A1 (Figure 4.20). Little is 
known about this gene but the protein product of FAM114A1 is called NOXP20 and 
contains a predicted caspase recruitment (CARD) domain so may be involved in apoptosis 
[259]. CARD9 has been associated with AS and NOXP20 may play a similar role. In 
addition neighbouring genes include Toll-like receptor TLR1 and TLR6 which are intimately 
involved in innate immunity, so are strong biological candidates for AS association. The 
second independent signal at the FAM114A1 locus was in the toll-like receptor 10 gene 
(TLR10). This missense variant (rs11096955) is predicted by Polyphen-2 to cause a 
benign change, however it may tag other more functional variants. This association 
implicates this important component of the innate immune system in AS aetiology. Toll like 
receptors recognise evolutionary conserved sequences on pathogens and trigger immune 
responses. TLR10 has been recently identified to induce pro-inflammatory cytokine 
production and interferon in response to influenza infection [260]. One of the current 
theories about the aetiology of AS is that it is immunodeficiency related to gut organisms 
that triggers the disease and if this association in TLR10 impairs innate immune responses 
then it is consistent with this theory [36]. 
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The associated variant rs6007594 in FAM118A is in high LD (r2 = 0.84 and D’ = 0.94) with 
another SNP in FAM118A (rs720682) that has been associated with hip bone mineral 
density at a modest level of significance (P = 1.4 ×10-3, Figure 4.18) [261]. The effect of 
rs720682 on hip bone mineral density was estimated to be -0.05 standard deviations from 
the population mean (95% CI -0.08 to -0.02). In addition that associated SNP rs6007594 is 
a missense mutation causing an arginine to be replace by a histadine. This missense 
change is predicted to be probably damaging with a Polyphen-2 score of 0.999 (sensitivity: 
0.14; specificity: 0.99) [252]. Low bone mineral density is seen in AS and pathological new 
bone formation is also a feature of AS so associations that impact on bone structure or 
function have high biological plausibility, however how this variant impacts on AS aetiology 
is not immediately evident. 
 
The mechanism for the association in PNPLA1 is not clear (Figure 4.21). The 
rs141744967 variant is a missense mutation that causes a change from alanine to valine. 
The functional effect is not available from the Polyphen-2 server; both amino acids are 
non-polar but differ in size by 28 Da. PNPLA1 is a gene involved in lipid metabolism but its 
function is not completely understood.  Variants in this gene are associated with the skin 
disorder ichthyosis [262]. 
 
There are several limitations that should be taken into account in interpreting this study. 
The major limitation is power. The power to detect rare variants is a function of their allele 
frequency and their effect size along with the population frequency of disease and your 
required statistical significance threshold. The power to detect a variant with a frequency of 
0.01, population disease frequency of 0.005 and a (ambitious) relative risk effect size of 2 
per allele and a significance threshold of P = 5 x 10-8 using the participant numbers in this 
study, is 41%. This demonstrates poor power to detect individual associations, and 
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increasing the number of cases would improve this power.  Nonetheless, if there are large 
numbers of rare variant associations contributing to AS, the study should have had good 
power to detect some of these, assuming its coverage of rare variants was good. 
However, the coverage of the microarray of rare variants is far from comprehensive. 
Sequencing of whole genomes has demonstrated millions of low frequency and rare 
variants that are not covered on the chip.  This suggests that comprehensive rare variant 
microarray studies will be unfeasible. 
 
The suggestive associations we identified require confirmation in independent cohorts for 
them to be considered robustly associated. Finally, rare variants do not share LD with 
many other surrounding variants to the extent that common variants do. Therefore if 
identified in a study such as this, a good check of a true association is good genotype 
clustering, confirmed by manual inspection, and biological plausibility. However, probes 
can map to other areas of the genome without our knowledge giving well clustered 
intensity plots. Biological plausibly is not necessarily a good judge of a true association as 
the association may be the first association in a hitherto unknown pathway involved in 
disease aetiology. This makes independent replication studies essential. 
 
This study has replicated 11 known AS risk loci, and also identified two novel common 
variants at a genomewide level of significance and four suggestive associations, one being 
of low frequency. Low frequency variants may show population structure that differs 
significantly from that of common variants. Currently a robust and reliable method for 
controlling population structure has not been recognised for low frequency and rare 
variants. This is because structure can exist in very small geographical areas due to the 
presence of spontaneous mutation. Therefore this caveat needs to be bore in mind when 
interpreting the low frequency result. The variants are both known to be associated with 
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related diseases like IBD and also novel variants not associated with related diseases. The 
challenge remains to confirm their association and elucidate their biological function. 
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5 Exomechip SNP microarray analysis of anterior acute anterior uveitis patients 
5.1 Introduction 
Acute anterior uveitis both occurs in isolation and complicates AS. It is potentially sight 
threatening and is associated with a number of other ophthalmological sequelae such as 
cataract, posterior synechiae and glaucoma.  
 
Acute anterior uveitis occurs in 30 – 40% of ankylosing spondylitis (AS) patients and 
increases in frequency with disease duration. In Chapter 4 a study examining acute 
anterior uveitis cases genotyped on the Immunochip microarray was presented. A number 
of shared associations with AS and also some suggestive novel associations were 
described. We extend this analysis but using the Illumina Exomechip SNP microarray to 
examine for further acute anterior uveitis associations. 
 
Exomes carry a disproportionally high number of potentially damaging or functionally 
important variants. The Illumina Exomechip was designed to capture non-synonymous 
variants, splice variants and stop altering variants in the coding region of the genome. In 
addition it also included 2,500 HLA tagging SNPs as well as variants for genomic control 
based analyses. We now report on a large study of AS patients who have had acute 
anterior uveitis and compare them to both AS patients who have not had acute anterior 
uveitis, and also healthy controls (HC).  
This study aims to identify genetic variants associated with acute anterior uveitis by using 
AS patients both with and without acute anterior uveitis. Comparing AS patients with acute 
anterior uveitis to AS patients without acute anterior uveitis is the best strategy to identify 
pure acute anterior uveitis risk loci but this analysis is underpowered due to delayed 
disease onset (meaning that many AS patients without acute anterior uveitis may 
ultimately develop acute anterior uveitis), and recall bias. Therefore we have both 
compared AS patients with acute anterior uveitis versus AS patients without acute anterior 
uveitis, and additionally examined for associations in the comparison of both these groups 
against HC. To augment these analyses a heterogeneity test has been applied to all SNPs 
shown to be associated with AS, AS with acute anterior uveitis or AS without acute 
anterior uveitis. This analysis aims to demonstrate whether there is a difference in effect 
size in AS patients with acute anterior uveitis compared to AS patients without acute 
anterior uveitis. Demonstrating a difference in effect size would suggest that the 
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association was not driven purely by the AS phenotype that all the disease participants 
have. 
 
5.2 Methods 
5.2.1 Patient Cohorts  
Ankylosing spondylitis patients who met the modified New York criteria [166] were 
recruited from rheumatology clinics in Australia, the United Kingdom and New Zealand. 
Patients who either have had acute anterior uveitis (n = 1,504) or have not had acute 
anterior uveitis (n =1,805) were used in this study. HC from a number of collaborating 
centres were used: (1) 1958 British Birth Cohort (n = 5,964); (2) GoDarts type 2 diabetes 
cohort  (n = 1,793); (3) Oxford Biobank (n = 4,522); (4) Twins UK cohort (n = 1,189); (5) 
Anglo-Australasian Osteoporosis Genetics Consortium (AOGC, n = 7,665). The frequency 
of HLA-B27 as measured by the rs4349859 genotype in the control groups after QC was 
9.0%, 8.7%, 8.4%, 8.3% and 8.5% respectively. Patients were included from the AOGC 
cohort if they were recruited as part of a population study; no patients recruited on the 
basis of their having extreme high or low bone mineral density were included as controls. 
All patients gave written informed consent and ethical approval and given by all 
appropriate institutional review boards. 
 
5.2.2 Genotyping and Quality Control 
Each cohort was genotyped using the Illumina Infinium HumanExome BeadChip version 
1.2. This Illumina microarray has ~240,000 markers, made up of exonic variants, splice 
variants, stop altering variants, ancestry informative markers and major histocompatibility 
complex (MHC) tag SNPs. Genotype calling was completed with zCall [244]. Each cohort 
had quality control (QC) completed separately, assessing missingness by individual 
(threshold <97%), missingness by genotype (threshold > 3%), Hardy-Weinberg equilibrium 
in controls (threshold P = 0.01), extreme heterozygosity (threshold > 3 standard deviations 
from the mean), and cryptic relatedness was assessed, with subjects with identity by 
descent threshold of PI_HAT> 0.20 being excluded. After laboratory QC that excluded 
~3,000 – 5,000 SNPs per cohort, 20,714 – 22,864 SNPs were removed from each set to 
form a common SNP basis, 1,033 SNPs were removed due to missingness, 526 SNPs 
were removed from control sets due to failing Hardy-Weinberg equilibrium and 11,711 
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SNPs were removed due to allele and frequency inconsistencies between the cohorts. 
During participant QC 219 subjects were removed due to non-European ethnicity status, 
979 subjects were removed due to excess relatedness, 207 were excluded due to extreme 
heterozygosity and 2 were excluded due to excessive missingness (this was after SNP 
QC). 
 
Common genotyped SNPs between cohorts were then used to perform principal 
component analysis for ethnicity identification using SHELLFISH 
(http://www.stats.ox.ac.uk/~davison/software/shellfish/shellfish.php). LD trimming was 
applied prior to the calculation of the principle components. Unsupervised model based 
clustering implemented in R with MCLUST was used to exclude patients deemed to be not 
European/Caucasian after plotting with HapMap controls. This model assigns a cluster to 
individuals based on their PCA values and in consideration of the weighted centre of each 
cluster and therefore assigns non-membership status to those who don’t cluster with core 
Hapmap groups.  
 
Classical alleles were imputed with SNP2HLA using genotyped SNPs that passed quality 
control. The intensity plots of all MHC SNPs with a P value less than 1 x 10-3 (n = 1,427) 
were checked manually prior to SNP2HLA classical allele imputation. The supplied Type 1 
Diabetes Genetics Consortium reference set (n = 5,225) was used as the imputation 
reference. 
 
In calculating the genomic control statistic, we utilised the set of SNPs designated by the 
Exomechip design team as ‘Random set of synonymous variants (as comparator)’ these 
SNPs were specifically chosen to perform genomic control analyses on. Further details are 
available: 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design#Random_set_of_synonymous_va
riants_.28as_comparator.29 
 
5.2.3 Association analysis 
For single variant and low frequency variant analysis we followed the procedure used by 
Peloso et al. [245]. For single variant analysis we restricted analysis to variants where the 
frequency was greater than 0.08%, that meant a minimum of 20 copies of the minor allele 
were present. We used logistic regression in PLINK to perform association analyses with 
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an eigenvector as a covariate for population stratification control [190]. Significance levels 
used were, genomewide P < 5 x 10-8, and suggestive 5 x 10-8 > P < 5 x 10-6. Secondary 
signals were reported if P ≤1 x 10-4. 
 
For low frequency variant analysis we used the sequence kernel association test-Optimal 
(SKAT-O) test that computes the SKAT test [246] and a burden test [247-250] and then 
selects the test with the best power [251]. This was implemented with the ‘skatMeta’ R 
package. For the low frequency variant analysis we used variants with a frequency of less 
than 5%. We also only included gene based tests where there were at least 2 variants 
contributing each with MAF greater than 0.08%, thus ensuring there were at least 40 
copies of the minor alleles in the test. Three sets of variants were sequentially used as 
inputs into the SKAT-O test. This is because non-damaging variants can reduce the power 
to detect associations in burden tests. The sets used were (a) All variants, (b) “Polyphen2 
set”: Polyphen-2 [252] predicted possibly damaging or probably damaging, and (c) 
“Damaging Set”: Variants causing the following consequences: frameshift substitution, 
nonframeshift substitution, nonframeshift deletion, nonframeshift insertion, frameshift 
deletion, frameshift insertion, nonsynonymous single nucleotide variant (SNV), stopgain 
SNV, stoploss SNV, missense variant, splice acceptor variant, splice donor variant, splice 
region variant, initiator codon variant, stop retained variant, incomplete terminal codon 
variant. 
 
Cluster plots for reported SNPs were checked manually in the case cohort and the 1958 
British Birth Cohort. Association of classical HLA alleles was completed with imputed 
SNP2HLA classical alleles and one principal component, in R. The level of significance for 
this analysis was 1.2 x 10-4, as 424 classical alleles were tested for association. 
Conditional analyses were completed by adding the allele being conditioned as a covariate 
to the logistic regression model. 
 
5.2.4 Comparison of SNP effects between AS with and without acute anterior 
uveitis 
The HC were split into two by random sampling (2 sets of 10,082) and allocated as 
controls to either the AS with acute anterior uveitis cases or the AS without acute anterior 
uveitis cases to ensure the independence of the two regressions. These two sets of cases 
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and controls were then allocated a dummy variable of 1 or 0 coded as Z. The following 
regression model was then used: 
 
logit(ψ) = β0 +βsnpSNP + βi
i=1
1
∑ ×PCi +βZZ +βZ 2SNP× Z
 
where ψ  is the acute anterior uveitis phenotype (either 1=acute anterior uveitis in the ‘AS 
with acute anterior uveitis’ cases, or 1=no acute anterior uveitis in the ‘AS without acute 
anterior uveitis’ cases, controls in both sets were coded=0). βsnp is the regression co-
efficient for the SNP dose, SNP is the dosage of the SNP genotype. βi
i=1
1
∑  is the regression 
coefficient of the principal component,PCi  is the principal component. βZ is the regression 
co-efficient for the dummy variable Z. BZ2 is the regression co-efficient for the interaction 
term between the dummy variable and the SNP dosage: SNP×Z. β0 is the intercept. We 
also analysed the model with the HLA-B*27 as a component: 
log it(ψ)= β0 + βsnpSNP +βB27B27+ βi
i=1
1
∑ ×PCi + βZZ +βZ 2SNP× Z  
In this modelβB27B27 is the SNP2HLA imputed dosage of HLA-B*27. Due to the 
exploratory nature of this analysis, small number of tests (~20) and the conservative 
nature of the method we choose not to apply a multiple testing burden to the results. 
 
5.3 Results 
5.3.1 Patients 
After participant QC there were 1,409 AS patients with acute anterior uveitis, 1,695 AS 
patients without acute anterior uveitis, and 20,164 healthy controls. After SNP QC there 
were 207,193 SNPs. The quantile-quanitle plots for the three single variant experiments 
are shown in Figure 5.1. 
 
The genomic control-1000 statistics calculated from the control SNPs (n = 5,000) was 
0.996 for AS with acute anterior uveitis versus healthy controls, 1.029 for AS without acute 
anterior uveitis versus healthy controls and 1.005 for AS with acute anterior uveitis versus 
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AS without acute anterior uveitis. The scree plots for the genomic control-1000 values for 
control SNPs versus eigenvectors used is shown in Figure 5.2. 
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Figure 5.1 Quantile-quantile plots for (A) AS with acute anterior uveitis versus healthy controls; (B) AS without acute anterior uveitis 
versus healthy controls and (C) AS with acute anterior uveitis versus AS without acute anterior uveitis analyses 
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Figure 5.2 Scree plots for (A) AS with acute anterior uveitis versus healthy controls; (B) AS without acute anterior uveitis versus 
healthy controls and (C) AS with acute anterior uveitis versus AS without acute anterior uveitis analyses 
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5.3.2 Single Variant Analysis: AS with acute anterior uveitis versus 
Healthy Controls 
5.3.2.1 The MHC 
In the MHC the strongest association observed was with the HLA-B*27 tag 
SNP rs4349859 (P < 10-300, allele A, OR = 86.7, 95% CI 72.4 – 103.8)(Figure 
5.3). Conditioning on rs4349859, the next associated SNP was rs9261438 (P 
= 6.3 x 10-8, allele T, OR = 1.32, 95% CI 1.19 – 1.46). This SNP is very close 
to HLA-A, and tags HLA-A*02 with 87% specificity and 89% sensitivity, and 
HLA-A*0201 with 87% sensitivity and 91% sensitivity. The linkage 
disequilibrium with the previously reported HLA-A*0201 association in AS is 
unavailable due to neither SNP being in the 1000 Genomes Pilot 1 dataset. 
After conditioning on both rs4349859 and rs9261438, association with an 
intronic variant rs2621321 in TAP2 was observed (P = 1.1 x 10-5, allele G, OR 
= 0.78, 95% CI 0.69 – 0.87). Conditioning on rs4349859, rs9261438 and 
rs2621321,  residual association was seen with the PSORS1C3 intronic 
variant rs3131018 (P = 4.7 x 10-5, allele A, OR = 0.78, 95% CI 0.68 – 0.87).  
 
5.3.2.2 Non-MHC loci 
Association was evident at five loci known to be associated with AS (ERAP1, 
IL23R, KIF21B-GPR25 and the chromosome regions 2p15 and 21q22). The 
new AS risk locus USP8 described in the previous chapter was also 
associated in this analysis (Table 5.1 and Figure 5.4 -  Figure 5.9). The 
associations are all the same previously reported SNPs, or are a close proxy 
in the case of GPR25-KIF21B (Table 5.2).  
 
Examining for secondary associations, at IL23R, conditioning on rs11209026 
showed association at rs10889677 just outside our reporting threshold (P = 
1.4 x 10-4, allele A, OR = 1.17, 95% CI 1.08 – 1.27)(see Figure 5.10). This 
SNP has been reported to be IBD associated [263, 264]. At the ERAP1 locus 
conditioning on rs30187 showed association at an ERAP1 nsSNP rs2287987, 
(Val349Met, P = 7.8 x 10-7, allele C, OR = 0.76, 95% CI 0.68 – 0.85)(see 
Figure 5.11). Conditioning on rs30187 and rs2287987, association was 
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observed with the ERAP2 SNP rs2549794 (P = 1.5 x 10-3, allele C, OR = 
1.15, 95% CI 1.05 – 1.25, see Figure 5.12). The rs2287987 SNP tags the 
other ERAP1 AS-associated haplotype (LD of r2 = 0.91, D’ = 1.00 with 
rs10050860). This confirms the same 2 associated ERAP1 haplotypes and 1 
conditional ERAP2 haplotype association seen in AS.  
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Table 5.1 Single variant analysis of AS with acute anterior uveitis versus healthy controls 
Chr SNP Position* 
Risk 
Allele 
Prot 
Allele Cases RAF Cont RAF OR (95% CI) P value Gene/Locus 
15 rs148783236 50785016 A G 0.94 0.88 2.39 (2.02 – 2.81) 3.19 x 10-25 USP8 
5 rs30187 96124330 T C 0.42 0.34 1.46 (1.35 - 1.58) 2.80 x 10-21 ERAP1 
1 rs11209026 67705958 G A 0.96 0.93 1.85 (1.52 - 2.25) 5.44 x10-10 IL23R 
1 rs296547 200892137 C T 0.69 0.64 1.29 (1.19 - 1.40) 1.50 x 10-9 
GPR25-
KIF21B 
2 rs10865331 62551472 A G 0.43 0.38 1.24 (1.15 - 1.34) 3.96 x10-8 2p15 
21 rs2836878 40465534 G A 0.77 0.73 1.25 (1.14 - 1.37) 1.28 x10-6 21q22 
Chr – Chromosome, Prot – Protective, RAF – Risk allele frequency, OR – Odds ratio, CI – Confidence interval, *HG19 
 
Table 5.2 SNPs reported in the AS with acute anterior uveitis versus healthy controls study in comparison to previously reported 
SNPs 
Chr Gene/locus SNP Previously reported SNP r2 D’ Study 
15 USP8 rs148783236 rs148783236 1.00 1.00 Chapter 4 
5 ERAP1 rs30187 rs30187 1.00 1.00 Burton et al. [126] 
1 IL23R rs11209026 rs11209026 1.00 1.00 Burton et al. [126] 
1 IL23R rs11209026 rs11209032 0.03* 0.97* Evans et al. [60] 
1 GPR25-KIF21B rs296547 rs2297909 0.83 0.96 Evans et al. [60] 
2 2p15 rs10865331 rs10865331 1.00 1.00 Reveille et al. [127] 
21 21q22 rs2836878 rs2836878 1.00 1.00 Reveille et al. [127] 
LD calculated from SNAP browser using 1000 genomes data. *LD calculated from Evans et al. dataset 
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Figure 5.3 Pattern of association in the MHC in the AS with acute anterior uveitis versus healthy controls 
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Figure 5.4 Local genome plot of USP8 showing the rs148783236 association 
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Figure 5.5 Local genome plot of ERAP1 showing the rs30187 association 
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Figure 5.6 Local genome plot of IL23R showing the rs11209026 association 
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Figure 5.7 Local genome plot of GPR25 showing the rs296547 association 
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Figure 5.8 Local genome plot of intergenic region chromosome 2p15 showing the rs10865331 association 
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 Figure 5.9 Local genome plot of intergenic region chromosome 21q22 showing the rs2836878 association 
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Figure 5.10 Local genome plot of IL23R locus after conditioning on rs11209026 showing association at rs10889677 
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Figure 5.11 Local genome plot of the ERAP1 locus after conditioning on rs30187, showing association at rs2287987 
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Figure 5.12 Local genome plot of ERAP1 locus after conditioning on rs30187 and rs2287987, showing association at rs2549794 
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5.3.3 Single Variant Analysis: AS without acute anterior uveitis versus 
healthy controls 
5.3.3.1 The MHC 
In the MHC, the HLA-B*27 tag SNP rs4349859 was again the lead signal, P < 
10-300, allele A, OR = 28.1, 95% CI 25.0 – 31.7 (Figure 5.13). Conditioning on 
rs4349859 the HLA-A*0201 tag SNP rs9261438 was associated (P = 9.2 x 
10-14, allele T, OR = 1.39, 95% CI 1.27 – 1.51). Conditioning on rs4349859 
and rs9261438, an intronic variant in C6orf10 rs9268148 was associated at P 
= 3.3 x 10-8, allele G, OR = 0.69, 95% CI 0.60 – 0.79. Conditioning on 
rs4349859, rs9261438 and rs9268148, there was no association observed P 
≤ 1 x 10-4. 
 
5.3.3.2 Non-MHC loci 
In the analysis of AS patients without acute anterior uveitis versus healthy 
controls there were 7 replicated AS associations (USP8, IL23R, ERAP1, the 
chromosome regions 21q22 and 2p15, GPR35 and TNFRSF1A, see Table 
5.3 and Figure 5.14 - Figure 5.21). The associations were either the same 
reported SNPs or close proxies (Table 5.4). There was also a new suggestive 
low frequency association evident at zinc finger protein 154 (ZNF154, P = 2.2 
x 10-6, allele G, OR = 3.93, 95% CI 2.23 – 6.93).  
 
Conditioning on the primarily associated ERAP1 SNP rs30187, residual 
association was observed at the ERAP2 SNP rs2549794 (P = 1.8 x 10-7, 
allele C, OR = 1.23, 95% CI 1.14 – 1.33, see Figure 5.22). Conditioning on 
rs30187 and rs2549794 showed association at rs17482078, the SNP tagging 
the other major ERAP1 haplotype (P = 9.0 x 10-3, allele T, OR = 0.88, 95% CI 
0.80 – 0.97, see Figure 5.23). At TNFRSF1A conditioning on rs1800693 
showed association at rs11616188 (P = 4.0 x 10-6, allele A, OR = 1.18, 95% 
CI 1.10 – 1.27, see Figure 5.24). 
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Table 5.3 Single variant analysis of AS without acute anterior uveitis versus healthy controls 
Chr SNP Position* 
Risk 
Allele 
Prot 
Allele Cases RAF Cont RAF OR (95% CI) P value Gene/Locus 
15 rs148783236 50785016 A G 0.93 0.88 1.89 (1.65-2.16) 5.97 x 10-20 USP8 
1 rs11465804 67702526 T G 0.96 0.93 1.81 (1.51-2.17) 1.41 x 10-10 IL23R 
21 rs2836878 40465534 G A 0.78 0.73 1.32 (1.21-1.43) 1.89 x 10-10 21q22 
2 rs10865331 62551472 A G 0.43 0.38 1.24 (1.16-1.33) 2.56 x 10-9 2p15 
2 rs3749171 241569692 T C 0.22 0.18 1.28 (1.17-1.39) 2.73 x 10-8 GPR35 
12 rs1800693 6440009 T C 0.64 0.59 1.23 (1.14-1.32) 3.55 x 10-8 TNFRSF1A 
5 rs30187 96124330 T C 0.38 0.34 1.21 (1.13-1.30) 2.52 x 10-7 ERAP1 
19 rs201756288 58213078 G A 0.005 0.001 3.93 (2.23-6.93) 2.17 x 10-6 ZNF154 
Chr – Chromosome; RAF – Risk allele frequency, OR – odds ratio, CI – Confidence interval, Prot – Protective. *HG19 
Table 5.4 SNPs reported in the AS without acute anterior uveitis versus healthy controls compared to previously reported SNPs 
Chr Gene/Locus SNP Previously reported SNP r2 D’ Study 
15 USP8 rs148783236 rs148783236 1.00 1.00 Chapter 4 
1 IL23R rs11465804 rs11209026 0.89 0.97 Burton et al. [126] 
1 IL23R rs11465804 rs11209032 0.03 1.00 Evans et al. [60] 
21 21q22 rs2836878 rs2836878 1.00 1.00 Reveille et al. [127] 
2 2p15 rs10865331 rs10865331 1.00 1.00 Reveille et al. [127] 
2 GPR35 rs3749171 rs4676410 0.86 1.00 Cortes et al. [86] 
12 TNFRSF1A rs1800693 rs1860545 1.00 1.00 Cortes et al. [86] 
12 TNFRSF1A rs1800693 rs7954567 0.05 0.34 Cortes et al. [86] 
5 ERAP1 rs30187 rs30187 1.00 1.00 Burton et al. [126] 
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Figure 5.13 Pattern of association in the MHC in the AS without acute anterior uveitis versus healthy controls 
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Figure 5.14 Local genome plot of USP8 showing the rs148783236 association 
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Figure 5.15 Local genome plot of IL23R showing the rs11465804 association 
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Figure 5.16 Local genome plot of intergenic region chromosome 21q22 showing the rs2836878 association 
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Figure 5.17 Local genome plot of intergenic region chromosome 2p15 showing the rs10865331 association 
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Figure 5.18 Local genome plot of GPR35 showing the rs3749171 association 
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Figure 5.19 Local genome plot of TNFRSF1A showing the rs1800693 association 
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Figure 5.20 Local genome plot of ERAP1 showing the rs30187 association 
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Figure 5.21 Local genome plot of ZNF154 showing the rs201756288 association 
238 
 
 
Figure 5.22 Local genome plot of ERAP1 locus after conditioning on rs30187, showing association at rs2549794 
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Figure 5.23 Local genome plot of ERAP1 locus after conditioning on rs30187 and rs2549794, showing association at rs17482078 
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Figure 5.24 Local genome plot of TNFRSF1A locus after conditioning on rs1800693, showing association at rs11616188 
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5.3.4 Single Variant Analysis: AS with acute anterior uveitis versus AS 
without acute anterior uveitis 
This analysis only demonstrated the association of the HLA-B*27 tag SNP 
rs4349859 (P = 1.5 x 10-27, allele A, OR 2.9, 95% CI 2.3 – 3.5). Conditioning 
on this SNP demonstrated no association with P ≤1 x 10-4. 
 
5.3.5 Heterogeneity Testing 
All SNPs associated with AS, AS with acute anterior uveitis and AS without 
acute anterior uveitis that were present in the dataset were tested in the 
heterogeneity test. Firstly all SNPs were tested with their independent control 
set with just one eigenvector (Table 5.5). Then the SNPs were tested with one 
eigenvector and HLA-B*27 as a component of the model (as indicated by 
dosage of rs4349859, see Table 5.6). The heterogeneity test was then 
performed firstly without HLA-B*27 as a component of the model (left side of 
Table 5.7), and then with HLA-B*27 as a component of the model (right side 
of Table 5.7). This addresses the interaction that SNPs can have with HLA-
B*27, SNPs in ERAP1 have been described to exhibit this characteristic [60]. 
 
The results demonstrate that rs30187 in ERAP1 is significantly associated in 
both heterogeneity models (interaction term P value = 0.01 in both models) 
which suggests that rs30187 has a bigger effect size in acute anterior uveitis 
than without acute anterior uveitis in the model incorporating HLA-B27, as 
demonstrated by a OR of 1.53 in Table 5.6 in the AS with acute anterior 
uveitis set and the OR of 1.19 in the AS without acute anterior uveitis set. The 
celiac disease associated SNP rs296547 in KIF21B-GPR25 was also shown 
to have a larger effect size in acute anterior uveitis (Interaction P value = 0.04, 
AS with acute anterior uveitis OR = 1.29, and AS without acute anterior uveitis 
OR  = 1.14, see Table 5.5 and Table 5.7). 
 
The TNFRSF1A rs1800693 SNP has a significant interaction term P value in 
the model with HLA-B*27 as a component and a non-significant P value in the 
model without HLA-B*27 as a component. This potentially suggests that HLA-
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B*27 interacts with rs1800693, but a formal test of this interaction in logistic 
regression in both the AS with acute anterior uveitis dataset and the AS 
without acute anterior uveitis was non-significant (P = 0.09 and P = 0.37 
respectively). 
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Table 5.5 Logistic regression of SNPs in the AS with acute anterior uveitis and AS without acute anterior uveitis model with 1 
eigenvector 
Gene/Region SNP Allele AS with AAU OR AS with AAU P value AS without AAU OR AS without AAU P value 
ERAP1 rs30187 T 1.44 (1.33 - 1.56) 1.18 x 10-18 1.23 (1.14 - 1.33) 6.77 x 10-08 
ERAP2 rs2549794 C 0.97 (0.90 – 1.05) 4.45 x 10-01 1.10 (1.03 – 1.19) 7.71 x 10-03 
KIF21B-GPR25 rs296547 C 1.29 (1.18 - 1.40) 4.17 x 10-09 1.14 (1.06 - 1.23) 7.97 x 10-04 
USP8 rs148783236 G 0.43 (0.36 - 0.51) 1.89 x 10-23 0.52 (0.46 - 0.60) 1.17 x 10-19 
KIF21B-GPR25 rs11584383 T 1.30 (1.19 - 1.42) 1.12 x 10-08 1.16 (1.07 - 1.26) 2.79 x 10-04 
C1orf106 rs7554511 C 1.32 (1.20 - 1.44) 2.44 x 10-09 1.18 (1.09 - 1.29) 5.99 x 10-05 
TNFRSF1A rs1800693 C 0.87 (0.80 - 0.94) 9.40 x 10-04 0.79 (0.74 - 0.86) 2.93 x 10-09 
ZNF154 rs201756288 G 1.50 (0.57 - 3.93) 4.13 x 10-01 3.82 (2.04 - 7.17) 3.01 x 10-05 
GPR35 rs3749171 T 1.20 (1.09 - 1.32) 2.51 x 10-04 1.30 (1.19 - 1.42) 1.03 x 10-08 
PNPLA1 rs141744967 T 2.92 (1.53 - 5.57) 1.19 x 10-03 1.70 (0.84 - 3.44) 1.41 x 10-01 
FCGR2A rs1801274 A 1.15 (1.06 - 1.24) 5.35 x 10-04 1.09 (1.01 - 1.17) 1.89 x 10-02 
NOS2 rs2297518 A 1.17 (1.06 - 1.28) 1.71 x 10-03 1.09 (1.00 - 1.20) 5.36 x 10-02 
IL23R rs11209026 G 1.91 (1.56 - 2.33) 2.07 x 10-10 1.70 (1.42 - 2.03) 4.90 x 10-09 
IL12B rs6871626 A 1.10 (1.01 - 1.19) 2.40 x 10-02 1.05 (0.98 - 1.14) 1.69 x 10-01 
FAM118A rs6007594 A 0.89 (0.81 - 0.97) 1.02 x 10-02 0.85 (0.78 - 0.93) 2.23 x 10-04 
IL1R1 rs2310173 T 1.18 (1.09 - 1.28) 5.48 x 10-05 1.14 (1.06 - 1.22) 4.44 x 10-04 
IL23R rs11465804 T 1.91 (1.56 - 2.35) 5.14 x 10-10 1.76 (1.46 - 2.11) 2.15 x 10-09 
2p15 rs10865331 A 1.23 (1.13 - 1.33) 5.89 x 10-07 1.26 (1.17 - 1.35) 1.03 x 10-09 
IL27-SULT1A1 rs35448675 A 1.07 (0.65 - 1.77) 7.83 x 10-01 1.25 (0.80 - 1.96) 3.23 x 10-01 
21q22 rs2836878 G 1.26 (1.15 - 1.39) 1.17 x 10-06 1.30 (1.19 - 1.42) 3.17 x 10-09 
CDKAL1 rs6908425 C 1.21 (1.09 - 1.34) 2.14 x 10-04 1.18 (1.07 - 1.29) 4.72 x 10-04 
FAM114A1 rs11555334 T 1.16 (1.06 - 1.27) 1.50 x 10-03 1.13 (1.04 - 1.23) 3.69 x 10-03 
C7orf72 rs1456896 T 1.12 (1.03 - 1.22) 1.02 x 10-02 1.09 (1.01 - 1.18) 2.47 x 10-02 
IL6R rs2228145 A 1.15 (1.06 - 1.25) 7.26 x 10-04 1.17 (1.08 - 1.26) 6.14 x 10-05 
IL6R rs4129267 C 1.15 (1.06 - 1.25) 7.09 x 10-04 1.16 (1.08 - 1.25) 9.01 x 10-05 
ANTXR2 rs4333130 C 0.86 (0.79 - 0.93) 3.77 x 10-04 0.86 (0.80 - 0.93) 1.69 x 10-04 
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Table 5.6 Logistic regression analyses of SNPs analysed with HLA-B*27 as component of the model in the AS with acute anterior 
uveitis and AS without acute anterior uveitis datasets 
Gene/Region SNP Allele ASwAAU-B27 OR ASwAAU-B27 P value ASwoAAU-B27 OR ASwoAAU-B27 P value 
ERAP1 rs30187 T 1.53 (1.36 - 1.72) 1.72 x 10-12 1.19 (1.08 - 1.31) 5.02 x 10-04 
ERAP2 rs2549794 C 1.03 (0.92 - 1.15) 6.45 x 10-01 1.15 (1.05 - 1.27) 2.79 x 10-03 
KIF21B-GPR25 rs296547 C 1.31 (1.17 - 1.47) 4.20 x 10-06 1.20 (1.09 - 1.33) 2.63 x 10-04 
USP8 rs148783236 G 0.78 (0.63 - 0.97) 2.49 x 10-02 0.86 (0.73 - 1.02) 8.37 x 10-02 
KIF21B-GPR25 rs11584383 T 1.32 (1.17 - 1.49) 8.25 x 10-06 1.21 (1.09 - 1.34) 3.49 x 10-04 
C1orf106 rs7554511 C 1.35 (1.19 - 1.53) 1.92 x 10-06 1.27 (1.14 - 1.41) 1.00 x 10-05 
TNFRSF1A rs1800693 C 0.94 (0.84 - 1.06) 3.00 x 10-01 0.79 (0.72 - 0.87) 1.50 x 10-06 
ZNF154 rs201756288 G 2.02 (0.46 - 8.80) 3.49 x 10-01 4.47 (1.90 - 10.52) 5.90 x 10-04 
GPR35 rs3749171 T 1.20 (1.05 - 1.38) 8.27 x 10-03 1.24 (1.10 - 1.39) 3.01 x 10-04 
PNPLA1 rs141744967 T 2.90 (1.03 - 8.21) 4.48 x 10-02 1.53 (0.59 - 3.98) 3.85 x 10-01 
FCGR2A rs1801274 A 1.18 (1.06 - 1.32) 2.78 x 10-03 1.09 (0.99 - 1.19) 8.33 x 10-02 
NOS2 rs2297518 A 1.08 (0.94 - 1.23) 2.65 x 10-01 1.10 (0.98 - 1.24) 9.49 x 10-02 
IL23R rs11209026 G 1.91 (1.49 - 2.46) 4.71 x 10-07 1.84 (1.48 - 2.30) 4.18 x 10-08 
IL12B rs6871626 A 1.11 (0.99 - 1.25) 7.04 x 10-02 1.09 (0.99 - 1.20) 7.87 x 10-02 
FAM118A rs6007594 A 0.96 (0.84 - 1.08) 4.87 x 10-01 0.88 (0.79 - 0.98) 1.81 x 10-02 
IL1R1 rs2310173 T 1.24 (1.11 - 1.39) 1.33 x 10-04 1.16 (.106 - 1.27) 1.39 x 10-03 
IL23R rs11465804 T 1.93 (1.49 - 2.50) 5.79 x 10-07 1.92 (1.53 - 2.41) 1.76 x 10-08 
2p15 rs10865331 A 1.23 (1.10 - 1.37) 3.58 x 10-04 1.24 (1.13 - 1.36) 5.69 x 10-06 
IL27-SULT1A1 rs35448675 A 1.34 (0.66 - 2.72) 4.20 x 10-01 1.06 (0.59 - 1.90) 8.43 x 10-01 
21q22 rs2836878 G 1.23 (1.08 - 1.40) 1.72 x 10-03 1.22 (1.09 - 1.36) 3.39 x 10-04 
CDKAL1 rs6908425 C 1.27 (1.11 - 1.46) 4.38 x 10-04 1.17 (1.04 - 1.31) 8.11 x 10-03 
FAM114A1 rs11555334 T 1.26 (1.11 - 1.43) 2.69 x 10-04 1.11 (1.00 - 1.23) 4.73 x 10-02 
C7orf72 rs1456896 T 1.18 (1.05 - 1.32) 5.71 x 10-03 1.13 (1.02 - 1.25) 1.63 x 10-02 
IL6R rs2228145 A 1.19 (1.06 - 1.33) 2.92 x 10-03 1.14 (1.04 - 1.26) 6.23 x 10-03 
IL6R rs4129267 C 1.19 (1.06 - 1.33) 3.00 x 10-03 1.14 (1.04 - 1.25) 7.07 x 10-03 
ANTXR2 rs4333130 C 0.89 (0.79 - 1.00) 5.24 x 10-02 0.91 (0.82 - 1.00) 5.03 x 10-02 
ASwAAU – AS patients with acute anterior uveitis; ASwoAAU – AS patients without acute anterior uveitis 
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Table 5.7 Heterogeneity test results. (B27) refers to the model with HLA-B27 as a component. 
Gene/Region SNP Allele SNP OR SNP P value Inter Tern P val SNP OR (B27) SNP P value (B27) 
Inter Term P 
value (B27) 
ERAP1 rs30187 T 1.44 (1.33-1.56) 1.2 x10-08 0.01 1.48 (1.33-1.65) 1.9 x10-12 0.01 
ERAP2 rs2549794 C 0.97 (0.89-1.05) 4.5 x10-01 0.02 1.01 (0.91-1.13) 7.8 x10-01 0.05 
KIF21B-GPR25 rs296547 C 1.29 (1.18-1.40) 4.2 x10-09 0.04 1.29 (1.16-1.44) 5.0 x10-06 0.52 
USP8 rs148783236 G 0.43 (0.36-0.51) 1.9 x10-23 0.07 0.72 (0.59-0.88) 1.6 x10-03 0.07 
KIF21B-GPR25 rs11584383 T 1.30 (1.19-1.42) 1.1 x10-08 0.08 1.29 (1.15-1.45) 9.9 x10-06 0.53 
C1orf106 rs7554511 C 1.32 (1.20-1.44) 2.5 x10-09 0.09 1.32 (1.18-1.48) 2.4 x10-06 0.83 
TNFRSF1A rs1800693 C 0.87 (0.80-0.94) 9.4 x10-04 0.11 0.93 (0.84-1.04) 2.1 x10-01 0.02 
ZNF154 rs201756288 G 1.50 (0.57-3.93) 4.1 x10-01 0.11 1.85 (0.50-6.89) 3.6 x10-01 0.21 
GPR35 rs3749171 T 1.20 (1.09-1.32) 2.5 x10-04 0.25 1.19 (1.05-1.35) 7.4 x10-03 0.63 
PNPLA1 rs141744967 T 2.92 (1.53-5.57) 1.2 x10-03 0.27 2.69 (1.06-6.81) 3.7 x10-02 0.44 
FCGR2A rs1801274 A 1.15 (1.06-1.24) 5.4 x10-04 0.35 1.17 (1.05-1.29) 3.3 x10-03 0.36 
NOS2 rs2297518 A 1.17 (1.06-1.28) 1.7 x10-03 0.35 1.08 (0.96-1.23) 2.0 x10-01 0.77 
IL23R rs11209026 G 1.91 (1.56-2.33) 2.1 x10-02 0.39 1.85 (1.45-2.35) 5.3 x10-07 0.81 
IL12B rs6871626 A 1.10 (1.01-1.19) 2.4 x10-02 0.47 1.10 (0.99-1.23) 7.4 x10-02 1.00 
FAM118A rs6007594 A 0.89 (0.81-0.97) 1.0 x10-02 0.53 0.95 (0.84-1.07) 3.8 x10-01 0.34 
IL1R1 rs2310173 T 1.18 (1.09-1.28) 5.4 x10-05 0.54 1.22 (1.10-1.35) 2.0 x10-04 0.65 
IL23R rs11465804 T 1.91 (1.56-2.35) 5.1 x10-10 0.54 1.87 (1.46-2.39) 6.8 x10-07 0.67 
2p15 rs10865331 A 1.23 (1.13-1.33) 5.9 x10-07 0.65 1.21 (1.09-1.35) 3.0 x10-04 0.64 
IL27-SULT1A1 rs35448675 A 1.07 (0.65-1.77) 7.8 x10-01 0.65 1.28 (0.67-2.45) 4.5 x10-01 0.64 
21q22 rs2836878 G 1.26 (1.15-1.39) 1.2 x10-06 0.65 1.22 (1.08-1.38) 1.2 x10-03 0.98 
CDKAL1 rs6908425 C 1.21 (1.09-1.34) 2.1 x10-04 0.69 1.25 (1.10-1.41) 7.1 x10-04 0.54 
FAM114A1 rs11555334 T 1.16 (1.06-1.27) 1.5 x10-03 0.69 1.23 (1.10-1.38) 4.9 x10-04 0.24 
C7orf72 rs1456896 T 1.12 (1.03-1.22) 1.0 x10-02 0.70 1.16 (1.04-1.29) 8.7 x10-03 0.89 
IL6R rs2228145 A 1.15 (1.06-1.25) 7.3 x10-04 0.81 1.17 (1.05-1.30) 3.8 x10-03 0.81 
IL6R rs4129267 C 1.15 (1.06-1.25) 7.1 x10-04 0.86 1.17 (1.05-1.30) 3.9 x10-03 0.79 
ANTXR2 rs4333130 C 0.86 (0.79-0.93) 3.8 x10-04 0.96 0.89 (0.80-1.00) 4.1 x10-02 0.80 
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5.3.6 SNP2HLA Analysis 
In the analysis of 2 digit classical alleles in the AS with acute anterior uveitis versus 
healthy controls, HLA-B*27 was strongly associated (P < 10-300, OR = 81.9, 95% CI 68.9 – 
97.5). Conditioning on HLA-B*27, HLA-B*40 was associated (P = 1.2 x 10-5, OR = 1.61, 
95% CI 1.30 – 2.00). Conditioning on HLA-B*27 and HLA-B*40, HLA-B*57 was associated 
just outside our significance level (P = 5.5 x 10-4, OR = 0.52, 95% CI 0.51 – 0.75). 
 
Examining 4 digit classical alleles in the AS with acute anterior uveitis versus healthy 
controls analysis HLA-B*2705 was strongly associated at P < 10-300, OR = 78.5, 95% CI 
66.5 – 92.7. The only other HLA-B*27 allele associated at our significance threshold was 
HLA-B*2702 P = 4.1 x 10-40, OR = 309, 95% CI 132 – 722. Conditioning on both HLA-
B*2705 and HLA-B*2702 the next 4 digit allele associated was HLA-A*0201 (P = 5.3 x 10-
5, OR = 1.23, 95% CI 1.11 – 1.37) and specifically looking only at the HLA-B locus the next 
associated B allele was HLA-B*4001 (P = 1.3 x 10-4, OR = 1.56, 95% CI 1.24 – 1.96). 
 
In the analysis of the classical alleles in the AS without acute anterior uveitis versus 
healthy controls, HLA-B*27 was strongly associated (P < 10-300, OR = 28.3, 95% CI 25.1 – 
31.9). After conditioning on HLA-B*27, HLA-A*02 was associated (P = 9.4 x 10-10, OR = 
1.32, 95% CI 1.20 – 1.43). After conditioning on HLA-B*27 and HLA-A*02, HLA-B*40 was 
associated at P = 3.4 x 10-6 (OR = 1.50, 95% CI 1.26 – 1.77). After conditioning on HLA-
B*27, HLA-A02 and HLA-B*40, HLA-B*07 was associated with a protective direction of 
effect (P = 1.0 x 10-4, OR = 0.74, 95% CI 0.64 – 0.86). 
 
Examining specifically the HLA-B locus in the AS without acute anterior uveitis versus 
healthy controls, the next associated B allele after HLA-B*27 conditioning was HLA-B*40 
(P = 5.5 x 10-7, OR = 1.54, 95% CI 1.30 – 1.83). Conditioning on both HLA-B*27 and HLA-
B*40, a protective association was evident with HLA-B*07 (P = 9.2 x 10-5, OR = 0.74, 95% 
CI 0.64 – 0.86). 
 
In the analysis of classical alleles in the AS with acute anterior uveitis versus AS without 
acute anterior uveitis HLA-B*27 was strongly associated (P = 1.6 x 10-26, OR = 2.8, 95% 
CI 2.3 – 3.4). No other alleles passed the Bonferroni significance threshold. 
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5.3.7 Rare Variant Analysis 
No genes were associated in the AS with acute anterior uveitis versus HC, AS without 
acute anterior uveitis versus HC or the AS with acute anterior uveitis versus AS without 
acute anterior uveitis analyses. This was despite using the three different variant sets and 
removing the minor allele frequency restriction. 
 
5.3.8 HLA-B*27 Frequency in the Disease Cohorts 
The frequency of HLA-B*27 as determined by the rs4349859 tag SNP in AS with acute 
anterior uveitis cohort was 92.7% (1307/1409) and the frequency of HLA-B*27 in the AS 
without acute anterior uveitis cohort was 76.4% (1296/1695). The frequency in healthy 
controls was 8.6% (1744/20162). 
 
5.3.9 HLA-B*27 Homozygosity Risk 
In the AS cases with acute anterior uveitis the odds of acute anterior uveitis with HLA-B*27 
heterozygosity (as defined by dosage of rs4349859) was 133.0 (95% CI 132.8 – 133.2). 
The risk of acute anterior uveitis with HLA-B*27 homozygosity was 234.8 (95% CI 234.3 – 
235.2). The risk of the additional copy of HLA-B*27 was 1.8 (95% CI 1.3 – 2.2). So 
homozygosity for HLA-B*27 does confer an additive risk for acute anterior uveitis. 
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5.4 Discussion 
This analysis reports replication of the HLA-B*27 association in the AS with acute anterior 
uveitis versus AS without acute anterior uveitis analysis. HLA-B*40 confers risk for acute 
anterior uveitis and HLA-B*57 is protective of acute anterior uveitis. The ERAP1 
association in this same analysis was not replicated but the ERAP1 SNP rs30187 was 
shown to have a larger effect size in the AS with acute anterior uveitis set than the AS 
without acute anterior uveitis set which suggests that it is not only an AS risk loci but an 
acute anterior uveitis risk loci. 
 
The study did describe a new association in zinc finger protein 154. This association was 
found in the AS without acute anterior uveitis analysis. The significance of this finding is 
not clear as it is not protective of acute anterior uveitis, because this should have been 
detected in the AS with acute anterior uveitis analysis. The zinc finger protein variant 
rs201756288 was seen at a frequency of 0.0017 in cases, 0.0012 in controls with an OR of 
1.47 (95% CI 0.58 – 3.69), P = 0.41 in the AS with AAU analysis. It is possible that the 
absence of an effect in AS with acute anterior uveitis analyses could be a type 2 error.  An 
ANTXR2 variant was also found to have a more significant effect size in the AS without 
acute anterior uveitis heterogeneity test in the Chapter 4 heterogeneity test in a similar 
way to the ZNF154 association. This potentially suggests that there are genetic subtypes 
of AS that phenotypes such as acute anterior uveitis may tag. 
 
A limitation of this experiment is the phenotype allocation of the patients. The majority of 
patients had self-reported acute anterior uveitis. However, we were able to use data 
collected primarily to investigate AS to investigate acute anterior uveitis and to that extent 
we have to accept that it will have limitations that can be addressed to some extent but not 
completely mitigated. The frequency of HLA-B*27 in each of the cohorts is in line with 
previous studies and therefore this provides reassurance that the phenotype allocation 
was robust. Power is also a major limitation of this experiment as with only 1,409 AS 
patients with acute anterior uveitis the ability to detect common variant associations will be 
limited, and the ability to detect rare variant associations is severely limited. 
  
The data would suggest, both from this study and the study detailed in Chapter 4 that 
HLA-B*27 and ERAP1 are not only AS risk loci but also play a different or additional role in 
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acute anterior uveitis. Both of these genes encode components of the MHC class I 
presentation pathway. The gene-gene interaction and there presence in the same 
biological pathway suggests that the mechanism of action is through the presenting 
function of HLA-B*27 and the peptide processing function of ERAP1. There are many 
mechanisms by which infectious agents can trigger immune system dysfunction including 
activation of auto-reactive T cells and molecular mimicry [265]. In addition, because of the 
potential association with IRAP, that is involved with cross presentation, a potential 
disease mechanism may be due to a foreign antigen being presented on MHC class I 
molecules via cross presentation. The mechanism by which these genetic influences could 
contribute to the aetiology of immune dysfunction could also include immune system 
deficiency in presentation of peptides, either presenting the wrong peptides, or not 
presenting enough of the correct peptides.  
 
To further investigate this the research community must firstly coordinate larger studies 
with greater sample sizes, and secondly accurately document the clinical findings in 
patients to enable fine scale dissection of genotype-phenotype associations. Practical 
issues that hamper these goals including the lack of objective, agreed upon disease and 
severity descriptors and the competing demands of clinical care. Currently genetic 
investigation in acute anterior uveitis trails that of other diseases such as IBD where 
disease cohorts now number greater than 75,000. There is no reason acute anterior 
uveitis genetic research cannot reach these sample sizes to investigate this important 
condition. 
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6 Conclusion  
6.1 Overview of the main results 
The results reported have to be viewed within the context of the experiments that 
produced their results. The studies of acute anterior uveitis are somewhat limited by the 
phenotype definition of their disease. This is not a problem for the AS studies as there is a 
robust criteria set that accurately identifies AS. The results reported at genome wide 
significance level are likely true associations however replication of these results should be 
should. The suggestive associations may be true results but should be followed up in 
additional studies. The benefit of reporting these suggestive associations is to provide a 
stimulus to other investigators to explore these potential associations. 
  
6.1.1 Chapter 2 
This chapter describes the fine mapping of association at the chromosome 5q15 locus in 
AS patients. A haplotype of ERAP2 was only associated in AS patients who were HLA-
B*27 negative or on conditioning on the two main associated haplotypes in neighbouring 
ERAP1. Formal tests of interaction using logistic regression did not support a statistically 
significant interaction of the ERAP2 association with HLA-B*27 but a lack of power may 
have prevented demonstrating this equivocally. The associated ERAP2 haplotype contains 
two functionally important SNPs, the first being rs2549782, which changes the rate of 
enzymatic function and the type of peptides it can process. The second functional SNP on 
the haplotype is rs2248374; this SNP causes an extended exon 10 due to skipping of the 
standard splice site. The extended exon 10 contains two stop codons and therefore results 
in a truncated mRNA that causes nonsense mediated decay of ERAP2 mRNA and 
consequently no ERAP2 protein. The rs2248374 SNP is in high LD with rs2549782 and so 
the enzyme variant with altered specificity will rarely be produced. This loss of ERAP2 
enzyme is protective of AS, analogous of the decreased ERAP1 enzyme function also 
being protective of AS. These data suggest a decrease in function of aminopeptidases in 
the ER helps reduce AS risk. 
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6.1.2 Chapter 3  
This chapter details a study using the Immunochip microarray to investigate the genetic 
associations of acute anterior uveitis. IL23R, the intergenic region chromosome 2p15, and 
ERAP1, were associated at genomewide significance (P < 5 x 10-8). Five loci harboring the 
immune-related genes IL10 - IL19, IL18R1 - IL1R1, IL6R, the chromosome 1q32 locus 
harboring KIF21B, as well as the eye related gene EYS were associated at a suggestive 
level of significance. The chromosome region 21q22 and ANTXR2 have an effect in only 
AS patients without acute anterior uveitis, and not in AS patients with acute anterior 
uveitis. Further, the chromosome 2p15 intergenic region shows significantly greater 
association in AS without acute anterior uveitis. These data demonstrate that the genetic 
associations of acute anterior uveitis overlap with but also have some differences from the 
genetic associations of AS, and that there seem to be genetic subgroups of AS patients. 
 
6.1.3 Chapter 4  
This chapter describes a study of the genetic associations of AS using the Illumina 
Exomechip microarray. Two novel associations with AS that are genomewide significant 
were described in USP8 and CDKAL1. Suggestive common variant associations were 
found in FAM118A, C7orf72, FAM114A1 and patatin-like phospholipase domain containing 
1 (PNPLA1). Three of these genes have been associated with IBD previously (CDKAL1 
and C7orf72). There is large overlap apparent between existing AS and IBD associations 
and with substantially better power in the latest IBD study (>75,000 cases) this additional 
overlap is not unexpected. The mechanism behind the FAM118A, FAM114A1 and 
PNPLA1 associations is less clear. The USP8 association has strong biological plausibility 
as USP8 is associated with ubiquination and the MHC class I pathway. USP8 has also 
been shown to regulate transmembrane proteins and basal cytokine receptor levels. A 
suggestive association with TLR10 is also further evidence of the importance of the innate 
immune system in AS aetiology. 
 
6.1.4 Chapter 5  
This chapter describes a study of acute anterior uveitis using the Exomechip microarray of 
AS patients with acute anterior uveitis, AS patients without acute anterior uveitis and 
healthy controls. This study replicated findings from Chapter 3 that HLA-B*27 is a risk for 
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acute anterior uveitis in additional to AS disease status. ERAP1 was also shown in the 
heterogeneity test to have a larger effect size in acute anterior uveitis than in AS.  
 
6.2 Scientific Implications 
6.2.1 Heritability Explained 
This work helps to explain an increased proportion of the heritability of AS. The design of 
the study in acute anterior uveitis and the co-phenotype with AS makes conclusions about 
heritability explained more difficult to draw in acute anterior uveitis. This is an end in itself 
but it also helps to inform the scientific community about the extent of different 
mechanisms of heritability in relation to specific diseases. Theoretically, once all variation 
has been explained it will fall into different classes, being common variants, rare variants, 
structural variation and potentially epigenetic sources of heritability. If multiple different 
efforts to quantify the heritability explained by one class (for example common variants) 
come to similar estimates then one can stop efforts to try to explore this avenue further, 
and think about other sources of heritability, like rare variants or epistasis. In reality large 
scale sequencing and other DNA analyses will be required to accurately quantify the 
heritability explained by sequence, structural and epigenetic variation. Better methodology 
is required to identify and quantify the contribution of epistasis and epigenetics. 
 
6.2.2 Pathways Implicated in pathophysiology 
Whilst explaining the total quantum of heritability is important, the type and pattern of 
association is of substantial interest. The hypothesis free approach of large scale genome 
wide genotyping allows regions or pathways not considered to be involved to be assessed. 
An excellent example of this is the discovery of the association of ERAP1 in AS. Prior to 
GWAS the field didn’t consider that components in the pathway prior to class I antigen 
presentation may be associated to susceptibility. This not only informs further efforts to 
explain heritability by guiding fine mapping efforts but also helps by illuminating involved 
pathways in disease aetiology. In addition this guides development of therapeutics and 
diagnostics. In this regard the association with USP8 and the suggestive association with 
PNPLA1 may point to additional pathways involved in AS aetiology. There are two classes 
of undefined associations, the first is where the function of the gene product or region is 
understood to some degree but how it contributes to AS aetiology is unknown, for example 
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GPR25, GPR35 and GPR65. Then there are genes or regions where the product or 
functional consequence is almost completely unknown, for example the intergenic regions 
chromosomes 21q22 and 2p15. There is a suggestion that non-coding RNA may be the 
mechanism by which these associations function but that is still to be confirmed 
definitively. Characterising each of these two types of association presents different 
challenges. 
 
6.2.3 Evolutionary Considerations 
It is interesting to consider the evolutionary reason why there should be common risk 
alleles for inflammatory disease in the community. Analysis of both ERAP1 and ERAP2 
found signatures of balancing selection in their sequences [179]. Raj and colleagues also 
identified, through systems analysis, over 20 inflammatory disease associations that have 
evidence of positive section [266]. The immune system is a complex system with many 
interconnecting nodes and negative and positive feedback systems. It also has multiple 
roles, including detecting foreign antigen and mutated self-antigen. Therefore it is very 
conceivable that variants that cause protection from infectious disease increase 
reproductive fitness, but they may also be prone to produce an excessive immune 
response to antigen that could manifest as chronic inflammatory disease. It is a salient 
reminder that our efforts to develop therapeutics to treat inflammatory disease need to 
consider the potentially beneficial effects of the variants or system being examined and 
remain vigilant for excess toxicity when targeting these pathways. 
 
6.3 Clinical Implications 
6.3.1 Diagnostics and genetic risk scores 
There are several potential clinical implications of the AS-association results. These can 
theoretically be used to create a genetic risk score in those individuals with high risk or 
suspicious clinical features. However, in AS the high prevalence and large effect size of 
HLA-B*27 means that there is only a small increase in the area under the receiver 
operator curve (< 10%) by adding common SNPs to HLA-B*27 compared to HLA-B*27 
alone (M. Brown – unpublished observations). This small increase may not translate into 
any clinical utility over the existing use of HLA-B*27 testing to justify the substantial effort 
involved in developing the test and educating the medical community on the difference 
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between the new test and HLA-B*27 testing. Adding rare variant associations similarly 
may not increase of area under the curve (AUC) to a clinically relevant degree.     
 
6.3.2 Therapeutic development 
The other more distant clinical implication is identification of drug targets. Previous work in 
AS identifying the association with the protective IL23R gene lead to the use of the 
monoclonal antibody ustekinumab in AS [267]. The identification of protective loss of 
function variants in ERAP1 has led to the pre-clinical development of ERAP1 inhibitors 
[268, 269]. The ERAP2 SNP that is associated with AS causes nonsense mediated decay 
of ERAP2 mRNA and consequently no ERAP2 protein. This SNP is protective, so is 
concordant with the AS associated protective loss of function ERAP1 SNP. This finding 
means efforts to inhibit the function of ERAP2 in those people with ERAP2 function could 
have therapeutic effect in AS. This potential therapeutic would be pointless in those who 
were homozygous for the knockout SNP (~25% of the European population), and would 
therefore require pre-treatment genotyping to target this therapy. The USP8 association, if 
shown to function through basal cytokine level regulation, may be a genetic demonstration 
of the mechanism of action of the TNF inhibitor agents. Other examples of genetic variants 
mimicking the effect of therapeutics is the TNFRSF1A variant that produces soluble TNF 
receptor in the blood mimicking the action of etanercept, a TNF inhibitor. This variant is 
protective of AS. 
6.4 Limitations 
There are limitations in the presented work; these include case identification, power & 
sample size considerations, experimental error and variant characterisation. 
6.4.1 Case Identification 
Accurate case identification is important because including subjects who do not have the 
disease under study decreases the statistical power of the study and thereby increases the 
likelihood of type 2 error. If the inclusion of subjects is systematically incorrect then the 
chance of a type 1 error exists. For example, a theoretical risk is that the condition diffuse 
idiopathic skeletal hyperostosis (DISH) imaging can look similar to AS, but the clinical 
features differentiate these two diseases well. If patients with DISH were systematically 
included in a study of AS then there is the potential to find genetic associations for DISH 
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but believe they are AS associations, or that the study power to identify AS associations 
would be diminished.    
 
The two diseases studied were AS and anterior uveitis. A robust diagnostic criteria set 
have been published for AS, called the modified New York criteria (mNYc). This criteria set 
is also used for classification purposes for clinical and scientific studies. It identifies 
patients well by virtue of the requirement for erosive sacroiliac joint damage and clinical 
features consistent with ankylosis or inflammatory back pain. The limitation of this criteria 
set is the significant heterogeneity in differentiating normal sacroiliac joint radiographs from 
those with early disease. However, the mNYc require bilateral erosive disease or unilateral 
(at least partial) ankylosis in the sacroiliac joint, findings that take years to accrue and are 
more consistently reported between readers. 
 
Acute anterior uveitis has short onset time and is associated with systemic immune 
mediated diseases like AS or Behçet’s disease. Therefore, when acute unilateral painful 
red eye occurs in the context of one of these diseases it can be assumed to be due to 
acute anterior uveitis and ophthalmological confirmation is not always sought. As a 
consequence identifying acute anterior uveitis patients by self-report has limitations. This 
not only includes incorrect aetiology of acute red eye but also recall bias as acute anterior 
uveitis can occur very intermittently to patients and therefore asking patients to self report 
acute anterior uveitis status risks them failing to recall a distant episode. In Chapter 3 and 
Chapter 5 acute anterior uveitis was identified by a combination of ophthalmologist report 
and patient self-report. A study that examined 9,757 SpA patients found the prevalence of 
acute anterior uveitis by self-report was 30.8% and by ophthalmologist examination it was 
32.8% [19]. This suggests that self-report acute anterior uveitis is a relatively good proxy 
for ophthalmologist examination acute anterior uveitis. 
6.4.2 Power & Sample Size 
Sample size is an important consideration in genetic association studies. This is for two 
reasons, firstly failing to recruit sufficient subjects risks type 2 error due to lower statistical 
power. Statistical power is related to a number of variables when analyzing genetic 
variants. Primarily it relates to the required level of statistical significance (α), the 
population prevalence of the disease (K), frequency of the genetic variant, its effect size 
and the sample size. Common variants with large effect size are the easiest to detect, 
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while rare variants with small effect size are the most difficult to detect and require 
extremely large sample sizes. Figure 6.1 shows the relationship between statistical power 
on the y axis and sample size required on the x axis, with different allele frequencies 
shown for four different hypothetical genetic variants with allele effect odds ratios of 2, 1.5, 
1.2 and 1.1. These curves are for a theoretical study with a 1:1 case:control ratio, which 
the preceding Exomechip studies did not have. These were generated using the Genetic 
Power Calculator [204]. 
 
 
Figure 6.1 Relationship between sample size and power based on disease frequency and 
effect size 
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Therefore, on the basis of the sample size of the Exomechip AS experiment (5,040 case 
sand 13,468 controls) there was moderate power (0.6 – 0.7) to detect variants with a 
frequency of 0.01, an effect size of 2 at an alpha of 5 x 10-8. However, for variants with 
smaller effect size or with lower allele frequency there was very poor power to detect these 
variants. 
 
6.4.3 Experimental error  
The potential for experimental error is present in any experiment. In the wet laboratory this 
can be due to mislabeling of DNA samples, correct handling or genotyping the samples. In 
the analysis phase this can be due to incorrect analysis techniques or mistakes in the 
analysis process. Systematic errors in the data can be detected in the analysis phase by 
using techniques such as testing for violations of Hardy-Weinberg relationship or 
missingness rates. Random experimental error is more difficult to detect but generally this 
can be signaled by results that fall outside the range of potentially expected results, for 
example extremely small P values or extremely large effect sizes. This therefore enables 
one to check these results and how they were generated to ensure random experimental 
error has not occurred. 
 
6.4.4 Correlation with causal variant, function or clinical relevance 
Whilst finding genetic associations with disease is important, one limitation of the research 
is that the basis for the association is often unknown. The association could represent a 
proxy association for the real causal association that is connected by linkage 
disequilibrium to the real causal association. Even if the causal variant is found, the 
mechanism whereby it influences disease risk is often not apparent.  
 
One way to address this issue is with fine mapping of the associated region to try to better 
understand the linkage disequilibrium structure of the region. Fine mapping can be 
achieved with either higher density genotyping or with sequencing. Sequencing provides 
much more information about rare variants than genotyping does. This may provide better 
resolution of the association and narrow down the list of potential causal variants. Another 
way to address this is to examine the pattern of association in another ethnic group. This 
can be helpful because often the pattern of linkage disequilibrium is different between 
different ethnic groups and if the same underlying causal variant is present in each group 
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then this can further help to narrow down the list of potential causal variants [270]. African 
populations have much lower levels of LD compared to European populations but the 
number of well characterised disease cohorts in African populations is much smaller than 
that available in European populations. An interesting technique that has been useful in 
the past is evolutionary modelling of haplotype development. This has been implemented 
in a programme called GeneCluster, used in Chapter 2 where Bayesian modelling is used 
to construct a plausible evolutionary framework and try to estimate where the associated 
variants occur in this modelled history [159]. Finally wet laboratory functional investigation, 
where the effect of the variant is modelled in an in vivo or in vitro experiment, is often 
highly fruitful but very time and resource intensive.  
6.5 Direction and areas for future research 
Two broad approaches can progress of the genetics of AS and acute anterior uveitis, the 
first is to try to determine what contribution rare variants have as a whole have to the 
heritability of disease. In parallel with this could be an attempt to try and quantify if there 
are sources of heritability that are not captured by assaying rare or common variants, for 
example epistasis or significant structural variation like large insertions or deletions. This 
need can be addressed by large scale sequencing of well characterised cohorts of 
patients. Currently cost is a major impediment to whole genome sequencing on a large 
scale however there are predictions that this will become drastically cheaper in the near 
future. Whether this will be achieved through new techniques like Nanopore or through 
iterative reductions in reagent cost for the existing sequencing technologies that are 
currently on the market is unclear. 
 
Taking a broader approach to better understand the aetiology and pathophysiology of AS 
and acute anterior uveitis we need to systematically characterise the genetic associations 
we have currently identified and will identify in the future. Individual in vivo or in vitro 
functional characterisation is enormously time consuming and resource intensive but can 
lead to an excellent understanding of the mechanism of causation. Doing this on a large 
scale across multiple diseases is currently a challenge that is facing the field of complex 
disease genetics. There is however much information that is publically available that can 
be leveraged in a systematic way to deeply characterise the functional effects of genetic 
variation. These datasets include the ENCODE consortium, FANTOM5, GTEX and a 
number more. ENCODE is an US National Institutes of Health project that aimed to 
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characterise all the functional elements of the human genome. This included charaterising 
genes, non-gene transcripts, transcription regulation region, chromatin changes and 
methylation patterns [110, 271]. GTEX aimed to make available a catalogue of gene 
expression patterns seen in multiple different human tissues, recognizing that expression 
varied across different regions and knowledge of this could help charaterising specific 
associations in diseases. FAMTOM is an atlas of promoter and enhancers of gene 
expression in humans. 
 
Integrating all these available databases will potentially enable rapid large scale 
characterisation of genetic associations identified in genome wide association studies or 
sequencing experiments. Although there are many very experienced and code literate 
biomedical researchers, having a user friendly browser based graphical user interface, 
where biomedical scientists can query a wide range of biological datasets for 
characterisation information, will enable rapid identification of the potential functional 
significance of genetic associations. This sort of resource will enable targeted efforts at in 
vivo and intro functional characterisation of genetic variants and reduce number of false 
positive associations followed up and help to target the specific functional experiments 
performed. I see this as a major priority for moving forward with implementing the findings 
of GWAS to the functional biology community and ultimately clinical medicine.  
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The Genetics of Ankylosing
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INTRODUCTION
The spondyloarthropathies (SpA) share characteristic clinical and histopathologic
manifestations, and have long been thought to share genetic causes, including
HLA-B27 and non-B27 genes. As more is learned about the genetics of ankylosing
spondylitis (AS), inflammatory bowel disease (IBD), and psoriasis, the known extent
of this sharing is expanding. This article outlines what is known about the genetics
of AS and related SpA and diseases.
GENETIC EPIDEMIOLOGY
AS is a highly heritable polygenic disease, in which environmental factors in developed
countries play only a minor role in determining risk of developing the disease. The
prevalence of AS varies according to some genetic and as yet undescribed
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! Ankylosing spondylitis is a polygenic disease with a strong association with HLA-B27.
! Thirteen non-MHC loci are now also associated with ankylosing spondylitis.
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the cause of AS.
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environmental factors. Differences in HLA-B27 prevalence drives most of the variation
in prevalence seen worldwide.1 For example, the carriage rate of HLA-B27 is approx-
imately 8% to 10% in white European populations and the prevalence of AS is esti-
mated at 0.1% to 1%.2 When the HLA-B27 carriage rate is increased, then SpA
prevalence rises accordingly. For example, in the Canadian Haida Indians the HLA-
B27 carriage rate is around 50% and the SpA prevalence is 5% to 6%.3
There has been gene-phenotype discordance reported, for example in the Fula ethnic
group, which inhabit The Gambia in Africa.4 Although in most African ethnicities HLA-
B27 is rare, among the Fula HLA-B27 carriage was 6%, yet no cases of AS were found
or have been reported. Cases of AS have been reported in American Africans carrying
the European HLA-B27 subtype B*2705, and the African subtype B*2703, indicating
that the paucity of AS in HLA-B27–positive Africans is likely not caused by protective
genetic effects. Rather, this suggests that although AS has a high heritability, environ-
mental factors do play a role in determining susceptibility in some populations.
MAJOR HISTOCOMPATIBILITY COMPLEX GENES
HLA-B Alleles
The association of HLA-B27 with AS was described in 1973, and remains one of the
strongest genetic associations with any common human disease. Nonetheless, only
a minority (likely <5%) of B27-positive individuals develop AS. The discovery that
allelic variation of HLA-DRB1*01 and *04 influenced the risk of rheumatoid arthritis
stimulated research into variation in HLA-B27 itself. There are now known to be
more than 90 subtypes of HLA-B*27, which have arisen from the common ancestral
subtype, HLA-B*2705. Unlike the situation in rheumatoid arthritis, for the most part
in AS B*27 subtype variation plays little role in influencing disease risk. There is strong
evidence to suggest that HLA-B*2706 (found in east Asian populations) and B*2709
(found in Sardinia) have reduced strength of association with AS. The common white
European subtypes, B*2705 and B*2702, are equally strongly associated with AS. The
primarily Asian subtype B*2704 is at least as strongly associated with AS as B*2705 in
the same populations, with some studies suggesting that it may be more strongly
associated. B*2707, also mainly found in Asians, seems equally strongly associated
with AS as B*2705. Although AS cases have been reported carrying many other
B27 subtypes, for most alleles the number of cases reported is too few to definitely
comment on their relative strength of association with the disease.
There are currently four main theories as to how HLA-B27 is involved in AS etiopa-
thogenesis. The arthritogenic peptide hypothesis proposes that HLA-B27 presents
a pathogenic peptide that initiates disease. This hypothesis is consistent with the
antigen presentation function of HLA-B27, and also is consistent with the gene-
gene interaction (epistasis) seen with ERAP1 (discussed later). Despite extensive
efforts, no definitive “arthritogenic peptide” has been identified. There are many
potential explanations for this including that the peptide may only be present at partic-
ular phases in the disease pathogenesis or at particular sites, that it may only repre-
sent a small fraction of HLA class I presented peptides, or that more than one
peptide may be involved. Because the arthritogenic peptide is proposed to be pre-
sented to CD8 T-lymphocytes, the finding that in the HLA-B27 transgenic rat model
of SpA disease is independent of CD8 cells is inconsistent with this hypothesis.5
However, no animal model perfectly captures human AS, and the relevance of this
finding to human AS is not entirely certain.
It has been shown thatHLA-B27 heavy chains, either alone or as heavy chain homo-
dimers, can form on the cell surface and then interact with antigen-presenting cells
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carrying receptors, such as killer-cell immunoglobulin-like receptors.6,7 These
antigen-presenting cells can then initiate a pathogenic T-helper 17 (Th17) response.
These homodimers are thought to occur when unstable HLA-B27:peptide complexes
dissociate on the cell surface.8 ERAP1-deficient cells have more unstable HLA-
peptide complexes on the cell surface, which one would expect to promote cell
surface homodimer formation, but the AS-protective alleles of the ERAP1 variants
are associated with decreased function, which is inconsistent with this hypothesis.9,10
Endoplasmic reticulum (ER) stress, which occurs when misfolding leads to accumu-
lation of HLA-B27 heavy chains in the ER, precipitates a stress response called the
unfolded protein response. The unfolded protein response is a homeostatic mecha-
nism that the cell initiates to clear the misfolded proteins and return the ER environ-
ment to normal. ER stress has been shown to be present in the HLA-B27 transgenic
rat model of SpA,11 and has been shown to induce interleukin (IL)-23 production,12
providing a potent link between HLA-B27 and AS.
Finally, HLA-B27may tag a nearby disease-causative gene, the association of HLA-
B27 with AS being caused by linkage disequilibrium with this nearby “linked gene.”
This theory was made much less likely by the findings of the Australian-Anglo-
American (TASC) genomewide association study (GWAS) that confirmed the highest
association with AS was with HLA-B27 and not a linked gene.10
There are mixed reports on whether homozygosity for HLA-B27 influences clinical
manifestations,13,14 and although some reports have suggested an increased risk of
AS among HLA-B27 homozygotes, the sample sizes involved in these studies were
not sufficient to produce definitive results either way.15,16 An association with HLA-
B60 has also been described in HLA-B27–positive and HLA-B27–negative individ-
uals,17–19 although the strength of association reported was not definitive.
The huge volume of genetic information produced by GWASs has allowed
researchers to examine further questions of interest relating to heritability of disease
and disease-genotype correlations. If one considers the known AS associations, there
is not a higher burden of genetic associations in familial AS than sporadic AS, except
for HLA-B27.20
HLA-B27–negative AS makes up only about 10% of AS cohorts, but does demon-
strate that an essentially identical disease can be evident without the major genetic
risk factor being present. HLA-B27–negative AS is less likely to be familial, has a later
disease onset, and is less likely to respond to anti–tumor necrosis factor (TNF) treat-
ment,21–23 but controlling for disease duration has similar disease severity (measured
by the Bath Ankylosing Spondylitis Functional Index), activity (measured by the Bath
Ankylosing Spondylitis Disease Activity Index),16 and radiographic severity (measured
by the modified Stoke Ankylosing Spondylitis Severity Score).24 HLA-B27–negative
AS has been shown to have similar, although not identical, genetic associations
with HLA-B27–positive AS,10 the main exception being the association with ERAP1,
which is restricted to HLA-B27–positive AS.
HLA-B27 Typing for Clinical Practice
Accurate HLA-typing is technically challenging and difficult to establish as a high
throughput method. This has reduced enthusiasm for the use of HLA-B27 in popula-
tion screening for risk of AS. Recently, an major histocompatibility complex (MHC) tag
single nucleotide polymorphism (SNP) rs4349859 was shown to be able to identify
HLA-B27 in those of European descent with a sensitivity of 98% and a specificity of
99%, within the likely boundaries of accuracy of direct HLA-B27 genotyping itself.10
Another SNP, rs13202464, was then reported that showed high sensitivity and spec-
ificity in east Asian populations.25 The use of these SNPs has significant advantages
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over the current methods for HLA-B27 typing in cost and complexity. Further research
incorporating other ethnic groups may lead to additional ethnicity-neutral HLA-B27
tag SNPs. This discovery has implications for potential screening of high-risk cohorts
either in the primary care or population-based settings. It may be able to be integrated
into referral strategies, by taking advantage of point-of-care testing, which is currently
being developed.26
NON-MHC GENES
Rapid progress has been made in identifying new non-MHC gene associations in
recent years through GWAS. Several these are in genomic regions and involve path-
ways not thought to be associated with AS, and this further validates the hypothesis-
free approach this type of study design affords. The contribution of the described
associations to the heritability of AS, as calculated by the variance in liability method,
is shown in Table 1.
Antigen-Presentation Genes
ERAP1 is amember of theMHCclass I presentation pathway and trims peptides before
presentation on MHC class I molecules, such as HLA-B27 (Fig. 1). ERAP1 has been
robustly associated with AS in multiple studies and populations including Europeans,
Hungarians, Portuguese, Taiwanese, Han Chinese, and Koreans.10,27–32 Recently, it
has been demonstrated that the association of ERAP1 with AS is restricted to HLA-
B27–positive disease.10 ERAP1 is also associated with psoriasis, and the association
in psoriasis is restricted to HLA-Cw6 carriers.33 The AS-protective SNPs in ERAP1
result in reduced peptide trimming function of the ERAP1 enzyme.10 It is not yet clear
whether the protective variants of ERAP1 lead to just quantitative reductions in trimmed
peptide availability, or if they also lead to qualitative changes in the peptides.34
Table 1
Contribution of genome-wide genetic associations to the heritability of AS in populations of
white European descent
Gene/Region Heritability % Function
HLA-B27 23.3 Antigen presentation
2p15 0.54 Unknown
ERAP1 0.34 Antigen presentation
IL23R 0.31 IL-23/Th17 pathway
KIF21B 0.25 Possibly NF-kb pathway
IL1R2 0.12 Innate immune responses
RUNX3 0.12 Antigen presentation
IL12B 0.11 IL-23/Th17 pathway
TNFRI/LTBR 0.08 TNF pathway
ANTXR2 0.05 Possibly skeletal involvement
PTGER4 0.05 Innate immune responses
TBKBP1/NPEPPS/TBX21 0.05 TNF pathway/antigen presentation/Th1
21q22 0.04 Unknown
CARD9 0.03 Innate immune responses
Data from Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in anky-
losing spondylitis implicates peptide handling in themechanism for HLA-B27 in disease susceptibility.
Nat Genet 2011;43:761–7; and Reveille JD, Sims AM, Danoy P, et al. Genome-wide association study of
ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123–7.
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The ERAP1 enzyme has also been described to have two other functions. First, it
has been described to act as a sheddase to cleave cytokine receptors, such as
IL-6, TNF, and IL-1b, from the cell surface.35–37 Studies of ERAP1-deficient mice
have demonstrated that the levels of TNF receptor and IL-6 receptor are no different
to control animals and in patients with AS there is no difference in serum cytokines
based on ERAP1 genotypes.10,38 Second, ERAP1 has also been described to be
secreted from macrophages in response to interferon-g and lipopolysaccharide and
assists in phagocytosis.39 Deficiency in phagocytosis could impair responses to
commensal or invasive microbes and HLA-B27’s restricted repertoire may interact
to exacerbate this, or push it over a disease-causing threshold.
ERAP2 encodes an aminopeptidase, which is encoded at chromosome 5p15 imme-
diately adjacent to ERAP1, and has also been shown to be associated with AS,
although whether this is independent of the ERAP1 association is not clear.28,40 An
ERAP2 association has been described with Crohn disease.41 ERAP2 is an aminopep-
tidase similar to ERAP1, which also trims peptides in the ER before their MHC class I
presentation on the cell surface. It has a different peptide preference from ERAP1 and
has been shown to form heterodimers with ERAP1.42,43
T-Helper 17 Pathway Genes
The association of multiple genes in the pathogenic T-helper 17 (Th17) cell pathway,
including IL23R, STAT3, and IL12B, suggests this is an important pathway in AS. The
preliminary report of the effective use of anti–IL-17 therapy is also a pragmatic demon-
stration that clinically this is a pathway that deserves further attention.44
IL-23 is made up of two subunits, IL-23p19 and IL-12p40. IL-12p40 is encoded by
IL12B. IL-23 signals through its receptor IL-23R, present on a wide range of cells, but
importantly on gamma-delta T cells and Th17 cells.45 This receptor, once activated,
signals through STAT3 by promoting its phosphorylation. This STAT3 phosphorylation
then promotes IL-17 production by Th17 cells.
In cells of the innate immune system and gs T cells, pattern recognition receptors,
such as dectin-1, signal through CARD9 after b-glucan stimulation (Fig. 2). The SKG
mouse model develops an SpA phenotype when stimulated with b-glucan, character-
ized by axial and peripheral spondyloarthritis, IBD, and unilateral iritis.46 After this
pathway is activated this promotes the production of prostaglandin E2.
47
Fig. 1. The antigen presentation pathways with ERAP1 (and ERAP2) trimming the peptide
before loading onto the MHC class I molecule.
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Prostaglandin E2 is a proinflammatory mediator that can signal through the aracha-
donic acid pathway and promote inflammation. Prostaglandin E2 can also upregulate
IL-23 and IL-17 by signally through prostaglandin E receptor 4, subtype EP4
(PTGER4). This receptor has been associated with AS at genomewide levels of signif-
icance.10 Nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase enzymes and
consequently the production of prostaglandins. The finding that nonsteroidal anti-
inflammatory drugs retard radiographic progression in AS and that nonsteroidal
anti-inflammatory drugs are used to reduce heterotopic ossification is a clinical
demonstration of the importance of this pathway to bone formation and
homeostasis.48,49
Potential Skeletal Structure and Mineralization Genes
ANTXR2, which encodes protein capillary morphogenesis protein 2, is an
AS-associated gene with potential impacts on bone and the skeleton. Defects in
this gene cause the human syndromes infantile systemic hyalinosis and juvenile
hyaline fibromatosis.50 How variants of this gene are involved in AS is unclear.
A recent GWAS in east Asians25 found GWAS-significant associations in two loci
harboring bone and cartilage related genes. The first associated locus harbors the
genes HAPLN1 and EDIL3 (P 5 9 ! 10"10; odds ratio [OR] 5 1.2). HAPLN1 encodes
hyaluronan and proteoglycan link protein 1, potentially relevant to AS etiology through
bone effects. EDIL3 encodes EGF-like repeats and discoidin I-like domains 3, which
promotes endothelial cell adhesion. The second association lies in an intron of ANO6
(P 5 2 ! 10"8; OR 5 1.3), which encodes a transmembrane protein involved in phos-
phatidylserine regulation on the cell surface. Phosphatidylserine exposure is involved
in macrophage phagocytosis of apoptotic cells, potentially mediating immune
responses.51 In addition, phosphatidylserine is involved in osteoclastogenesis.52 It
will be valuable to see if these loci replicate in other east Asian or European cohorts.
TNF-Associated Genes
Multiple genes in the TNF pathway have been associated with AS, consistent with this
pathway playing a major role in AS etiopathogenesis. Association has been described
Fig. 2. The interaction of microbial b-glucan and dectin-1, which signals through CARD9 to
promote pathogenic proinflammatory cytokines.
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at the 17q21 locus, which was attributed to TBKBP1, a member of the TNF signaling
pathway. There are, however, two other plausible candidate genes at this locus include
NPEPPS, an aminopeptidase similar to ERAP1 and ERAP2, and TBX21, a Th1 transcrip-
tion factor. Further follow-up studies are required to clarify the association at this locus.
Association has also been reported at chromosome 12p13 at a locus containing two
TNF-receptors,TNFRSF1A andLTBR27.LTBR encodes the lymphotoxin beta receptor;
lymphotoxin is a member of the TNF family. Further TNF genes that have been associ-
atedwith AS include TBKBP1, which is a component of the TNF signaling pathway, and
TRADD,27,53 another TNF receptor protein has also been associated. An animal model
of extreme supraphysiologic TNF overexpression causes an SpA phenotype; how this
correlates to human SpA is not yet clear.54 Several factors implicate this biologic
pathway in AS including raised TNF-a in patients with AS and the effectiveness of ther-
apies that block TNF, such as anti-TNF biologics and thalidomide.55
Other Genetic Associations
Two intergenic regions at 2p15 and 21q22 have now been robustly associated with
AS at genomewide levels of significance.10,27 Proteasome assembly chaperone 1
(PSGM1) gene is found near the 21q22 locus; the proteasome is part of the MHC class
I presentation pathway. It is therefore plausible that the association operates through
this gene. Against this, the association is not in close proximity to the gene. At chro-
mosome 2p15 there is no nearby candidate gene. RNA-sequencing studies identified
long noncoding RNA transcripts at both loci, and it may that the associations operate
through cis- or trans-gene regulation, potentially through noncoding RNA (ncRNA).27
RUNX3 encodes Runt-related transcription factor 3, which has been shown to be
expressed in thymocytes on signaling by IL-7.56 These IL-7–stimulated CD4 and
CD8 double-positive cells then differentiate into CD8 positive lymphocytes. Further
evidence to support this finding is the moderate level of association found in the IL-
7 receptor (P5 8 ! 10"5) in the TASC AS GWAS.10 Consistent with this it will be infor-
mative to examine other components of this pathway, such as the cytokine IL-7 itself,
for association in future experiments.
IL1R2 encodes the IL-1 receptor 2, the biologic action of which is to inhibit IL-1 by
acting as a decoy receptor. This protein exists in two forms, a long membrane-bound
form and a shorter soluble form, which is produced by alternate splicing.57 The longer
membrane-bound form is the functionally active inhibitory molecule. IL-1b is stimu-
lated by conserved microbial sequences, such as pathogen-associated molecular
patterns or damage-associated molecular patterns. Inhibition of an appropriate
response to microbial colonization or infection may be the mechanism by which this
association acts.
KIF21B has been associated with AS and with other autoimmune disorders
including multiple sclerosis,58 Crohn disease,59 and ulcerative colitis.60 It is expressed
in a variety of tissues, but best characterized in dendrites. It is involved in trafficking of
components within the cell. It is also expressed in B cells, T cells, and natural killer
cells.61 Preliminary evidence suggests KIF21B and a nearby open reading frame
C1orf106 at the 1q32 locus are involved in ER stress and the NF-kb pathway but
further functional work is required.62
OVERLAP WITH OTHER DISEASES
There is overlap of important risk variants between AS and a whole host of other
immune-mediated diseases including but not limited to psoriasis, IBD, multiple scle-
rosis, rheumatoid arthritis, and anterior uveitis (see Table 1).
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Psoriasis is a chronic inflammatory autoimmune skin condition present in 3% to 4%
of the general population; about 15% of patients with AS have psoriasis. Psoriasis has
a major class I MHC association in HLA-Cw6, and in a directly analogous situation to
AS, there is also an epistatic association with ERAP1.33
The IL-23 pathway is also a common component of several autoimmune diseases.
Genetic associations with IL23R, IL12B, PTGER4, CARD9, STAT3, and JAK2, which
have been reported variously with AS, psoriasis, and IBD, likely operate through
effects on IL-23 signaling. Various components of this pathway have been described
to be associated with psoriasis, IBD, ulcerative colitis, Crohn disease, and multiple
sclerosis. The downstream mechanisms by which these associations operate,
including the key cytokines involved (IL-17 or IL-22) and cell types (Th17 or noncanon-
ical IL-17–expressing cells, such as gamma-delta cells, mast cells, neutrophils, or
dendritic cells), are not clear. Nonetheless, blockade of the pathway including with
anti–IL-12p40 and IL-17 antibodies is effective in these conditions (Table 2).
THE GENETICS OF AXIAL SPONDYLOARTHRITIS VERSUS AS
Consistent with the differences in the clinical phenotypes seen in patients with SpA
there are differences in the genetics between AS and axial SpA. To date the only pub-
lished data on the genetics of axial SpA is on HLA-B27 carriage rate. A summary of the
published cohorts of patients with SpA is presented in Table 3. One of the limitations
of examining the HLA-B27 carriage rate in cohorts of patients with axial SpA is the
ascertainment bias that may result from recruiting patients based on their HLA-B27
status, as would occur with the HLA-B27 arm of the 2009 ASAS Axial SpA criteria.63
From these data it is clear that theHLA-B27 carriage rate is lower is axial SpA than in
AS cohorts, with a 58% to 75% carriage rate compared with 82% to 89% in AS
cohorts. Because classification criteria for axial SpA include patients with AS, it is
likely that there are significant genetic overlaps between axial SpA and AS.
GENETIC PREDICTORS OF RADIOGRAPHIC PROGRESSION
Studies on the heritability of radiographic change in AS have found that there is a good
correlation (r 5 0.86) between siblings, and the additive heritability of radiographic
disease severity based on the Bath Ankylosing Spondylitis Radiographic Index
(BASRI) is 0.62.64,65
Haroon and colleagues66 genotyped 13 coding SNPs from antigen-presentation
genes (ERAP1, LMP2, LMP7, TAP1, and TAP2) in the Spondyloarthritis Research
Consortium of Canada cohort with the aim of investigating the genetic predictors of
radiographic progression. In multivariate analysis allele G of rs17587 in large multi-
functional peptidase 2 (LMP2) was associated with the baseline modified Stoke
Table 2
Shared genetic associations and pathways in multiple immune mediated
Ankylosing
Spondylitis Psoriasis
Inflammatory Bowel
Disease
MHC class I antigen
processing
HLA-B27, ERAP1,
ERAP2a, RUNX3
HLA-Cw6, ERAP1
IL-23 pathway IL23R, IL12B, CARD9,
PTGER4, STAT3a
IL12B, IL23R IL12B, IL23R, CARD9,
PTGER4, STAT3
a Suggestive level of association.
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Ankylosing Spondylitis Spinal Score but not with progression. This result has not been
replicated.
Bartolome and colleagues67 investigated 384 SNPs from 190 genes and reported
that SNPs in theMHC, TAP2, NELL1, and ADRB1, and clinical factors, such as gender
and later age at disease onset, could be used to in a model to predict radiographic
severity of AS. The predictive model had an area under the receiver operator curve
of 0.76 (95% confidence interval, 0.71–0.80); this dropped to 0.68 (96% confidence
interval, 0.63–0.73) when the SNPs were removed from the model. The MHC genes
were in or near the classical alleles HLA-DRB1, HLA-B, and HLA-DQA1. NELL1 is
expressed in bone and promotes bone formation in animal models.68 ADRB1 is the
gene that encodes the b1 adrenergic receptor. b-blockers have effects on bone
mineral density and fracture risk, which supports this finding.69,70 These data have
not been replicated.
In contrast to the previously described studies, which examined the patient’s radio-
graphic progression over time, Ward and colleagues71 examined the genetic predic-
tors of the ratio of BASRI of the spine to disease duration as an indicator of disease
progression in patients with disease duration of 20 years or more. They found
HLA-B*4100 (OR 5 12), HLA-DRB1*0804 (OR 5 12), HLA-DQA1*0401 (OR 5 5),
HLA-DQB1*0603 (OR 5 3), and HLA-DPB1*0202 (OR 5 23) associated with more
progressive disease. In this study HLA-DRB1*0801 was associated with protection
from radiographic progression with an OR of 0.03.
In contrast to its important effects in disease onset HLA-B27 has not been associ-
ated with radiographic change in multiple studies.15,24,72
FUTURE DEVELOPMENTS
The continuing development of genomics offers further potential for genetic discov-
eries in AS. Study design features likely to lead to further progress include the
following:
1. Increase in sample sizes: Thus far the largest genetic study in AS involved a GWAS
of 3023 cases, far fewer than have been studied for other autoimmune diseases of
Table 3
HLA-B27 carriage rates in ankylosing spondylitis and axial spondyloarthritis patient cohorts
Cohort SpA Definition AS Definition
SpA HLA-B27
Rate %
AS HLA-B27
Rate %
GESPIC78 Modified ESSG mNY 74.7 82.2
GESPIC79 Modified ESSG mNY 72.6 84.3
Kiltz et al,80 2012 ASAS ASpA mNY 86.4 89.1
ABILITY-175 ASAS ASpA MRI
Arma
— 58.4 —
Haibel et al,76
2008
b — 59 —
a MRI arm used solely because of the HLA-B27 arm of the study being affected by ascertainment
bias, because HLA-B27 is part of the entry criteria for this part of the study.
b To be included patients had to have low back pain for greater than 3 months and a symptom
onset before the age of 50 years and at least three of the following six criteria and at least two
of criteria 1 to 3: 1. Inflammatory back pain; 2. Carry HLA-B27; 3. Active inflammation in the spine
or sacroiliac joints demonstrated on MRI; 4. Good response to nonsteroidal anti-inflammatory
drugs; 5. Current or past anterior uveitis, peripheral arthritis, or enthesitis; 6. A family history of
spondyloarthritis. Patients who met the modified New York criteria for AS were excluded.
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similar population frequency, such as multiple sclerosis,73 or even rheumatic
diseases of much lower population frequency than AS, such as systemic lupus er-
ythematosus. There is a clear link between sample size and productivity.74 Much
larger studies in AS are clearly indicated, and are likely to flow from international
collaborative studies, such as the International Genetics of AS Consortium Immu-
nochip study.
2. Transethnic studies: Most studies to date of AS genetics have been performed in
white European populations, and little data are available about other important
ethnic groups including east Asians and Indian Asians. These studies are likely to
be beneficial particularly in localizing genetic effects, using differences in the
linkage disequilibrium structure of the various populations studied.
3. Low-frequency and rare-variant studies: Early sequencing studies and studies
using microarray genotyping targeting low-frequency variants have already been
productive in AS-related diseases, notably in IBD.77 These variants are not well
detected by current GWAS microarrays, which target common variants. Although
they will take large studies to identify, sequencing and low-frequency targeted
microarray studies are likely to be productive in such diseases as AS, where
a significant fraction of the disease’s heritability remains unaccounted for.
4. Genetic studies of AS-disease manifestations: Very little is known about the
genetics of disease severity in AS, or of associated features, such as the develop-
ment of acute anterior uveitis. These are likely to have genetic determinants, and to
be addressable by GWAS and other genetic studies.
The use of genetic prediction of those at risk of AS is likely to be one of the earliest
genetic screens adopted for common conditions, because the high heritability of the
disease suggests that genetic risk prediction will be informative. At this stage,
however, more evidence regarding the benefit of early intervention is required before
this approach can be recommended.
SUMMARY
Genetic discoveries in AS have identified associated pathways previously not consid-
ered important. These discoveries have enabled direct translation to clinical practice
as agents to target the pathways have been developed with other uses in mind but are
now being turned to treat AS. This is the exciting future for the genetics of AS, from the
laboratory to the clinic, and in doing so improving the lives of patients.
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ABSTRACT
New classification criteria for axial spondyloarthritis have
been developed with the goal of increasing sensitivity of
criteria for early inflammatory spondyloarthritis. However
these criteria substantially increase heterogeneity of the
resulting disease group, reducing their value in both
research and clinical settings. Further research to
establish criteria based on better knowledge of the
natural history of non-radiographic axial spondyloarthritis,
its aetiopathogenesis and response to treatment is
required. In the meantime the modified New York criteria
for ankylosing spondylitis remain a very useful
classification criteria set, defining a relatively
homogenous group of cases for clinical use and research
studies.
Disease classification criteria aim to define cases of
high clinical and aetiopathogenic similarity to
facilitate clinical and basic research which other-
wise would be adversely affected by disease hetero-
geneity. The more that is understood about the
pathogenesis of diseases, generally the greater our
ability to subdivide them into more homogeneous
subsets, thereby enabling better prediction of
natural history, facilitating research into aetio-
pathogenesis, and identifying effective treatments.
In rheumatology, recent examples of major
advances through tighter disease classification
include the division of rheumatoid arthritis into
anti-citrullinated protein antibody positive and
negative disease, and the division of vasculitis
according to anti-neutrophil cytoplasmic antibody
status. These improvements in classification have
come about through research demonstrating het-
erogeneity (including in genetic and environmental
aetiopathogenesis, immunology, natural history
and treatment response) in cases meeting previous
classification criteria, and have benefited both
research and clinical practice.
The modified New York (mNY) criteria for anky-
losing spondylitis (AS) have long been recognised
to have low sensitivity to establish a diagnosis of
AS in early disease. There have been many
attempts to produce improved criteria with greater
sensitivity in early spondyloarthritis, including
most recently the development of the Assessment
of SpondyloArthritis International Society (ASAS)
axial spondyloarthritis (axSpA) criteria.1 2 While
these criteria have been developed with honourable
intent, we argue here that they have been devel-
oped without sufficient reference to what we
know of the natural history of axial SpA and its
underlying aetiopathogenic mechanisms. As a con-
sequence, while they capture a higher proportion
of patients with axial SpA than previous criteria,
they do so at a cost of substantially increasing the
heterogeneity of the resulting disease group and
reducing the utility of these criteria for both clin-
ical and research applications.
The diagnosis of AS has been defined historically
by the Rome, New York, and then most recently
by the mNY criteria.3 4 The salient features of
these sets of criteria have been the presence of
sacroiliac joint plain radiographic change and
symptoms and signs of axial arthritis. The mNY
criteria are specific, in that a patient who can be
classified as AS by these criteria really does have
the disease entity which rheumatologists recognise
as AS.4 However, the requirement for radiographic
sacroiliitis clearly reduces the sensitivity of the
mNY criteria, particularly in early disease, contrib-
uting at least in part to the often considerable
diagnostic delay in AS.5 The introduction of MRI
scanning in SpA has confirmed the long held belief
that there is a very large group of patients with
inflammatory axial SpAwho do not yet have radio-
graphic changes. These patients are currently
largely officially excluded from public funded pro-
grammes of tumour necrosis factor (TNF) antag-
onist treatment, although there is good evidence
that carefully selected cases do respond to such
treatment.6
It has been proposed that SpA patients with pre-
dominately axial symptoms should be considered
as having the same disease entity as AS, and that
all patients with axSpA are essentially early cases
of AS.7 To further advance this proposal, a new
disease concept for SpA patients was created
which included both those with, and those
without radiographic sacroiliitis.7 The ASAS group
then developed criteria that included non-
radiographic or pre-radiographic axSpA.1 2 There is,
however, a growing body of evidence which sug-
gests that the two entities of axSpA and AS are
different, and that while a currently unknown pro-
portion of patients with axSpA do indeed have
early AS, this is far from universal.
A compelling paper described the evidence that
axSpA and AS are in fact the same disease entity,7
and there has been considerable debate within the
AS research community as to whether the term AS
should be replaced with axSpA. We argue that the
term AS should be retained, because axSpA cases
have far greater clinical heterogeneity than AS, and
have a broader aetiopathogenesis; furthermore, the
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natural history of axSpA has not yet been reliably established—
it clearly varies more between cases than does AS.
Why is this important to make this distinction? For both
clinical practice and biological research into AS and spondyloar-
thritis, it is important that we accurately classify disease. The
risk of misdiagnosis has been rightly highlighted when using
classification criteria to make diagnoses.7 Despite this, classifi-
cation criteria are commonly used in clinical practice to make
diagnoses and can lead to misdiagnosis. The axSpA criteria
have already being presented as diagnostic criteria in rheuma-
tology practice.8 9 Treatments, especially with immunosuppres-
sants, are not without risk, can be extremely expensive, and
their risk/benefit ratio is affected by knowledge of prognosis. In
addition, our ability to advance our knowledge of the biology
of AS and axSpA depends critically upon assembling homoge-
neous groups of patients to study.
Although AS and axSpA are clearly overlapping entities, there
are also many differences between them. Considering natural
history, few longitudinal studies have assessed the risk of ultim-
ately developing AS in cases of axSpA. Mau et al followed 88
patients with suspected AS not meeting mNY criteria for
10 years.10 After 10 years, 54 patients remained in the study, of
whom 22 (41%) had not reached the New York criteria for AS;
indeed 12 (22%) had AS excluded and an alternative diagnosis
made, such as psoriatic arthritis, degenerative disc disease or
fibromyalgia.10 The Leeds Inflammatory Back Pain (IBP) study
followed 29 patients with symptoms suggestive of axSpA and
positive MRI scans, meeting the ASAS axSpA criteria; a mean
follow-up of 7.7 years has been published.11 Eight patients ful-
filled the mNY criteria at baseline, but of the remaining 21, only
three had developed mNY AS at follow-up. Including all
patients, at follow-up 11 had mNY AS, two had psoriatic spon-
dyloarthritis (not further defined), five had reactive arthritis
(ReA) and 11 had undifferentiated SpA. The study found that
the imaging arm of the axSpA criteria has 100% sensitivity but
low (22%) specificity for mNY AS, and the HLA-B27 arm had
67% sensitivity and 56% specificity for mNY AS. Ten of the 21
patients showed radiographic progression of their sacroiliitis, but
insufficient to fulfil the mNY criteria after 8 years. Thus, while
we do not yet have good data about the natural history of
axSpA, it is clear that the diversity of outcomes is far greater in
cohorts with axSpA than with mNYAS.
A number of studies demonstrate that AS and axSpA
differ in their genetics. First, examining the German
Spondyloarthritis Inception Cohort (GESPIC),12 the rates of
HLA-B27 carriage differ between the non-radiographic axSpA
and AS (72.6% vs 84.3%, respectively). In the ABILITY-1 trial
of adalimumab conducted on patients who fulfilled the ASAS
axSpA criteria, only 58% of the MRI imaging arm were
HLA-B27 positive, whereas in most AS cohorts, >80% of
patients are HLA-B27 positive.6 In another trial of adalimumab
in axSpA, patients were required to have two out of three fea-
tures (IBP, HLA-B27 or acute inflammation on MRI). In this
trial the HLA-B27 rate was only 67%.13 AS is a highly heritable
disease; these data indicate that for the major gene causing AS
(HLA-B27), axSpA has a significantly weaker association, sug-
gesting greater heterogeneity of genetic risk underlying axSpA.
HLA-B27 carriage itself has been shown not to be associated
with the severity of radiographic disease in AS,14 and thus the
lower prevalence of HLA-B27 in axSpA cohorts is not simply
due to ascertainment for cases prone to osteoproliferative
disease.
Gender ratios have also been noted to be different between
axSpA and AS. Data from the GESPIC cohort show that gender
ratios differ significantly, with 34–43% men in the axSpA group
and 65% in the AS group.12 15 Braun et al recently reported that
in a consecutive case series, only 31.8% of those with non-
radiographic axSpA were male, compared 76.8% of those with
AS.16 As well as differing in their genetics and demographics,
these disease groups also differ in their response to treatment. A
French study showed that therapeutic response and partial remis-
sion rates to TNF inhibitors were significantly different between
those with positive imaging and those without.17 Those with
positive imaging also have an increased chance of progressing to
mNY AS.18 In the ABILITY-1 trial of adalimumab in axSpA, the
response to treatment was much lower than in studies in AS
despite similar self-reported levels of disease activity.6
Further data from ReA suggest that axSpA and early AS are
different though overlapping entities. ReA is thought to be an
aberrant immune response triggered by infection, and a signifi-
cant proportion of cases settle spontaneously, with chronic
SpA developing in only a quarter to a third of patients.19 The
clinical features of ReA encompass the spectrum of SpA fea-
tures and 14–80% are HLA-B27 positive, depending on the
cohort, mode of ascertainment and causative organism.19 A
high proportion would undoubtedly meet the axSpA criteria,2
but two-thirds to three-quarters then spontaneously resolve, in
contrast to AS, where the natural history is more persistent.
In conclusion, there is compelling evidence that axSpA and
AS are different though overlapping entities associated with
different prognoses, demographics, genetics and responses to
treatment. The axSpA concept therefore likely captures those
who will progress to AS, but also a significant proportion of
individuals with other diseases of varying relatedness to AS.
This proposed new disease entity is a timely and welcome ini-
tiative to encourage recognition of patients with early disease
in order to initiate effective treatment early. However, the het-
erogeneity of cases is high and the natural history poorly char-
acterised. Long-term studies are needed to determine the
prognosis of this new axSpA group, and the proportion that
will develop into mNY AS; and the clinical, immunological and
genetic subgroups that meet the current axSpA criteria must be
better dissected to achieve greater homogeneity.4
Research into the biological and genetic basis of AS should,
until the outcome of these long-term trials is known, concentrate
on patients who fulfil the mNY criteria.4 There may be value in
conducting biological research on the remaining patients, but to
maximise the chances of success in our research endeavours it is
highly desirable to concentrate on homogeneous groups.
It is salient to consider the comment made by Dr Gene
Hunder in reference to rheumatic classification criteria: ‘We
must keep in mind that classification criteria and diagnoses are
not diseases. They are descriptors that change as new knowl-
edge is acquired’.8 We eagerly await this new knowledge to
help further refine the concepts of AS and axSpA for the
benefit of all our patients.
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Classification Criteria: Peripheral Spondyloarthropathy
and Psoriatic Arthritis
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Abstract Recent proposals for re-classification of
spondyloarthropathies according to the predominance of pe-
ripheral and axial manifestations and for non-radiographic
ankylosing spondylitis to be re-named axial spondyloarthritis
are reviewed. It is argued that such proposals are less likely to
advance knowledge in the study of spondyloarthopathies and
that accurate classification criteria for defined diseases, for
example psoriatic arthritis, remain as necessary now as they
ever did. The CASPAR criteria remain the best performing
classification criteria for psoriatic arthritis.
Keywords Psoriatic arthritis . Spondyloarthritis .
Classification criteria . Peripheral spondyloarthropathy
Introduction
Disease nosology, terminology, and classification are evolving
processes, greatly dependent upon ever-better understanding
of pathology and aetiology. Such changes often occur because
of advances in technology that result in novel perspectives and
new data. Recently, a significant shift in the understanding of
ankylosing spondylitis (AS) has been facilitated by the use of
magnetic resonance imaging (MRI), which has enabled the
possibility of detecting objective changes of sacroiliitis and
spondylitis before such changes are visible on conventional
radiography.
Non-radiographic ankylosing spondylitis is not exactly a
novel concept, because it is well-recognised that symptoms
attributable to the disease can be present for many years
before radiographic changes. Yet the requirements of the
modified New York (mNY) classification criteria for AS
[1], which include radiographic changes, meant that clinical
research into this disease was largely limited to patients with
radiographic disease. Therefore, what we knew about AS
was mainly confined to this group of patients. One question
which arises, then, is whether non-radiographic AS is a
different disease or the same disease at an earlier point in
its natural history. We shall review evidence that seems to
support both positions and ultimately argue that clarification
can only come with more, rather than less, precision in the
classification of these disorders.
The Assessment of SpondyloArthritis International Society
(ASAS) formally known as the Assessments in Ankylosing
Spondylitis working group, has developed new classification
criteria that go beyond the need for radiographic sacroiliitis
and have suggested the term “axial spondyloarthritis”
(axSpA) to designate the disease identified by these classifi-
cation criteria [2]. Because spondyloarthropathies do not al-
ways involve the spine, a complementary approach was also
taken to define “peripheral spondyloarthritis” (pSpA) [3••].
This paper reviews the logical basis and the implications of
these new classification criteria, with particular reference to
psoriatic arthritis (PsA). We argue that these classification
criteria actually have the potential to obscure advances in
knowledge and suggest that there are more advantages in
trying to distinguish particular diseases than there are in trying
to amalgamate diseases into a single disorder.
A Question of Perspective
The degree to which granularity is useful is highly depen-
dent on the purpose of the observer. From the moon, the
earth is a unitary body, with only land and water apparently
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separable. To distinguish the earth from other objects in
space it does not help the observer on the moon to know
that there are many distinguishable countries on earth. For
many years, it was sufficient to only be able to identify
“arthritis” to recommend treatment, whereas in the modern
era, distinguishing between different diseases that present
with arthritis is crucial for correct therapy.
So we need to understand the purpose of the concept of
SpA. Moll andWright originally introduced the term seroneg-
ative polyarthritis or seronegative spondarthritis to emphasize
the profound differences between a set of conditions and
rheumatoid arthritis [4]. The important diseases that formed
the SpA group were AS, psoriatic arthritis (PsA), reactive
arthritis (ReA), and enteropathic arthritis associated with in-
flammatory bowel disease (EnA) [5]. Later, cases of patients
with features consistent with SpA but without manifestations
that would enable classification into one of these defined
disease groups were identified as “undifferentiated SpA” [6].
Classification criteria for the SpA group as a whole
were first proposed by Amor [7] and the European
Spondyloarthropathy Study Group (ESSG) [8]. These
enabled study of individuals who did not fulfil classifi-
cation criteria for more definable SpA, for example the
mNY criteria for AS. One such study, of 102 patients
diagnosed by Spanish rheumatologists as having “possible
SpA” showed that 49 % met the Amor criteria for SpA and
70 % met the ESSG criteria [9]. Half of these patients were
followed for five years and most (29/52) were eventually
diagnosed with a different condition. Only 6/52 patients
met Amor’s or the ESSG criteria at baseline and at five
years but did not have a more specific SpA; these were
designated as undifferentiated SpA (uSpA). Thus, for most
patients with possible SpA the disease evolved into something
else or into a more definable SpA and only 11 % remained
undifferentiated. This suggests that “undifferentiated SpA” is
unlikely to be a distinct disease and more likely to be an earlier
phase of a more defined condition. Another cohort study of
patients with peripheral arthritis as their main manifestation
suggested that patients with PsA had a worse clinical outcome
over two years than those with ReA, and that patients with
uSpA had a somewhat intermediate outcome [10]. The crucial
usefulness of the SpA concept is probably recognition of
patients who are seen at an early stage, who have not yet
expressed the complete phenotype, to signal the need for
ongoing monitoring of the patient and possible appropriate
intervention.
Classification Criteria
The purpose of classification criteria is to identity a relative-
ly (depending upon purpose) homogenous group of patients
(usually) for clinical research purposes [8]. In rheumatic
diseases, it is rare that a pathological gold-standard for diagno-
sis exists; this is both the reason for classification criteria and
also the major problem with classification criteria. Generally,
classification criteria are developed in order to mimic as closely
as possible a “gold-standard” diagnostic test for the condition it
is supposed to identify. That is, the existence of the condition is
pre-supposed, a gold-standard diagnostic procedure exists, and
steps are taken to derive criteria to classify cases with known
error in comparison with the gold-standard procedure. In many
rheumatic diseases, the physician’s opinion is taken to be the
diagnostic gold-standard. Classification criteria cannot be used
to justify the existence of a condition, because this is entirely
circular reasoning. In the case of classification criteria for
axSpA and pSpA, the external-standard against which the
criteria were developed were not axSpA or pSpA, but SpA in
the judgment of the clinical rheumatologist. The label of axial
or peripheral was applied only by virtue of the entry criteria for
the derivation study—pSpA patients had to have peripheral
manifestations without chronic back pain that commences be-
fore age 45 years; axSpA patients had to have chronic back
pain that started before the age of 45 years [2]. This actually
means that the criteria identify SpA in people (by definition)
with or without back pain, respectively, but do not necessarily
identify the conditions of axSpA or pSpA. There is little
evidence that rheumatologists in ordinary clinical practice di-
agnosed the conditions of axSpA or pSpA before the introduc-
tion of the classification criteria that define them. This is putting
the cart before the horse.
Spondyloarthritis Classification Criteria
If one examines SpA classification sets with the preceding
context in mind one can consider the value of classification
criteria which are intended to cover the whole concept of
SpA. There are two well-established general sets of SpA
criteria, the Amor and the European Spondylarthropathy
Study Group (ESSG) criteria and the more recently pro-
posed Assessment of Spondyloarthritis International Society
(ASAS) criteria for axSpA and pSpA which, when com-
bined, resemble the Amor and ESSG criteria in that they
attempt to capture the entire range of SpA [2, 3••, 7, 11].
The Amor Criteria and the ESSG Criteria
The Amor and ESSG criteria were developed to enable
classification of SpA which did not meet sets of criteria for
individual phenotypes and specifically classified uSpA [7,
11]. There was recognition that some patients did not meet
classification criteria for specific diseases but clearly had
features that resembled the SpA typology.
The Amor criteria were developed from 1,219 SpA pa-
tients and 157 other rheumatic disease controls [11]. The
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gold-standard used was clinician judgment of SpA. The set
of criteria has no entry restrictions but requires a cumulative
score of six based on 12 differently weighted items
encompassing clinical items, pelvic radiographs, human
leucocyte antigen (HLA)-B27, and/or family history and
response to non-steroidal anti-inflammatory drugs. The
criteria, when tested on a prospective group, were found to
have sensitivity of 90.0 % and specificity of 86.6 %.
The ESSG criteria study recruited 403 SpA patients and
674 control rheumatology patients and used as their gold-
standard clinician judgment of SpA [7]. The entry criteria
are either inflammatory spinal pain or synovitis (asymmetric
or predominantly in the lower limbs). These two entry
criteria cover the two major manifestations of axial and
peripheral SpA respectively and the patient, in addition,
requires one more SpA feature from a list of seven which
includes psoriasis, inflammatory bowel disease, and
enthesopathy. They noted that adding HLA-B27 did not
change the performance of their set of criteria, and, there-
fore, this was not included. This gave sensitivity of 78.4 %
and specificity of 89.6 %. Both the Amor and the ESSG
criteria have also been modified to include MRI, a modifi-
cation which substantially improves sensitivity [2, 3••].
The ASAS SpA Sets of Criteria
The ASAS group has proposed separate sets of criteria for
axSpA and pSpA. These were developed initially by clinical
reasoning and then modified on the basis of the study results
[2, 3••, 12]. The developers stated they wanted to compare
the new sets with the established Amor and ESSG classifi-
cation. When tested with the ASAS patient set the axSpA set
has sensitivity of 82.9 % and specificity of 84.4 %. The
pSpA set has sensitivity of 77.8 % and specificity of 82.2 %.
When combined as a set of criteria to classify all SpA they
have sensitivity of 79.5 % and specificity of 83.3 %.
Issues with the SpA Criteria Construction
There has been much discussion about issues related to sets of
SpA criteria [8, 13•, 14, 15]. Some of these issues relate to
weaknesses of particular sets of criteria, but there are general
issues also; SpA is a heterogeneous disease with significant
challenges to the development of appropriate criteria.
Use of criteria with no or broad requirements enable
classification of patients without symptoms or evidence of
joint pathology. This could be regarded as indicating lack of
validity, although this depends somewhat on the observers’
perspective of the disease construct used. For example,
using the ESSG criteria, a patient with iritis, psoriasis, and
HLA-B27 can be classified as ESSG SpA, whereas the
ASAS pSpA criteria are satisfied by enthesitis and HLA-
B27. Therefore the population prevalence of HLA-B27 can
affect the proportion classifiable by use of the criteria, as
demonstrated by Bakland and colleagues in Norway, where
the prevalence of HLA-B27 is 16 % [16•]. This issue is not
restricted to peripheral SpA, because the axSpA criteria also
enable classification without objective evidence of disease
[12].
The ESSG criteria were developed with few assumptions
of which items would be important for classification where-
as the ASAS pSpA criteria were developed from pre-
specified sets of items. These sets were then modified on
the basis of the results of the study. Development of criteria
items primarily on the basis of their sensitivity and specific-
ity seems an inherently more robust method of constructing
criteria, which are then modified to be feasible in practice.
Otherwise pre-existing ideas about what is important for
classification may excessively affect the outcome of the
derivation study.
General Concerns about SpA Classification Criteria
There are issues inherent to SpA that make the construction of
classification criteria challenging. The foremost is the lack of
the biological understanding of SpA. For example, we know
the phenotypes of SpA are related and can even change from
one to another, but how related are they? What is the basis for
their shared relationship? Is SpA one disease with different
manifestations, or are SpA more distinct diseases with pheno-
typic overlap, phenocopies of a type [17••]? Because of this
problem, in all sets criteria clinician judgment is the gold-
standard. This judgment is affected by the clinician’s under-
standing of the essence of SpA, which is likely to vary among
clinicians, one reason why classification criteria are necessary
for clinical studies in the first place. However it doesmean that
the same criteria can have variable sensitivity and specificity
depending on the cohort tested. The sensitivity and specificity
of the Amor and ESSG criteria were good when the criteria
were tested on their development cohort (Table 1) but when
these two sets of criteria were applied to the ASAS pSpA
cohort their sensitivity and specificity decreased (Table 2).
What is this telling us? Although it is logically inevitable that
criteria are more accurate for the cohort from which they were
derived, it also seems likely that the patient cohorts are some-
how different. This could result from different study designs
or different populations fromwhich the cohorts were sampled.
But, in fact, the studies were designed similarly and patients
were recruited from secondary care rheumatology clinics. One
possible difference, very difficult to confirm, might be differ-
ent allocation of the gold-standard, directly affected by the
concept with the disease of the clinician making the diagnosis.
Seemingly the only way to make progress on this issue is to
improve our understanding of the biology of SpA. Such
understanding is more likely to progress with more rather than
fewer precisely defined disease categories.
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Construction of criteria for an entity such as SpA is
challenging because it is an heterogeneous disorder, and
therefore sets of criteria introduced with the purpose of
including “all” SpA will end up including a very heteroge-
neous group [18], whereas including only one of the phe-
notypic entities that is more homogenous, for example AS
or PsA, as with the modified New York or CASPAR criteria,
will lead to a more homogenous group [1, 19]. The approach
chosen (either broadly inclusive or sub-type specific) will
depend on the intended purpose of the criteria. If one wishes
to study biological phenomena, for example immune cells or
genes, then a very homogenous patient set defined by more
precise criteria is desirable. But if one wants to include a
large heterogeneous group for epidemiological purposes or
to test the effect of a drug across broader categories of
disorders, then a more inclusive set of criteria may be more
appropriate. It is possible that the use of broad inclusive
criteria will enable the description of prognostic factors
which differentiate divergent outcomes. Nevertheless all
criteria must be properly constructed and tested in practice
before their usefulness can be determined.
Peripheral SpA and axial SpA
The only logical reason for the concept of pSpA is the
concept of axSpA. It is therefore necessary to review in
further detail the basis for axSpA and how this relates to
existing concepts of the diseases regarded as SpA. One
possible concept of SpA is shown in Fig. 1a, in which each
circle represents a clearly recognisable disease and that these
diseases overlap, to illustrate that some patients may seem to
have more than one disease. In fact, it is more plausible that
such overlap patients have a single disease which has fea-
tures of more than one disorder. For example, patients with
PsA and AS could be labelled with either disease but have
features of each. There could be an argument that particular
radiographic, genetic or clinical features might help distin-
guish such overlapping cases [20], but the essential point is
that a specific diagnosis is possible and that a broad term
such as axSpA is actually not necessary for such patients.
In this concept, radiographic AS is regarded as a subset of
AS, because, clearly, patients with AS do not have radiograph-
ic changes at the earliest moment of the disease. Such cases
may now be recognised by characteristic MRI abnormalities.
However, the question which arises is whether such cases are
necessarily destined to become radiographic AS or whether
they will always remain non-radiographic, in which case
should they really be regarded as having AS? There are data
to suggest that only 60% of patients developmNYAS after ten
years of observation [21, 22]. There are, therefore, cases of
“undifferentiated SpA” that appear similar to nr-axSpA but do
not evolve into radiographic (mNY)AS. Such a situation could
be imagined in Fig. 1b.
Here, the complete range of SpA is bounded by the
rectangle but includes cases that are “undifferentiated”. In
addition, the concepts of peripheral and axSpA are intro-
duced as mutually exclusive types of SpA that together form
the complete range of SpA. Here axSpA encompasses all of
these disorders: radiographic AS, non-radiographic AS, and
disorders that have axial manifestations but are never des-
tined to be AS; this last category we have already specified
as “undifferentiated SpA”. It is difficult to distinguish what
else axSpA could be. Because understood terms are already
Table 1 Characteristics of SpA classification criteria based on the patient cohort used to construct and/or validate the criteria
Criteria Controls Sensitivity (%) Specificity (%) Ref.
Amor Other rheumatic diseases 90.0 86.6 [11]
ESSG Other rheumatic diseases 87.0 87.7 [7]
ASAS axSpA Other rheumatic diseases 82.9 84.4 [12]
ASAS pSpA Other rheumatic diseases 77.8 82.2 [3••]
ASAS SpA Other rheumatic diseases 79.5 83.3 [3••]
ESSG European Spondylarthropathy Study Group; ASAS Assessment of SpondyloArthritis International Society
Table 2 Characteristics of the overall and peripheral SpA classification criteria in the ASAS pSpA patient set only
Criteria Controls Sensitivity (%) Specificity (%) Ref.
Amor criteria Other rheumatic diseases 55.6 86.7 [3••]
Modified Amor criteria (with MRI) Other rheumatic diseases 67.5 86.7 [3••]
ESSG criteria Other rheumatic diseases 66.7 72.0 [3••]
Modified ESSG criteria (with MRI) Other rheumatic diseases 79.1 68.8 [3••]
ASAS pSpA criteria Other rheumatic diseases 77.8 82.2 [3••]
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available for describing the constituents of axSpA, is there
really any advantage in introducing this new term? Further-
more, we have seen above that persistent “undifferentiated
SpA” is actually uncommon, suggesting that the condition is
more likely to be an earlier phase of a more definable disease.
This leaves AS, for which there is a much clearer phenotype
and understanding. There is a definite disadvantage in com-
bining the three conditions under a single name—it is impos-
sible to study whether, or the extent to which, non-
radiographic AS or undifferentiated SpA evolves into radio-
graphic AS or other disorders unless each condition is prop-
erly classified and defined.
There is the possibility that the 10 % of cases of
undifferentiated SpA that remain undifferentiated is actually
a disease distinct from AS. It is also necessary to consider
whether axSpA is a useful label to apply to those instances of
other (non-AS) SpA that happen to have axial involvement
and therefore fulfil axSpA criteria. If cases of (persistent)
undifferentiated SpA with axial involvement, AS, and other
definable cases of SpA (reactive arthritis, psoriatic arthritis,
enteropathic arthritis) with axial involvement are all classified
as axSpA, it prevents sensible study of these different disor-
ders (even in order to show that they are or are not different).
At a pragmatic level, the currently constructed classifica-
tion criteria for axSpA may have insufficient specificity for
the purpose of enrolment into clinical trials. With specificity
of approximately 80 %, there may be issues with the includ-
ed population, as was seen in the ABILITY-1 trial, namely
lack of efficacy for those with normal CRP and negative
MRI. This group did no better than placebo [12, 23•, 24].
The European Medicines Agency (EMA) has approved
adalimumab for axSpA only for those with a raised CRP
or positive MRI findings [25]. Such patients may be more
likely to have “true” pre-radiographic AS, again raising the
possibility that axSpA is merely describing AS at a milder or
earlier phase.
There are additional practical problems. It is specified that
patients with inflammatory-type back pain should be classi-
fied as axSpA, even if they also have peripheral disease. As
Zeidler and Amor point out, it is not clear how to handle cases
for whom spinal symptoms change over time, leading to
inconsistent classification in longitudinal studies [26].
The overall conclusion is that classification of patients as
axSpA is not a useful concept.
Psoriatic Arthritis and pSpA or axSpA
Psoriatic arthritis may involve peripheral joints and/or
axial joints. Asymptomatic radiographic sacroiliitis is
common in psoriatic arthritis patients who were identified
by virtue of active peripheral arthritis [27]. Thus, psoriatic
arthritis cannot be easily classified as either axSpA or pSpA,
but may fit into either group. Is it prudent that the disease be
completely re-defined on the basis of whether spinal symp-
toms predominate?
Notwithstanding the problems of the classification criteria
discussed above, the performance of the pSpA criteria and
CASPAR criteria were directly compared in an early arthritis
cohort [28••]. This showed that the CASPAR criteria [19] are
much more sensitive for detecting PsA (88.7 %) than the
ASAS pSpA criteria (52 %) but are very poor at detecting
SpA in general (sensitivity 5.3 %). This is not surprising,
because CASPAR was never designed for that purpose. But
even the ASAS pSpA criteria have unsatisfactory sensitivity
for early SpA (48.7 %) as do the ESSG and Amor criteria for
SpA (sensitivity of 48.7 % and 26.3 %, respectively). Overall,
this study supports the ongoing use of CASPAR when the
intention is to identify psoriatic arthritis, but it leaves the
question of how to identify early SpA still unanswered.
Conclusions
Advances in classification criteria will come from an itera-
tive process of proposing new sets of criteria and testing
them in real situations, and from advances in our knowledge
of how these diseases interrelate. For most purposes, the
Fig. 1 Possible concepts of SpA
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advantages of the new ASAS pSpA and axSpA criteria are
outweighed by their disadvantages.
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Ankylosing spondylitis is a common, highly heritable inflammatory arthritis affecting primarily the spine and pelvis. In addition 
to HLA-B*27 alleles, 12 loci have previously been identified that are associated with ankylosing spondylitis in populations 
of European ancestry, and 2 associated loci have been identified in Asians. In this study, we used the Illumina Immunochip 
microarray to perform a case-control association study involving 10,619 individuals with ankylosing spondylitis (cases) and 
15,145 controls. We identified 13 new risk loci and 12 additional ankylosing spondylitis–associated haplotypes at 11 loci.  
Two ankylosing spondylitis–associated regions have now been identified encoding four aminopeptidases that are involved in 
peptide processing before major histocompatibility complex (MHC) class I presentation. Protective variants at two of these loci 
are associated both with reduced aminopeptidase function and with MHC class I cell surface expression.
Crohn’s disease and ulcerative colitis, along with several classic 
autoimmune diseases, were used in the chip design, making it a power-
ful platform for studies of pleiotropic genetic effects in these related 
diseases. In this study, we aimed to identify new associations with 
ankylosing spondylitis and to dissect and refine the boundaries of 
known associated loci by performing a dense SNP genotyping study 
in 10,619 cases and 15,145 controls of European, East Asian and Latin 
American ancestry using the Immunochip.
RESULTS
Primary association findings
After all sample quality control filters, the European cohort consisted 
of 9,069 cases and 13,578 controls, and the East Asian cohort con-
sisted of 1,550 cases and 1,567 controls. The genomic inflation factor 
(L) calculated using 1,922 SNPs included on the Immunochip from 
studies of reading and writing ability, psychosis and schizophrenia 
was 1.047 (L1000 for an equivalent study of 1,000 cases and 1,000 con-
trols = 1.0285), indicating minimal evidence of residual population 
stratification in the overall data set (quantile-quantile plots are pre-
sented in Supplementary Fig. 1).
Association at genome-wide significance (P < 5 × 10−8) was observed 
for 25 loci, including the MHC (Table 1 and Supplementary Fig. 2; 
genomic control–corrected results are shown in Supplementary 
Table 1). Suggestive association (P < 5 × 10−7) was observed at six 
additional loci (Supplementary Table 2). As with all GWAS, there is 
uncertainty as to the genes contributing to association at specific loci. 
At previously reported loci, association (P < 5 × 10−8) was seen with 
the most strongly associated previously reported SNPs at CARD9, 
ERAP1, IL12B, IL23R, KIF21B, RUNX3, NPEPPS-TBKBP1-TBX21, 
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Inflammatory arthritis in ankylosing spondylitis causes pain and stiff-
ness and progressively leads to new bone formation and ankylosis 
(fusion) of affected joints. It affects 0.55% of populations of European 
ancestry (herein termed Europeans)1 and 0.23% of Chinese2, but is 
uncommon in Africans and Japanese, mostly owing to the low preva-
lence in these ancestry groups of HLA-B*27, the major genetic variant 
associated with ankylosing spondylitis. Whereas effective treatments 
are available that suppress inflammation and improve symptoms, 
there are not yet any treatments that have been shown to robustly 
slow the rate of ankylosis or induce disease remission.
Ankylosing spondylitis is highly familial (sibling recurrence risk ratio 
of >52)3 and heritable (h2 > 90%)4. It is two to three times more preva-
lent in men than in women, and men tend to be more severely affected. 
More than 80% of cases are positive for the HLA-B*27 allele, but only a 
minority of HLA-B*27 carriers develop ankylosing spondylitis (1–5%). 
The low proportion of HLA-B*27 carriers who develop ankylosing 
spondylitis reflects the fact that numerous other non–HLA-B*27  
variants are likely to influence disease susceptibility3. In addition to 
HLA-B*27, 12 loci have previously been confirmed to be associated 
with ankylosing spondylitis in Europeans (ANTXR2, CARD9, ERAP1, 
IL12B, IL23R, KIF21B, PTGER4, RUNX3, TBKBP1, TNFRSF1A and 
chromosomes 2p15 and 21q22)5–7, and 2 loci have recently been 
reported in Han Chinese (HAPLN1-EDIL3 and ANO6)8.
The Immunochip Consortium has developed a custom microarray 
SNP genotyping chip (the Immunochip), the design of which has 
been informed by available genome-wide association study (GWAS) 
and deep sequencing data from various autoimmune and inflamma-
tory diseases to provide a cost-effective platform for immunogenetic 
studies9,10. Genetic data from ankylosing spondylitis, psoriasis, 
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TNFRSF1A and chromosomes 2p15 and 21q22 (Table 1). At PTGER4, 
the previously associated SNP (rs10440635) also showed moderate 
association in the current study (P = 3.0 × 10−5; imputed). No SNPs 
at the ANTXR2 locus were included on the Immunochip.
We observed little evidence of association with the two previously 
reported loci in Han Chinese, either in Europeans, East Asians 
(Chinese, Taiwanese and Koreans) or in the combined data set 
(P > 0.05)8. To increase power for these variants, we genotyped a total 
of 2,998 East Asian cases and 5,547 East Asian controls. No associa-
tion was seen (P > 0.05) for either rs4552569 (chromosome 5q14, 
between HAPLN1 and EDIL3) or rs17095830 (chromosome 12q12, 
ANO6) (Supplementary Table 3). rs4552569 showed only nominal 
significance in Europeans (P = 0.02). rs17095830 was not directly 
typed on the Immunochip, but, in a previous GWAS6, no association 
was observed with this SNP (P > 0.1).
Genome-wide significance was seen at 13 loci not previously known to 
be associated with ankylosing spondylitis (Table 1). The strongest asso-
ciation at each locus was with a common variant (minor allele frequency 
(MAF) > 5%), but several associations were also seen with rare variants 
(MAF < 1%) at these loci, including in the genes CARD9, IL23R, LNPEP 
and TYK2. Both rare variants in IL23R were nonsynonymous coding 
variants, whereas the CARD9, TYK2 and LNPEP variants were located 
at exon-intron boundaries and were predicted to influence splicing.
In total, 24.4% of the heritability of ankylosing spondylitis 
is now explained: 4.3% from loci other than HLA-B and 20.1% due 
to HLA-B*27 itself.
IL-23 pathway genes
Genetic studies provided the first evidence that interleukin (IL)-23 
is involved in the pathogenesis of ankylosing spondylitis, and vari-
ants in several genes involved in the IL-23 proinflammatory cytokine 
pathway have been shown to be associated with the disease. This study 
adds to that list, with loci containing TYK2, IL6R and IL27 achieving 
genome-wide significance.
IL-6 signaling through IL-6R has diverse proinflammatory effects. 
rs4129267, the most strongly associated IL6R SNP in this study, is also 
associated with asthma11 but with the opposite direction of associa-
tion to ankylosing spondylitis. The allele associated with risk of anky-
losing spondylitis at this SNP is strongly associated with lower serum 
concentrations of the soluble form of the IL-6 receptor (sIL-6R), with 
each allele associated with a 1.4-fold variation in serum IL-6R conc-
netrations12. We found that sIL-6R concentrations varied strongly by 
rs4129267 genotype, both overall and separately, in cases and controls 
(Fig. 1). Overall, homozygous carriers of the T allele at rs4129267 had 
sIL-6R concentrations 73% higher than homozygous carriers of the 
C allele (28.9 versus 16.7 ng/ml; P = 7.8 × 10−17). This SNP has previ-
ously been associated with serum C-reactive protein (CRP) concen-
trations at genome-wide significance; in the current study, serum CRP 
concentrations were 30% higher in cases homozygous for the T allele 
than in cases homozygous for the C allele (19.2 versus 14.8 mg/l).
At IL23R, we previously identified two independent disease-
 associated haplotypes6 tagged by rs11209026 and rs11209032. Here, 
after conditioning on rs11209026, the strongest association was with 
Table 1 Non-MHC associations with ankylosing spondylitis susceptibility
SNP Chr. Positiona Nearby gene(s) Combined P
Risk/ 
non-risk 
allele
Combined  
OR
Europeans East Asians
RAF  
(case/control) OR P
RAF  
(case/control) OR P
Loci previously associated with ankylosing spondylitis at genome-wide significance
rs6600247 1p36 25177701 RUNX3 2.6 × 10−15 C/T 1.15 0.540/0.501 1.16 1.3 × 10−14 0.731/0.708 1.12 0.047
rs11209026 1p31 67478546 IL23R 2.0 × 10−27 G/A 1.62 0.959/0.934 1.65 6.0 × 10−28 1.000/1.000 NA NA
rs41299637 1q32 199144473 GPR25-KIF21B 1.9 × 10−15 T/G 1.19 0.757/0.715 1.20 7.0 × 10−16 0.999/0.998 1.05 0.42
rs6759298 2p15 62421949 Intergenic 4.9 × 10−47 C/G 1.29 0.447/0.378 1.31 3.6 × 10−41 0.437/0.374 1.28 1.6 × 10−6
rs12186979 5p13 40560617 PTGER4 4.3 × 10−6 G/A 1.08 0.516/0.498 1.09 5.4 × 10−6 0.202/0.191 1.06 0.26
rs30187 5q15 96150086 ERAP1 4.4 × 10−45 T/C 1.29 0.405/0.338 1.32 1.3 × 10−41 0.542/0.486 1.36 2.0 × 10−5
rs6871626 5q33 158759370 IL12B 3.1 × 10−8 A/C 1.10 0.360/0.337 1.12 6.0 × 10−8 0.324/0.310 1.08 0.17
rs1128905 9q34 138373660 CARD9 7.0 × 10−9 C/T 1.10 0.529/0.503 1.12 1.6 × 10−9 0.316/0.315 1.00 0.99
rs1860545 12p13 6317038 LTBR- 
TNFRSF1A
2.8 × 10−10 C/T 1.13 0.634/0.605 1.13 8.3 × 10−10 0.862/0.851 1.07 0.21
rs9901869 17q21 42930205 NPEPPS- 
TBKBP1-TBX21
6.0 × 10−15 A/G 1.14 0.548/0.516 1.15 2.3 × 10−12 0.667/0.626 1.18 0.002
rs2836883 21q22 39388614 Intergenic 6.5 × 10−17 G/A 1.18 0.768/0.734 1.19 1.8 × 10−14 0.817/0.774 1.30 3.5 × 10−5
New loci associated with ankylosing spondylitis at genome-wide significance
rs4129267 1q21 152692888 IL6R 3.4 × 10−13 C/T 1.14 0.635/0.592 1.18 2.1 × 10−15 0.619/0.620 1.00 0.99
rs1801274 1q23 159746369 FCGR2A 1.4 × 10−9 T/C 1.11 0.487/0.476 1.12 9.9 × 10−10 0.706/0.698 1.04 0.46
rs12615545 2q31 181756697 UBE2E3 1.0 × 10−9 C/T 1.12 0.451/0.421 1.11 2.3 × 10−7 0.710/0.673 1.20 8.5 × 10−4
rs4676410 2q37 241212412 GPR35 9.9 × 10−9 T/C 1.13 0.232/0.209 1.13 2.1 × 10−7 0.346/0.312 1.15 8.4 × 10−3
rs17765610 6q15 90722494 BACH2 5.3 × 10−8 G/A 1.15 0.131/0.118 1.17 3.3 × 10−8 0.017/0.018 1.00 0.96
rs1250550 10q22 80730323 ZMIZ1 1.5 × 10−9 G/T 1.11 0.678/0.652 1.11 5.8 × 10−7 0.583/0.539 1.20 3.9 × 10−4
rs11190133 10q24 101268715 NKX2-3 4.9 × 10−14 C/T 1.15 0.737/0.707 1.18 1.7 × 10−14 0.629/0.617 1.10 0.30
rs11065898 12q24 110346958 SH2B3 4.7 × 10−8 T/C 1.11 0.237/0.216 1.13 1.7 × 10−7 0.348/0.329 1.10 0.082
rs11624293 14q31 87558574 GPR65 1.5 × 10−10 C/T 1.20 0.106/0.087 1.23 1.8 × 10−10 0.158/0.145 1.11 0.14
imm_16_
28525386
16p11 28525386 IL27-SULT1A1 2.6 × 10−9 A/G 1.11 0.421/0.393 1.11 1.4 × 10−7 0.258/0.232 1.16 0.012
rs2531875 17q11 23172294 NOS2 1.2 × 10−10 G/T 1.12 0.396/0.367 1.12 1.3 × 10−8 0.296/0.256 1.22 4.6 × 10−4
rs35164067 19p13 10386181 TYK2 3.4 × 10−10 G/A 1.14 0.819/0.796 1.16 6.5 × 10−9 0.574/0.549 1.11 0.039
rs7282490 21q22 44440169 ICOSLG 6.2 × 10−9 G/A 1.11 0.411/0.390 1.10 1.4 × 10−6 0.581/0.543 1.18 1.3 × 10−3
Locus plots for reported associations are shown in Supplementary Figure 5. Chr., chromosome; RAF, risk allele frequency; NA, not available.
aNCBI Build 36 human genome coordinates.
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rs12141575 (odds ratio (OR) = 1.15; P = 9.4 × 10−11); this SNP is in 
strong linkage disequilibrium (LD) with rs11209032 (r2 = 0.993) and 
also with rs1495965, which has been reported to be associated with 
Behçet’s disease13,14. Behçet’s disease is complicated by sacroiliitis 
resembling ankylosing spondylitis in up to 10% of cases15.
Six loci showed suggestive association (5 × 10−8 < P < 5 × 10−7), 
including a region on chromosome 2q11 encoding IL1R2 and IL1R1. 
Conditional analyses showed that there were two separate signals at 
this locus (Table 2), one in each gene. Both genes encode receptors for 
the cytokine IL-1, which, among diverse proinflammatory functions, 
also promotes T helper 17 (TH17) lymphocyte differentiation.
Aminopeptidase genes
We previously identified a strong association between ERAP1 
and ankylosing spondylitis5 that is restricted to HLA-B*27– 
positive disease6. This observation was replicated here (Table 3 and 
Supplementary Figs. 3 and 4), with strong interaction observed 
in the European cases between HLA-B*27 and both independently 
associated ERAP1 haplotype–tagging SNPs (rs30187: B = 0.390, 
P = 2.9 × 10−11; rs10045403: B = −0.282, P = 9.3 × 10−6; Supplementary 
Table 4). We observed no evidence of epistasis between HLA-B*27 and 
rs30187 (or other SNPs in ERAP1) in the East Asian samples, probably 
because of inadequate statistical power. In this analysis, we had 35% 
power to detect an association at a significance level of P < 0.05 with 
the observed allele frequency of rs30187 in controls and the effect size 
observed in the overall analysis. The low power to detect a major effect 
at rs30187 in HLA-B*27–positive East Asian samples suggests that the 
power to detect an interaction would be quite small. The observed 
OR (95% confidence interval (CI)) in HLA-B*27–positive subjects 
at rs30187 was 0.73 (0.53–1.03) compared to 1.20 (0.89–1.61) in 
HLA-B*27–negative subjects. Although these analyses did not detect 
significant interaction (P > 0.05), they are consistent with an interac-
tion between rs30187 and HLA-B*27, where rs30187 is only associated 
in HLA-B*27–positive disease. This finding warrants further explora-
tion with larger sample sizes in East Asian populations.
LNPEP and ERAP2 are both members of the endoplasmic reticulum 
(ER) aminopeptidase family and have substantial sequence homology 
with ERAP1. They are both encoded on chromosome 5q15, imme-
diately centromeric to the ERAP1 locus. A previous study, which did 
not control for the association of ERAP1 with ankylosing spondylitis, 
observed no association of an ERAP2 loss-of-function variant with 
ankylosing spondylitis16. Other studies have identified associations 
with ERAP2 but have not dissected them from the known associations 
of ERAP1 SNPs5,17. Here, controlling for the association of ERAP1 with 
ankylosing spondylitis, two functionally important SNPs in ERAP2 
were found to be associated with ankylosing spondylitis: rs2549782, 
which leads to a change in ERAP2 catalytic activity18, and rs2248374, 
where the protective G allele causes complete loss of ERAP2 mRNA 
and absence of ERAP2 protein19. In the European samples, control-
ling for the association with ERAP1, we identified SNPs in ERAP2 
and LNPEP that were associated with ankylosing spondylitis (lead 
SNP, rs2910686: OR = 1.2, P = 4.5 × 10−17; Supplementary Fig. 3b). 
Because the association of ERAP1 variants was restricted to HLA-
B*27–positive ankylosing spondylitis, analyzing ERAP2 and LNPEP 
SNPs in HLA-B*27–negative cases and controls produced simi-
lar results to analyses of the combined (HLA-B*27–positive and 
HLA-B*27–negative) cases and controls when the association with 
ERAP1 was controlled for. Thus, we observed association with ERAP2 
SNPs in HLA-B*27–negative ankylosing spondylitis cases (rs2910686: 
OR = 1.19, P = 2.13 × 10−5). To investigate the possibility that this 
finding might be an artifact caused by the strong LD between the 
ERAP2 locus and HLA-B*27 in cases, we tested association at this 
locus in a multivariate analysis, controlling in the one analysis for 
association of the two ankylosing spondylitis–associated ERAP1 hap-
lotypes (tagged by rs30187 and rs10045403), their interaction with 
HLA-B*27 and HLA-B*27 itself. In this analysis, association with 
rs2910686 was robust (P = 6.6 × 10−8), suggesting that ERAP2-LNPEP 
is independently associated with ankylosing spondylitis. Haplotype 
counts for rs2910686 and rs30187 in both HLA-B*27–positive and 
HLA-B*27–negative cases are shown in Table 3.
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Figure 1 IL6R polymorphism alters IL-6R serum concentrations.  
IL-6R concentrations were determined in cases and controls who were 
homozygous for either the T or C allele at the rs4129267 SNP. In both 
cases and controls, individuals homozygous for the C allele showed 
significantly lower concentrations of circulating IL-6R. ***P < 0.0001; 
NS, not significant. Bars represent mean ± s.e.m.
Table 2 Secondary signals in Europeans at loci known to be associated with ankylosing spondylitis
Chr. SNP Position Nearby gene(s)
Risk/non-risk 
allele Conditional SNP P OR
RAF  
(case/control)
LD (r2/D `) with  
conditional SNP
1p31 rs12141575 67520024 IL23R A/G rs11209026 9.4 × 10−11 1.15 0.370/0.330 0.034/0.983
1q23 rs2039415 159121069 FCGR2A C/T rs1801274 7.4 × 10−5 1.09 0.702/0.682 0.002/0.062
2q12 rs2192752 102135805 IL1R2-IL1R1 C/A rs4851529 4.1 × 10−6 1.11 0.239/0.222 0.007/0.192
5q15 rs10045403 96173489 ERAP1-ERAP2 A/G rs30187 and rs2910686 5.8 × 10−14 1.20 0.783/0.730 0.178/0.958
0.091/0.429
5q15 rs2910686 96278345 ERAP1-ERAP2 C/T rs30187 4.5 × 10−17 1.17 0.450/0.440 0.153/0.617
5q33 rs6556416 158751323 IL12B C/A rs6871626 4.4 × 10−6 1.11 0.704/0.675 0.048/0.443
6q15 rs639575 91047852 BACH2 A/T rs17765610 8.6 × 10−5 1.08 0.624/0.609 0.000/0.042
12p13 rs7954567 6361386 LTBR-TNFRSF1A A/G rs1860545 1.2 × 10−7 1.11 0.363/0.341 0.002/0.068
16p11 rs35448675 28236248 IL27-SULT1A1 A/G imm_16_28525386 2.4 × 10−4 1.24 0.007/0.006 0.003/0.955
17q11 rs2297518 23120724 NOS2 A/G rs2531875 6.3 × 10−7 1.13 0.212/0.190 0.000/0.048
19p13 rs6511701 10486067 TYK2 A/C rs35164067 1.4 × 10−4 1.10 0.220/0.218 0.162/0.419
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In addition to these ERAP1 and ERAP2 associations, we observed 
genome-wide significant association of SNPs on chromosome 17q21 
around the gene NPEPPS, which encodes puromycin-sensitive ami-
nopeptidase (rs9901869: OR = 1.14, P = 6.0 × 10−15) (Supplementary 
Fig. 5). The NPEPPS protein localizes to the cytoplasm and is thought 
to be involved in processing proteasome-derived peptides before their 
transport to the endoplasmic reticulum and presentation by human 
leukocyte antigen (HLA) class I molecules20. Association had previ-
ously been reported at this locus and was ascribed to TBKBP1 or 
TBX21. Here SNPs mapping to NPEPPS and TBX21 were independ-
ently associated with ankylosing spondylitis, and conditional analysis 
suggested that there are at least two independent signals at this locus. 
When conditioning on rs9901869, SNP rs11657479 in the 3` UTR of 
TBX21 remained significantly associated with ankylosing spondylitis 
(OR = 1.09; P = 1.8 × 10−3). The data did not allow us to determine 
whether TBKBP1 or TBX21 was primarily associated with ankylos-
ing spondylitis, but both represent attractive candidates. TBKBP1 is 
a component of the tumor necrosis factor (TNF) signaling pathway, 
and TBX21 is a transcription factor that influences the differentiation 
of T helper 1 (TH1) and natural killer (NK) cells21.
Genes influencing lymphocyte activation and differentiation
It has recently been shown that cell type–specific trimethylation of his-
tone H3 at lysine 4 (H3K4me3) chromatin marks can inform the fine 
mapping of associated SNPs to identify causal variation22. We therefore 
tested all ankylosing spondylitis–associated SNPs against H3K4me3 
chromatin marks in different cell lines from the Encyclopedia of DNA 
Elements (ENCODE) Project23. This analysis showed a strong enrich-
ment of disease-associated SNPs associated with H3K4me3 chromatin 
marks in cells of immune origin (Supplementary Fig. 6).
Because of this association and taking into account the likely 
pathogenic role of T lymphocytes in ankylosing spondylitis and the 
involvement of several genes associated with ankylosing spondylitis 
in T-lymphocyte differentiation, we tested association of the SNPs 
for ankylosing spondylitis with CD4+ and CD8+ T cell counts in a 
previously published GWAS data set24. Association (P < 0.005) was 
seen between CD8+ lymphocyte counts and ankylosing spondylitis– 
associated SNPs in the loci harboring the genes IL7R, RUNX3 and 
ZMIZ1 (Supplementary Table 5). Association was also observed 
between SNPs in EOMES and CD8+ lymphocyte counts, but these 
were not the same EOMES SNPs that were associated with ankylosing 
spondylitis. We also showed association of the genes SH2B3 and 
BACH2 with both ankylosing spondylitis and CD4+ lymphocyte 
counts (Supplementary Table 5). We previously showed that CD8+ 
lymphocyte counts are lower in ankylosing spondylitis cases than in 
healthy age- and sex-matched controls6. In contrast, in this study, 
we found that ankylosing spondylitis cases not on biological therapy 
had similar CD4+ lymphocyte counts as age-matched controls 
(Supplementary Fig. 7).
HLA Region
After SNP imputation in the MHC region, rs116488202 was found 
to tag HLA-B*27 more accurately in both Europeans and Asians than 
our previously reported tagging SNP rs4349859 and also rs13202464, 
reported to tag HLA-B*27 in Asian populations8 (Supplementary 
Table 6). The expected strong association was observed with 
HLA-B*27 (OR = 46; P < 1 × 10−100) (Supplementary Fig. 8). 
Risk of ankylosing spondylitis was further increased in HLA-B*27  
homozygotes; HLA-B*27 homozygosity was more prevalent in 
HLA-B*27–positive cases than in HLA-B*27–positive controls 
(OR = 2.07; P = 0.0025).
Controlling for association with HLA-B*27, there was residual 
signal with SNPs near HLA-A and HLA-B (Fig. 2). The residual 
signal at HLA-B may reflect either imperfect HLA-B*27 tagging by 
rs116488202 or association of other HLA-B alleles with ankylosing 
spondylitis. No other individual non–HLA-B*27 allele was associated 
with ankylosing spondylitis, although this may represent imperfect 
HLA-B imputation using single SNPs.
The most strongly associated SNP near HLA-A, rs2394250, tags the 
classical allele HLA-A*0201 (Supplementary Table 7). Association 
of the HLA-A*0201 allele was independent of HLA-B*27 genotype, 
present in both HLA-B*27–positive (OR = 1.21, P = 6.5 × 10−12; 
conditioning on rs116488202) and HLA-B*27–negative (OR = 1.36, 
P = 3.2 × 10−13) disease (Supplementary Table 7b). No significant 
correlation was noted between HLA-B*27 and SNPs tagging 
Table 3 Association analysis of rs30187 and rs2910686 haplotypes in samples positive and negative for HLA-B*27
Sample SNP (ERAP1)
Haplotype counts  
(controls/cases) SNP (ERAP2) Haplotype
Haplotype counts  
(controls/cases) OR (95% CI)
rs2910686  
association P value
HLA-B*27 positive
rs30187[T] 790/5,641 rs2910686[T] TT 662/4,595 1.18 (0.96–1.44) 0.12
rs2910686[C] TC 128/1,046
rs30187[C] 1,580/7,979 rs2910686[T] CT 646/2,923 1.20 (1.07–1.34) 1.5 × 10−3
rs2910686[C] CC 934/5,056
HLA-B*27 negative
rs30187[T] 8,298/763 rs2910686[T] TT 6,902/629 1.05 (0.87–1.28) 0.64
rs2910686[C] TC 1,396/134
rs30187[C] 16,240/1,515 rs2910686[T] CT 6,842/548 1.28 (1.15–1.43) 7.7 × 10−6
rs2910686[C] CC 9,398/967
Association was assessed by 1-degree-of-freedom C2 test.
0
5
10
15
30,000
–l
og
10
 (
P
)
rs2394250 HLA-A HLA-C HLA-B
31,000 32,000
Chromosome 6 position (kb)
33,000
Conditioning on rs116488202
Conditioning on rs116488202 and rs2394250
Figure 2 Ankylosing spondylitis susceptibility associations in the MHC 
region conditioning on the HLA-B*27–tagging SNP rs116488202 and 
further conditioning on the HLA-A*02–tagging SNP rs2394250.  
The 85-kb gap between positions 32,465 kb and 32,550 kb corresponds 
to an assembly correction between NCBI Genome Builds 36 and 37 of the 
human genome.
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HLA-A*0201 (r2 < 0.01), and, thus, this association is not a manifesta-
tion of LD with HLA-B*27.
Overlap with other immune-mediated diseases
Considering the loci associated with ankylosing spondylitis in this 
study, we found substantial overlap with other immune-mediated 
diseases (Fig. 3 and Supplementary Table 8), notably, inflammatory 
bowel disease (either Crohn’s disease or ulcerative colitis) and celiac 
disease. Ankylosing spondylitis–associated loci were associated with 
the same SNP in the same direction of association at 12 loci shared 
with Crohn’s disease, at 11 loci shared with ulcerative colitis and at 
6 of 7 loci shared with celiac disease. Overlap of associated loci with 
other diseases was not as marked, including for rheumatoid arthritis 
(one concordant, one discordant), psoriasis (two concordant), multi-
ple sclerosis (three concordant, three discordant) and type 1 diabetes 
(two concordant, two discordant).
Refinement of disease associations and secondary signals
In the design of the Immunochip, eight loci already known to be 
associated with ankylosing spondylitis were selected for fine mapping. 
Compared with available ankylosing spondylitis GWAS data, the cur-
rent study had greater marker density at these loci and larger sample 
size (from 3,023 cases and 8,779 controls to 10,619 cases and 15,145 
controls). Nonetheless, for most loci studied, the disease-associated 
region was not substantially narrowed; less than 10% narrowing of the 
region was observed for four of the eight loci that were fine mapped 
(Supplementary Table 9). This suggests that, for many loci associated 
with common variants, the extent of LD at the locus will be too great 
to permit substantial refinement of the locus using sample sizes and 
marker densities of the magnitude employed here.
Two or more independent signals were identified at 12 of 
the 25 genome-wide significant loci (P < 5 × 10−4; Table 2 and 
Supplementary Fig. 9), including 1 locus (ERAP1 on chromosome 
5q15) with 3 associated haplotypes (Supplementary Fig. 3). This is 
a similar proportion to that found in celiac disease (13 of 36 loci)10. 
Taken together, these secondary signals contribute 0.75% of the herit-
ability of ankylosing spondylitis (Supplementary Table 10).
Rare variants
Because of the likelihood of population stratification affecting rare 
variant associations, rare variant associations (MAF < 1%) were only 
tested on a reduced sample subset of indi-
viduals from the UK (7,447 cases and 11,479 
controls). Considering loci with common 
variant associations achieving genome-wide 
significance, we identified six that harbored 
rare SNPs that were disease associated (P < 
5 × 10−3; Supplementary Table 11). These 
associations remained significant after con-
ditioning on the common variants, and vari-
ants at three loci (IL23R, TYK2 and KEAP1) 
remained significant after controlling for the number of variants 
studied per locus. Four loci had exonic rare variant associations in 
the absence of a common variant association (P < 5 × 10−5) (KLKB1, 
RAD50, PRDM1 and DYRK4; Supplementary Table 11b). The rare 
variant with the largest effect was a predicted splice-site variant in 
TYK2 (rs280518: OR = 7.7, P = 0.002).
Comparisons across ancestry groups
The power of our East Asian case-control cohort was much lower than 
for our European cohort; nonetheless, at least nominal association 
(P < 0.01) was detected in East Asians at 13 of the 23 loci for which 
we identified associations at genome-wide significance in the overall 
data set (Table 1).
At some loci, association was seen in both East Asians and 
Europeans but with different SNPs. At IL23R, the primary associ-
ated variant in Europeans, rs11209026, was not polymorphic in East 
Asians, as we and others have previously reported25. However, asso-
ciation was observed at IL23R with a low-frequency nonsynonymous 
SNP in East Asians (rs76418789: p.Gly149Arg, OR = 1.5, P = 8.2 × 
10−4). The minor, protective allele was predicted to be deleterious by 
both SIFT26 and PolyPhen analysis27. The same SNP was also nomi-
nally associated with ankylosing spondylitis in Europeans (P = 0.01). 
The MAF of rs76418789 was ~10 times greater in East Asians than in 
Europeans (East Asians, 3.7%; Europeans, 0.34%). Of the other loci 
associated with ankylosing spondylitis in Europeans but not in East 
Asians, only at BACH2 was the key associated variant present at a 
much lower frequency in East Asians (rs17765610; MAF of 11.8% in 
Europeans and 1.8% in East Asians), suggesting that, at most loci with 
discordant association between ancestry groups, this was not due to 
differences in the population frequency of the associated SNP.
At PTGER4, association in Europeans peaked 155 kb 5` of the gene 
(peak associated SNP, rs12186979: OR = 1.1, P = 5.4 × 10−6), whereas 
the peak of association in East Asians was in intron 2 of the gene 
(rs13354346: OR = 1.3, P = 1.5 × 10−5) (Supplementary Fig. 5).
DISCUSSION
This study confirmed the association of 12 of the 13 previously reported 
loci associated with ankylosing spondylitis in Europeans and identified 
13 additional loci at genome-wide significance. We found no inde-
pendent support for two loci previously reported to be associated with 
ankylosing spondylitis in Han Chinese, suggesting that the original 
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Figure 3 Ankylosing spondylitis genetic 
susceptibility loci overlap with those of 
other autoimmune diseases. Diseases are 
represented in columns, and ankylosing 
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if effect size is discordant. Data are shown in 
Supplementary Table 8. SLE, systemic lupus 
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associations of these loci may have been false positives. Additional 
associated haplotypes were identified at 13 loci, increasing the total 
number of distinct ankylosing spondylitis associations to 43.
These findings highlight the role of some major biological pathways 
in the pathogenesis of ankylosing spondylitis, including the IL-23 
pathway, gut immunity, T-lymphocyte differentiation or activation, 
and peptide processing before HLA class I presentation.
We identified three new ankylosing spondylitis–associated genes 
(TYK2, IL27 and IL6R) with known effects on the IL-23 pathway. 
TYK2 is a member of the Janus kinase family of intracellular signaling 
proteins and is involved in signal transduction from IL-23R, as well 
as other cytokine receptors, including those in interferon (IFN)-A, 
IFN-B, IL-6, IL-10 and IL-12 signaling. Common TYK2 variants are 
also associated with Crohn’s disease28 and psoriasis29. A different, rare 
TYK2 variant, rs34536443, is associated with multiple sclerosis30. IL-6 
signaling through IL-6R has diverse proinflammatory effects. In com-
bination with transforming growth factor (TGF)-B, it influences the 
ratio of TH17 to regulatory T (Treg) cells, promoting the differentiation 
of TH17 cells from naive T cells and inhibiting TGF-B–induced differ-
entiation into Treg cells31. Previous studies have reported no increase 
in TH17 lymphocyte counts in ankylosing spondylitis, suggesting that 
the IL6R association with ankylosing spondylitis operates through 
mechanisms other than effects on TH17 lymphocytes32,33. Whether 
IL-6 has a role in the differentiation or activation of non-canonical 
cellular sources of IL-17 such as GD T cells, NK cells, neutrophils and 
mast cells, which have been implicated in ankylosing spondylitis, is 
unclear. IL-27 potentiates the differentiation of CD4+ TH1 cells, while 
suppressing the differentiation of T helper 2 (TH2) and TH17 cells. 
IL27 has previously been associated with both Crohn’s disease and 
type 1 diabetes (Supplementary Table 8), with the association in type 
1 diabetes being in the opposite direction to that observed in both 
ankylosing spondylitis and Crohn’s disease.
At IL23R, we identified rare variant associations with ankylosing 
spondylitis in addition to the two known common variant haplotypes 
at this locus. Although one of these haplotypes has been shown to 
be due to association with the rs11209026 coding SNP6,25, it is not 
clear from these genetic studies whether the second haplotype tagged 
by the intergenic SNP rs12141575 influences ankylosing spondylitis 
through effects on IL23R or IL12RB2. IL12RB2 encodes one of the 
two subunits of IL-12R, the stimulation of which drives CD4+ lym-
phocyte differentiation toward the TH1 lineage and away from the 
TH17 lymphocyte phenotype.
We identified six ankylosing spondylitis–associated genes that 
were also associated either with variation in CD8+ lymphocyte counts 
(EOMES, IL7R, RUNX3 and ZMIZ1) or CD4+ lymphocyte counts 
(BACH2 and SH2B3). EOMES encodes eomesodermin, a transcrip-
tion factor involved in CD8+ T cell differentiation whose expression is 
induced by RUNX3 (refs. 34–36). Where eomesodermin is deficient, 
CD8+ T cells have been shown to express IL-17 (ref. 37). IL-7 acts 
through IL-7R to induce RUNX3 expression in developing T cells, in 
turn favoring differentiation toward the CD8+ T cell lineage38. ZMIZ1 
is a transcriptional coactivator of the protein inhibitor of activated 
STAT (PIAS)-like family and thus may have effects on STAT-mediated 
cytokine signaling. ZMIZ1 has recently been shown to cooperate with 
activating NOTCH1 mutations in inducing T cell acute lymphoblastic 
leukemia, consistent with it having a role in T cell differentiation39. 
Whether these genes affect risk of ankylosing spondylitis directly 
through effects on CD8+ T cell differentiation is unclear. For example, 
although the risk haplotype at RUNX3 is associated with lower CD8+ 
T cell counts, at IL7R, the opposite phenotype is observed, suggesting 
that the mechanisms involved are more complex than a simple effect on 
CD8+ T cell counts. IL-7 treatment has been shown to increase TH17 
lymphocyte counts, and it may be that the association of IL7R with 
ankylosing spondylitis operates directly through such an effect40.
One of the genes associated with both ankylosing spondylitis and 
CD4+ lymphocyte counts, BACH2, encodes a B cell–specific transcrip-
tion factor with diverse effects on B cell differentiation and function41; 
association of ankylosing spondylitis with CD4+ lymphocyte counts 
may thus be an indirect effect mediated by B cells. This is particu-
larly noteworthy given the recent evidence suggesting that rituximab, 
a B cell–targeted therapy, may have beneficial effects in ankylosing 
spondylitis42. SH2B3 (also known as LNK) encodes an adaptor pro-
tein involved in T cell receptor signaling43. CD8+ lymphocytes are 
activated by the interaction of MHC class I peptides with their T cell 
receptors and may in turn become cytotoxic or memory T cells.
The association of four aminopeptidases involved in peptide trim-
ming before HLA class I presentation is particularly noteworthy. We 
have shown here and previously that genetic variants associated with 
reduced function of ERAP1 and loss of expression of ERAP2 are pro-
tective for ankylosing spondylitis. Whether LNPEP is also involved is 
uncertain, and identification of the key associated variants at NPEPPS 
will require further studies. It is possible that these genes operate in 
ankylosing spondylitis through a quantitative effect on HLA class I 
peptide presentation or a qualitative effect on the peptide reper-
toire presented. Downregulation of ERAP1 (refs. 44,45) and ERAP2 
(ref. 19) expression has been shown to reduce cell surface expression 
of HLA class I molecules. ERAP1 preferentially cleaves hydrophobic 
amino acids, whereas ERAP2 preferentially cleaves basic residues. 
ERAP1-ERAP2 heterodimers may thus act in concert, particularly in 
cleaving longer peptides45. It has been suggested that misfolding of 
nascent HLA-B*27 in the ER, leading to ER stress, may be involved in 
the pathogenesis of ankylosing spondylitis46. It is also possible that, 
by influencing the quantity of peptide available during HLA-B*27 
folding, ERAP1 and ERAP2 variants associated with disease risk slow 
the rate of this folding, thereby increasing ER stress.
In this study, over one-third of loci with common variant associa-
tions were found to harbor more than one disease-associated haplo-
type. Identifying these additional haplotypes increased the proportion 
of genetic variance explained in ankylosing spondylitis and, more 
notably, led to valuable biological insights. For example, association 
of ankylosing spondylitis with SNPs on chromosome 12p13 has previ-
ously been reported, although it was not clear whether the association 
was primarily with TNFRSF1A or LTBR, both plausible candidate 
genes6,7,47. The current study shows that there are two signals at this 
locus, one in TNFRSF1A and the other in LTBR. The primary associ-
ated SNP at TNFRSF1A (rs1860545) is in strong LD with a multiple 
sclerosis–associated SNP, rs1800696 (r2 = 0.96, D` = 0.98) but with the 
opposite direction of association. rs1800696 has recently been shown 
to lead to the splicing out of exon 6 of TNFR1, resulting in loss of 
the transmembrane domain48. The resulting protein acts as a soluble 
decoy receptor for TNF, akin to the TNF inhibitor drug etanercept. 
TNF inhibitors are highly effective therapeutic drugs in ankylosing 
spondylitis, but their use can lead to induction or exacerbation of 
multiple sclerosis. The association with ankylosing spondylitis sug-
gests the possibility that disease activity and response to TNF inhibi-
tor therapy may be affected by this SNP.
Comparison of the genetic associations of ankylosing spondylitis 
with other diseases reinforces the considerable overlap with Crohn’s 
disease, ulcerative colitis and ankylosing spondylitis. Ankylosing 
spondylitis frequently complicates inflammatory bowel disease 
(both Crohn’s disease and ulcerative colitis), and increased cofamili-
ality with inflammatory bowel disease has been demonstrated49,50, 
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 suggesting shared etiopathogenesis. Overlapping genetic susceptibil-
ity between ankylosing spondylitis and inflammatory bowel disease 
has previously been reported51,52. The genes involved include many 
with effects on the IL-23 pathway, supporting the notion of this being 
a key pathway in the pathogenesis of these conditions, most likely 
through effects on gut mucosal immunology. However, the major loci 
for each disease are not shared, with ankylosing spondylitis showing 
no association with NOD2 or ATG16L1 and neither Crohn’s disease 
nor ulcerative colitis showing association with HLA-B*27. This sug-
gests that these disease-specific loci contribute to the organ and tissue 
specificity of the diseases with which they are associated, whereas 
the IL-23 pathway is involved in the core immunological pathway 
underlying all these conditions.
We also identified associations with three loci encoding G protein–
coupled receptors, including GPR35, GPR37 and GPR65, and a fourth 
(GPR25) is close to KIF21B, an established ankylosing spondylitis 
locus where the key associated variants are not yet defined. The func-
tions of these genes and their ligands are not well established. GPR35 
is reported to act as a receptor for 2-acyl lysophosphatidic acid, and 
GPR65 is reported to be a receptor for glycosphingolipids and pro-
tons; the ligands for GPR25 and GPR37 are not known. GPR65 has 
previously been associated with Crohn’s disease53 and multiple sclero-
sis54. The mouse homolog of GPR65, T cell death–associated gene 8, 
inhibits proinflammatory cytokine production (including of TNF-A 
and IL-6) in acidic conditions55, suggesting a potential mechanism 
in diverse autoimmune diseases. However, it also has anti-apoptotic 
effects and an ability to activate not only cyclic AMP (cAMP) intracel-
lular signaling but also other pathways, including mitogen-activated 
protein kinase (MAPK) and MEK/ERK signaling and thus is likely to 
have multiple functions56. Further research is needed into the func-
tions of these genes and their roles in autoimmune diseases.
It has long been suspected that associations in the MHC region 
with ankylosing spondylitis are not completely explained by 
HLA-B*27. The association of HLA-A*0201 with ankylosing 
 spondylitis at genome-wide significance in both HLA-B*27–positive 
and HLA-B*27–negative cases confirms that suspicion. HLA-A*02 
has previously been reported to be associated with anterior uveitis 
complicating ankylosing spondylitis57 and is a risk factor for vitiligo58. 
HLA-A*0201 has a protective effect in multiple sclerosis54 and is a risk 
allele for type 1 diabetes59, but no HLA-A association has previously 
been reported with ankylosing spondylitis itself.
In conclusion, we have increased the number of ankylosing spond-
ylitis–associated loci to 31, identifying 13 new loci and 12 additional 
ankylosing spondylitis–associated haplotypes at 11 loci, bringing the 
total number of genetic signals independently associated with anky-
losing spondylitis to 43. These loci reinforce the mounting evidence 
that aberrant peptide processing before MHC class I presentation and 
alterations of the IL-23 pathway are key elements in the pathogenesis 
of ankylosing spondylitis.
URL. Haploxt, http://genome.sph.umich.edu/wiki/Haploxt.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Samples. All cases had definite ankylosing spondylitis according to the modi-
fied New York criteria60. Written informed consent was obtained from all cases 
with approval from the relevant research ethics authorities at each participating 
center. A total of 12,252 DNA samples passed genotyping control filters. The 
case collection consisted of 10,417 individuals of European ancestry, 1,560 of 
Asian ancestry and 275 from Latin America (Colombia and Mexico). Of these, 
2,425 cases of European ancestry have previously been reported in GWAS.
We obtained 12,338 controls of European ancestry, 1,570 of East Asian 
ancestry and 445 from Latin America. These included shared controls from 
the UK 1958 Birth Cohort, the UK Blood Services Common Controls and the 
United States and from participating centers from France, The Netherlands, 
Norway, Spain, Mexico, Colombia, China, Taiwan and Korea.
Genotyping. Samples were genotyped using the Immunochip, an Illumina 
Infinium platform, according to the manufacturer’s recommendations. 
Control samples from the UK were genotyped at the Sanger Centre (Hinxton, 
Cambridge, UK) and at the University of Virginia (Charlottesville, Virginia, 
USA), control samples from the United States were genotyped at the Feinstein 
Institute (New York, New York, USA), and all other controls and all cases were 
genotyped at the University of Queensland Diamantina Institute (Brisbane, 
Queensland, Australia). Bead intensity data were processed and normalized 
for each sample in GenomeStudio; data for successfully genotyped samples 
were extracted, and genotypes were called within collections using optiCall61. 
NCBI Build 36 (hg18) mapping was used (Illumina manifest file Immuno_
BeadChip_11419691_B.bpm).
SNPs rs4552569, rs13210693 and rs17095830 were genotyped in 2,998 East 
Asian cases and 5,547 East Asian controls using TaqMan probes according to 
the manufacturer’s instructions.
The genotyping accuracy of seven disease-associated SNPs with MAF < 1% 
was confirmed by custom TaqMan genotyping assays. Taking into considera-
tion the five successfully developed assays, genotypes were completely con-
cordant with Immunochip genotyping. Assays could not be developed for 
two SNPs (rs280518 in TYK2 and rs75430612 in IL2R2). However, given the 
clean clustering achieved for these SNPs in microarray genotyping and the 
fact that they had previously been reported, it is likely that they represent 
true positives.
Data quality control. We first excluded, for each of the collections separately, 
SNPs with call rate below 95% or with a Hardy-Weinberg equilibrium P value 
of <1 × 10−6 in controls, as well as samples with call rate below 95%. For the 
overlapping SNPs, we performed pairwise missingness tests between the col-
lections and removed all SNPs with differential missingness (P < 1 × 10−7). 
After merging data sets, SNPs with call rate below 98% and samples with call 
rate below 98% were removed. A total of 128,935 SNPs were analyzed. Cluster 
plots were visually inspected for all SNPs used to inform conclusions.
The origins of samples of European and Asian ancestry were confirmed by 
principal-component analysis. Immunochip data were merged with genotype 
information from seven HapMap 3 populations (CEU, TSI, YRI, MEX, JPT, 
CHD and CHB), and samples were identified as European or East Asian on 
the basis of their projection onto the first five principal components of genetic 
variation (Supplementary Figs. 10–12). Ancestry outliers were removed by 
assigning samples to an ancestry group using a model-based unsupervised 
clustering approach62. A second round of principal-component analysis was 
performed on the European and Asian populations independently to better 
resolve ancestry differences within the cohorts. In both cases, only the first 
principal component was correlated with the places of origin of the samples, 
and only in the European collection was the principal component marginally 
correlated with case-control status (P = 0.016). The projection of the samples 
analyzed onto the first two principal components is shown in Supplementary 
Figures 3 and 4.
Duplicated samples (intentional or unintentional) and those showing 
cryptic relatedness were assessed for the European and Asian cohorts sepa-
rately by calculating identity by descent using PLINK (v1.07)63. For each pair 
of related samples (PI_HAT > 0.2), the sample with the lower call rate was 
removed, and, where the pair involved a case and a control with similar call 
rates (both above 98%), cases were preferentially selected for inclusion.
Association analysis. Association analysis and population stratification con-
trol was performed using linear mixed models as implemented in FaST-LMM 
(v1.05)64. For each chromosome, a relationship matrix was constructed with 
all SNPs, excluding those in the chromosome being analyzed and in the MHC 
region. Conditional analysis for secondary signal detection was performed by 
fitting the primary SNP as a fixed effect as implemented in FaST-LMM and 
using the same SNP set for the relationship matrix.
The decision to apply linear mixed models rather than principal-component 
analysis for population stratification was informed by a comparison of 
logistic regression with principal components as covariates against linear 
mixed models, including different strategies for computing the kinship (or 
similarity) matrix. In this analysis, we concluded that linear mixed models, 
when using a kinship matrix, outperformed logistic regression with principal 
components as covariates, as assessed by the genomic inflation factor in all 
SNPs (data not shown). We also noticed that including all SNPs when comput-
ing the kinship matrix resulted in further loss of power, particularly matrices 
calculated including HLA-B*27–tagging SNPs, which are a good proxy for 
phenotype status in a case-control study such as ours. Thus, including SNPs 
tagging HLA-B*27 in the kinship matrix would have the effect of controlling 
for affected status, reducing statistical power in a case-control study.
Transformation of SNP effects from the linear 0–1 scale to the liability 
scale is described in the Supplementary Note. Association plots were gener-
ated using LocusZoom, with recombination rates estimated from the HapMap 
CEU panel (Utah residents of Northern and Western European ancestry) and 
pairwise LD r2 values estimated from the set of control samples65.
Low-frequency SNP association analysis. A collection of 7,447 cases and 
11,479 controls were selected for low-frequency SNP association analysis. 
These samples were of UK European origin according to principal-component 
analysis (Supplementary Fig. 11) and recruitment center informaiton. 
Association analysis was performed with Fisher’s exact test and with logistic 
regression conditioning on common variant association within the locus.
Imputation. We imputed genotypes in candidate regions for the European 
and Asian cohorts using the EUR and ASN reference panels, respectively, from 
the 1000 Genomes Project (Phase 1, 2010–2011 data freeze)66. Genotype data 
were phased with MACH, and genotypes were imputed with Minimac67. SNPs 
with low imputation quality (r2 < 0.5) were excluded. Association analysis in 
imputed genotypes was assessed with probabilistic genotypes, correcting for 
population stratification with the first five principal components as covariates, 
using logistic regression as implemented in mach2dat.
HLA-B*27–tagging SNP. Imputed SNPs in the MHC region were tested 
for association and for tagging of HLA-B*27. Performance as a tagging SNP 
was assessed with a cohort of samples previously genotyped at this locus 
(Supplementary Table 6b), including 754 controls from the 1958 Birth Cohort 
population68, 542 ankylosing spondylitis cases from the UK and Australia and 
104 ankylosing spondylitis cases and 5 controls from China. SNP rs116488202 
was used to tag HLA-B*27 in all analyses.
Overlap with other autoimmune diseases. For all genome-wide significant and 
suggestive loci for ankylosing spondylitis susceptibility, we searched in a chromo-
somal window of 0.5 cM around the lead SNP for associations with other autoim-
mune diseases in the National Human Genome Research Institute (NHGRI) 
GWAS catalog (accessed 5 June 2012). We then computed the LD between the 
ankylosing spondylitis–associated SNP and the reported SNP using phased data 
from the 1000 Genomes Project. If the ankylosing spondylitis–associated SNP 
was not found, we searched for the next most significant SNP in the locus. When 
a pair of SNPs was in LD (either r2 > 0.40 or D` > 0.40), a connection between the 
two diseases was noted. Positively correlated alleles were then compared for their 
risk or protective effect on the two diseases to determine whether the directionali-
ties of effect were concordant or discordant. LD was computed with Haploxt.
HLA-B*27 experiment-wide interactions. Testing for interaction between 
HLA-B*27–tagging SNP rs116488202 and all other non-MHC SNPs was 
performed in samples of European ancestry by logistic regression fitting a 
dominant term for the HLA-B*27–tagging SNP and an additive term for each 
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test SNP, including a multiplicative interaction term, and five principal com-
ponents for ancestry correction:
y x x x x i i
i
    r 

£C C C C C0 1 1 2 2 12 1 2
1
5
PC PC
where y is the log odds of disease, Bo is the intercept, x1 is a SNP variable 
reflecting an HLA-B*27 dominant effect (0 or 1), x2 is a SNP variable coded 
to reflect an underlying additive effect (0, 1 or 2), PCi codes for the projec-
tion of samples onto the ith principal component and B terms are regression 
coefficients estimated from the data.
CD4+ lymphocyte counts in ankylosing spondylitis cases and controls. 
Peripheral blood was obtained from 20 individuals with active ankylosing spond-
ylitis (erythrocyte sedimentation rate of >25 mm/h and CRP concentration of 
>10 mg/l) who were naive for TNF inhibitor and 20 age-matched healthy con-
trols. Peripheral blood mononuclear cells (PBMCs) were extracted using standard 
density gradient centrifugation over Ficoll-Paque Plus (GE Healthcare). Extracted 
PBMCs were frozen in FBS with 10% DMSO until needed. Frozen PBMCs were 
thawed into RPMI supplemented with 20% FBS and were washed once in RPMI 
supplemented with 10% FBS. Cells were rested in RPMI supplemented with 
10% FBS for approximately 1 h at 37 °C at 5% CO2 before further use. Cells 
were stained with CD3 ECD (UCHT1, Beckman Coulter) and CD4 Pacific Blue 
(13B8.2, Beckman Coulter). Antibodies were used at final dilutions of 1:100 of 
antibody stocks. Dead cells were excluded using a Live/Dead Fixable Dead Cell 
Stain kit (Invitrogen). Cells were acquired on a Gallios flow cytometer (Beckman 
Coulter), and staining was analyzed using Kaluza software (Beckman Coulter).
IL-6R measurements in serum. Serum was collected from ankylosing spond-
ylitis cases and controls of European ancestry attending the Princess Alexandra 
Hospital Brisbane Ankylosing Spondylitis Specialist Clinic who were either 
homozygous for the T or C allele of rs4129267. Serum concentrations of IL-6R 
were measured using an IL-6R Quantikine ELISA (R&D Systems), and optical 
density (OD) was determined on a Synergy 2 Microplate reader (BioTek). 
Serum was diluted 1:100, and ELISAs were performed according to the 
manufacturer’s instructions. All data shown in graphs represent mean o s.e.m., 
and differences between groups were analyzed using non-parametric one-way 
ANOVA; Kruskal-Wallis test with Dunn’s multiple-comparison post-hoc 
test in GraphPad Prism 5 software. Statistical significance was accepted at a 
significance level of P < 0.05.
60. van der Linden, S., Valkenburg, H.A. & Cats, A. Evaluation of diagnostic criteria 
for ankylosing spondylitis. A proposal for modification of the New York criteria. 
Arthritis Rheum. 27, 361–368 (1984).
61. Shah, T.S. et al. optiCall: a robust genotype-calling algorithm for rare, low-frequency 
and common variants. Bioinformatics 28, 1598–1603 (2012).
62. Fraley, C. & Raftery, A.E. Model-based clustering, discriminant analysis, and density 
estimation. J. Am. Stat. Assoc. 97, 611–631 (2002).
63. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
64. Lippert, C. et al. FaST linear mixed models for genome-wide association studies. 
Nat. Methods 8, 833–835 (2011).
65. Pruim, R.J. et al. LocusZoom: regional visualization of genome-wide association 
scan results. Bioinformatics 26, 2336–2337 (2010).
66. 1000 Genomes Project Consortium.. A map of human genome variation from 
population-scale sequencing. Nature 467, 1061–1073 (2010).
67. Li, Y., Willer, C.J., Ding, J., Scheet, P. & Abecasis, G.R. MaCH: using sequence 
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Genet. Epidemiol. 34, 816–834 (2010).
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5"
"
Supplementary!Table!3"TaqMan"genotyping"of"2,998"east"Asian"cases"and"5,547"east"Asian"controls"
of"the"non5MHC"SNPs"reported"to"be"associated"to"AS"susceptibility"in"the"Han"Chinese"populations"
(8)."
!
!
SNP" Call"Rate"
Controls"HWE"
test"P5value"
Genotypes" Association"
P5value"Controls" Cases"
rs4552569" 0.974" 0.412" 975/933/210" 825/704/158" 0.212"
rs13210693" 0.967" 0.018" 540/1071/491" 479/806/406" 0.098"
rs17905830" 0.978" 0.243" 1630/462/21" 1336/359/28" 0.178"
Nature Genetics: doi:10.1038/ng.2667
6"
"
Supplementary!Table!4!HLA5B*27"interactions."Epistasis"(interaction"term"significant"at"P5value"<"5"x"
1055)"was"assessed"via"logistic"regression"as"described"in"the"methods."The"term" "corresponds"to"
the"SNP"effect"and" "to"the"interaction"effect."See"Supplementary"Figure"4"for"experiment"wide"
HLA5B*27"correlations"in"controls"and"in"cases"and"Q5Q"plot"of"the"interaction"term"for"non5MHC"
SNPs.!
SNP" LD"(r)"with"HLA5B*27" "(se)" P5value" "(se)" P5value"Controls" Cases"
rs30187" 50.0052" 0.0543" 50.0016"(0.0477)" 0.9727" 0.3897"(0.0586)" 2.94"x"10511"
rs10045403" 0.0115" 50.0482" 50.0591"(0.0519)" 0.2545" 50.2819"(0.0636)" 9.29"x"1056"
"
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"
Supplementary!Table!7"HLA5A*02"tagging"performance"and"AS"susceptibility"association"results"in"
samples"of"European"ancestry."
Supplementary!Table!7a!Correlation"between"rs2394250"and"classical"MHC"alleles"in"1,223"1958"
Birth"Cohort"controls"with"PCR"based"genotypes"in"the"HLA+A%locus."MAF,"minor"allele"frequency;"
PREV,"allele"prevalence;"R2,"Pearson"correlation"between"HLA+A"genotype"and"rs2394250"coded"as"
0,"1"or"2."
HLA+A"
allele 
MAF PREV R2 Sensitivity Specificity 
2 0.283 0.482 0.411 0.669 0.934 
1 0.182 0.321 0.179 0.224 0.462 
3 0.130 0.245 0.112 0.173 0.594 
11 0.061 0.117 0.063 0.169 1.000 
32 0.042 0.083 0.055 0.118 0.997 
24 0.070 0.135 0.042 0.102 0.792 
"
Supplementary!Table!7b!Association"results"for"HLA5A*0201"tag"SNP"rs2394250"in"samples"of"
European"ancestry.!
" All"samples" HLA5B*27"negative"samples"a"
MAF"
Controls"
MAF"
Cases" OR" P5value" Controls" Cases" OR" P5value"
rs2394250" 0.421" 0.53" 1.541" 8.00"x"10551" 0.300" 0.355" 1.361" 1.75"x"10511"
""""conditioning%on"rs116488202% 1.214" 6.48"x"10512" "
a) As"tagged"by"rs116488202"
"
"
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"
Supplementary!Table!10!Heritability"explained"by"susceptibility"loci"under"an"additive"model."Allele"
frequency"and"odds"ratio"are"as"reported"for"samples"of"European"ancestry."Disease"prevalence"
0.5%."
Locus! Gene! SNP!
Risk!Allele!
Frequency!
(Case/Control)!
OR!
Heritability!
explained!
(%)!
1p36" RUNX3% rs6600247" 0.540/0.501" 1.164" 0.138"
1p31" IL23R% rs11209026" 0.959/0.934" 1.650" 0.352"
1p31" IL23R% rs12141575" 0.370/0.330" 1.147" 0.100"
1q21" IL6R% rs4129267" 0.635/0.592" 1.176" 0.151"
1q23" FCGR2A% rs1801274" 0.487/0.476" 1.123" 0.080"
1q23" FCGR2A% rs2039415" 0.702/0.682" 1.088" 0.037"
1q32" GPR25+KIF21B% rs41299637" 0.757/0.715" 1.201" 0.162"
1q32" HHAT% rs12758027" 0.479/0.453" 1.094" 0.048"
2p15" intergenic" rs6759298" 0.447/0.378" 1.308" 0.407"
2q11" IL1R2+IL1R1% rs4851529" 0.630/0.609" 1.103" 0.055"
2q12" IL1R2+IL1R1% rs2192752" 0.239/0.222" 1.112" 0.047"
2q31" UBE2E3% rs12615545" 0.451/0.421" 1.109" 0.062"
2q37" GPR35% rs4676410" 0.232/0.209" 1.131" 0.060"
3p24" EOMES% rs13093489" 0.361/0.334" 1.119" 0.067"
5p13" PTGER4% rs12186979" 0.516/0.498" 1.093" 0.047"
5p13" IL7R% rs11742270" 0.750/0.728" 1.113" 0.054"
5q15" ERAP1% rs30187" 0.405/0.338" 1.318" 0.411"
5q15" ERAP1% rs1065407" 0.703/0.645" 1.171" 0.136"
5q15" ERAP2% rs2910686" 0.450/0.440" 1.171" 0.147"
5q33" IL12B% rs6871626" 0.360/0.337" 1.117" 0.066"
5q33" IL12B% rs6556416" 0.704/0.675" 1.107" 0.054"
6p21" HLA+B*27% rs116488202" 0.450/0.045" 60" 20.089"
6p21" HLA+A*02% rs2394250" 0.530/0.421" 1.214" 0.220"
6q15" BACH2% rs17765610" 0.131/0.118" 1.172" 0.064"
6q15" BACH2% rs639575" 0.624/0.609" 1.081" 0.034"
7q31" GPR37% rs2402752" 0.727/0.706" 1.108" 0.052"
9q34" CARD9% rs1128905" 0.529/0.503" 1.124" 0.082"
10q22" ZMIZ1% rs1250550" 0.678/0.652" 1.110" 0.059"
10q24" NKX2+3% rs11190133" 0.737/0.707" 1.181" 0.136"
12p13" LTBR+TNFRSF1A% rs1860545" 0.634/0.605" 1.131" 0.086"
12p13" LTBR+TNFRSF1A% rs7954567" 0.363/0.341" 1.113" 0.062"
12q24" SH2B3% rs11065898" 0.237/0.216" 1.129" 0.060"
14q31" GPR65% rs11624293" 0.106/0.087" 1.234" 0.086"
16p11" IL27+SULT1A1% imm_16_28525386" 0.421/0.393" 1.112" 0.064"
16p11" IL27+SULT1A1% rs35448675" 0.007/0.006" 1.236" 0.007"
17q11" NOS2% rs2531875" 0.396/0.367" 1.122" 0.074"
17q11" NOS2% rs2297518" 0.212/0.190" 1.129" 0.055"
Nature Genetics: doi:10.1038/ng.2667
16"
"
17q21" NPEPPS+TBKBP1+TBX21% rs9901869" 0.548/0.516" 1.146" 0.111"
19p13" TYK2% rs35164067" 0.819/0.796" 1.155" 0.080"
19p13" TYK2% rs6511701" 0.220/0.218" 1.098" 0.036"
21q22" intergenic" rs2836883" 0.768/0.734" 1.190" 0.140"
21q22" ICOSLG% rs7282490" 0.411/0.390" 1.100" 0.052"
22q11" UBE2L3% rs2283790" 0.216/0.196" 1.124" 0.052"
"
"
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"
Supplementary!Figure!1!Q5Q"plots"of"association"for"the"three"analyses"presented:"A)"all"ethnicities,"
B)"European"ethnicity"and"C)"east"Asian"ethnicity."Observed"versus"expected"association"for"all"SNPs"
tests"are"shown"in"blue,"for"all"SNPs"not"on"previously"associated"AS"susceptibility"loci"are"shown"in"
orange"and"for"a"set"of"negative"control"SNPs"in"regions"included"on"Immunochip"for"studies"of"
reading"and"writing"disabilities,"psychosis"and"schizophrenia."95%"confidence"intervals"are"shown"for"
the"expected"association"in"the"negative"control"SNP"set.""For"each"of"the"analyses,"the"negative"
control"SNP"lists"contained"SNPs"that"were"unlinked"(r2"<"0.3)"and"common"(MAF">"0.05)"in"the"
respective"controls"sample"set."This"resulted"in"a"list"of"1,922"SNPs"for"the"all"ethnicities"analysis,"
1,924"SNPs"for"the"European"ethnicity"analysis"and"1,767"SNPs"for"the"east"Asian"ethnicity"analysis."
The"genomic"inflation"factor"in"the"negative"control"SNP"list"in"the"overall"analysis"was"1.047,"in"the"
white"European"analysis"1.110,"and"in"the"east"Asian"analysis"1.027."
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"
Supplementary!Figure!7!CD4+"T"cells"are"similar"in"the"peripheral"blood"of"AS"patients"and"healthy"
controls."PBMC"from"patients"with"active"AS"and"age5matched"healthy"controls"(n"="20"for"both"
groups)"were"stained"for"cell"surface"T"cell"markers"and"analysed"by"flow"cytometry.""
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"
Supplementary!Figure!8"Evidence"of"association"to"AS"susceptibility"in"samples"of"European"ancestry"
in"the"MHC"region."A)"Associations"over"the"MHC"correcting"for"ancestry"with"five"principal"
components"without"and"with"conditioning"on"HLA5B*27"tagSNP"rs116488202."SNS"with"P5value"<"
105320"are"set"P5value"="1×105320."B)"Association"at"rs2394250,"HLA5A*02"tagSNP,"after"further"
conditioning"on"HLA5B"residual"association"signal"rs4947311."The"85kb"gap"between"positions"
32,465kb"and"32,550kb"corresponds"to"an"assembly"correction"between"NCBI"human"genome"build"
36"and"37.""
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Supplementary!Figure!10!Principal"components"analysis"of"Immunochip"samples"with"7"HapMap"
populations."Individuals"are"plotted"for"the"first"two"principal"components."
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"
Supplementary!Figure!11!Principal"components"analysis"of"Immunochip"samples"of"European"
ancestry."Individuals"are"plotted"for"the"first"two"principal"components."Principal"component"one"
(plotted"on"the"y5axis)"correlates"with"the"North5South"gradient"of"European"origin"of"individuals."
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Supplementary!Figure!12!Principal"components"analysis"of"Immunochip"samples"of"East"Asian"
ancestry."
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Abstract
Aim: Non-radiographic axial spondyloarthritis (nr-axSpA) is axial inflammatory arthritis where plain radio-
graphic damage is not evident. An unknown proportion of these patients will progress to ankylosing spondylitis
(AS). The increasing recognition of nr-axSpA has been greatly assisted by the widespread use of magnetic reso-
nance imaging. The aim of this article was to construct a set of consensus statements based on a literature review
to guide investigation and promote best management of nr-axSpA.
Methods: A literature review using Medline was conducted covering the major investigation modalities and
treatment options available. A group of rheumatologists and a radiologist with expertise in investigation and
management of SpA reviewed the literature and formulated a set of consensus statements. The Grade system
encompassing the level of evidence and strength of recommendation was used. The opinion of a patient with
nr-axSpA and a nurse experienced in the care of SpA patients was also sought and included.
Results: The literature review found few studies specifically addressing nr-axSpA, or if these patients were
included, their results were often not separately reported. Fourteen consensus statements covering investigation
and management of nr-axSpA were formulated. The level of agreement was high and ranged from 8.1 to 9.8.
Treatment recommendations vary little with established AS, but this is primarily due to the lack of available evi-
dence on the specific treatment of nr-axSpA.
Conclusion: The consensus statements aim to improve the diagnosis and management of nr-axSpA. We aim to
raise awareness of this condition by the public and doctors and promote appropriate investigation and manage-
ment.
Key words: ankylosing spondylitis, non-radiographic axial spondyloarthritis, spondyloarthritis, tumor necrosis
factor-alpha inhibitors.
INTRODUCTION
Spondyloarthritis (SpA) is a group of inter-related
immune-mediated diseases with the hallmark clinical
feature of axial inflammatory arthritis.1 Recent efforts
have focused on redefining their classification, with
patients manifesting predominant axial features
classified as axial spondyloarthritis (axSpA).2 axSpA
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encompasses both ankylosing spondylitis (AS) and
non-radiographic axial spondyloarthritis (nr-axSpA).3
nr-axSpA was first described as ‘spondylitic disease with-
out radiological evidence of sacroiliitis’.4 Patients with
AS meet the modified New York criteria including radio-
graphic sacroiliitis of at least grade 2 bilaterally or grade
3 unilaterally.5 This degree of radiographically evident
sacroiliac joint (SIJ) damage takes years to appear.6
Patients with nr-axSpA do not meet this radiographic
criterion, but are classified as nr-axSpA either through
evidence of acute inflammation on magnetic resonance
imaging (MRI) and one SpA feature (for example psori-
asis, dactylitis or uveitis) or the presence of human leu-
cocyte antigen (HLA)-B27 and two SpA features.2
The Assessment of Spondyloarthritis International
Society (ASAS) axial SpA classification criteria were
developed in an attempt to: (i) enable earlier diagnosis,
as early treatment may improve outcome;7,8 and (ii)
include patients with unclassifiable or undifferentiated
SpA who fail to meet other classification or diagnostic
criteria but who require treatment.2,9 Although all
patients with nr-axSpA do not progress to modified
New York-defined AS,10 the disease activity, functional
impairment, quality of life effects and health status as
measured by Bath Ankylosing Spondylitis Disease Activ-
ity Index, Bath Ankylosing Spondylitis Functional
Index, Ankylosing Spondylitis Quality of Life question-
naire and the Short Form 36 health survey are similar
to patients with AS.11,12 In addition, the number of
inflammatory lesions in the spine and SIJs on whole
body MRI do not differ between active nr-axSpA and
AS.13
Over the last decade, there have been major develop-
ments in the investigation, classification and treatment
of SpA. To address these developments there have been
a number of position or consensus statements on the
treatment of spondyloarthritis, but to date they have
focused primarily on AS14,15 or concentrated only on
tumour necrosis factor inhibitor (TNFi) treatment.16,17
Why is another consensus statement needed? nr-axSpA
is a distinct clinical entity because its demographics,
genetics and response to treatment are different from
AS.10,18 In addition the prognosis and outcome of nr-
axSpA is more heterogenous so one needs to view it as
different from AS, where radiographic damage has
already occurred.10 The aim of this study was to con-
struct a set of consensus statements, supported by a lit-
erature review that encompasses the optimal
investigation and management of nr-axSpA. The target
population for this statement is all those involved in
referring, treating and reviewing nr-axSpA. The
relevance of the statement is both Australian and inter-
national by virtue of the exhaustive literature search.
Recognition and referral of suspected nr-axSpA was not
addressed, but has been studied19–21 and reviewed22,23
recently.
METHODS
A group of clinician rheumatologists and a radiologist,
all experienced in the clinical presentation, imaging
and management of nr-axSpA was assembled. A set of
questions was developed to define the topics to be
addressed by the literature review (see Table S1). These
questions were reviewed by the consensus panel and
edited to ensure inclusion of the most clinically perti-
nent topics in investigation and management of
nr-axSpA. A literature search was conducted covering
Medline (English language-restricted) 1966 to 31
August 2013 using the search terms: ‘spondyloarthritis’
OR ‘axial spondyloarthritis’ OR ‘non-radiographic axial
spondyloarthritis’. This was combined with specific
search terms as detailed in Table S2. Titles and abstracts
of all search results were then reviewed and full text
reviewed if there was a possibility that the publication
was relevant to the question. Other literature known to
the panel or found in parallel searches was also
included. ‘Ankylosing spondylitis’ was not used as a
search term in the literature review as the major goal
was to review studies related specifically to nr-axSpA.
The results of the literature review were then dis-
cussed and consensus statements developed. Partici-
pants agreed on the level of evidence, strength of
recommendation and level of individual agreement
with each consensus statement. The Grade level of evi-
dence and strength of recommendation system for
assigning scores was used.24
These recommendations were then reviewed by a
patient representative diagnosed with nr-axSpA and a
nurse specialized in the care of patients with SpA. Their
comments and feedback are reported herein.
RESULTS
The consensus group formulated statements on 11 of
14 questions addressed in the literature review. Three
questions are therefore discussed solely in the text of
the manuscript. In addition three further consensus
statements covering other areas were formulated at the
meeting. The consensus statements, levels of evidence,
strengths of recommendation and levels of agreement
are presented in Table 1.
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Consensus statements
The patient’s views, preferences and goals are central
and care should be a partnership between the clinical
team and the patient
This recognizes that the care of patients with nr-axSpA
is a partnership between healthcare professionals and the
patient. There is some evidence that increased involve-
ment of patients in decisions regarding their care
improves outcomes, although no evidence is available
specifically in nr-axSpA.25 Individual preferences for
treatment andanacceptable riskbenefit ratio for interven-
tions differ between patients. The patient should there-
forebe central to themanagementof their condition.
Patient education is a key part of the management of
nr-axSpA
This recognizes the role of education in empowering
patients. Numerous randomized controlled studies,
although none in nr-axSpA, have found improvements in
a variety of outcome measures in both acute and chronic
medical conditions with educational interventions.26–29
When patients understand the nature of their medical
problems and the significance of investigations, treatments
and their prognoses, outcomes are likely to be improved
through mechanisms such as alignment of treatment
goals,30 increased adherence with therapies, and better
attendance at investigations and follow-up appointments.
A comprehensive history and physical examination
should be carried out for the assessment of suspected
nr-axSpA
This reflects good medical practice and is supported
by evidence that recognitions of the signs and symp-
toms of nr-axSpA clearly contribute to diagnosis.31,32
C-reactive protein (CRP) should be measured when
considering the diagnosis of nr-axSpA; high-sensitivity
CRP (hsCRP) does not add value to normal CRP
This reflects the evidence that elevated CRP contrib-
utes to the diagnosis of a combined group of both nr-
Table 1 nr-axSpA investigation and management consensus statements
Consensus statements Level of
evidence
Grade of
recommendation
Level of agreement,
mean (SD)
The patient’s views, preferences and goals are central and care should
be a partnership between the clinical team and the patient
D 1 9.5 (1.1)
Patient education is a key part of the management of nr-axSpA D 1 9.4 (1.2)
A comprehensive history and physical examination should be carried
out for the assessment of suspected nr-axSpA
D 1 9.4 (0.7)
CRP should be measured when considering the diagnosis of nr-axSpA;
high sensitivity CRP does not add value to normal CRP
C 1 8.8 (1.0)
HLA-B27 status should be determined when considering the diagnosis
of nr-axSpA
C 1 9.1 (1.0)
Plain pelvic radiographs may be useful to distinguish non-inflammatory
and inflammatory causes of back pain; a normal radiograph does not
exclude nr-axSpA
D 2 9.5 (0.8)
Sacroiliiac joint MRI should be used in those with clinical suspicion of
nr-axSpA. T1 and STIR without gadolinium is the recommended protocol
B 1 9.8 (0.5)
Computed tomography is not recommended for the investigation of
suspected nr-axSpA
C 1 9.5 (1.1)
Classification criteria have value in the diagnosis of nr-axSpA, but
classification criteria sets should not be used to include or exclude this
diagnosis in individual patients
C 1 8.1 (1.0)
Physiotherapy may be useful in the management of nr-axSpA D 2 9.1 (0.8)
There is no role for DMARDs in the management of axial manifestations
in nr-axSpA. Sulphasalazine can be considered for those with peripheral
manifestations in nr-axSpA
C 2 8.1 (1.9)
Non-steroidal anti-inflammatories are recommended as first-line
pharmacological treatment for the management of nr-axSpA
B 1 9.1 (1.1)
TNF inhibitors are useful in the management of nr-axSpA B 1 9.6 (0.5)
Glucocorticoids may have a limited role in NSAID-refractory nr-axSpA. D 2 9.0 (0.9)
CRP, C-reactive protein; DMARDs, disease-modifying anti-rheumatic drugs; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial
spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; STIR, short T1 inversion recovery.
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axSpA and AS.31 There was no evidence in the literature
to support the utility of erythrocyte sedimentation rate
(ESR) but this can also be used in practice as a measure
of systemic inflammation. Two studies addressed the
additional benefit of whether hsCRP offered any signifi-
cant clinical advantages compared to non-hsCRP mea-
surements. Navarro-Comparos et al. found there was
no improvement in classification using hsCRP in the
DESIR cohort, although it should be noted the question
for the consensus group was related to diagnosis, not
classification.33 Poddubbnyy et al. reported that in the
GESPIC cohort, there was a correlation between clinical
parameters and hsCRP in AS, but not in nr-axSpA.34
Therefore in nr-axSpA the panel felt that there was no
greater benefit from the use of hsCRP compared with
routine CRP measures.
HLA-B27 status should be determined when consid-
ering the diagnosis of nr-axSpA
This statement reflects evidence that HLA-B27 status
has good sensitivity and specificity from studies diag-
nosing SpA. In the Ability-1 trial 45% of the imaging-
arm nr-axSpA patients were HLA-B27-positive (i.e., 45%
sensitive), although it is required for classification in
the ASAS clinical arm and therefore is confounded by
circularity.35 In the SPACE cohort of chronic back pain
patients with the physician diagnosis as gold standard,
HLA-B27 was 78% sensitive and 94% specific for axSpA
(both nr-axSpA and AS).32 In the ASAS classification cri-
teria cohort HLA-B27 was 66% sensitive and 73% spe-
cific for axSpA (both nr-axSpA and AS), with physician
diagnosis as the gold standard.
Plain pelvic radiographs may be useful to distinguish
non-inflammatory and inflammatory causes of back
pain; a normal radiograph does not exclude nr-axSpA
Differentiation of nr-axSpA and AS requires X-ray of
the SIJs. A plain antero-posterior (AP) radiograph of the
pelvis that has gradable change as defined by the modi-
fied New York criteria (for example unilateral grade 2)
but does not meet the criteria for AS, may increase clini-
cal suspicion of inflammatory disease, but the accuracy,
reliability and reproducibility of scoring SIJ changes in
plain radiographs is low.36–39 The plain AP radiograph
of the pelvis is the recommended view, as oblique pel-
vic views or angled AP views do not improve diagnostic
value compared to the plain AP view and are associated
with an increased radiation exposure.40 The AP view
also allows assessment of the hip joints that are com-
monly involved in axSpA.
SIJ MRI should be used in those with clinical suspicion
of nr-axSpA. T1 and short tau inversion recovery (STIR)
without gadolinium is the recommended protocol
This statement recognizes the increasingly important
role of this imaging modality in demonstrating the
presence of inflammatory disease in those with chronic
back pain. MRI is sensitive for bone marrow edema, a
characteristic feature of acute inflammation of the SIJ.
Significant research effort has focused on the definitions
of positive imaging in the SIJ and the spine. Currently
the ASAS definition includes only inflammatory disease
in the SIJs,41 but there has been research suggesting the
inclusion of structural disease (for example erosions)
improves sensitivity.42 In addition, a global assessment
of the positive or negative nature of an SIJ scan also
improves sensitivity.43 T1 and STIR imaging are the
optimal sequences used and gadolinium enhancement
is not additive in making the diagnosis of axSpA.41,44,45
There is also research to suggest there is little value in
scanning the spine in addition to the SIJs,46 although it
should be noted that often an MRI scan is not just used
to include/exclude nr-axSpA, but also investigate for the
presence of other pathology that could explain chronic
back pain.
Computed tomography (CT) is not recommended
for the investigation of suspected nr-axSpA
This statement reflects the poor sensitivity of CT for
inflammatory disease and the significant radiation expo-
sure it involves. Although CT has greater sensitivity than
plain radiography for chronic structural changes (e.g.,
sclerosis, erosions), as by definition nr-axSpA does not
have significant structural lesions, this property is not
advantageous in this setting. Bone marrow edema that is
often present in nr-axSpA cannot be detected by CT scan.
Classification criteria have value in the diagnosis of
nr-axSpA, but classification criteria sets should not be
used to include or exclude this diagnosis in individual
patients
Classification criteria are designed to define a homog-
enous group of patients for use in research and clinical
trial settings, and therefore are not developed specifi-
cally for diagnosis. However, in fulfilling the classifica-
tion criteria for nr-axSpA, a patient’s post-test
probability of having a clinician diagnosis of SpA is
increased, and not fulfilling the criteria set reduces the
post-test probability of SpA. By necessity, classification
criteria include many features of the relevant disease,
but using the clinician diagnosis as gold standard, no
SpA classification criteria set has 100% specificity. Infor-
mation is lacking for nr-axSpA, but for SpA in general
the specificity of different SpA classification criteria
ranges from 83% to 88%.47 A hypothetical clinical
example of the potential issue is: a 30-year-old patient
who has Crohn’s disease and mechanical back pain
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from a herniated disc, who is HLA-B27-positive and has
a raised CRP from their bowel disease could be classi-
fied as nr-axSpA (based on the ASAS criteria2) when
they do not in fact have nr-axSpA. Therefore classifica-
tion criteria should not be used solely in individual
patients to establish or exclude the diagnosis of SpA.
Physiotherapy may be useful in the management of
nr-axSpA
There is a notable absence of published studies on
physiotherapy in nr-axSpA. While physiotherapy has
been shown to reduce pain and improve function inAS,48
the only trial of physiotherapy that included nr-axSpA
found during the literature search was small and did not
separately report the results of the nr-axSpApatients.49
There is no role for disease-modifying antirheumatic
drugs (DMARDs) in the management of axial manifes-
tations in nr-axSpA. Sulphasalazine can be considered
for those with peripheral manifestations in nr-axSpA
There is no evidence of DMARD efficacy for axial man-
ifestations of nr-axSpA. In AS, where there is evidence
available, the use of sulphasalazine (SSZ) for axial mani-
festations is not supported.15 The ESTHER trial com-
pared etanercept with SSZ in axSpA (nr-axSpA and AS)
and the 64 joint count and enthesitis scores decreased
substantially on SSZ, with no difference detected
between etanercept and SSZ in these outcome measures;
however, there was no placebo arm in this trial.50
Non-steroidal anti-inflammatory drugs (NSAIDs) are
recommended as first-line pharmacological treatment
for the management of nr-axSpA
NSAIDs were demonstrated to be effective in the IN-
FAST trial of early axSpA: in the 1000 mg naproxen
monotherapy arm 57% achieved ASAS40 and 35%
achieved ASAS Partial Remission (the primary outcome)
at week 28.7 There was no placebo comparison arm in
this trial. Of all theNSAIDs naproxen has the best efficacy
data and also the best cardiovascular risk profile.51,52
TNF inhibitors are useful in the management of
nr-axSpA
There are a number of trials of TNFi for treatment of
nr-axSpA, including adalimumab,35 certolizumab,53
etanercept50 and infliximab.7 These demonstrate good
efficacy, especially in early disease and in combination
with NSAIDs. The INFAST trial7 (comparing infliximab
with naproxen with naproxen alone in axSpA) demon-
strated ASAS40 response rates of 75% in the infliximab/
naproxen arm at week 28. Treatment responses of nr-ax-
SpA patients with positive SIJ MRI scans are similar to
those observed in patients with AS.53,54 The Ability-1
trial included both MRI-positive and -negative nr-axSpA
and a post hoc subgroup analysis suggested that those
patients with a positive SIJ MRI or a CRP above the
upper limit of normal (ULN) had higher absolute
response rates. All other trials have included only
patients with a positive SIJ MRI or CRP above the ULN
so the question of whether response to TNFi agents var-
ies according to MRI or CRP status is currently difficult
to answer. Ciurea and colleagues reported results from
the Swiss Clinical Quality Management cohort and
found ASAS40 and ASAS Major Improvement response
rates were higher in patients with AS compared to nr-ax-
SpA (odds ration [OR] = 2.2, P = 0.02).11 In those
patients with an elevated CRP at baseline (both AS and
nr-axSpA) the ASAS40 response was higher in the AS
group compared to nr-axSpA (52% and 38%, respec-
tively). Further research is clearly required to determine
the best predictors of response in nr-axSpA.
Glucocorticoids (GCs) may have a limited role in
NSAID-refractory nr-axSpA.
There is a lack of evidence for GCs in nr-axSpA. A
recent trial of prednisolone in AS demonstrated rela-
tively poor efficacy, which is consistent with clinical
experience.55 GCs have substantial medium- and long-
term adverse effects, especially on glucose and bone
metabolism and therefore their use should be consid-
ered carefully in light of the risks, benefits and treat-
ment alternatives.
The group did not make statements about the role of
bisphosphonates, antibiotics or biological agents other
than TNFi agents in the treatment of nr-axSpA. There is
no evidence for the efficacy of bisphosphonates in nr-
axSpA, and some evidence for the use of bisphospho-
nates in AS,56 but the group had differing clinical experi-
ence with these agents. Antibiotics have a role for the
treatment of active symptomatic infection that can pre-
cipitate reactive arthritis (ReA); the goal for this treat-
ment is elimination of the active symptomatic infection.
There is, in addition, some conflicting evidence for the
use of chronic antibiotics in the treatment of ReA;57–60
however, this practice is not universally accepted or
widespread, potentially reflecting uncertainties around
the strength of the evidence, selection of appropriate
patients and the risk/benefit balance with the potential
adverse effects of long-term antibiotic therapy.
A number of alternative biologic agents have been
trialed in AS, including rituximab (anti-CD20),61,62
abatacept (CTLA4 Ig),63 tocilizumab (anti-interleukin
[IL]-6R),64 sarilumab (anti-IL-6R),65 secukinumab
(anti-IL-17)66 and anakinra (IL-1 receptor antagonist)67
but there have been no trials, and limited clinical expe-
rience with these agents in nr-axSpA and therefore the
group did not make any statement regarding their use.
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Patient perspective
The patient with nr-axSpA agreed with the consensus
statements and made the following additional com-
ments: (i) ‘As a patient I want to be treated in the best
possible way through solid evidence and what the cur-
rent research findings are’; (ii) regarding physiotherapy,
‘It is the first tool of pain relief, it is very helpful with
the management of this condition. I would like to think
all physiotherapists are keeping up to date with new
techniques’; and (iii) ‘I would like to see national guide-
lines for all patients, so that we all receive the same val-
ued care, doesn’t matter where you live’.
Nursing perspective
A nurse practitioner with extensive experience in care of
SpA patients agreed with the statements and made the
following comments: (i) ‘I like the fact that the patient’s
views are the first statement as I believe this is of para-
mount importance and that patient education is also
identified as a key issue’; and (ii) ‘For the management
of this disease, all patients should have equal access to
appropriate investigations and potentially life-changing
treatments. Consensus statements from experienced
rheumatologists such as these provide evidence for the
standards that should be met.’
CONCLUSIONS
Improvements in the care of patients with nr-axSpA will
come from increased recognition of the condition by
the public, primary care physicians and medical special-
ists as well as the use of effective therapies. A patient
passes through the stage of nr-axSpA on their way to
AS, although not all patients who have nr-axSpA will
eventually develop AS.10 Historically there has been a
long delay in recognizing and treating patients with
AS,6 and the wider recognition of nr-axSpA is likely to
make a significant difference to patient symptom bur-
den due to appropriate treatment, regardless of whether
they progress to AS or not. We know that those patients
with nr-axSpA have similar levels of disease activity to
AS patients, and active nr-axSpA patients have similar
levels of inflammation on MRI scan to patients with
AS.11–13 The set of consensus statements compiled from
both evidence and expert opinion will guide clinicians
in the investigation and management of nr-axSpA. In
addition the group hopes it will encourage better access
to TNFi agents for appropriate patients with nr-axSpA.
There are limitations to the evidence base and the
consensus statements. In many diseases including
axSpA, where the etiology and disease mechanisms are
incompletely understood, the physician’s opinion is
often used as the gold standard to validate diagnostic
procedures and tests. However, the result is that assess-
ments of individual diagnostic tests or procedures is
then confounded by circularity, because the same tools
used to define the gold standard are then tested against
the gold standard. This is a limitation of the assessment
of diagnostic tests against a gold standard where knowl-
edge of the true disease mechanisms is uncertain.
Another limitation is the lack of evidence relating spe-
cifically to nr-axSpA, and even when studies include
these patients the results of AS and nr-axSpA are not
always separately reported.2,32,49
As with early treatment in rheumatoid arthritis,
there is the potential for early treatment in SpA to
change prognosis. The INFAST 1 and 2 trials of very
early axSpA patients showed high response rates from
combined NSAID–TNFi treatment and if patients
reached partial remission on TNFi almost half
remained in partial remission 6 months after discon-
tinuing their TNFi with or without NSAIDs.7,8 This is
encouraging early data that early treatment could lead
to drug-free remission for a proportion, perhaps the
‘window of opportunity’ may be applicable to SpA as
it is to rheumatoid arthritis. Research on TNFi use in
AS also suggests that early use may improve radio-
graphic outcome.68
These consensus statements are the product of the
currently available evidence, which is somewhat lim-
ited. Currently the treatment for nr-axSpA varies little
from that of AS, but this relates primarily to the lack of
evidence on the specific treatment of nr-axSpA. How-
ever, evidence is growing about this important condi-
tion, and increased recognition and research focus will
enable future iterations of these consensus statements
to be progressively improved.
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COMMENTARY
The window of opportunity: a relevant concept
for axial spondyloarthritis
Philip C Robinson* and Matthew A Brown
Abstract
The window of opportunity is a concept critical to rheumatoid arthritis treatment. Early treatment changes the
outcome of rheumatoid arthritis treatment, in that response rates are higher with earlier disease-modifying
anti-rheumatic drug treatment and damage is substantially reduced. Axial spondyloarthritis is an inflammatory axial
disease encompassing both nonradiographic axial spondyloarthritis and established ankylosing spondylitis. In axial
spondyloarthritis, studies of magnetic resonance imaging as well as tumor necrosis factor inhibitor treatment
and withdrawal studies all suggest that early effective suppression of inflammation has the potential to reduce
radiographic damage. This potential would suggest that the concept of a window of opportunity is relevant not
only to rheumatoid arthritis but also to axial spondyloarthritis. The challenge now remains to identify high-risk
patients early and to commence treatment without delay. Developments in risk stratification include new
classification criteria, identification of clinical risk factors, biomarkers, genetic associations, potential antibody
associations and an ankylosing spondylitis-specific microbiome signature. Further research needs to focus on
the evidence for early intervention and the early identification of high-risk individuals.
Axial spondyloarthritis (axSpA) is an inflammatory dis-
ease of the axial skeleton and pelvis. Regardless of
whether it progresses onto ankylosing spondylitis (AS),
axSpA has an appreciable disease burden. axSpA is also
associated with co-morbidities such as uveitis, psoriasis,
inflammatory bowel disease, cardiovascular disease,
osteoporosis and significant loss of work productivity.
There is emerging evidence that early treatment may
change the outcome in axSpA.
The window of opportunity is a concept of critical im-
portance in rheumatoid arthritis (RA). Early treatment
results in reductions of disease activity, joint erosions,
and better treatment responses the earlier disease-
modifying anti-rheumatic drugs are commenced. It also
results in a greater proportion of patients in drug-free
remission after treatment withdrawal. These findings
have led to changes in RA treatment paradigms, with in-
creasing emphasis on early diagnosis and treatment.
So how is this concept relevant to axSpA? A number
of studies have demonstrated early treatment that
suppresses inflammation may change the outcome of
axSpA.
Whilst initial studies suggested that radiographic pro-
gression of AS is not slowed by treatment with tumor
necrosis factor inhibitor (TNFi) medications, two obser-
vational studies have now shown a reduction in radio-
graphic progression with these agents [1,2]. One of these
studies also showed that delay in starting TNFi medica-
tions was associated with greater radiographic progres-
sion [2]. Magnetic resonance imaging (MRI) studies
have also supported the link between inflammation and
progression of ankylosis. Acute inflammatory lesions are
more likely to progress to chronic fatty lesions than
areas devoid of inflammation [3]. Vertebral corners with
inflammation on MRI are more likely to progress to syn-
desmophytes than those without [4]. There is good evi-
dence that all of the TNFi medications reduce MRI-
detected inflammatory lesions.
Intriguingly there is also new evidence that the age of
the inflammatory lesion may influence progression to
ankylosis, suggesting that a longer duration of inflamma-
tion is associated with more syndesmophyte formation.
Maksymowych and colleagues have shown that early,
acute type A lesions, without fatty metaplasia, infiltra-
tion or erosion, are less likely to progress to
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syndesmophytes as compared with type B lesions char-
acterized by loss of signal at the vertebral corner [5].
This loss of vertebral corner signal is postulated to be
erosion, sclerosis, reparation or fatty infiltration, and
may be a sign of a more longstanding mature inflamma-
tory lesion. This work supports the theory that early cor-
ner lesions in the spine which have not developed
reparative changes of fat infiltration can potentially re-
gress, whilst more advanced corner lesions with signs of
fatty reparative change are more likely to progress to an-
kylosis. This work potentially marks fat metaplasia as an
event that precedes ankylosis and indicates that suppres-
sion of fatty change by treatment may slow progression
to ankylosis.
Taken together, these observations provide strong cir-
cumstantial evidence that treatment, especially early ef-
fective treatment, may influence radiographic outcome.
Trials of TNFi therapy in early axSpA have yielded en-
couraging results, with greater treatment responses than
in disease of longer duration. In Barkham and col-
leagues’ study of very early axSpA (mean symptom dur-
ation 15.3 months), infliximab achieved an Assessment
of SpondyloArthritis international Society (ASAS) partial
remission rate of 56% [6], compared with 22% in the
registration trial of infliximab in established AS (the
ASSERT study). Similarly, in the INFAST study of inflixi-
mab treatment in axSpA patients with disease duration
less than 3 years (mean 1.8 to 1.9 years), higher numer-
ical response rates (40% improvement from baseline
using the ASAS criteria (ASAS40) of 75%) were ob-
served than in the ASSERT study (ASAS40 of 45%) or
trials of the other TNFi agents in established AS
(ASAS40 responses of 39 to 47%) [7-10]. In the ESTHER
trial of etanercept, where symptom duration was a mean
2.9 years, ASAS40 was achieved in 70% of patients, com-
pared with ASAS40 of 45% for the etanercept trial in
established AS [8,11]. Although one should note that
these efficacy comparisons are not head to head in the
same trials, they are consistent with a difference in re-
sponse based on disease duration.
Withdrawal studies of TNFi agents in early axSpA and
AS also suggest that the frequency of drug-free remis-
sion is higher the earlier a patient is treated. In estab-
lished AS patients treated with a TNFi agent and
monitored for 6 months or more after discontinuation,
91 to 100% of patients flare [12-14]. In the INFAST trial,
40 to 48% of patients who received early infliximab
treatment remained in drug-free remission 6 months
after stopping their infliximab [15]. In the Barkham and
colleagues study mentioned above of infliximab in early
axSpA, after only four infusions 33% (four of 12) of pa-
tients remained symptom free 5 years after treatment,
whereas 100% (13 of 13) of patients initially randomized
to placebo were still requiring TNFi therapy [6,16].
The definition of flare varies between studies, and
standardization of this definition as well as other issues
relating to trial design would enable better conclusions
to be drawn. However, the data do suggest that early
treatment may change the prognosis of disease. The dif-
ference between the studies may relate to study design
or exactly how large the window of opportunity is.
The major challenge now remains to accurately iden-
tify patients who have poor prognosis. The ASAS axSpA
criteria have gone some way to enabling earlier identifi-
cation of early axSpA but do have some limitations in-
cluding the ability to capture self-limiting disease
[17,18]. Clinical predictors of radiographic progression
identified to date include elevated C-reactive protein, to-
bacco smoking, and the presence of baseline syndesmo-
phytes. Other potentially promising research findings
that may enable better identification of patients who will
have persisting or bad prognosis disease include bio-
markers such as vascular endothelial growth factor,
matrix metalloprotein-3, sclerostin, citrullinated vimen-
tin and dikkopf-1. Antibodies to major histocompatibil-
ity complex class II-associated invariant-chain peptide
have been associated with axSpA by two independent
groups; if their specificity is validated in larger studies
and they become commercially available, these anti-
bodies hold great promise.
Emerging work examining the gut microbiome of
axSpA patients may provide information not only about
etiology, but also about prognosis. A distinct microbial
signature has been associated with AS (M Brown, un-
published observation). In very recent work Van Praet
and colleagues have also found an association be-
tween the degree of bowel inflammation, and MRI-
demonstrated bone marrow edema of the sacroiliac
joints [19].
Finally, clinical prediction from genetic analysis -
whilst essentially dominated by HLA-B27 until recently
- has progressed significantly, and there are now many
independent AS genetic associations [20]. This analysis
may become powerful enough in the future to enable
prediction of prognosis and particularly radiographic
severity.
There may therefore be a time when genetic analysis,
probably combined with other biomarkers or clinical
features, enables accurate prognostication of disease on-
set, features and severity. Early, or even potentially
prophylactic, treatment could then be applied to stop or
attenuate disease.
We should also acknowledge that the data currently
available are not conclusive and that a number of studies
are required before the evidence becomes compelling.
Randomized controlled trials of TNFi therapy with-
drawal in very early disease are needed, and some
are underway. Longitudinal studies of cohorts of
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nonradiographic axSpA are required to better under-
stand the natural history of early disease, including re-
mission and progression rates. Further work is required
for the development of better biomarkers of early dis-
ease and case-identification strategies, which will be re-
quired to implement an early intervention strategy.
In conclusion, there is mounting evidence that early
effective treatment of inflammation in axSpA can change
disease outcome. Identification of high-risk individuals
and prompt institution of therapy is going to have in-
creasing importance in clinical practice. We should
therefore encourage industry and independent investiga-
tors to design and conduct studies in axSpA to confirm
the importance of the window of opportunity as well as
the accurate identification of high-risk individuals. Early
treatment combined with another concept borrowed
from RA, treat to target, will hopefully enable patients
to enjoy the huge therapeutic progress seen in RA to be
translated into axSpA.
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Ankylosing  spondylitis  (AS)  is a chronic  inflammatory  arthritis  that  affects  the  spine  and  sacroiliac  joints.
It  causes  significant  disability  and  is  associated  with  a number  of other  features  including  peripheral
arthritis,  anterior  uveitis,  psoriasis  and  inflammatory  bowel  disease  (IBD).  Significant  progress  has  been
made  in  the  genetics  of AS  have  in the  last  five  years,  leading  to new  treatments  in trial,  and  major  leaps
in  understanding  of the aetiopathogenesis  of  the  disease.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis
that affects the spine and sacroiliac joints. It causes significant dis-
ability and is associated with a number of other features including
peripheral arthritis, anterior uveitis, psoriasis and inflammatory
bowel disease (IBD). Significant progress has been made in the
genetics of AS have in the last five years, leading to new treatments
in trial, and major leaps in understanding of the aetiopathogenesis
of the disease.
2. Major Histocompatibility Complex Genetics of AS
It has long been known that AS runs strongly in families, with
the risk of disease in first-degree relatives of AS cases being >52
times that of unrelated subjects (Brown et al., 2000). Whether this
cofamiliality was due to shared environmental or genetic factors
was unclear until the demonstration in the early 1970s of asso-
ciation of the HLA-B27 allele with the disease (Brewerton et al.,
1973b; Schlosstein et al., 1973). Heterozygote HLA-B27 carriage has
an odds ratio of ∼50 for AS, and homozygosity with an odds ratio of
∼100 (International Genetics of Ankylosing Spondylitis et al., 2013;
Jaakkola et al., 2006; Khan et al., 1978). The recurrence risk for AS
in monozygotic twins is 63%, first degree relatives 8.2% and second
! This article belongs to Special Issue on The Pathogenetic Role of HLA-B27 and
other Genes in Ankylosing Spondylitis.
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degree relatives 1.0%. The parent–child recurrence risk is 7.9% and
the sibling–sibling recurrence risk is 8.2% (Brown et al., 2000).
The HLA-B27 association in AS remains amongst the strongest
genetic association with any common human disease, but the
molecular mechanism underlying this association remains unclear.
In nearly all populations studied worldwide, HLA-B27 is strongly
associated with AS. One hundred and thirty subtypes of HLA-
B27 have now been reported (European Bioinformatics Database
Immuno Polymorphism Database, 2013), and AS has been reported
to occur with the following subtypes: B*2702 (MacLean et al., 1993),
*2703 (Reveille et al., 2000), *2704 (Lopez-Larrea et al., 1995), *2705
(MacLean et al., 1993), *2706 (Gonzalez-Roces et al., 1997), *2707
(Armas et al., 1999), *2708 (Armas et al., 1999), *2710 (Garcia
et al., 1998), *2714 (Garcia-Fernandez et al., 2001), *2715 (Garcia-
Fernandez et al., 2001), and *2719 (Djouadi et al., 2001). The vast
majority of HLA-B27 subtypes occur in too few individuals to defini-
tively establish their association with disease. Of  those studied in
sufficient numbers of carriers, HLA-B*2702-5, *2707, *2708 and
*2710 clearly significantly increase AS risk. There is some evidence
suggesting that HLA-B*2704 may  carry higher risk than the ances-
tral HLA-B*2705 allele, and that the risk associated with B*2703
may  be lower. Two subtypes, B*2706 and B*2709, are not associ-
ated with disease, but AS has been reported in carriers of each allele,
indicating that they are not protective for AS. It is beyond the scope
of this article to discuss the potential mechanisms by which HLA-
B27 induces AS, but as we  and others have proposed previously,
any hypothesis as to explain this must also explain how these two
subtypes are not AS-associated (Brown, 2009; McLean et al., 1985).
It has also long been suspected that other, non-HLA-B27, MHC
alleles are involved in AS-pathogenesis. Whilst many studies have
attempted to study this further, the difficulty of distinguishing link-
age disequilibrium with HLA-B27 from direct associations across
0161-5890/$ – see front matter ©  2013 Elsevier Ltd. All rights reserved.
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the MHC  has until recent large scale studies precluded convincing
demonstration of any replicated non-HLA-B association with AS. An
exception to this has been the association of HLA-B60 with AS, first
reported by Robinson et al. in 1986 (Robinson et al., 1989) and con-
firmed subsequently in populations of both white European (Brown
et al., 1996) and east Asian ancestry (Wei  et al., 2004).
The International Genetics of AS Consortium has recently
extended this observation, using the findings of 10,619 AS cases and
15,145 controls densely genotyped across the MHC to genetically
dissect the region further (International Genetics of Ankylosing
Spondylitis et al., 2013). A major finding from this study was the
identification of a single tagSNP, rs116488202, that is highly sensi-
tive and specific for HLA-B27 (>98.5%, within the limit of accuracy
of direct genotyping of HLA-B27), and which can be genotyped for
a small fraction of the cost of typing HLA-B27 itself. This should
have a major impact on genetic screening for AS either in high risk
or even in the general population. An early application is that it
has enabled imputation of HLA-B27 in large cohorts, and thus the
ability to study non-HLA-B27 MHC  associations of AS in sufficiently
powered studies. These studies have shown genomewide signif-
icant association of HLA-A*0201 with AS with odds ratios of 1.21
and 1.36 in HLA-B27 positive and negative cases respectively. It is
likely that the further associations of MHC  genes will be identified
in future studies, particularly as better imputation methods for HLA
loci become available.
3. Non-MHC genetic associations
Strong epidemiological evidence of the existence of significant
non-MHC genetic associations of AS was presented well before any
such genes were convincingly identified. HLA-B27 positive first-
degree relatives of AS cases are 5.6–16 times more likely to develop
disease themselves than HLA-B27 positive carriers in the general
community (Calin et al., 1983; van der Linden et al., 1983). Identi-
cal twins are much more likely to be concordant for AS (60–75%)
than HLA-B27-positive dizygotic twins (24%) (Brown et al., 1997;
Pedersen et al., 2008).
The GWAS era has enabled rapid progress in identifying non-
MHC  associations of AS to be made. These findings have highlighted
a number of important pathways in AS pathogenesis including the
IL-23 pathway, aminopeptidases and peptide presentation, innate
immune stimulation and the interaction and homeostasis of resi-
dent microbial communities. Included among them are pathways
for which we currently have therapeutics available, particularly in
the IL-23 pathway, and it will be important to test these therapeu-
tics in AS patients.
3.1. Ubiquitination, aminopeptidases and MHC  class I
presentation
Ubiquitination is the process of adding ubiquitin groups onto
proteins that directs them to a specific sub-cellular compartment
or for degradation via the multi-catalytic complex called the pro-
teasome (Pickart, 2001). The proteasome degrades the protein and
either recycles the resultant products or the peptides can be pre-
sented on MHC  class I molecules on the cell surface. Ubiquitination
therefore plays an important role in determining what antigens
are presented to the immune system. UBE2E3 and UBE2L3 have
recently been associated with AS and these genes encode the
enzymes UbcH9 and UbcH7 respectively (International Genetics of
Ankylosing Spondylitis et al., 2013). However, UbcH9 is unable to
form bonds with ubiquitin but can with a similar protein SUMO
(Desterro et al., 1997). When a protein undergoes sumoylation it
is not degraded, it may  enhance the proteins stability, change its
location or direct involvement in other cellular processes like signal
transduction (Muller et al., 2001). Variants in UBE2L3 are involved
with NF-!" regulation and UBE2L3 has been associated with a num-
ber of other inflammatory diseases implicating this intracellular
signalling pathway as a shared pathogenic pathway (Wang et al.,
2012).
Two loci (chromosomes 5p15 and 17q21) containing genes
encoding four aminopeptidases have now been implicated in AS
aetiology (International Genetics of Ankylosing Spondylitis et al.,
2013). The chromosome 5p15 locus contains genes that encode the
aminopeptidases endoplasmic reticulum aminopeptidase (ERAP)-
1, ERAP2, and insulin regulated aminopeptidase (IRAP or LNPEP).
The chromosome 17q21 locus contains the NPEPPS gene that
encodes puromycin-sensitive aminopeptidase. The same primary
ERAP1 haplotype associated with AS is also associated with psoria-
sis (Strange et al., 2010), and the AS-associated ERAP2 haplotype is
also associated with both psoriasis and inflammatory bowel disease
(Chapman et al., 2010). Suggestive evidence has been presented
that ERAP1 variants may  be associated with type 1 diabetes and
cervical cancer but these findings have not been universal and in
no study have definitive associations been reported (Dendrou et al.,
2009; Mehta et al., 2007).
ERAP1 and 2 are resident in the endoplasmic reticulum (ER) and
are an integral part of the MHC  class I presentation pathway. Once
peptides have been processed through the proteasome, the Trans-
porter associated with Antigen Processing (TAP) takes the resultant
peptide from the cytoplasm into the ER. ERAP1 and ERAP2 then
trim any N-terminally extended peptides longer than 9 amino-
acids down to that length (Chang et al., 2005; York et al., 2002),
which is the favoured length for subsequent loading onto MHC  class
I molecules such as HLA-B27.
ERAP1 was  the first aminopeptidase associated with AS (Burton
et al., 2007). The association has been widely replicated with similar
allelic and haplotypic associations reported in both populations of
white European ancestry and in east Asians, implying that common
variants are involved rather than multiple rare variants (Choi et al.,
2010; Davidson et al., 2009, 2011; Harvey et al., 2011; Li et al., 2010;
Lin et al., 2011; Maksymowych et al., 2009; Pimentel-Santos et al.,
2009).
Recently interaction between HLA-B27 and ERAP1 variants has
been described in AS, such that variants of ERAP1 were shown only
to influence AS disease risk if HLA-B27 is present (Evans et al., 2011).
This suggests that ERAP1 associated variants operate by effects on
peptide processing prior to HLA Class I presentation. It had previ-
ously been reported that ERAP1 is involved in cleavage of cytokine
receptors from cell membranes (Cui et al., 2002, 2003a,b; Goto et al.,
2011), but studies comparing serum levels of receptor levels in
wild type and ERAP knockout mouse found no differences (Evans
et al., 2011). Further, in humans there is no association between
ERAP1 polymorphisms and serum cytokine receptor levels (Haroon
et al., 2010). Fine-mapping studies indicate that the SNP rs30187
(Lys528Arg) is directly disease-associated, and that the variation
rs10050860 (Asp575Asn) marks an AS-associated haplotype that
also carries rs17482078 (Arg725Gln) (Evans et al., 2011). The link-
age disequilibrium between rs10050860 and rs17482078 is very
tight, and it has not been possible thus far to determine which of
these two polymorphisms is the key AS-associated variant, or if
both are actually disease associated. Certainly they have a profound
effect, with a reduction in AS risk in HLA-B27 positive homozygous
carriers of ERAP1 protective variants of 3–4 fold (Evans et al., 2011).
In vitro studies of peptidase activity of ERAP1 and its variants
show that the protective variants of rs30187 and rs17482078 are
associated with a 40% reduction in peptidase function, whereas
rs10050860 has no effect (Evans et al., 2011). This suggests that
rs10050860 is not the true disease-associated variant but rather
rs17482078 is. Using recombinant ERAP1 and comparing wild type
protein with rs30187 and rs27044 (Q730E) variants, Evnouchidou
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et al. demonstrated that the functional properties of these variants
depend on the substrate concentration and sequence (Evnouchidou
et al., 2008).
Crystallization of the ERAP1 enzyme and resolution of its struc-
ture has shown that AS-associated variants are variously located
in the transition zone, C-terminal cavity and in the active site
(Kochan et al., 2011; Nguyen et al., 2011). ERAP1 efficiently pro-
cesses peptides 9–16 residues long and prefers substrates with
a positively charged side chains and a large hydrophobic C ter-
minal residue (Chang et al., 2005; Evnouchidou et al., 2008). But
variants shown functionally to negatively affect trimming veloc-
ity (rs30187, rs17482078) influence the transition of the enzyme
from the open to the closed state (Evans et al., 2011; Kochan et al.,
2011). Therefore it is more likely the other mapped variants are
not the functionally important variations, but are in LD with the
transition state variants. ERAP knockout (KO) mice (mice do not
have ERAP2)  are fertile with no obvious phenotype except they
are more susceptible to intra-cellular infection with toxoplasmo-
sis (Blanchard et al., 2008). ERAP KO mice have 20–80% fewer cell
surface class I molecules and the resultant complexes are more
unstable, and don’t illicit normal CD8T cells responses (Hammer
et al., 2006). HeLa cells treated with 90% effective siRNA show sig-
nificantly increased MHC  class I expression and a greater supply
of peptide for presentation (York et al., 2002). This suggests that
ERAP1 degrades some antigenic peptides and prevents their pre-
sentation. Therefore AS-associated variants in ERAP1 change the
amount and length of peptides presented as well as the stability of
the peptide-MHC molecule (Garcia-Medel et al., 2012). Therefore
ERAP1 could influence AS disease risk through either changes in
the type or volume of peptides presented.
ERAP2 was first reported to be associated with AS along with the
initial description of association of ERAP1 with the disease (Burton
et al., 2007). Harvey et al. demonstrated haplotypic association
across the ERAP1 locus which was not fully explained by association
at any individual SNP (Harvey et al., 2011), and Tsui et al. reported
a SNP haplotype involving ERAP1 and ERAP2 to be associated with
AS (Tsui et al., 2010). This was better defined by a conditional anal-
ysis demonstrating an associated haplotype spanning ERAP2 and
LNPEP influencing AS risk independently of ERAP1 (International
Genetics of Ankylosing Spondylitis et al., 2013). Because of the
extreme linkage disequilibrium between ERAP1 and HLA-B27 and
between ERAP1 and ERAP2,  it is not possible to determine if ERAP2
is associated with AS in HLA-B27 positive cases, but it is clearly
AS-associated in HLA-B27 negative cases. ERAP2 is also associated
with psoriasis, inflammatory bowel disease and juvenile idiopathic
arthritis (Chapman et al., 2010; Hinks et al., 2013; Tsoi et al.,
2012). ERAP2 is another ER resident aminopeptidase that trims N-
extended peptides prior to loading onto MHC  class I molecules;
it has 49% sequence homology to ERAP1 (Birtley et al., 2012).
ERAP1 and ERAP2 have been identified to form heterodimers to
a minor degree (10–30%) and in such a way synergistically cleave
some peptides, but the significance of this finding is not known
(Saveanu et al., 2005). The crystal structure of ERAP2 has been
determined and its internal cavity has more positively charged
side chains compared to ERAP1, potentially explaining the differ-
ing peptide trimming preferences (Birtley et al., 2012). Further,
ERAP2 does not have the additional pocket for C-terminal peptide
recognition that enables ERAP1 to trim in a length dependent way
(Birtley et al., 2012). There are two functionally important vari-
ants in ERAP2 that are associated with AS (International Genetics of
Ankylosing Spondylitis et al., 2013). The most important is a vari-
ant (rs2248374) that changes the strength of the exon 10 splice site
resulting in an extended exon 10 transcript that contains two  stop
codons (Andres et al., 2010). A truncated mRNA is transcribed and
nonsense-mediated decay then degrades this truncated mRNA and
the protein is never produced. This variant causing loss of ERAP2
protein is associated with reduced MHC  class I surface expression
in cell lines (Andres et al., 2010). This loss-of-enzyme variant is
protective of AS, in an analogous way  to the loss-of-function vari-
ants in ERAP1 being protective of AS (International Genetics of
Ankylosing Spondylitis et al., 2013). Another variant (rs2549782)
has been shown to alter both the rate and specificity of ERAP2
trimming, and is also associated with AS (International Genetics
of Ankylosing Spondylitis et al., 2013; Evnouchidou et al., 2012).
This variant is in strong LD with the loss-of-enzyme variant (from
1000 Genomes D′ = 1.00, r2 = 0.90), and therefore is almost never
transcribed into functioning protein. It therefore implicates the
loss-of-enzyme variant (rs2248374) as the functional AS associated
variant.
The conditional association of the chromosome 5p15 locus
that implicates ERAP2 also includes the LNPEP gene (International
Genetics of Ankylosing Spondylitis et al., 2013). This gene encodes
the aminopeptidase IRAP. IRAP is involved in trimming of peptides
during the process of cross-presentation (Saveanu et al., 2009).
Cross presentation is primarily described in dendritic cells (Joffre
et al., 2012), whereby exogenous antigens are internalized and
loaded onto class I molecules either through the traditional MHC
class I pathway in the ER or through phagosomes in the cytosol, and
then presented on the cell surface. There are no known functional
variants identified in LNPEP associated with AS and the relevance
to AS of cross-presentation is unknown, so further research in this
area is required.
At the chromosome 17 locus harbouring the aminopeptidase
NPEPPS there still remains to be fine mapping and functional work
is required to localize the association. This locus has two indepen-
dent signals, one involving NPEPPS, and the other involving the
neighbouring genes TBX21 and TBKBP1. NPEPPS exists in the cyto-
plasm and is the only cytosolic aminopeptidase known to cleave
polyQ sequences (Menzies et al., 2010). Research in murine mod-
els of neurodegenerative diseases shows over-expression reduces
protein accumulation and enhances macro-autophagy (Kudo et al.,
2011). The genetic association of IBD with autophagy genes such
as ATG16L1 identified for the first time a role for autophagy in
IBD pathogenesis (Rioux et al., 2007). Whilst AS is not associated
with ATG16L1 (Danoy et al., 2010), evidence of autophagy has been
demonstrated in ileal biopsies in AS, and has been shown to be a
driver of IL-23 expression in the gut (Ciccia et al., 2013). Whether
NPEPPS operates in AS through effects on autophagy or through
alternate effects on intracellular peptide handling requires further
study.
Potentially other aminopeptidases may  be implicated in AS aeti-
ology in the future. Peptides are trimmed either in the cytosol or
ER and the relative importance of each of these compartments is
dependent on their individual N-terminal sequence (Hearn et al.,
2010; Weimershaus et al., 2013). There are many other aminopep-
tidases present in the cytosol that may  play a role in trimming
of peptides that could potentially impact on the risk of AS, and
new aminopeptidases continue to be described (Akkad et al., 2012;
Dutoit et al., 2012; Saveanu et al., 2002).
3.2. IL-23 pathway
Multiple constituents of the IL-23/IL-17 pathway have now been
associated with AS. The IL-23 cytokine is made up of two subunits:
IL-12p40 and IL23p19. IL12p40 is encoded by the IL12B. Variants
near IL12B have established association with AS (Danoy et al., 2010;
Evans et al., 2011).
IL-23 signals through the IL23R, and protective variants that
reduce sensitivity to IL-23 stimulation are strongly associated with
AS (Di Meglio et al., 2011; Sarin et al., 2011). The finding was  initially
described in white Europeans (Burton et al., 2007), and the corre-
sponding alleles were not polymorphic in Han Chinese (Davidson
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et al., 2009), but a sequencing study has now found different IL23R
variants in Han Chinese which are associated with AS (Davidson
et al., 2013), with the protective alleles of these variants being
loss-of-function variants.
Once stimulated, IL-23R signals through the JAK-STAT pathway,
involving the kinases TYK2 and JAK2, and STAT3, to the nucleus. The
genes encoding each of these proteins have been associated with
AS susceptibility (International Genetics of Ankylosing Spondylitis
et al., 2013; Danoy et al., 2010), with TYK2 variants achieving
genomewide significance. Indeed a rare variant of TYK2 which is
predicted to affect TYK2 splicing has an odds ratio of 7.7 for the dis-
ease, making it the strongest non-MHC genetic effect as measured
by odds ratio (International Genetics of Ankylosing Spondylitis
et al., 2013).
These findings were the first evidence that the IL-23 pathway
was involved in AS (Brown, 2008), and have stimulated trials of
antagonists to the pathway in AS. There is already good evidence
that anti-IL-12p40 antibody treatment (ustekinumab) and anti-IL-
17 antibody treatment (secukimumab) are effective in AS, and trials
of tofacitinib (a JAK inhibitor) and fostamatinib (a TYK2 inhibitor)
are now underway in the disease.
Research stimulated by the genetic findings is now demon-
strating that the IL-23 pathway is a critical pathway in the
aetiopathogenesis of AS, and that IL-23 over-expression alone is
sufficient to cause spondyloarthritis in mouse models of disease
(Adamopoulos et al., 2011). It is known that IL-23 is over-expressed
in the bowel of AS patients (Ciccia et al., 2009). Over-expression
of IL-23 with a mini-circle vector has previously been shown
to cause arthritis (Adamopoulos et al., 2011). Sherlock and col-
leagues used a mini-circle vector to endogenously over-express
IL-23 in mice, resulting in the development of axial and periph-
eral spondyloarthritis and aortitis. They identified a population of
IL-23R positive cells resident in the enthesis, a key site where dis-
ease occurs in AS (Sherlock et al., 2012). These entheseal resident
cells secreted TNF, IL-17 and IL-22 in response to IL-23; inhibiting
either IL-17 or IL-22 could block disease, but IL-17 over-expression
alone was not sufficient to cause disease. This suggests that IL-23
may  be the key cytokine controlling many of the disease manifesta-
tions in AS and other spondyloarthropathies. Consistent with these
data, all major mouse and rat models of spondyloarthritis show
involvement of the IL-23 pathway, including the proteoglycan-
induced model, TNF-overexpression model, skg model and even
B27-transgenic rats (Boldizsar et al., 2009; DeLay et al., 2009;
Kontoyiannis et al., 2002; Ruutu et al., 2012). Thus it appears that
almost irrespective of the cause of IL-23 over-expression, the func-
tional consequence is a spondyloarthritis-like phenotype.
3.3. Intergenic regions
Two replicated associations with AS have been to intergenic
regions at chromosomes 2p15 and 21q22, where no translated
gene product is encoded (Reveille et al., 2010). At chromosome
21 PSMG1 is the nearest gene, but is 82 kb away, and there is no
difference in expression of this gene in AS cases compared with con-
trols or in relation to the AS-associated SNPs at this locus (Reveille
et al., 2010). At both these intergenic regions RNA-seq data identi-
fied novel long non-coding RNA transcripts, raising the possibility
that the molecular mechanism underlying these associations is
through effects of germline sequence variation on non-coding RNA
sequence or transcription (Reveille et al., 2010).
3.4. Lymphocyte development and activation
Multiple transcription factors involved in lymphocyte develop-
ment and activation have been associated with AS. These include
EOMES,  RUNX3,  TBX21,  ZMIZ1,  IL7,  and IL7R (Danoy et al., 2010;
International Genetics of Ankylosing Spondylitis et al., 2013;
Reveille et al., 2010). RUNX3 influences thymic T cell develop-
ment (Park et al., 2010) and AS associated RUNX3 variants, as
well as the AS-associated variants in IL7R and ZMIZ1,  are associ-
ated with reduced CD8T cell counts in healthy individuals (Evans
et al., 2011). RUNX3 knockout (KO) mice spontaneously develop
inflammatory bowel disease at four weeks of age, demonstrating
its important role in AS-organ specific immune function (Brenner
et al., 2004). IL7R is another gene involved in T cell development
as IL7R ! chain KO mice are devoid of "# T cells and very deficient
in !$ T cells and B cells – the defect causes a lack of T cell recep-
tor " locus rearrangement (Candeias et al., 1997). EOMES encodes
eomesodermin, a transcription factor involved in CD8 differentia-
tion, the expression of which is induced by RUNX3 (Cruz-Guilloty
et al., 2009; Pearce et al., 2003; Yagi et al., 2010). Eomesodermin
deficiency promotes IL-17 expression by CD8 T-cells (Intlekofer
et al., 2008). IL-7 acts through IL-7R to induce RUNX3 expres-
sion in developing T-cells, in turn favouring differentiation towards
the CD8-lineage (Franke et al., 2010). ZMIZ1 is a transcriptional
co-activator of the Protein Inhibitor of Activated STAT (PIAS)-
like family; thus it may  affect STAT-mediated cytokine signalling.
ZMIZ1 interacts with activating NOTCH1 mutations to induce T-cell
acute lymphoblastic leukaemia, suggesting a role in T-cell differen-
tiation (Rakowski et al., 2013). TBX21 encodes T-bet, a transcription
factor which is important in regulation of T- and NK-cell function
and development. T-bet expression is controlled by IL-23 (Klose
et al., 2013), and T-bet itself controls IL-22 secretion by innate
lymphoid cells in the gut (Sciume et al., 2012). These associations
implicate the differentiation of immune cells as being important to
AS pathogenesis, but it is not clear which of these cells are primar-
ily affected by the genetic variants identified. The recent discovery
of the expansion of innate lymphoid cell populations, such as "#T
(Kenna and Brown, 2013) and NKp46 IL-22 expressing cells (Ciccia
et al., 2012), in AS cases is particularly relevant as these genes are
known to be major determinants of differentiation and activation
of these cell types, suggesting that they play a causative role in AS
pathogenesis (reviewed in Kenna and Brown, 2013).
3.5. G-protein coupled receptors
Three G-protein coupled receptors (GPR) (GPR35,  GPR37 and
GPR65) have now been associated with AS (International Genetics
of Ankylosing Spondylitis et al., 2013). Generally these receptors
are not well characterized, but are known to mediate a wide range
of cellular signalling (Rosenbaum et al., 2009). GPR35 is known to
be expressed predominately in immune and gastrointestinal tis-
sues, both sites important in AS (Wang et al., 2006). It is thought
indoleamine 2,3-dioxygenase (IDO), an important immune system
mediator signals through GPR35 (Ren et al., 2009). Amongst other
actions, IDO influences tolerance in dendritic cells (Pallotta et al.,
2011) and therefore alterations in its ability to signal could well
influence inflammatory disease.
GPR37 was noted to be down regulated in children with severe
influenza, but other immune functions are unknown (Heltzer et al.,
2009). It is also called Parkin-Associated Endothelin Receptor-
Like Receptor, over-expression of which causes it to misfold,
accumulate and induce macro-autophagy (Marazziti et al., 2009).
This association with macro-autophagy, along with the role of
NPEPPS in clearing large accumulated proteins may  suggest
this pathway is important in AS, as it is in IBD (Khor et al.,
2011).
GPR65 is also known as T cells death – associated gene 8
(TDAG8) has been shown to be involved in thymocyte apoptosis,
implicating this important process of T cell development, already
highlighted by the genetic associations described above (Tosa et al.,
2003).
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3.6. IL-1 genes
Prior to the GWAS era, suggestive evidence of the involvement
of IL-1 genes in AS-pathogenesis was reported (Djouadi et al.,
2001; Sims et al., 2008; van der Paardt et al., 2002). These asso-
ciations have not been subsequently replicated in GWAS studies,
likely because this region is now known to be subject to substan-
tial population stratification effects that earlier studies were not
able to control for. Nonetheless, GWAS studies have now conclu-
sively demonstrated the association of the IL1R1-IL1R2 locus with
AS (International Genetics of Ankylosing Spondylitis et al., 2013;
Reveille et al., 2010). Two independent association signals are found
at this locus, implicating both genes in AS pathogenesis. Innate
immune stimulation through pattern recognition receptors stimu-
lates the production of pro-IL-1! that is cleaved to IL-1! by the
inflammasome and released. IL1R1 mediates many of the responses
of IL-1! whereas IL1R2 encodes a decoy receptor for IL-1!, compet-
itively binding IL-1 ! and preventing its binding to IL-1R1. A role
for IL-1 in AS inflammation is supported by the efficacy of anakinra
in AS, although the level of benefit from this agent was  much lower
than that observed with TNF-inhibitors and therefore it has not
entered clinical practice for AS management (Haibel et al., 2005;
Tan et al., 2004).
Historically B cells were thought not to play a role in AS patho-
genesis, but recently the efficacy of rituximab has been reported,
especially in those naïve to TNF blockers (Song et al., 2013). A high
prevalence of antibodies to CD74, that target the HLA class II invari-
ant chain peptide, has also been reported, particularly in early AS
(Baerlecken et al., 2013; Baraliakos et al., 2013). Intriguingly, sug-
gestive association of CD74 with AS has previously been reported
(Burton et al., 2007), suggesting a possible role in disease causation.
These data suggest that contrary to the long held belief, B cells may
play some role in AS pathogenesis. This hypothesis is supported by
the recent association of AS with the B-cell specific transcription
factor BACH2. This gene transcribes the BACH2 protein that has high
expression in B cells prior to the plasma cell stage of B cell develop-
ment (Muto et al., 2004). BACH2 is a critical player in class switch
recombination and somatic hypermutation (Muto et al., 2004). Lit-
tle more is known about the mechanisms by which this association
operates.
The receptor through which IL-6 signals, IL6R, has been asso-
ciated with AS (International Genetics of Ankylosing Spondylitis
et al., 2013). The AS associated SNP has been shown to be associ-
ated with asthma, CRP levels and pulmonary function in previous
studies (Dehghan et al., 2011; Evans et al., 2011; Wilk et al., 2007).
IL6 is a proinflammatory cytokine with pleiotropic effects, and is
instrumental in directing pathogenic TH17 responses (Burton et al.,
2007). The IL6R SNP correlates with CRP levels, which are elevated
in AS. Two therapeutics directed against IL-6R have been trialled
and found not to be sufficiently effective to progress through full
development and marketing.
4. Non-axial AS manifestations
4.1. Age of symptom onset
The age at which AS patients develop their first symptoms is
significantly influenced by genetics, with family studies suggesting
the heritability of age of onset is 33–50% (Brown et al., 2003; Sims
et al., 2007). Many studies have found HLA-B27 positive patients
develop symptoms 3–9 years earlier than their B27-negative coun-
terparts (Feldtkeller et al., 2003; Jaakkola et al., 2006; Queiro et al.,
2008). A large Finnish family study also found association between
HLA-DRB1 alleles and age at symptom onset (Jaakkola et al., 2006).
There does not seem to be an association between age of onset
and severity, suggesting susceptibility and severity are not linked
(Brophy and Calin, 2001).
4.2. Anterior uveitis
Autoimmune anterior uveitis (AU) is a T cell mediated condition
that causes inflammation of the iris and ciliary body of the eye. It
occurs in 30–40% of AS patients episodically and is also strongly
associated with HLA-B27 (Brewerton et al., 1973a). It also occurs in
other autoimmune conditions such as Bechet’s disease, sarcoidosis
and Vogt–Koyanagi–Harada disease.
One of the issues with determining uveitis specific genetic asso-
ciations apart from HLA-B27 is the challenge of separating genes
that are AS-specific, AU-specific or predispose to both conditions.
Few genes have been robustly replicated as AU specific risk genes.
Non-B27 MHC  alleles that have been associated with anterior
uveitis include HLA-A02, HLA-B58 and HLA-DRB1*08 (Martin and
Rosenbaum, 2011). As mentioned above, HLA-A*0201 has recently
been associated with AS-susceptibility independent of HLA-B27
and in both HLA-B27 positive and negative cases, at genome-
wide significance (International Genetics of Ankylosing Spondylitis
et al., 2013). A number of loci outside of the MHC  have also
been associated with anterior uveitis including complement factors
(Yang et al., 2011, 2012), killer immunoglobulin receptors (KIRs)
(Levinson, 2011; Levinson et al., 2010), IL10 and the TNF region
(Atan et al., 2010). The only systematic genomewide study of uveitis
found the 9p21-24 loci as a uveitis specific locus and the MHC  as
a shared AS-AU susceptibility region (reflecting HLA-B27) (Martin
et al., 2005).
4.3. Peripheral arthritis
Small studies have looked at the genetic associations of periph-
eral arthritis in AS. A study of 100 patients found an association
between peripheral arthritis and the HLA-DR4 allele (Miehle et al.,
1985). A study of 51 AS patients observed no difference in HLA-A, B,
C, DR and DQ antigens between those with both peripheral and axial
compared to those with axial arthritis alone, however this study did
note 7 of 9 with erosive peripheral arthritis were HLA-DR7 positive
(Sanmarti et al., 1987). HLA-DR7 was also found to be associated
with peripheral disease by two  other groups (Aaron et al., 1985;
Armstrong et al., 1983). Another study of 151 patients found no
effect of HLA-DR genes on peripheral arthritis (Brown et al., 1998).
These studies were all of small sample size compared with current
GWAS studies, and were further hampered by the challenge of dis-
tinguishing whether arthritis in peripheral joints in AS patients is
due to the AS, or other conditions.
5. Axial spondyloarthritis
Axial spondyloarthritis (axSpA) is a new classification criteria
that has been published that captures both AS and early and/or
abortive forms of inflammatory axial arthritis (Rudwaleit et al.,
2009). The demographics of axSpA are quite different from AS itself,
with a higher proportion of affected women  and lower HLA-B27
prevalence (reviewed in Robinson et al., 2013). These distinc-
tions also vary considerably between cohorts meeting the same
classification criteria, suggesting substantial heterogeneity in the
cohorts involved (Lin et al., 2013). The only non-HLA-B27 genetic
study using the axSpA classification criteria confirms an association
with ERAP1 that would be expected since the classification criteria
include patients with AS (Kadi et al., 2013). There is a clear need
to perform large scale prospective studies to develop criteria that
distinguish cases with inflammatory back pain that is truly inflam-
matory from other causes of back pain, and to identify those with
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inflammatory spinal arthritis that develop osteoproliferative dis-
ease, with its consequent long-term functional effects. Although
cases with axSpA have similar self-reported symptom levels as
patients with primary AS, it is self-evident that cases that develop
spinal fusion in the long-term have a greater disease burden than
those that do not, given similar levels of back pain.
6. Psoriasis and inflammatory bowel disease
Psoriasis is present in 10–30% of AS patients and IBD occurs in
about 10% of AS patients, but up to 70% have histological evidence
of bowel inflammation at colonoscopy (Costello et al., 2013). Both
these conditions share risk alleles with AS that implicate shared
pathogenic pathways. The notable shared associations between
AS and psoriasis and IBD are the IL-23 pathway (IL23R, IL12B,
STAT3, JAK2) and the MHC  class I pathway (MHC, ERAP1,  ERAP2)
(Danoy et al., 2010; Robinson and Brown, 2012). In the recent AS
Immunochip study, amongst the 41 independent association sig-
nals associated with AS, 12 were shared with Crohn’s disease and
11 with ulcerative colitis, all with the same direction of associa-
tion (International Genetics of Ankylosing Spondylitis et al., 2013).
This amazingly strong overlap in genetic association implies that
the pathogenesis of these three diseases are very closely related.
Genetic defects in the control of commensal micro-organisms
or maintenance of barrier function is a common theme with
AS, IBD and psoriasis. Clinical and sub-clinical bowel inflamma-
tion is a common feature of AS and genetic associations such as
NOD2/CARD15 and CARD9 in AS and IBD may  influence the abil-
ity to maintain homeostasis with the resident bowel microbiome
(Costello et al., 2013). Analogously deletions and copy number vari-
ations in Late Cornified Epithelium (LCE) genes LCE3B and LCE3C
are associated with psoriasis (Bergboer et al., 2012; Strange et al.,
2010). These genes are not expressed by immune cells, but in
the skin and suggest genetic influences on primary barrier func-
tion. If these changes in barrier function allowed the invasion of
commensal or pathogenic microbes then this could provide the
environmental trigger for disease onset. But, although the trigger
was broadly similar between conditions, in that they are micro-
bial, the type and ability to trigger the innate immune system in an
aberrant way could well differ substantially based on route of entry
and other deficits identified in immune signalling such as the MHC
class I pathway.
7. Pleiotropy
Family studies have not only shown high cofamiliality of AS,
but also of other seronegative diseases with each other; it has also
been shown that the classical autoimmune diseases tend to co-
occur in families and in individual subjects. This suggests that for
each set of conditions there may  exist an underlying set of predis-
posing genetic variants, with disease-specific variants determining
the ultimate disease phenotype that results (Visscher et al., 2012).
As increasing numbers of disease-associated loci are identified, this
model is being rapidly validated, with large numbers of pleiotropic
genetic variants identified, some with associations in the same
direction in different diseases, and others with opposite directions
of association (Cotsapas et al., 2011; Zhernakova et al., 2009). For
example, the TNF receptor SNP rs1800693 increases the risk of mul-
tiple sclerosis, but is protective in AS. The variant means a soluble
form of TNFR1 is produced and acts in the same way as the AS ther-
apeutic etanercept, which is a fusion protein that traps soluble TNF
(Gregory et al., 2012). Clinically, etanercept has been observed to
increase MS  risk, and increase MS  activity when used in MS  cases,
mirroring the effect of the genetic variant. Such findings are of great
potential benefit in predicting likely toxicities of therapeutically
targeting genes associated with more than one disease.
In future it is anticipated that classification criteria for many
diseases will be modified on the basis of their genetic dissection.
It is not that long ago that AS was  termed “rheumatoid spondyli-
tis” and considered a manifestation of rheumatoid arthritis (Polley
and Slocumb, 1947). The discovery of the HLA-B27 association
(Brewerton et al., 1973b; Caffrey and James, 1973; Schlosstein et al.,
1973) revolutionized how people viewed AS, and launched a huge
separate research effort that continues to this day. Given the phe-
nomenal cost and significant toxicities associated with modern
biological treatment for AS, improved case stratification to improve
long-term outcome and short-term treatment response prediction
would clearly be major advances for the field.
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Abstract  
 
The field of spondyloarthritis has seen huge advances over the past 5 years. 
The classification of axial disease has been redefined by the axial 
spondyloarthritis criteria that incorporate disease captured before radiographic 
damage is evident as well as established erosive sacroiliac joint disease. Our 
knowledge of genetics and basic immunological pathways has progressed 
significantly. In addition, revolutionary progress has been achieved with the 
availability of tumour necrosis factor inhibitors for treating patients with 
moderate to severe disease. In parallel a number of novel biomarkers have 
been identified that show significant promise for the future. Advances in 
magnetic resonance imaging have helped define positive disease. We have 
identified that T1 and short tau inversion recovery sequences are best for the 
diagnosis of axial spondyloarthritis and gadolinium contrast is not additive for 
diagnosis. Progress has been made in identifying potential agents and 
strategies that reduce radiographic progression. A number of referral 
strategies aimed at appropriate identification of patients have been trialed and 
found to be effective. There is still substantial work ahead but the advances of 
the last 5 years have made a huge and tangible difference at the clinical 
coalface and we suggest this trend will continue.  
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In the last five years the field of spondyloarthritis (SpA) has seen significant 
progress. New classification criteria have been proposed and there have been 
significant advances in basic science and therapeutics. This progress is 
welcome as for decades little progress was made in treating this disease. This 
review aims to cover the significant advances in ankylosing spondylitis (AS) 
and axial spondyloarthritis (axSpA), a term now being used to encompass AS 
and other forms of axial SpA. 
 
Classification 
The classification of SpA has been, and continues to be, an area of significant 
interest and controversy [1, 2]. We currently lack a thorough understanding of 
the basic mechanisms of disease pathogenesis. Therefore diagnosis and 
classification remains, at this present time, based primarily on signs and 
symptoms. 
Initial classification criteria for SpA as a whole included the Amor criteria [3] 
and European Spondyloarthritis Study Group (ESSG) criteria [4]. These 
criteria were designed to capture the entire spectrum of SpA, not purely axial 
disease. When measured against physician diagnosis as gold standard the 
Amor and ESSG criteria have sensitivity and specificity of 87 - 90% each [5]. 
These criteria had some scope to capture SpA earlier in its disease course, 
but their more general nature meant they were unable to specifically identify 
early axial SpA. The New York criteria, and then the modified New York 
(mNY) criteria capture established long standing AS by virtue of the 
requirement for limitation in movement and erosive sacroiliac joint damage [6]. 
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There were always clearly patients who did not meet the mNY criteria but had 
active debilitating axial SpA, and a proportion of these patients progress to 
mNY AS [7]. With the stimulus of the introduction of tumour necrosis factor 
(TNF) inhibitors as effective treatments, a new classification system was 
proposed by Assessment of SpondyloArthritis International Society (ASAS) 
that aimed to capture both early and established disease [8]. This introduced 
the concept of axial spondyloarthritis (axSpA) that includes two groups. The 
first is patients with mNY AS and the second is patients who do not meet the 
mNY criteria but have classifiable disease called non-radiographic axial 
spondyloarthritis (nr-axSpA). Patients can meet criteria for axSpA in two ways 
(see Table 1): (1) By virtue of having plain film evidence of erosion (the same 
as for the mNY criteria) or magnetic resonance imaging (MRI) evidence of 
sacroiliac joint inflammation and one feature of SpA from a list of 11, such as 
psoriasis  or  anterior  uveitis  (“Imaging  arm”);; or (2) By being Human Leucocyte 
Antigen (HLA)-B27 positive and having two features of SpA, from a list of 10 
(“HLA-B27  arm”).  
The ASAS axSpA criteria (both arms combined) against a physician gold 
standard have a sensitivity and specificity of 83% and 84% respectively. The 
imaging arm alone has a sensitivity of 66% and a specificity of 97%. This 
clearly demonstrates that positive imaging, be that with plain film or MRI has 
high specificity but lacks sensitivity when assessed against physician gold 
standard. An interesting longitudinal study that performed MRI and sacroiliac 
joint biopsies in patients with early SpA and followed them up demonstrated 
that the sensitivity for MRI may not be as high as thought, the study 
suggested 31%. Although correlation between histological sacroiliac joint A
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inflammation and clinical symptoms is not something the SpA community has 
any experience with, so the actual clinical relevance of this finding is unclear 
[9]. 
 
The introduction of the axSpA criteria has demonstrated that there is a set of 
patients with disease that will not progress to mNY AS, as these cohorts have 
lower HLA-B27 carriage rates and more females compared to cohorts of 
established AS [1, 10]. It has enabled the identification of early disease that 
previously was not well captured and precipitated trials of effective agents 
such as anti-TNF in early disease, demonstrating excellent efficacy [11]. 
Therefore it seems the field is moving towards the use  of  the  term  ‘axial  
spondyloarthritis’  instead  of  ‘ankylosing  spondylitis’  to  describe  the  wider  axial  
disease group. However AS will continue to be used to describe the more 
advanced form and provide homogenous groups for biological research. 
 
Basic Science - Genetics 
The genetics of AS has come a long way since the discovery of HLA-B27 in 
1973 [12-14]. The advent of large scale array based genotyping, the genome 
wide association study (GWAS) and significant international collaboration now 
means there are 41 independent genetic associations for AS [15-18]. The 
salient features of these associations is the clustering in immunological 
pathways such as the IL-23, antigen processing and presentation and 
lymphocyte development and activation [19]. In addition a genetic interaction 
has been identified between HLA-B27 and a gene that encodes an enzyme 
called endoplasmic reticulum aminopeptidase (ERAP1), this enzyme A
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processes peptides prior to presentation on the cell surface on MHC class I 
molecules. Variants of ERAP1 only increase the risk of AS when HLA-B27 is 
present. In addition the same interaction is observed with HLA-B40, another 
AS associated HLA-B allele [20]. These interactions strongly suggest that the 
mechanism by which HLA-B27 contributes to AS development is through its 
antigen presentation function [19]. Whether it is presenting the wrong antigen, 
not presenting an antigen or changing the mix of presented antigens is wholly 
unclear [21]. In fact a newer theory suggests that HLA-B27 may contribute to 
disease  pathogenesis  in  the  setting  of  an  ‘immunodeficient’  state.  A  summary  
of the current theories of how HLA-B27 might contribute to SpA pathogenesis 
is shown in Table 2. 
The other interesting and important finding from the significant body of recent 
genetic research is the significant sharing of risk variants between immune 
mediated diseases such as inflammatory bowel disease, rheumatoid arthritis, 
multiple sclerosis and systematic lupus erythematosus [22]. This sharing is 
both concordant, and discordant, in that variants, can at times be protective 
for one disease but increase risk for another disease. An excellent example is 
the TNFRSF1A variants that reduces risk in AS but increases risk for multiple 
sclerosis [23]. 
 
Basic Science – Immunology 
Advances in genetic research has allowed for concurrent evolution in 
understanding the basic immunology underpinning the pathogenesis of SpA. 
GWAS studies have identified susceptibility genes common to SpA and 
associated conditions including psoriasis and inflammatory bowel disease A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved. 
(IBD). Polymorphisms in these commonly shared genes implicate innate 
immunity, antigen presentation and interleukin-23 (IL-23) modulated pathways 
in SpA disease development [24]. 
 
IL-23-signalling appears pivotal in the pathogenesis of SpA. Human data 
demonstrates increased production and sensitivity to IL-23 and expansion of 
both adaptive and innate IL-23-responsive cells, within joints and the 
periphery of patients with various forms of SpA [25-28]. However the initial 
inflammatory and/or microbial stimulus resulting in IL-23 production, where 
anatomically this might occur, and how IL-23 drives SpA in genetically prone 
individuals has been puzzling.  
Understanding the mechanisms of IL-23 signalling and subsequently the 
pathogenesis of SpA, have been hindered by the lack of appropriate SpA 
animal models. However a recent publication by Sherlock et al. utilising 
minicircle DNA technology to systemically overexpress IL-23 in B10.RIII mice 
resulted in the subsequent identification of a previously undescribed lineage 
of IL-23 responsive, resident entheseal T cells. This has been widely 
acknowledged as a significant advance [29]. The entheseal cells identified are 
CD3+CD4-CD8+IL-23R+RORγt+   and   show   up-regulated expression of both 
IL-17 and IL-22 (IL-23-dependent cytokines). This model provides an elegant 
link between enthesitis and systemic expression of IL-23, allowing further 
postulation that disease initiation in SpA may be linked to IL-23 produced at a 
distant site. Intriguingly the mice where also shown to develop a psoriasis-like 
phenotype in the setting of the IL-23 overexpression, further linking Ps with IL-
23 and SpA. In addition the CD3+CD4-CD8+IL-23R+RORγt+   cells   were  A
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shown to produce IL-22 and subsequently activate STAT-3 dependent 
osteoblast-mediated bone remodelling at the enthesis [29]. This IL-22 and 
STAT-3-dependent osteoproliferative effect at the enthesis, recapitulates the 
characteristic disease phenotype seen in human SpA. 
Leading on from this work IL-23 signalling involving gut, joints and skin in 
SpA, has been investigated in a further new animal model of SpA. Ruutu et al 
demonstrated that BALB/c ZAP-70W163C-mutant SKG mice systemically 
exposed to â-1,3-glucan (curdlan) develop a disease closely resembling 
human SpA [30]. After curdlan administration SKG mice develop both axial 
and peripheral SpA, 50–60% develop small intestine inflammation reminiscent 
of human Crohn's disease, 25% develop unilateral uveitis and all the mice 
develop psoriasis-like skin inflammation. Inhibition of IL-23 in the curdlan 
treated SKG mice, suppresses the development of SpA (both axial and 
peripheral arthritis) and the ileitis. Interestingly IL-23 is secreted by the gut in 
response to curdlan and promotes ER stress and proinflammatory cytokine 
production locally whilst altering intestinal mucosal barrier integrity [31]. 
 
These recent data highlight that the development of SpA may be driven by 
microbial stimuli and likely involve multiple IL-23-mediated downstream 
pathways at various tissue sites, in genetically predisposed individuals [32]. 
The field remains enthusiastic towards the development of therapeutics 
targeting IL-23-responsive cells or their generation to improve clinical 
outcomes for patients with SpA. 
 
Clinical Science A
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The introduction of anti-TNF agents into clinical practice was a landmark in 
the treatment of axSpA. Since that time there have been a number of 
compounds trailed that have shown promise, and a number that have not. 
Originating from the discovery of the involvement of IL-17 and IL-23 in SpA 
monoclonal antibodies to these agents have been trialed in axSpA patients 
[33, 34]. Both of these agents have shown promise in phase 2 trials. However 
one caveat with the use of anti-IL-17 in axSpA is the observation that it 
worsens inflammatory bowel disease (IBD) [35]. Around 60-70% of axSpA 
patients have either overt or subclinical IBD and therefore this may 
substantially curtail the use of this agent for axSpA treatment unless a 
biomarker or other means to stratify patients is found. Unfortunately trials of 
anti-CD20 therapy (rituximab) only showed efficacy in those who had not 
failed anti-TNF therapy in a small trial [36]. This suggests that failure of anti-
TNF agents marks a slightly different biological sub-type of disease. A trial of 
the co-stimulatory blocking agent CTLA-Ig (abatacept) in 30 patients failed to 
show a major response [37]. Two agents targeting IL-6 agents (tocilizumab 
and sarilumab) and an anti-IL-1 agent (anakinra) have also been tested in 
small trials and failed to show significant efficacy [38-40]. Although sustained 
responses have been noted in individual patients to anakinra [41] and in 
sarilumab (personal observation, P. Robinson). In addition the 
phosphodiesterase 4 inhibitor, apremilast showed encouraging results in 
phase 2 trials. Currently in trial is the janus kinase inhibitor tofacitinib in AS 
and aminopeptidase inhibitors are in preclinical development [42]. Therefore it 
is likely a number of new therapeutics will make it to the clinic in the next 5 - 
10 years. A
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Magnetic Resonance Imaging 
MRI is the technological advance that enables the recognition of axSpA at an 
early stage or in those who do not have erosive disease. Research has shown 
that T1 and short tau inversion recovery (STIR) sequences are best to 
demonstrate axSpA and that gadolinium contrast is not additive in making the 
diagnosis and is therefore not justified [43, 44]. Definitions of a positive 
sacroiliac joint scan have been proposed and include 2 discrete STIR lesions 
on the same slice or 1 STIR lesion that is observed on more than one slice 
[45]. A positive spinal MRI is currently defined as 3 or more corner 
inflammatory lesions (osteitis) with each lesion having to be present on at 
least 2 slices [46]. Work on including structural lesions like erosions in the 
ASAS definition is in progress [47]. Finally research examining the value of 
scanning the entire spine in addition to the sacroiliac joints in the diagnosis of 
nr-axSpA has shown there is little additive value in the spine imaging [48]. 
However it should be noted that in daily clinical practice the purpose of an 
MRI is not only to include or exclude SpA but to diagnose chronic back pain.  
 
Referral Strategies 
Referral strategies aimed at effective identification and referral of suspected 
axSpA have been trailed in multi-centre randomized trials. These have shown 
in those patients with chronic back pain the presence of one item such as 
inflammatory back pain or HLA-B27 identifies 25 - 42% of patients [49-52]. 
Increasing the complexity the referral algorithm did not significant improve A
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identification rates in one large German trial [50]. Large scale campaigns 
aimed at the public are also effective at increasing referral rates [53]. 
 
Biomarkers 
A number of biomarkers have shown some promise in identification of both 
axSpA from non-axSpA and poor prognosis disease in those with axSpA. 
These include vascular endothelial growth factor, matrix metalloprotein 3, 
sclerostin, citrullinated vimentin, dikkopf-1 and antibodies to MHC class II-
associated invariant chain [54-60]. Whilst identification of individual 
biomarkers is important, evaluating the capacity of panels of multiple 
biomarkers is required. Evaluation of these biomarker panels in a number of 
independent and longitudinal cohorts would determine their prognostic value 
in the clinical setting. 
 
Radiographic progression and the potential window of opportunity 
Observational cohort studies have shown that smoking, an elevated CRP, 
pre-existing syndesmophytes and being male all increase the risk of 
radiographic progression [61]. 
First described in 1973 with a drug called phenylbutazone, the potential for 
non-steroidal anti-inflammatory drugs (NSAIDs) to reduce radiographic 
progression has gained more credence with the increasing evidence base 
[62]. A 2 year randomized trial of celecoxib noted a significant difference in 
radiographic progression of the spine in those who took celecoxib regularly 
compared to those with took it as required. Supporting this is an additional 
observational report of NSAIDs ability to retard radiographic damage from the A
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GESPIC cohort [63]. A re-analysis of the celecoxib trial demonstrated that 
those with an elevated CRP had the most benefit from continuous NSAID 
therapy in regard to radiographic progression [64]. 
There is substantial circumstantial evidence that early effective treatment of 
inflammatory disease in axSpA could reduce radiographic progression - 
analogous  to  the  ‘window  of  opportunity’  in  rheumatoid  arthritis  [65]. This 
stems from the substantial longitudinal MRI studies of anti-TNF drug therapy. 
In addition two observational studies have suggested that anti-TNF reduces 
radiographic progression over the long term [66, 67]. Therefore combined 
NSAID and anti-TNF therapy may be effective at significantly slowing or 
halting radiographic progression in patients. However definitively 
demonstrating this is challenging, primarily because of the very slow baseline 
rate of radiographic progression. This is demonstrated by the difference 
observed in the 2 year celecoxib trial in the PRN dosing group (those that 
progressed the fastest), they progressed a mean of 1.5 modified Stoke 
Ankylosing Spondylitis Spine Score (mSASSS) units, although the standard 
deviation was 2.5 mSASSS units [68]. One mSASSS unit is erosion of one 
corner of a vertebrae, sclerosis or squaring of a vertebrae [69]. This 
demonstrates the low average progression rate but a high level of variance 
between individuals, thereby requiring large sample sizes over a long time. 
The effect of newer agents on radiographic progression is unknown but will be 
of substantial interest. Their effect will help determine whether it is just 
suppression of inflammation or a specific biological action that helps reduce 
radiographic progression. 
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Conclusion 
The advances in therapeutics have brought back to rheumatology clinics a 
huge cohort of patients who often felt there was little to be gained from visiting 
a rheumatologist. There are also a number of additional novel agents in the 
pipeline that may also join TNF inhibitors in the clinic in the near future. With 
huge recent gains made in both genetics research and in basic mechanisms 
of pathogenesis, coupled with improved classification criteria and diagnostic 
tools the future looks bright.  
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Table 1: Assessment of SpondyloArthritis International Society axial 
spondyloarthritis classification criteria (adapted from ref [8]) 
 
Patients need to have back pain or at least 3 months and have an age of 
onset of that back pain of less than 45 years. 
Imaging Arm HLA-B27 Arm 
Sacroiliitis on MRI‡ or plain 
radiograph* and one or more feature 
of SpA 
HLA-B27 plus two or more features of 
SpA† 
SpA features: Inflammatory back pain, arthritis, heel enthesitis, uveitis, 
dactylitis,  psoriasis,  Crohn’s  disease/ulcerative colitis, Good response to non-
steroidal anti-inflammatory agents, Family history of SpA, HLA-B27, elevated 
CRP 
‡ Lesions demonstrated on short tau inversion recovery (STIR) indicative of 
acute inflammation. *As per the modified New York criteria grading of at least 
unilateral grade 3 or bilateral grade 2 sacroiliitis. † Excluding HLA-B27 as an 
SpA feature  
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Table 2: Theories of how HLA-B27 could cause disease in axial spondyloarthritis 
 
Theory Explanation  
Arthritogenic peptide hypothesis HLA-B27 presents a peptide to CD8 T cells through its classical presentation function 
contributing to the induction of disease 
Endoplasmic reticulum stress hypothesis Properties of HLA-B27 results in protein misfolding in the endoplasmic reticulum and 
causes stress, subsequently inducing disease through IL-23 production and 
subsequent modulation of downstream pathways 
Cell surface homodimer hypothesis HLA-B27 forms homodimers on the cell surface that interact with innate immune cells 
to induce disease 
Immunodeficiency hypothesis HLA-B27 presents an altered type or number of peptides resulting in the immune 
system inadequately or inappropriately dealing with gut microbes 
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ORIGINAL ARTICLE
Disease-associated polymorphisms in ERAP1 do not alter
endoplasmic reticulum stress in patients with ankylosing
spondylitis
TJ Kenna1, MC Lau1, P Keith1, F Ciccia2, M-E Costello1, L Bradbury1, P-L Low1, N Agrawal1, G Triolo2, R Alessandro2, PC Robinson1,
GP Thomas1 and MA Brown1
The mechanism by which human leukocyte antigen B27 (HLA-B27) contributes to ankylosing spondylitis (AS) remains unclear.
Genetic studies demonstrate that association with and interaction between polymorphisms of endoplasmic reticulum
aminopeptidase 1 (ERAP1) and HLA-B27 influence the risk of AS. It has been hypothesised that ERAP1-mediated HLA-B27 misfolding
increases endoplasmic reticulum (ER) stress, driving an interleukin (IL) 23-dependent, pro-inflammatory immune response.
We tested the hypothesis that AS-risk ERAP1 variants increase ER-stress and concomitant pro-inflammatory cytokine production in
HLA-B27+ but not HLA-B27− AS patients or controls. Forty-nine AS cases and 22 healthy controls were grouped according to HLA-B27
status and AS-associated ERAP1 rs30187 genotypes: HLA-B27+ERAP1risk, HLA-B27+ERAP1protective, HLA-B27−ERAP1risk and HLA-
B27−ERAP1protective. Expression levels of ER-stress markers GRP78 (8 kDa glucose-regulated protein), CHOP (C/EBP-homologous protein)
and inflammatory cytokines were determined in peripheral blood mononuclear cell and ileal biopsies. We found no differences in
ER-stress gene expression between HLA-B27+ and HLA-B27− cases or healthy controls, or between cases or controls stratified by
carriage of ERAP1 risk or protective alleles in the presence or absence of HLA-B27. No differences were observed between
expression of IL17A or TNF (tumour necrosis factor) in HLA-B27+ERAP1risk, HLA-B27+ERAP1protective and HLA-B27−ERAP1protective cases.
These data demonstrate that aberrant ERAP1 activity and HLA-B27 carriage does not alter ER-stress levels in AS, suggesting that
ERAP1 and HLA-B27 may influence disease susceptibility through other mechanisms.
Genes and Immunity advance online publication, 6 November 2014; doi:10.1038/gene.2014.62
INTRODUCTION
Susceptibility to ankylosing spondylitis (AS), the prototypic
spondyloarthropathy, is largely genetically determined, with the
heritability of disease risk estimated at 490%.1 The endoplasmic
reticulum aminopeptidase 1 (ERAP1) gene is strongly associated
with AS; only the class I major histocompatibility complex allele,
HLA-B27 (human leukocyte antigen B27) shows stronger
association.2 ERAP1 (formerly known as ARTS-1) is an aminopepti-
dase with a ubiquitous tissue distribution, which is expressed in
the endoplasmic reticulum (ER). ERAP1 has two reported
functions. First, in vitro studies have suggested that ERAP1 may
function as a 'sheddase', cleaving cytokine receptors off the cell
surface, including interleukin-6 receptor subunit alpha (IL-6R),
interleukin-1 receptor type 2 (IL-1R2) and tumour necrosis factor
receptor (TNF-R), each of which are encoded by genes associated
with AS.3–6 However, we have demonstrated that spleen cells from
ERAP− /− mice did not show altered cleavage of IL-6R and TNF-R
in vitro.2 Moreover, in the context of AS, Haroon et al.7
demonstrated that ERAP1 polymorphisms do not alter serum
levels of inflammatory cytokines. Second, ERAP1 has been shown
to act as a ‘molecular ruler’, trimming peptides that have been
partially processed in the proteasome to the optimal length for
presentation on major histocompatibility complex class I
molecules.8 Polymorphisms in ERAP1 influence the quality and
quantity of major histocompatibility complex class I complexes
assembled and presented on the cell surface.9,10
Considering the imputed and genotyped data across ERAP1,
association with AS is most strongly localised to a block of single
nucleotide polymorphisms (SNPs) lying in a 4.6 kb region between
rs27529 (in exon 9) and rs469758 (in intron 12).2,11 In this region,
the only common (minor allele frequency 41%) coding
polymorphisms are rs30187 (Arg528Lys) and rs10050860
(Asp575Asn),12 and fine-mapping and haplotype evolutionary
studies suggest that rs30187 is directly disease associated, and
that a second haplotype, tagged by rs10050860, is also AS
associated.2 We previously reported an interaction between ERAP1
and the major HLA class I alleles associated with AS, with
association of ERAP1 polymorphisms with AS being restricted to
HLA-B27-positive cases.2 In ERAP1, the Arg528Lys substitution
encoded by the protective SNP rs30187 causes a significant
reduction in aminopeptidase activity towards a synthetic peptide
substrate when compared with the wild type, resulting in a two- to
threefold decrease in substrate affinity.2 This is consistent with the
structural data demonstrating that Lys528Arg disease-protective
variants prevent the closed conformation of the protein catalytic
site,2 thereby leading to loss of ERAP1 function, though the exact
1The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia
and 2Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università di Palermo, Palermo, Italy. Correspondence: Dr TJ Kenna or Professor
MA Brown, The University of Queensland Diamantina Institute, Level 7, Translational Research Institute, 37 Kent Street, Princess Alexandra Hospital, Woolloongabba, Brisbane,
Queensland 4102, Australia.
E-mail: t.kenna@uq.edu.au or matt.brown@uq.edu.au
Received 10 August 2014; revised 25 September 2014; accepted 29 September 2014
Genes and Immunity (2014), 1–8
© 2014 Macmillan Publishers Limited All rights reserved 1466-4879/14
www.nature.com/gene
mechanism of how this might contribute to AS pathogenesis
remains unclear.
Despite the association between HLA-B27 and AS being known
for almost 40 years, how HLA-B27 participates in AS pathogenesis
is still unresolved. Leading theories include the arthritogenic
peptide theory,13 and two theories involving non-canonical
properties of HLA-B27, the unfolded protein response (UPR) and
HLA-B27 homodimer formation.5 Compared with other HLA
molecules, HLA-B27 is slow to fold and associate with β2-
microglobulin.14 The UPR hypothesis postulates that the slow
rate of HLA-B27 folding triggers an intracellular signalling cascade
in the ER, which, in macrophages, stimulates production and
secretion of interleukin 23 (IL23). Evidence in support of the UPR
hypothesis is strongest in the HLA-B27-transgenic rat model, 15 but
has also been reported in the synovium of AS patients.16
ER stress, buffered by the activation of the UPR, is a homeostatic
signalling network that orchestrates the restoration of ER
function.17 UPR activation leads to upregulation of expression of
pro-inflammatory cytokines, such as TNF, IL17 and IL23, which are
also known to be pathogenic in AS. Studies in the HLA-B27-
transgenic rat model have implicated the association of HLA-B27
misfolding and ER-stress-dependent activation of UPR in spondy-
loarthritis. Bone marrow-derived macrophages sampled from
colon tissue from rats with inflammatory arthritis were demon-
strated to exhibit ER stress in the form of upregulated, UPR-
inducing levels of the transcription factor gene X-box-binding
protein 1 (XBP-1). Furthermore, the production of IL23 was
enhanced in colonic tissue.15 Unlike in human AS though, where
patients can have at most two copies of HLA-B27, in the HLA-B27-
transgenic rat model, multiple copies of the transgene are
required for arthritis to develop.18
To directly assess the role of ERAP1 in AS-attributed ER stress,
we examined the gene expression of ER-stress markers 78 kDa
glucose-regulated protein (GRP78) and C/EBP-homologous protein
(CHOP) using quantitative polymerase chain reaction (qPCR), and
correlated their levels with pro-inflammatory cytokine expression
levels in AS patients.
RESULTS AND DISCUSSION
The AS-risk associated rs30187 allele of ERAP1 does not lead to
altered levels of ER stress
Accumulation of unfolded proteins in the ER initiates stress
responses. The ER-resident chaperone GRP78 (GRP78/BiP) is
sequestered which then allows the activation of three main
effector molecules: activating transcription factor 6, serine/
threonine-protein kinase/endoribonuclease IRE1 and PRKR-like
ER kinase (PERK).19 One arm of this pathway involves the
activation of CHOP by PRKR-like ER kinase, ultimately resulting
in the upregulation of pro-inflammatory cytokines such as IL23.9
To assess whether AS-associated ERAP1 variants alter levels of ER
stress, we compared the relative expression of ER-stress genes
GRP78 and CHOP in peripheral blood mononuclear cells (PBMCs)
from patients carrying either the risk or protective allele of
rs30187. Gene expression was normalised to the expression
of the constitutive ribosomal gene RPL32. There were
no differences in the relative expression levels (ΔCT) of
GRP78 or CHOP between AS HLA-B27+rs30187risk (GRP78: ΔCT =
0.009 ± 0.001; CHOP: ΔCT = 0.024 ± 0.006; mean± s.e.m.), HLA-
B27+rs30187protective (GRP78: ΔCT = 0.007 ± 0.006; CHOP: ΔCT =
0.024 ± 0.002) and HLA-B27−rs30187protective individuals (GRP78:
ΔCT = 0.009 ± 0.001; CHOP: ΔCT = 0.022 ± 0.008; Figures 1a and b).
Excluding patients on TNF inhibitors and only studying those that
were anti-TNF naive did not alter the findings (data not shown).
Interferon gamma (IFN-γ) exposure is an important contributor
to ER stress in HLA-B27-expressing PBMC.20 To determine whether
ERAP1 variants alter HLA-B27 misfolding and ER stress, we
cultured PBMC from HLA-B27+ AS cases in the presence or
absence of IFN-γ using conditions described previously.15 After
24 h co-culture with IFN-γ all samples showed elevated expression
of GRP78 but not CHOP (Figure 1e). However, no differences were
seen in the ER-stress signature between HLA-B27+ cases carrying
either rs30187risk or rs30187protective alleles (Figures 1c and d).
ER stress is not different between HLA-B27+ and HLA-B27− AS
patients
To assess ER stress in AS patients independent of ERAP1 genotype,
we compared GRP78 and CHOP gene expression in HLA-B27+ and
HLA-B27− cases without stratification by ERAP1 genotype. GRP78
and CHOP levels are not significantly higher in AS HLA-B27+
patients, with either the rs30187 risk or protective allele of ERAP1,
than those who are not carriers of the allele (GRP78: P= 0.32;
CHOP: P= 1.0; Figures 1c and d). Therefore, differences in ER stress
are not observed in PBMC samples from AS cases carrying the
HLA-B27 allele compared with samples from HLA-B27-negative
cases (Figures 1e and f).
To test the possibility that the ER-stress signature observed
in AS patients has been saturated by ongoing inflammation,
we examined ER-stress gene expression in HLA-B27+ or
HLA-B27- healthy controls HLA-B27+rs30187risk (GRP78: ΔCT =
0.007 ± 0.001; CHOP: ΔCT = 0.023 ± 0.003; mean± s.e.m.), HLA-
B27+rs30187protective (GRP78: ΔCT = 0.010 ± 0.001; CHOP: ΔCT =
0.012 ± 0.003) and HLA-B27−rs30187protective individuals (GRP78:
ΔCT = 0.012 ± 0.007; CHOP: ΔCT = 0.024 ± 0.008). Similar levels of
GRP78 and CHOP gene expression were seen in controls (Figures
1g and h) as that was seen in AS patients (Figures 1a and b).
Pro-inflammatory cytokine gene expression is unaffected by
ERAP1 variants
Because inflammatory cytokines TNF, IL23 and IL17 are associated
with AS pathogenesis, we examined whether carriers of the
rs30187-risk allele would display elevated levels of TNF and IL17.
Both TNF and IL17 gene expression levels in PBMC were not
different between AS patients who were HLA-B27+rs30187risk (TNF:
ΔCT = 0.002 ± 0.001; IL17A: ΔCT = 1.4x10
− 6 ± 8.3× 10− 7; IL23: ΔCT =
0.014 ± 0.004), HLA-B27+rs30187protective (TNF: ΔCT = 0.002 ± 0.001;
IL17A: ΔCT = 7.91x10
− 7 ± 1.52x10− 7; IL23: ΔCT = 0.025 ± 0.009) and
HLA-B27−rs30187protective (TNF: ΔCT = 0.002 ± 0.001; IL17A: ΔCT =
2.5x10− 6 ± 2.0x10− 6; IL23: ΔCT = 0.016 ± 0.006; Figure 2).
Serum levels of pro-inflammatory cytokines were independent of
ERAP1 genotype
To confirm that the lack of association of ERAP1 genotype
with inflammatory cytokine gene expression corresponded
with a similar lack of association at the protein level, we
measured serum concentrations of disease-relevant cytokines in
HLA-B27+ patients with ERAP1-risk and protective alleles. Serum
was analysed only from anti-TNF therapy naive patients, not
receiving corticosteroids, at their first presentation at our AS
specialist clinic. In total, serum cytokines were measured in 11
HLA-B27+rs30187risk and 20 HLA-B27+rs30187protective patients.
ERAP1 genotype did not alter serum expression of either TNF-α
(HLA-B27+rs30187risk: 12.46±17.03 pgml−1, HLA-B27+rs30187protective:
19.34±29.61 pgml−1) or IL17 (HLA-B27+rs30187risk: 2.45±7.22 pg-
ml−1, HLA-B27+rs30187protective: 4.23 ± 7.22 pgml− 1; P4 0.05 in
all cases; Figure 3).
Gene expression of markers of ER stress did not correlate with
disease severity
Having observed no differences in ER-stress and cytokine gene
expression between subjects with risk or protective ERAP1 alleles,
we investigated the correlation between measures of ER stress
and disease activity in AS patients. For HLA-B27+ individuals with
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Figure 1. GRP78 and CHOP gene expression is not altered by HLA-B27 status or ERAP1 genotype. qRT–PCR was used to determine the level of
GRP78 (a and c) and CHOP (b and d) gene expression from active AS patients (n= 49). AS patients carrying the rs30187-risk allele of ERAP1 and
those with the protective allele of ERAP1 rs30187 showed no significant difference in GRP78 (a) or CHOP (b) gene expression. ERAP1 genotype
also did not alter ER-stress response to IFN-γ stimulation as measured by either GRP78 (c) or CHOP (d) gene expression. Furthermore, there was
no difference in either GRP78 (e) or CHOP (f) gene expression between HLA-B27+ and HLA-B27- patients irrespective of ERAP1 genotype
(P40.5 in all comparisons). Similar levels of ER-stress gene expression were seen in patient and control samples (g and h).
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AS, no correlation was observed between GRP78 expression and
erythrocyte sedimentation rate (R2 = 0.05, P= 0.14), C-reactive
protein (R2 = 0.0005, P= 0.91) or Bath Ankylosing Spondylitis
Disease Activity Index scores (R2 = 0.005, P= 0.66; Figures 4a–c).
Similarly, no correlation was observed between CHOP expression
and erythrocyte sedimentation rate (R2 = 0.056, P= 0.14), C-reac-
tive protein (R2 = 0.0005, P= 0.90) or Bath Ankylosing Spondylitis
Disease scores (R2 = 0.00005, P= 0.98). Thus, disease activity
appears to operate independently of ER stress. Because ER stress
activates the UPR, which is implicated in the production of
pro-inflammatory cytokines, correlations between expression of
ER-stress markers and that of TNF and IL17 were assessed. GRP78
and CHOP expression showed no linear relationship with
expression of either TNF (GRP78: R2 = 0.043, P= 0.19; CHOP:
R2 = 0.084, P= 0.06) or IL17 (GRP78: R2 = 0.016, P= 0.44; CHOP:
R2 = 0.004, P= 0.88; Figure 4). This indicates that ER stress is
unlikely to enhance the production of pro-inflammatory cytokines
in HLA-B27+ AS patient PBMC.
ER-stress signature in the gut is not altered by ERAP1 genotype
21 HLA-B27+ patients used for analysis of ER stress in the gut were
genotyped using TaqMan probes (Applied Biosystems, Mulgrave,
VIC, Australia) for a single-coding-region SNP rs30187 in the ERAP1
gene (Supplementary Material); 5 cases were homozygous for
the protective ‘G’ allele, 11 cases were heterozygous and 5 cases
were homozygous for the risk ‘A’ allele. ER-stress measures
were investigated in terminal ileal biopsies from these patients.
Gene expression of GRP78 was not altered in the gut by ERAP1
genotype (Figure 5a). Similarly, XBP-1 splicing, as determined by
examining the ratio of spliced:unspliced XBP-1, was not affected
by ERAP1 genotype in the gut of AS patients (Figure 5b). The
protein levels of GRP78 and XBP-1 were also evaluated by
immunohistochemistry. No significant differential expression of
GRP78 or XBP-1 was observed in AS with risk or protective alleles
of ERAP1 (Figures 5c and d).
The forces driving the inflammation underlying immune-
mediated diseases such as AS remain elusive. Compelling genetic
data point to a strong role for antigen presentation in AS but how
this altered or aberrant antigen presentation affects disease is still
unclear.21 It has been recognised for several years that, relative to
other HLA molecules, HLA-B27 is slow to fold and assemble into a
functional HLA:peptide complex.14 Studies in the HLA-B27-
transgenic rat model of spondyloarthritis have indicated that
HLA-B27 misfolding invokes a UPR15 that can drive IL23
production by macrophages.9 The HLA-B27-transgenic rat model
also suggests a role for HLA-B27 independent of antigen
presentation in this model, since depletion of CD8 T cells had
no effect on disease development in this model.22 Polymorphisms
in those ERAP1 alleles associated with AS encode protein
differences that lead to altered rates of ERAP1 enzyme activity.2
Furthermore, we have demonstrated gene–gene interaction
between ERAP1 and HLA-B27 in AS.2 Altered rates of ERAP1
activity may therefore affect the rate at which HLA-B27:peptide
complexes fold in the ER which may, in turn, increase the levels of
UPR-derived inflammatory cytokines that are secreted by macro-
phages. To date, this has not been examined in AS patients. In this
study, we investigated the effects of the risk allele rs30187 of
ERAP1 on ER stress in AS. Our human data show, for the first time,
that ER stress is not different in either PBMC or terminal ileal
biopsies from AS cases either positive or negative for HLA-B27, or
carrying AS risk or protective ERAP1 genotypes. Nor did we
observe ERAP1-modified responses to in vitro challenge with UPR-
inducing IFN-γ.
Figure 2. Inflammatory cytokine gene expression is not altered by ERAP1 genotype. Expression of TNF (a), IL17 (b) and IL23 (c) were
determined by qRT–PCR. The relative expression of these genes did not differ between AS patients carrying the ERAP1 rs30187 risk or
protective allele in either HLA-B27+ or HLA-B27− individuals (P40.5 in all comparisons).
Figure 3. Serum levels of IL17 and TNF. Serum was collected from 11 HLA-B27+ERAP1Risk and 20 HLA-B27+Protective AS patients not receiving
biologic or corticosteroid therapy. IL17 and TNF protein levels were determined in these samples by ELISA. No differences were seen in either
IL17 (a) or TNF (b) between patients with risk or protective ERAP1 genotypes (P40.05 for all comparisons).
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In the HLA-B27 transgenic rat model, bone marrow-derived
macrophages displaying increased levels of ER stress also secrete
elevated levels of IL23, providing a plausible mechanism for
induction of IL17-mediated autoinflammatory events in this
model.15 However, in AS patients we show there is no difference
in the gene expression of ER-stress markers or pro-inflammatory
cytokines between individuals carrying the HLA-B27 allele
irrespective of rs30187 status. Previous studies examining ER
stress and the UPR in HLA-B27+ or HLA-B27− AS patients
compared with controls similarly found no difference in ER stress
between these groups23,24 but this study failed to investigate the
effects of altered ERAP1 expression on ER-stress signatures.
A lack of support for ER-stress modulation in AS by either HLA-
B27 or ERAP1 is suggested in this study. That said, these findings
are underpowered for HLA-B27− individuals due to the small
number of HLA-B27- samples available to us for this study. In
addition, whether PBMC or terminal ileal biopsies isolated from AS
patients are the most appropriate target cells for examining ER
stress remains uncertain, but these tissues are the only readily
accessible disease-relevant tissues in AS patients. Lack of
involvement of the UPR in blood samples from AS has been
suggested in other studies,23 but our examination of disease-
relevant gut biopsies indicates that even in sites of high cellular
turnover and likely inflammation in AS patients ER-stress
responses are still not upregulated.
Our data show that ERAP1 genotype does not alter expression
of ER-stress genes in human PBMCs or terminal ileal biopsies of
gut samples. Furthermore, ER-stress gene expression levels are not
different between HLA-B27+ and HLA-B27− patients. Together
these data suggest that the mechanism of action of HLA-B27 and
ERAP1 in AS patients is independent of ER-stress induction. This
conclusion is further supported by the lack of correlation seen
between clinical measures of disease (erythrocyte sedimentation
rate, C-reactive protein and Bath Ankylosing Spondylitis
Disease Activity Index) and expression of ER-stress genes. Instead,
HLA-B27 may be pathogenic through formation of cell-surface
homodimers, which are recognised by auto-reactive T cells,
including KIR3DL2+ CD4 T cells.25 Altered ERAP1 function may
result in cell-surface presentation of aberrant HLA-B27:self-peptide
complexes, or ERAP1-risk alleles in combination with HLA-B27 may
result in reduced mucosal immunity and increased bacterial
invasion of the gut mucosa, driving IL23 production.26 These
theories, along with recent suggestions that autophagy maybe be
critical to development of inflammation in AS,27 warrant further
investigation.
SUBJECTS AND METHODS
Patient groups
Forty-nine patients diagnosed with AS were included in this study and
grouped by their genotype; HLA-B27+rs30187risk (n= 14), HLA-B27+
rs30187protective (n= 28), HLA-B27−rs30187risk (n= 1) and HLA-B27−
rs30187protective (n= 6). AS was defined according to the modified New
York criteria.22 Patient demographics, erythrocyte sedimentation rate,
C-reactive protein and Bath Ankylosing Spondylitis Disease Activity Index
scores are described in detail in Table 1. Thirteen of the 49 patients have
taken TNF inhibitors at the time of blood collection; all other patients had
not received TNF inhibitor therapy. No participant received corticosteroids.
Peripheral venous blood was collected from AS patients attending the
Princess Alexandra Hospital Ankylosing Spondylitis Clinic. Ethical approval
was granted by the Princess Alexandra Hospital and University of
Queensland Ethics Committees. Written informed consent from all
participants was received prior to inclusion in the study.
Terminal ileal biopsies were consecutively sampled from 21 AS patients
without clinical symptoms of bowel inflammation at the University of
Palermo (Italy) Ankylosing Spondylitis Clinic. Ten out of 21 AS patients have
taken non-steroidal anti-inflammatory drugs at the time of ileocolono-
scopy, none received DMARDs, corticosteroids or biological agents. As a
control group 10 normal subjects (7 male and 3 female patients, age
ranging from 35 to 68 years) who have undergone ileocolonscopy for
routine evaluation were also evaluated. Paired specimens for histological
analysis and qPCR were obtained. All patients and controls provided a
signed agreement for this study, and the protocol was approved by the
local Ethics Committee of the University of Palermo.
Figure 4. No correlation between ER-stress gene expression and inflammation in HLA-B27+ AS patients. Linear regression analyses were
performed to compare clinical measures of disease activity with levels of GRP78 (a–c) and CHOP (d–f) gene expression. No relationship was
found between ER-stress levels and clinical measures of disease activity.
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Sample preparation
PBMCs were extracted from heparinised blood using a standard density
gradient centrifugation over Ficoll-Paque Plus (GE Healthcare, Uppsala,
Sweden). RNA was extracted from isolated PBMC using TRIzol (Life
Technologies, Rockville, MA, USA) and cDNA was reverse transcribed
(Bioline, Alexandria, NSW, Australia) for qPCR analysis. Serum was collected
in serum-separating tubes and centrifuged at 3000 g for 10 min. Ileal
biopsies soon after removal were stored in RNAlater solution (Applied
Biosystems, Foster City, CA, USA). Each sample was lysed in a tissue
homogeniser and RNA was extracted using the commercially available
illustra RNAspin mini isolation kit (GE Healthcare, Little Chalfont, UK),
according to manufacturer’s instructions. Total RNA was reverse tran-
scribed to cDNA using the high capacity cDNA reverse transcription kit
(Applied Biosystems). Samples were stored at –20 °C until use.
Quantitative polymerase chain reaction
Expression of GRP78, CHOP, IL17A and TNF were assayed by SYBR Green
(Invitrogen, Carlsbad, CA, USA) qPCR assays using the primers described
in Supplementary Material. Gene expression was normalised against
expression of 60S ribosomal protein L32 (RPL32). IL23 gene expression
was assayed using a TaqMan (Applied Biosystems) pre-designed assay
and normalised against expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).
IFN-γ stimulation
PBMC from six HLA-B27+rs30187risk and six HLA-B27+rs30187protective
individuals were cultured in vitro in the presence or absence of 100 Uml− 1
recombinant human IFN-γ (R&D Systems, Minneapolis, MN, USA) for 24 h,
as described previously,15 prior to RNA extraction.
Enzyme-linked immunosorbent assay
TNF-α and IL17 enzyme-linked immunosorbent assay (ELISA) were
performed on serum samples using ELISA Max Deluxe ELISA kits
(BioLegend, San Diego, CA, USA). Assays were performed according to
the manufacturer’s instructions using neat serum for IL17 and 1:5 dilution
of serum in PBS for TNF-α. ELISA plates were read on FluoStar Optima
microplate fluorometer (BMG Labtech, Mornington, VIC, Australia).
TaqMan SNP rs30187 genotyping
SNP rs30187 was genotyped on a ViiA 7 Fast Real-Time PCR System
Instrument by using allele-specific TaqMan MGB probes (Applied
Biosystems) labelled with fluorescent dyes FAM and VIC (Applied
Biosystems, Catalogue no. 4351379), according to the manufacturer's
protocols. Allelic discrimination was made with the ViiA 7 Software v1.2.2
(Applied Biosystems). All the cases were run as triplicates to check for
genotyping errors. We studied one SNP in the ERAP1 gene, rs30187
(Lys528Arg).
Figure 5. ER-stress signature is not altered by ERAP1 in the gut of AS patients. Terminal ileal biopsies were taken from AS patients with active
disease. ERAP1 genotype (rs30187) was determined using TaqMan genotyping probes. All patients were HLA-B27+. Expression of GRP78
(a) and the ratio of spliced:unspliced XBP-1 (b) were determined by qRT–PCR. Neither the relative expression of GRP78 nor the ratio of spliced:
unspliced XBP-1 was altered by carriage of risk or protective alleles of ERAP1 rs30187. (c) Representative immunohistochemical staining for
GRP78 and XBP-1 in ileal biopsies from healthy (original magnification x250). The number of GRP78+ (d) and XBP-1+ (e) cells per section was
also unaltered by ERAP1 genotype (P40.05 in all comparisons).
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Table 1. Patient demographic and clinical details
HLA-B27 ERAP1 rs30187 Gender Age ESR CRP BASDAI Anti-TNF DMARDS
+ Risk M 35 10 o1.0 ND N NSAIDs
+ Risk M 36 39 30 5.4 N NSAIDs
+ Risk F 62 8 21 6.4 N NSAIDs
+ Risk M 41 22 14 6.1 N NSAIDs
+ Risk M 62 54 19 7.3 N —
+ Risk M 46 52 65 5.3 N NSAIDs
+ Risk M 39 28 7.4 8.6 N NSAIDs
+ Risk M 35 21 14 5.9 N NSAIDs
+ Risk M 35 7 1.2 3.8 N NSAIDs
+ Risk M 48 10 20 8.6 N Sulfasalazine, NSAIDs
+ Risk F 44 0.1 7 0.1 Y Methotrexate
+ Risk F 27 4 1.6 0.7 Y —
+ Risk M 31 2 1 5 N NSAIDs
+ Risk M 41 2 1.9 1.1 N NSAIDs
+ Risk M 33 2 1.8 1.5 Y NSAIDS
+ Protective F 59 38 19 1.7 Y —
+ Protective M 53 ND ND 1.2 N NSAIDs
+ Protective M 44 58 44 3.1 Y NSAIDs
+ Protective M 47 8 20 3.4 Y —
+ Protective M 38 3 o1.0 0.2 N NSAIDs
+ Protective M 37 4 13 2.4 Y —
+ Protective M 41 16 12 4.4 N —
+ Protective M 28 4 3 2.3 Y —
+ Protective M 59 6 8.5 2.4 Y NSAIDs
+ Protective M 47 6 o1.0 0.8 Y —
+ Protective M 37 5 4.2 6.8 N NSAIDs
+ Protective M 60 33 8 4.7 N NSAIDs
+ Protective M 31 25 11 8.6 N NSAIDs
+ Protective F 24 45 8.6 8.2 N NSAIDs
+ Protective M 45 5 o1.0 0.8 Y —
+ Protective F 38 14 3.5 4.8 N —
+ Protective M 35 13 2.9 3.2 N NSAIDs
+ Protective M 21 13 3.6 1 N —
+ Protective M 60 9 1.4 0.7 Y Sulfasalazine
+ Protective M 38 19 24 1.1 N —
+ Protective M 29 5 2.2 ND N NSAIDs
+ Protective M 26 19 21 7.8 N NSAIDs
+ Protective F 51 13 38 9.4 N NSAIDs
+ Protective M 26 19 21 7.8 N NSAIDs
+ Protective M 55 5 2.6 3.4 N NSAIDs
+ Protective M 67 52 34 5.6 N Methotrexate, sulfasalazine
+ Protective M 30 8 4.6 1.6 N Sulfasalazine, NSAIDs
+ Protective M 33 23 12 9.3 N Sulfasalazine, NSAIDs
− Risk M 61 16 29 8.8 N Sulfasalazine, NSAIDs
− Protective M 45 27 16 7.2 N NSAIDs
− Protective M 55 26 11 6.2 N Sulfasalazine, NSAIDs
− Protective M 34 o2 o1 0.9 Y —
− Protective F 52 11 1 2.9 N NSAIDs
− Protective M 37 ND ND 5.2 N Unknown
− Protective F 24 20 14 5.5 N NSAIDs
− Protective M 65 57 30 1.4 N NSAIDs
+ Protective M 35 33 12 6.8 N NSAIDs
+ Protective F 28 28 7 7 N —
+ Protective M 37 18 3 6.2 N —
+ Protective M 43 44 18 7.8 N NSAIDs
+ Protective M 40 16 1.8 5.6 N —
+ Protective M 35 8 2 4.2 N —
+ Risk M 46 18 3 4.5 N NSAIDs
+ Protective F 24 9 0.8 4.4 N NSAIDs
+ Protective F 33 26 1.2 5 N NSAIDs
+ Risk M 37 33 3 6 N —
+ Protective M 38 21 1.6 6.6 N —
+ Risk M 54 18 0.9 7 N NSAIDs
+ Protective M 47 7 0.5 6 N NSAIDs
+ protective M 22 34 12 6.7 N NSAIDs
+ Protective F 43 27 5 7 N —
+ Risk M 45 56 33 8 N —
+ Protective M 44 33 11 5.6 N —
+ Risk M 52 21 4 4.5 N —
+ Protective M 48 22 2 5 N NSAIDs
+ Protective M 33 14 0.5 6 N NSAIDs
+ Protective M 47 9 0.9 7.7 N —
Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity Index scores; CRP, C-reactive protein; DMARDs, disease-modifying anti-rheumatic drugs;
ERAP1, endoplasmic reticulum aminopeptidase 1; ESR, erythrocyte sedimentation rate; F, female; HLA-B27, human leukocyte antigen B27; M, male; N, not
receiving anti-TNF; ND, not determined; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumour necrosis factor; Y, receiving anti-TNF.
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Histology and immunohistochemistry
Specimens from patients with AS were divided into three subgroups as
previously described:28 those with normal gut histology, those with acute
inflammation and those with chronic inflammation. Briefly, acute
inflammation was defined by the presence of neutrophils and/or
eosinophils in the crypt and villus epithelium with preservation of normal
architecture. Chronic inflammation was defined by alterations of the
mucosal architecture, with villous blunting and fusion in the ileal mucosa,
an increased mononuclear cell infiltrate and formation of basal lymphoid
aggregates in the lamina propria. Immunohistochemistry for XBP-1 and
HSPA5 was performed on 5-μm-thick paraffin-embedded sections
obtained from intestinal biopsy specimens from patients and controls,
and lymph node (used as positive controls) as previously described.27 The
primary antibodies, rabbit anti-human GRP78 (1:100 dilution; LSBio, Seattle,
WA, USA) and rabbit anti-human XBP-1 (1:100 dilution; Novus Biological,
Littleton, CO, USA) were added and incubated for 1 h at room temperature.
Ileal and lymph nodal sections incubated with an isotype-matched control
antibody were used as negative control. The number of GRP78 and XBP-1-
expressing cells was determined by counting the immunoreactive cells on
photomicrographs obtained from three random high-power microscopic
fields (original magnification x400) under a Leica DM2000 optical
microscope using a Leica DFC320 digital camera (Leica Microsystems,
North Ryde, NSW, Australia). Results were reported as the median (range).
Statistical analysis
Quantitation data from the qPCR were generated by the Rotor-Gene 1.7.75
software (Qiagen, Doncaster, VIC, Australia). All data displayed in graphs
represent the mean± s.e.m. For comparisons between multiple groups
differences were compared using the Kruskal–Wallis one-way analysis of
variance test with Dunn’s multiple comparison post-hoc test. For
comparison of two groups Mann–Whitney U-test was used to determine
the statistical significance. Correlation between ER-stress gene expression
and clinical measures of disease activity were analysed using linear
regression. All statistical analyses were performed in GraphPad Prism 5
software (GraphPad, San Diego, CA, USA). Statistical significance was
accepted at a significance level of Po0.05.
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Objective. Ankylosing spondylitis (AS) is a common highly heritable immune mediated 
arthropathy that occurs in genetically susceptible individuals exposed to an unknown but 
likely ubiquitous environmental trigger. There is a close relationship between the gut and 
SpA, exemplified in reactive arthritis patients where a typically self-limiting arthropathy 
follows either gastrointestinal or urogenital infection. Microbial involvement has been 
suggested in AS, however, no definitive link has been established. We sought to 
determine if the AS gut carries a distinct microbial signature, in comparison to healthy 
controls (HC).  
 
Methods. Microbial profiles from terminal ileal (TI) biopsies from subjects with recent-
onset, TNF-antagonist naïve AS and HC, were generated using culture-independent 16S 
rRNA gene sequencing and analysis techniques.  
 
Results. Our results show the TI microbial communities of patients with AS differ 
significantly (P<0.001) from HC, driven by higher abundance of five families of bacteria 
Lachnospiraceae (P=0.001), Veillonellaceae (P=0.01), Prevotellaceae (P=0.004), 
Porphyromonadaceae (P=0.001), and Bacteroidaceae (P=0.001); two of which, 
Lachnospiracecae, and Prevotellaceace, have been strongly associated with colitis and 
CD.  
 
Conclusions. We show evidence for a discrete microbial signature in the TI of cases with 
AS compared to HC. The microbial composition was found to correlate with disease 
status and greater differences were observed between than within disease groups. These 
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results are consistent with the hypothesis that genes associated with AS act at least in part 
through effects on the gut microbiome.  
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Intestinal microbiome dysbiosis and microbial infections have been implicated in a 
number of immune mediated diseases, including multiple sclerosis, inflammatory bowel 
disease (IBD), and type 1 diabetes. Bacterial infections in the gut and urogenital tract are 
known to trigger episodes of reactive arthritis, a form of spondyloarthropathy (SpA) 
belonging to a group of related inflammatory arthropathies of which ankylosing 
spondylitis (AS) is the prototypic disease.  There is a close relationship between the gut 
and SpA, exemplified in reactive arthritis patients, where a typically self-limiting 
arthropathy follows either gastrointestinal infection with Campylobacter, Salmonella, 
Shigella or Yersinia, or urogenital infection with Chlamydia.   Microbial involvement has 
been suggested in AS, however, no definitive link has been established (1).  
 
Up to 70% of AS patients have subclinical gut inflammation with 5-10% of these patients 
with more severe intestinal inflammation going on to develop clinically defined IBD 
resembling Crohn’s disease (CD) (2). The high heritability of AS, the global disease 
distribution and the absence of outbreaks of the disease suggests that AS is triggered by a 
common environmental agent in genetically susceptible individuals (3).  Multiple genes 
associated with AS also play a role in gut immunity such as genes involved in the IL-23 
pathway (4), which are important regulators of intestinal ‘health’. There is a marked 
over-representation of genes associated with CD that are also associated with AS (5); this 
suggest the two diseases may have similar aetiopathogenic mechanisms, possibly 
involving gut dysbiosis.  
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Several studies have shown that AS patients and their first-degree relatives have 
increased intestinal permeability relative to unrelated healthy controls, again consistent 
with a role for the gut microbiome in the disease (6). To date, no comprehensive 
characterization of intestinal microbiota in AS patients has been performed.  Here we 
performed culture-independent microbial community profiling of terminal ileal (TI) 
biopsies to characterize and investigate differences in the gut microbiome between AS 
patients and HC. 
MATERIALS AND METHODS 
Terminal ileal biopsies were collected at colonoscopy from nine consecutively enrolled 
TNF-inhibitor naïve, recent onset (duration from symptom onset ≤48 months) AS cases 
(defined according to the modified New York classification criteria for AS) and nine 
healthy controls (Table 1, Supplementary Table 1).  All patients gave written informed 
consent and the study protocol was approved by the relevant Universities of Palermo and 
Queensland research ethics committees. One AS patient was on NSAIDs at the time of biopsy. AS03, AS04 and AS10 had reported occasional although interrupted use of NSAIDs due to GI upset. Other AS patients did not report use of NSAIDs but were using either paracetamol and/or tramadol.  
 
The TI microbial and mock communities were profiled by high-throughput barcoded 
amplicon sequencing of the 16S rRNA gene 2x250bp on an Illumina MiSeq using dual 
indexed V4 region primers 517F GCCAGCAGCCGCGGTAA and 803R 
CTACCRGGGTATCTAATCC. In addition to exploring community-level differences 
between disease states, we evaluated technical and biological replication. Biological 
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replication was examined by halving biopsies, and performing all subsequent studies in 
parallel to assess the reproducibility of findings from biopsy forward.  Technical replication was performed by analyzing forward and reverse sequencing reads separately and then comparing them. The resulting sequence libraries were analyzed 
using the QIIME pipeline (7).  Alpha diversity metrics, which look at the diversity within 
a sample, were generated using the QIIME workflow. Hierarchical clustering was 
employed using Unweighted Pair Group Method with Arithmetic mean (UPGMA) both 
weighted and unweighted unifrac distance, to detect significant differences within 
microbial communities between AS and HC. The Weighted Unifrac distance metric 
detects changes in how many organisms are present in a community, taking into account 
the relative abundance of microbes present. The Unweighted Unifrac distance metric 
describes community membership. UniFrac enabled in QIIME was used to generate 
sample distance metrics as well as Principal Coordinate Analysis (PCoA). Core 
microbiome analysis, as well as supervised learning, was performed to further 
characterize the intestinal microbial signature using the workflow pipelines in QIIME(7). 
Function of bacteria and communities were predicted using PICRUSt (8).  
 
To determine differences in microbial load, the total microbial biomass in biopsy samples 
was quantified using real-time qPCR of the 16S rRNA gene as described in Wilner et al., 
2013 (9). 
 
PERMANOVA analysis was conducted at the genus level using the R package vegan to 
test the relationship between the whole microbial community and disease. Indicator 
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species analysis was performed using the labdsv R package. Co-occurrence network 
analysis was conducted using the Spaa package in R.  
 
RESULTS 
The microbial communities in the TI of AS cases were significantly different (Figure 1A) 
and more diverse (Figure 1C) than those communities associated with HC (P<0.001; 
PERMANOVA).  PCoA showed that AS samples, including biological replicates, group 
separately to HC, indicating that disease is the primary factor influencing community 
differences (Figure 1B; Supplementary Figure 1).  To further demonstrate the distinct 
grouping of AS from HC, supervised learning was conducted to test the predictive 
capacity of the microbiome differences, with all nine AS samples predicted as AS (Figure 
1B).  PERMANOVA analysis further confirmed the presence of a significant relationship 
between disease status and microbial community composition (P<0.001). This was not 
due to heterogeneity in biopsy samples as biological replicates showed no significant 
difference between each other (Figure 1D). Biomass q-PCR showed no significant 
difference on average in 16S rRNA copy number between AS and HC, indicating that the 
observed differences were not due to overgrowth or dominance of bacteria driving 
community differences (Supplementary Figure 2). Average Unifrac distances 
demonstrated that differences between both biological and technical replicates were 
significantly less than differences between individuals and disease states (P<0.001; Mann 
Whitney) (Figure 1D).  
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Community profiling showed 51 genera present across all biopsies, with major 
differences observed at the phylum level between AS and HC (Figure 1A). Indicator 
species analysis was performed to determine if alterations in specific species were driving 
the differences observed between communities in cases with AS and HC. Analysis 
showed that, compared to and HC, the microbial communities in AS cases were 
characterized by higher abundances of Lachnospiraceae including Coprococcus spp. and 
Roseburia spp. (P=0.001), Veillonellaceae including Dialster spp. (P=0.01), 
Prevotellaceae (P=0.004), Porphyromonadaceae including Parabacteriodes spp. 
(P=0.001), and Bacteroidaceae (P=0.001). Decreases were noted in Ruminococcaceae 
and Rikenellaceae (Figure 2A).  Further drilling down into the AS microbiome signature, 
co-occurrence analysis, which looks at the correlation between microbes, showed that 
bacterial interactions further shape the AS microbial community signature with positive 
correlations observed between the indicator species Lachnospiraceae and 
Ruminococcaceae, and negative correlations observed between Veilonella and Prevotella  
(Figure 2B).  Microbial functional prediction using PICRUSt indicated 31 significant 
pathways with differential representation in AS compared to HC (Bonferroni corrected 
P<0.02) (Supplementary Table 2). These included a decrease in Bacterial invasion of 
epithelial cells (P=4.33x10-5), an increase in antimicrobial production in the Butirosin 
and neomycin biosynthesis pathway (P=0.002), which is consistent with an increase in 
bacteria from Bacteriodaceae family, and an increase in the Secondary bile acid 
biosynthesis pathway (P=0.004) consistent with an increase in Clostridia and 
Ruminococcaceae species.  
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We were interested in further interrogating the AS microbiome signature, which is the 
overall combination of microbes which distinguishes AS from HC, by investigating if 
there was an assemblage or ‘core’ microbes present in all AS and HC samples at varying 
levels, and to probe their functional capacity. Exploring the core microbiome is 
imperative to better understand the stable and consistent components across complex 
microbial communities, given the distinct AS microbial signature. The Core 100 
(microbes present in all samples) included Clostridia, Actinomycetaceae, Bacteroidaceae, 
Lachnospiraceae, Porphyromonadaceae, Rikenellaceae, Ruminococcaceae and 
Veillonellaceae families of bacteria. These families of bacteria are also AS indicator 
species suggesting that the core microbiome is driving the AS microbial signature (Figure 
2A).  
 
The Core 100 species belonged to 22 significant pathways (Bonferroni corrected P < 
0.02) (Supplementary Table 3) that again included Bacterial invasion of epithelial cells 
(P = 0.004), antimicrobial production in the Butirosin and neomycin biosynthesis 
pathway (P=0.007) and the Secondary bile acid biosynthesis pathway (P = 0.013). 
Members of Bacteriodies, Clostridium and Ruminococcus are known to be involved in 
cholesterol metabolism and secondary bile synthesis; disordered bile acid synthesis due 
to intestinal dysbiosis has previously been implicated in inflammatory bowel disease 
pathogenesis (10).  
 
As the threshold for core membership was reduced to 90, 75 and 50% of the time, the 
families of bacteria present remained the same however the number of genus and species 
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within these families increased, especially in Clostridia, Lachnospriaceae and 
Ruminococcus. This demonstrates the structure of the core microbiome is robust and that 
decreasing the threshold only expands the number of genera and species of bacteria 
within these families. However, as the core threshold was decreased the number of 
significant pathways also decreased suggesting that as the threshold is relaxed, the 
expansion of genera and OTUs dilutes pathway signals.  
 
Indicator species analysis also determined that healthy controls had an increased 
abundance of Streptococcus and Actinomyces when compared to AS.   No difference was 
noted between AS cases and controls in either bacteria known to be associated with 
reactive arthritis, or Klebsiella species, which have been proposed to play a role in 
triggering AS (11). 
 
 
DISCUSSION 
Here we present the first characterization and identification of intestinal dysbiosis is the 
AS microbiome using 16S rRNA community profiling of TI biopsies.  We show evidence 
for a discrete microbial signature in the TI of cases with AS, compared to HC. The 
microbial profile differences are not due to differences in overall bacterial quantity 
between cases with different diseases, but are qualitative. PCoA was able to show the 
distinct grouping of AS cases from HC; larger studies will be required to define the 
individual bacterial species involved. Statistically the relationship between disease status 
and microbial community composition was confirmed indicating that the differences 
Page 11 of 25
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
12  
between the microbial community compositions were not due to heterogeneity in the 
biopsy or lack of technical reproducibility, but that the driving force is disease state.  
 
Of the five families of microbes with increased abundance in the AS microbiome, 
Lachnospiracecae, Ruminococcaceae and Prevotellaceace are strongly associated with 
colitis and CD with Prevotellaceace especially known to elicit a strong inflammatory 
response in the gut (12). Further investigations showed that correlations between these 
families of bacteria further shape the AS microbial signature, and that these microbes are 
present in all AS samples studied suggesting that they are not only driving the microbial 
signature, but they are at the core of the AS microbial signature. Increases in 
Prevotellaceae and decreases in Rikenellaceae have also recently been reported in the intestinal microbiome in the HLA-B27 transgenic rat model of spondyloarthritis, suggesting that underlying host genetics may play a role in sculpting the gut microbiome in this animal model (13). 
 
There is an increase in the diversity of the AS community without an overall change in 
microbial load, showing there is not an overgrowth or dominance of a particular microbe 
driving the signature. However, murine experiments demonstrate that both the overall 
composition of the intestinal microbiome and the presences and/or absence of specific 
microbes can have a substantial impact on host response, regulation of inflammation and 
development of intestinal cells. In the K/BxN mouse model of arthritis it was shown that 
the introduction of a single gut-residing species, Segmented Filamentous Bacteria, into 
GF animals was sufficient to reinstate the Th17 cells, leading to the production of 
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autoantibodies and arthritis. If IL-17 was neutralized in specific-pathogen-free K/BxN 
mice, arthritis development was prevented. Thus, a single commensal microbe, via its 
ability to promote a specific T helper cell subset, can drive immune mediated disease 
(14).  
 
Further studies are needed into whether the changes in intestinal microbial composition 
are due to host genetics, and how this affects the overall function of the gut microbiome 
in AS cases, including how the microbiome then goes on to shape the immune response 
and influence inflammation.  In particular, given the strong association of HLA-B27 with 
AS, the hypothesis has been raised that HLA-B27 induces AS by effects on the gut 
microbiome, in turn driving spondyloarthritis-inducing immunological processes such as 
IL-23 production (15). Our data here, showing intestinal dysbiosis in AS cases is 
consistent with this hypothesis, but further studies are clearly required to distinguish 
cause and effect interactions between the host genome and immune system, and the gut 
microbiome.  These investigations will provide new insights and help us to better 
understand AS disease pathogenesis. 
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Table 1. Clinical details of patients supplying biopsies at time of collection.  Disease duration is from date of onset of symptoms. 
ID Diagnosis Biopsy 
site 
Age Gender Disease 
duration 
ESR 
mm/Hr 
CRP 
mg/l 
BASDAI HLA-B27 
status 
NSAID 
treatment 
Histological 
inflammation 
AS01 Ankylosing 
spondylitis 
Ileum 56 M 
7 years 
34 18 7 Pos Current 
Chronic 
AS02 Ankylosing 
spondylitis 
Ileum 33 M 
4 years 
22 1 5.5 Pos None 
Acute 
AS03 Ankylosing 
spondylitis 
Ileum 24 F 
5 years 
18 5 4.8 Pos None 
Normal 
AS04 Ankylosing 
spondylitis 
Ileum 22 M 
3 years 
33 3 5.5 Pos None 
Normal 
AS05 Ankylosing 
spondylitis 
Ileum 33 M 
5 years 
41 2.7 6 Pos None 
Chronic 
AS06 Ankylosing 
spondylitis 
Ileum 28 M 
6 years 
28 1.5 6.2 Pos None 
Normal 
AS08 Ankylosing 
spondylitis 
Ileum 36 M 
8 years 
34 1.5 5.6 Pos None 
Acute 
AS09 Ankylosing 
spondylitis 
Ileum 38 F 
6 years 
45 2.2 6.7 Pos None 
Chronic 
AS10 Ankylosing 
spondylitis 
Ileum 31 M 
11 years 
27 1.3 8 Pos None 
Normal 
HC01 Healthy 
Control 
Ileum 58 F N/A N/A 0.3 N/A N/A N/A N/A 
HC02 Healthy 
Control 
Ileum 43 M N/A N/A 0.5 N/A N/A N/A N/A 
HC03 Healthy 
Control 
Ileum 38 F N/A N/A 0.05 N/A N/A N/A N/A 
HC04 Healthy 
Control 
Ileum 65 M N/A N/A 0.8 N/A N/A N/A N/A 
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 HC05 Healthy 
Control 
Ileum 48 F N/A N/A 0.02 N/A N/A N/A N/A 
HC06 Healthy 
Control 
Ileum 34 F N/A N/A 0.03 N/A N/A N/A N/A 
HC07 Healthy 
Control 
Ileum 45 M N/A N/A 0.5 N/A N/A N/A N/A 
HC08 Healthy 
Control 
Ileum 44 F N/A N/A 0.8 N/A N/A N/A N/A 
HC09 Healthy 
Control 
Ileum 56 F N/A N/A 0.02 N/A N/A N/A N/A 
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